

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
14 February 2008 (14.02.2008)

PCT

(10) International Publication Number
WO 2008/019372 A2

(51) International Patent Classification: **Not classified**

(21) International Application Number:
PCT/US2007/075378

(22) International Filing Date: 7 August 2007 (07.08.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/821,646 7 August 2006 (07.08.2006) US

(71) Applicant (for all designated States except US): **AMR TECHNOLOGY, INC.** [US/US]; 5429 Main Street, Manchester, VT 05255 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **FAIRFAX, David J.** [GB/US]; 72 McCormack Road, Slingerlands, NY 12159 (US). **YANG, Zhicai** [CN/US]; 8 Remington Road, Schenectady, NY 12302 (US).

(74) Agent: **PUNIA, Surinder S.**; Heslin Rothenberg Farley & Mesiti P.C., 5 Columbia Circle, Albany, NY 12203 (US).




(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

(54) Title: 2-AMINOBENZOXAZOLE CARBOXAMIDES AS 5HT3 MODULATORS



(57) Abstract: Compounds of Formulae (I), (II) and (III): are disclosed as 5-HT3 inhibitors. The compounds are useful in treating CINV, IBS-D and other diseases and conditions.

2-AMINOBENZOXAZOLE CARBOXAMIDES AS 5HT3 MODULATORS**CROSS-REFERENCE TO RELATED APPLICATIONS**

[0001] This application claims priority from U.S. Provisional Application Serial Number 60/821,646, filed August 7, 2006, the entire contents of which are incorporated herein by reference.

FIELD OF THE INVENTION

[0002] The invention relates to a genus of 2-aminobenzoxazole carboxamides that are useful in treating chemotherapy-induced nausea and vomiting (CINV) and in treating diarrhea-predominant Irritable Bowel Syndrome (IBS-D).

BACKGROUND OF THE INVENTION

[0003] Nausea and vomiting caused by chemotherapy remain among the most distressing side effects for patients undergoing treatment for cancer. Depending upon the chemotherapy agents or regimens given, up to 90% of patients may suffer from some form of chemotherapy-induced nausea and vomiting (CINV). Symptoms from CINV can be severely debilitating and often result in patients refusing further courses of chemotherapy, with obviously unfavorable consequences with respect to progression of the cancer. Furthermore, CINV is burdensome on the medical system, consuming time from the healthcare staff, who could otherwise attend to other patients or medical issues.

[0004] CINV is divided into two main categories: acute CINV and delayed CINV. Acute CINV occurs within the first 24 hours of treatment; delayed CINV occurs from 24 hours to 120 hours following treatment. Delayed CINV remains a highly under-treated side effect in patients undergoing chemotherapy, as healthcare providers tend to underestimate the number of patients who suffer from delayed CINV. Furthermore, delayed CINV greatly impairs patients' ability to provide care to themselves once they have been discharged.

[0005] Compounds that inhibit serotonin receptors are currently the most effective anti-emetics; they constitute the single greatest advance in the management of nausea and vomiting in patients with cancer and have had additional application in radiation-induced nausea and vomiting (RINV) and post-operative nausea and vomiting (PONV). Blocking the 5-HT₃ receptor from the serotonin signal produced from chemotherapy-induced damage to the gut's enterochromaffin cells, which house the majority of the body's serotonin reserves, via either a peripheral or central mechanism appears to prevent acute emesis. Except for palonosetron (Aloxi[®]), 5-HT₃ inhibitors have been approved for and most effective against the treatment of acute CINV. Palonosetron, which must be given intravenously, is the only 5-HT₃ inhibitor currently approved for the prevention of both acute and delayed CINV. The efficacy of palonosetron against delayed emesis has been postulated to be due to its long serum half-life. Therefore persons of skill in the art accept that 5-HT₃ inhibitors that have long serum half-lives will be effective therapeutic agents for both acute and delayed CINV, while those that have short half-lives will be useful to treat acute CINV. In addition, the combination of palonosetron, a 5-HT₃ inhibitor, and aprepitant (EMEND[®]), a neurokinin antagonist, has been shown to be highly effective in preventing both acute and delayed CINV following a variety of moderately to highly emetogenic chemotherapy regimens in clinical trials. Notably, combination therapy of either NK1 antagonists or 5-HT₃ antagonists with corticosteroids such as dexamethasone, improve the performance of these drugs against acute or delayed emesis. To that point, EMEND[®] labeling indicates that the drug is dosed with a corticosteroid and a 5-HT₃ antagonist.


[0006] Irritable Bowel Syndrome (IBS) generally occurs in three types: diarrhea predominant (IBS-D), constipation predominant (IBS-C) and IBS with alternating symptoms termed IBS-A or mixed-mode (IBS-M). Diarrhea predominant Irritable Bowel Syndrome is a debilitating, though seldom fatal, disease. The typical sufferer of IBS-D exhibits primary symptoms including multiple and daily explosive diarrhea attacks and severe daily abdominal cramps. The most common secondary side effects include panic attacks, depression, withdrawal from social and family activities and malnutrition.

[0007] At present, compounds that inhibit 5-HT₃ receptors are the only effective treatment for IBS-D. The only drug currently approved for IBS-D is alosetron, which was introduced by Glaxo, withdrawn by the FDA because it appeared to cause ischemic colitis, then reinstated by the FDA because the demand was so great for some treatment for IBS-D. In 2002, the US Food and Drug Administration approved alosetron hydrochloride (LOTRONEX[®]) tablets under restricted conditions for women in whom the medical benefits outweigh the risks. The restrictions on the approval reflect the serious gastrointestinal adverse events that have been reported with the use of alosetron. A second structurally related 5-HT₃ inhibitor, cilansetron, had been making its way through clinical trials and recently received a non-approvable letter from the FDA. New, structurally unrelated 5-HT₃ inhibitors may be useful for the treatment of IBS-D.

[0008] Clearly there is a need for improved therapy for both CINV and IBS-D.

SUMMARY OF THE INVENTION

[0009] It has now been found that compounds of formulae I, II and III are potent and selective inhibitors of the 5-HT₃ receptor:



[0010] In these compounds R₁, R₂, and R₃ are independently selected from hydrogen, halogen, cyano, alkyl or aryl sulfoxide, alkyl or aryl sulfone, amino, alkylamino, dialkylamino, acylamino, morpholinyl, -O-loweralkyl, hydroxy,

loweralkyl, fluoroloweralkyl, O lowerfluoroalkyl, methylenedioxy, ethylenedioxy, alkoxy-loweralkyl and hydroxyloweralkyl.

[0011] R₄ is a saturated nitrogen heterocycle or methyl-substituted saturated nitrogen heterocycle, in which said nitrogen is tertiary, said heterocycle containing at least one 5 or 6-membered ring;

R₁₀ is chosen from the group consisting of

- (i) hydrogen;
- (ii) (C₁-C₁₀)alkyl;
- (iii) substituted (C₁-C₁₀)alkyl;
- (iv) heterocyclyl;
- (v) substituted heterocyclyl;
- (vi) aryl; and
- (vii) substituted aryl;

R₁₁ is chosen from the group consisting of hydrogen and (C₁-C₁₀)alkyl;

or

taken together R₁₀, R₁₁, and the nitrogen to which they are attached form a nitrogenous heterocycle or substituted nitrogenous heterocycle.

[0012] In another aspect, the invention relates to pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of formula I, II, or III. The compositions may comprise an additional antiemetic agent, particularly a neurokinin antagonist. The compositions may also comprise a corticosteroid.


[0013] In another aspect, the invention relates to a method of treating a disorder arising from inappropriate activity of the serotonin type 3 receptor or dependent upon modulation of the serotonin type 3 receptor. The method comprises administering a therapeutically effective amount of a compound of formula I, II, or III. Exemplary disorders arising from inappropriate activity of the serotonin type 3 receptor or dependent upon modulation of the serotonin type 3 receptor include emesis, particularly CINV, IBS-D, post-operative induced nausea and vomiting and radiation induced nausea and vomiting. Other such disorders include psychological

disorders, obesity, substance abuse disorders, dementia associated with a neurodegenerative disease, cognition loss, pain, fibromyalgia syndrome and chronic fatigue syndrome (see US published application 2004/0204467). Serotonin type 3 receptor antagonists are also known to be useful for the prevention and treatment of bronchial asthma, bulimia nervosa, sleep apnea, pruritis and migraine (see Costall and Naylor, *Current Drug Targets – CNS & Neurological Disorders*, 2004:3 27-37 and Israili, *Current Med. Chem. – CNS Agents*, 2001:1 171-199.). Serotonin type 3 receptor antagonists are also known to be useful for the prevention and treatment of epilepsy. Application of such compounds for the treatment of epilepsy has been demonstrated in International Application Number PCT/GB2006/002733.







DETAILED DESCRIPTION OF THE INVENTION

[0014] Throughout this specification the substituents are defined when introduced and retain their definitions.


[0015] In a first aspect the invention relates to compounds of formula I, II, or III:





In general, it has been found that compounds of the foregoing formulae are potent and selective inhibitors of the 5-HT₃ receptor. Each of the three genera may be divided into two subgenera: the 4-carboxamides (Ia, IIa, and IIIa) and the 7-carboxamides (Ib, IIb, and IIIb):



[0016] In these compounds, R_4 represents a saturated nitrogen heterocycle or methyl-substituted saturated nitrogen heterocycle, in which the nitrogen is tertiary. A nitrogen heterocycle (also referred to as a nitrogenous heterocycle) is a heterocycle containing at least one nitrogen in the ring; it may contain additional nitrogens, as well as other heteroatoms. Nitrogenous heterocycles include piperidine,

methylpiperidine, tropane, 9-azabicyclo[3.3.1]nonan-3-one, and , in which X is NCH_3 , O, S, SO or SO_2 . In some embodiments, R_4 is





in which m is 1, 2, 3 or 4; n is 0, 1, 2, 3 or 4; Q is $N(CH_3)$ or $-O-$; and R_5 is hydrogen or methyl. For example, R_4 may be quinuclidine, tropane, azabicyclo[3.3.1]nonane, methyl azabicyclo[3.3.1]nonane, dimethyl diazabicyclo[3.3.1]nonane, methylpiperidine or methyl-3-oxa-9-azabicyclo[3.3.1]nonane.

[0017] In some embodiments, R_1 , R_2 , and R_3 are hydrogen; in others one of R_1 , R_2 , and R_3 is halogen.

[0018] In some embodiments of the parent genus, R_{10} is chosen from the group consisting of hydrogen and $(C_1$ to $C_3)$ alkyl. In other embodiments of the genus II, R_{11} is H or CH_3 and R_{10} is chosen from the group consisting of phenyl, substituted phenyl, (C_1-C_6) alkyl, 4 to 7-membered monocyclic nitrogenous heterocycle, 4 to 10 carbon bicyclic nitrogenous heterocycle, 4 to 7-membered monocyclic nitrogenous heterocycle substituted with one or more (C_1-C_6) alkyl, 4 to 10 carbon bicyclic nitrogenous heterocycle substituted with one or more (C_1-C_6) alkyl, dimethylamino (C_1-C_6) alkyl, 4 to 7-membered monocyclic nitrogenous heterocyclyl (C_1-C_6) alkyl, (C_1-C_6) alkoxy (C_1-C_6) alkyl, hydroxy (C_1-C_6) alkyl, and dialkylaminocarbonyl (C_1-C_6) alkyl.


[0019] In other embodiments, R_{10} and R_{11} , taken together, form a nitrogenous heterocycle or substituted nitrogenous heterocycle. Examples include morpholine, piperazine, piperidine, diazepane, tetrahydroquinoxaline, azabicyclo[3.3.1]nonane, triazolopyrazine, diazabicyclo[2.2.1]heptane, or any of the foregoing substituted with one, two or three substituents chosen independently from (C_1-C_6) alkyl, (C_1-C_6) haloalkyl, (C_1-C_6) alkoxy phenyl, heteroaryl, substituted heteroaryl, heterocyclyl, and substituted heterocyclyl.

[0020] Compounds falling within the foregoing parent genus and its subgenera are useful as 5-HT₃ inhibitors. It may be found upon examination that compounds that are not presently excluded from the claims are not patentable to the

inventors in this application. In that case, the exclusion of species and genera in applicants' claims are to be considered artifacts of patent prosecution and not reflective of the inventors' concept or description of their invention. The invention, in a composition aspect, is all compounds of formulae I, II and III, except (a) those compounds that are in the public's possession, and (b) the single species of example 55, falling within the subgenus IIa, in which R₁₀, R₁₁ and nitrogen form a morpholine ring and R₄ appears (based on NMR data) to be *endo* 3,9-dimethyl-3,9-diazabicyclo[3.3.1]nonan-7-yl. This compound has not exhibited the level of potency established as the threshold for the screen.

DEFINITIONS

[0021] Alkyl is intended to include linear, branched, or cyclic hydrocarbon structures and combinations thereof. Lower alkyl refers to alkyl groups of from 1 to 6 carbon atoms. Examples of lower alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, s-and t-butyl and the like. Preferred alkyl groups are those of C₂₀ or below. Cycloalkyl is a subset of alkyl and includes cyclic hydrocarbon groups of from 3 to 8 carbon atoms. Examples of cycloalkyl groups include c-propyl, c-butyl, c-pentyl, norbornyl and the like. Certain moieties require explicit mention. The statement that alkyl is intended to include linear, branched, or cyclic hydrocarbon structures and combinations thereof means that the following combination of linear and cyclic structural elements



(and similar combinations) is considered an "alkyl" group. C₁ to C₂₀ hydrocarbon includes alkyl, cycloalkyl, alkenyl, alkynyl, aryl and combinations thereof. Examples include phenethyl, cyclohexylmethyl, camphoryl and naphthylethyl.

[0022] Alkoxy or alkoxyl refers to groups of from 1 to 8 carbon atoms of a straight, branched, cyclic configuration and combinations thereof attached to the parent structure through an oxygen. Examples include methoxy, ethoxy, propoxy,

isopropoxy, cyclopropyloxy, cyclohexyloxy and the like. Lower-alkoxy refers to groups containing one to four carbons.

[0023] Oxaalkyl refers to alkyl residues in which one or more carbons has been replaced by oxygen. Examples include methoxypropoxy, 3,6,9-trioxadecyl and the like.

[0024] Acyl refers to groups of from 1 to 8 carbon atoms of a straight, branched, cyclic configuration, saturated, unsaturated and aromatic and combinations thereof, attached to the parent structure through a carbonyl functionality. One or more carbons in the acyl residue may be replaced by nitrogen, oxygen or sulfur as long as the point of attachment to the parent remains at the carbonyl. Examples include acetyl (Ac), benzoyl, propionyl, isobutyryl, t-butoxycarbonyl, benzyloxycarbonyl and the like. Lower-acyl refers to groups containing one to four carbons.

[0025] Aryl and heteroaryl mean a 5- or 6-membered aromatic or heteroaromatic ring containing 0-3 heteroatoms selected from O, N, or S; a bicyclic 9- or 10-membered aromatic or heteroaromatic ring system containing 0-3 heteroatoms selected from O, N, or S; or a tricyclic 13- or 14-membered aromatic or heteroaromatic ring system containing 0-3 heteroatoms selected from O, N, or S. The aromatic 6- to 14-membered carbocyclic rings include, e.g., benzene, naphthalene, indane, tetralin, and fluorene and the 5- to 10-membered aromatic heterocyclic rings include, e.g., imidazole, pyridine, indole, thiophene, benzopyranone, thiazole, furan, benzimidazole, quinoline, isoquinoline, quinoxaline, pyrimidine, pyrazine, tetrazole and pyrazole.

[0026] Arylalkyl refers to a residue in which an aryl moiety is attached to the parent through an alkyl. Examples are benzyl, phenethyl and the like. Tolyl is not arylalkyl; tolyl is alkylaryl. Heteroarylalkyl means a heteroaryl residue attached to the parent via alkyl. Examples include, e.g., pyridinylmethyl, pyrimidinylethyl and the like.

[0027] Heterocycle means a cycloalkyl or aryl residue of one to three rings in which from one to four carbons is replaced by a heteroatom selected from the group consisting of N, O and S. The nitrogen and sulfur heteroatoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized. Examples of heterocycles include pyrrolidine, pyrazole, pyrrole, indole, quinoline, isoquinoline, tetrahydroisoquinoline, benzofuran, benzodioxan, benzodioxole (commonly referred to as methylenedioxyphenyl, when occurring as a substituent), tetrazole, morpholine, thiazole, pyridine, pyridazine, pyrimidine, thiophene, furan, oxazole, oxazoline, isoxazole, dioxane, tetrahydrofuran and the like. Nitrogen heterocycles are heterocycles containing at least one nitrogen. They may additionally include other heteroatoms and multiple nitrogens. Examples include quinuclidine, tropane, piperidine, piperazine, morpholine, quinoline, benzo[b][1,4]oxazine, 1,2,4-triazolo[4,3-a]pyrazine, perhydroquinoxaline and thiazole. It is to be noted that heteroaryl is a subset of heterocycle in which the heterocycle is aromatic. Dihydroheteroaryl are, as the name implies, heteraryl residues formally reduced by one mole of hydrogen. An example of a dihydroheteroaryl residue is 2,3-dihydrobenzofuran.

[0028] Substituted alkyl, aryl, cycloalkyl, heterocyclyl etc. refer to alkyl, aryl, cycloalkyl, or heterocyclyl wherein up to four H atoms in each residue are replaced with halogen, haloalkyl, hydroxy, loweralkoxy, carboxy, alkoxycarbonyl (COOR), oxo, carboxamido (-CONR₂), sulfonamido (-SO₂NR₂), cyano, carbonyl, nitro, amino, alkylamino, dialkylamino, mercapto, alkylthio, sulfoxide, sulfone, acylamino, amidino, phenyl, benzyl, heterocyclyl, heterocyclylcarbonyl, phenoxy, benzyloxy, or heteroaryloxy. In the foregoing listing, R is hydrogen or alkyl.

[0029] The term "halogen" means fluorine, chlorine, bromine or iodine.

[0030] Some of the compounds described herein may contain one or more asymmetric centers and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)-. The present invention is meant to include all such possible isomers, as well as, their racemic and optically pure forms. Optically active (R)- and (S)- isomers may be prepared using chiral synthons or chiral reagents, or resolved using

conventional techniques. When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers. Likewise, all tautomeric forms are also intended to be included. The configuration of any carbon-carbon double bond appearing herein is selected for convenience only and is not intended to designate a particular configuration; thus a carbon-carbon double bond depicted arbitrarily herein as trans may be Z, E or a mixture of the two in any proportion.


[0031] It will be recognized that the compounds of this invention can exist in radiolabeled form, i.e., the compounds may contain one or more atoms containing an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Radioisotopes of hydrogen, carbon, phosphorous, fluorine, chlorine and iodine include ^3H , ^{14}C , ^{35}S , ^{18}F , ^{36}Cl and ^{125}I , respectively. Compounds that contain those radioisotopes and/or other radioisotopes of other atoms are within the scope of this invention. Tritiated, i.e. ^3H , and carbon-14, i.e., ^{14}C , radioisotopes are particularly preferred for their ease in preparation and detectability. Radiolabeled compounds of this invention can generally be prepared by methods well known to those skilled in the art. Conveniently, such radiolabeled compounds can be prepared by carrying out the procedures disclosed in the Examples and Schemes by substituting a readily available radiolabeled reagent for a non-radiolabeled reagent.

[0032] Terminology related to "protecting", "deprotecting" and "protected" functionalities occurs throughout this application. Such terminology is well understood by persons of skill in the art and is used in the context of processes, which involve sequential treatment with a series of reagents. In that context, a protecting group refers to a group, which is used to mask a functionality during a process step in which it would otherwise react, but in which reaction is undesirable. The protecting group prevents reaction at that step, but may be subsequently removed to expose the original functionality. The removal or "deprotection" occurs after the completion of the reaction or reactions in which the functionality would interfere. Thus, when a sequence of reagents is specified, as it is in the processes of the invention, the person of ordinary skill can readily envision those groups that would be suitable as "protecting groups". Suitable groups for that purpose are discussed in standard

textbooks in the field of chemistry, such as Protective Groups in Organic Synthesis by T.W. Greene [John Wiley & Sons, New York, 1991], which is incorporated herein by reference.

[0033] The term “preventing” as used herein refers to administering a medicament beforehand to forestall or obtund an attack. The person of ordinary skill in the medical art (to which the present method claims are directed) recognizes that the term “prevent” is not an absolute term. In the medical art it is understood to refer to the prophylactic administration of a drug to substantially diminish the likelihood or seriousness of a condition, and this is the sense intended herein. Indeed, the 2006 edition of the Physician’s Desk Reference, which is the standard text in the field, employs the term “prevent”, or “prevention” not less than 10 times in its description of the indications for palonosetron.

[0034] The graphic representations of racemic, ambiscalemic and scalemic or enantiomerically pure compounds used herein are taken from Maehr J. Chem. Ed. 62, 114-120 (1985): solid and broken wedges are used to denote the absolute configuration of a chiral element; wavy lines indicate disavowal of any stereochemical implication which the bond it represents could generate; solid and broken bold lines are geometric descriptors indicating the relative configuration shown but denoting racemic character; and wedge outlines and dotted or broken lines denote enantiomerically pure compounds of indeterminate absolute configuration. A simple solid line implies nothing about stereochemistry. For example, a solid line is shown in the graphic for example 2 in the table below, but the compound of the example is actually a single enantiomer of the S configuration and could have been accurately depicted as



[0035] As used herein, and as would be understood by the person of skill in the art, the recitation of “a compound” is intended to include salts, solvates and


inclusion complexes of that compound. The term "solvate" refers to a compound of Formula I in the solid state, wherein molecules of a suitable solvent are incorporated in the crystal lattice. A suitable solvent for therapeutic administration is physiologically tolerable at the dosage administered. Examples of suitable solvents for therapeutic administration are ethanol and water. When water is the solvent, the solvate is referred to as a hydrate. In general, solvates are formed by dissolving the compound in the appropriate solvent and isolating the solvate by cooling or using an antisolvent. The solvate is typically dried or azeotroped under ambient conditions. Inclusion complexes are described in Remington: The Science and Practice of Pharmacy 19th Ed. (1995) volume 1, page 176-177, which is incorporated herein by reference. The most commonly employed inclusion complexes are those with cyclodextrins, and all cyclodextrin complexes, natural and synthetic, are specifically encompassed within the claims.

[0036] The term "pharmaceutically acceptable salt" refers to salts prepared from pharmaceutically acceptable non-toxic acids or bases including inorganic acids and bases and organic acids and bases. When the compounds of the present invention are basic, salts may be prepared from pharmaceutically acceptable non-toxic acids including inorganic and organic acids. Suitable pharmaceutically acceptable acid addition salts for the compounds of the present invention include acetic, benzenesulfonic (besylate), benzoic, camphorsulfonic, citric, ethenesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric acid, p-toluenesulfonic, and the like. When the compounds contain an acidic side chain, suitable pharmaceutically acceptable base addition salts for the compounds of the present invention include metallic salts made from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc or organic salts made from lysine, N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and procaine.

[0037] A comprehensive list of abbreviations utilized by organic chemists appears in the first issue of each volume of the Journal of Organic Chemistry. The list, which is typically presented in a table entitled "Standard List of Abbreviations" is incorporated herein by reference.

[0038] Generalized synthetic schemes are presented below:

[0039] General Procedures for Modifying the Benzoxazole Core



[0040] General procedure (GP-A) for the amination of the benzoxazole core:

[0041] A mixture of an appropriate 2-chlorobenzoxazole, **A1** (1 eq), and appropriate amine (2 eq) and optional base (e.g. K₂CO₃, triethylamine, diisopropylamine, 1,8-diazabicyclo[5.4.0]undecene, or sodium hydride) in THF (or DME, DMF) was heated in the range of 20 to 80 °C up to 24 h. After cooling to room temperature, the reaction mixture was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (typical eluents include 9:1 dichloromethane/methanol, ethyl acetate, hexanes) to afford the desired product 2-aminobenzoxazole. Product structure was confirmed by ¹H NMR or by mass analysis.

[0042] General Procedure (GP-B1) for the hydrolysis of the methyl ester:

[0043] A mixture of the methyl ester **A2** in 2 N NaOH and THF was stirred at room temperature for 12 h. The reaction mixture was neutralized by 2 N HCl, and then extracted with dichloromethane. The combined organics were dried (Na₂SO₄), filtered and concentrated to afford the desired carboxylic acid **A3**. Product structure was confirmed either by ¹H NMR or by mass analysis.

[0044] General Procedure (GP-B2) for the hydrolysis of the methyl ester (lithium carboxylate salt):

[0045] A mixture of the methyl ester A2 and lithium hydroxide monohydrate (1-3 eq) in methanol/water (3:1) was stirred at room temperature until the reaction was complete by LC-MS. The solvent was removed in vacuum and the crude lithium salt A3 was dried under high vacuum and subsequently used without further purification. The product structure was confirmed by ¹H NMR or by mass analysis.

[0046] General Procedure (GP-B3) for the hydrolysis of the methyl ester:

[0047] A mixture of the methyl ester A2, lithium hydroxide monohydrate (1-3 eq) and a mixture of methanol/water or THF/water (3:1 to 5:1) was stirred at room temperature until the reaction was complete by LC-MS. The reaction mixture was concentrated under reduced pressure. The resulting residue was diluted in water, acidified (pH 1-5) with 3 N hydrochloric acid and concentrated to dryness. The solid was triturated in dichloromethane, and the filtrate was concentrated under reduced pressure to afford the desired carboxylic acid A3. The product structure was confirmed either by ¹H NMR or by mass analysis.

[0048] General Procedure (GP-C1) for amidation:

[0049] A mixture of the carboxylic acid or lithium carboxylate salt A3 (1 eq), appropriate amine (e.g. *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride (1 eq), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride) (2 eq) and 1-hydroxybenzotriazole (2 eq) in DMF was stirred at room temperature for 5 min, then triethylamine (2 to 4 eq) was added. The resulting reaction mixture was stirred at room temperature for 12 h. The mixture was diluted with dichloromethane, and then washed with a saturated solution of sodium bicarbonate. The aqueous layer was further extracted with dichloromethane. The combined organics were dried (Na₂SO₄), filtered and concentrated. The crude material was purified by silica gel chromatography (typical eluents ethyl acetate/hexanes, ethyl acetate/methanol, dichloromethane, dichloromethane/methanol or dichloromethane/methanol/concentrated ammonium hydroxide) to afford the desired carboxamide A4. The product structure was verified by ¹H NMR.

[0050] General Procedure (GP-C2) for amidation:

[0051] A mixture of the carboxylic acid or lithium carboxylate salt **A3** (1 eq), an appropriate amine (e.g. *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride) (1 eq), and HBTU (1.3-2 eq) in DMF was stirred at room temperature for 5 min, then triethylamine (2 to 4 eq) was added. The resulting reaction mixture was stirred at room temperature for 12 h. The mixture was diluted with dichloromethane, and then washed with a saturated solution of sodium bicarbonate. The aqueous layer was further extracted with dichloromethane. The combined organics were dried (Na₂SO₄), filtered and concentrated. The crude material was purified by silica gel chromatography (typical eluents ethyl acetate/hexanes, ethyl acetate/methanol, dichloromethane, dichloromethane/methanol or dichloromethane/methanol/concentrated ammonium hydroxide) to afford the desired carboxamide **A4**. The product structure was verified by ¹H NMR.

[0052] General Procedure (GP-D1) for conversion to the HCl salt:

[0053] To an ice-cold solution of the carboxamide **A4** (1 eq) in dichloromethane and ethyl ether was added hydrogen chloride (2 eq) in methanol. The mixture was stirred at room temperature for 5 min, and then diluted with anhydrous ethyl ether. The mixture was left at room temperature for 2 h, and then the resulting precipitate was collected by filtration and washed with ethyl ether. The solid was dried under vacuum to afford the desired **A4** hydrochloride salt. The product was verified by mass analysis and ¹H NMR.

[0054] General Procedure (GP-D2) for conversion to the HCl salt:


[0055] An ice-cold solution of the Boc-protected carboxamide from GP-C (1 eq) was treated with an excess of either TFA or HCl (in diethyl ether, dioxane or methanol) in dichloromethane. The crude salt was diluted with methanol and loaded onto a cation exchange resin (Isolute SCX-2, 10g Column). The column was washed with methanol (50 mL) and the product then eluted with 2 N ammonium hydroxide in methanol (50 mL). The solution was concentrated under reduced pressure. The crude material was purified by silica gel chromatography (typical eluents

dichloromethane/methanol, dichloromethane/methanol/concentrated ammonium hydroxide) to afford the desired carboxamide. The carboxamide was subsequently treated with HCl (1-2 equivalents) in dichloromethane and concentrated under reduced pressure. The amorphous hydrochloride salt was lyophilized from acetonitrile/water (6:1) to afford the desired **A4** hydrochloride salt. The product was verified by mass analysis and ^1H NMR.

[0056] General procedure (GP-E) for acylation of *endo*-N-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2*S*,6*S*)-2,6-dimethyl-piperazin-1-yl)benzoxazole-4-carboxamide:

[0057] To an ice-cold mixture of *endo*-N-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2*S*,6*S*)-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxamide and triethylamine in CH_2Cl_2 was added the appropriate acyl chloride, chloroformate, or sulfonyl chloride. The mixture was allowed to warm to ambient temperature and then stirred for up to an additional 24 h. The reaction was quenched with CH_3OH /brine and the resulting mixture extracted with dichloromethane (2x). The combined organic layers were washed successively with 10% citric acid and brine, then dried (Na_2SO_4), filtered, and concentrated under reduced pressure. Purification by column chromatography (silica gel, 9:1 $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$ to 90:9:1 $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}/\text{NH}_4\text{OH}$) afforded the corresponding *endo*-N-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2*S*,6*S*)-2,6-dimethyl-4-acylpiperazin-1-yl)benzoxazole-4-carboxamide.

[0058] Preparation of methyl 2-chlorobenzoxazole-4-carboxylate



Conditions: (A) TMSCHN_2 ; (B) potassium O-ethylxanthate, pyridine; (C) PCl_5 , POCl_3


[0059] Step A: To an ice-cold suspension of 2-amino-3-hydroxybenzoic acid hydrobromide (3.0 g, 12.8 mmol) in toluene (30 mL) and methanol (30 mL) was added (trimethylsilyl)diazomethane (16.0 mL, 2 M solution in ethyl ether, 32.0 mmol)

slowly, then the mixture was stirred at 0 °C for 20 min. Acetic acid (5 mL) was added into the reaction mixture at 0 °C, then the mixture was stirred at room temperature for 0.5 h. The reaction mixture was concentrated under reduced pressure, and then the crude was dissolved in ethyl acetate and washed with a saturated solution of sodium bicarbonate and brine. The organic layer was dried (Na₂SO₄), filtered and concentrated. The crude product was purified by column chromatography (silica gel, 1:1 hexanes/ethyl acetate) to afford the desired ester (2.04 g, 95%) as a light brown solid: ¹H NMR (500 MHz, CDCl₃) δ 7.48 (dd, *J* = 8.0, 1.5 Hz, 1H), 6.81 (dd, *J* = 7.5, 1.5 Hz, 1H), 6.50 (t, *J* = 8.0 Hz, 1H), 5.80 (br s, 2H), 3.87 (s, 3H); MS (ESI+) *m/z* 168 (M+H).

[0060] Step B: A mixture of methyl 2-amino-3-hydroxybenzoate from Step A (2.04 g, 12.2 mmol) and potassium O-ethylxanthate (1.37 g, 8.56 mmol) in pyridine (8 mL) was heated to reflux for 2 h, then cooled to room temperature and poured into a mixture of ice-water (45 mL) and conc. HCl (4.8 mL). The resulting precipitate was collected by filtration and washed with water, dried on vacuum to give methyl 2-thioxo-2,3-dihydrobenzoxazole-4-carboxylate (1.33 g, 52%) as a light brown solid: ¹H NMR (500 MHz, CDCl₃) δ 10.40 (br s, 1H), 7.82 (dd, *J* = 8.0, 1.0 Hz, 1H), 7.49 (dd, *J* = 8.0, 1.0 Hz, 1H), 7.28 (t, *J* = 8.0 Hz, 1H), 4.01 (s, 3H); MS (ESI+) *m/z* 210 (M+H).

[0061] Step C: A mixture of the thione from Step B (0.65 g, 3.11 mmol) and phosphorus pentachloride (0.65 g, 3.11 mmol) in phosphorus oxychloride (6 mL) was heated to 95 °C for 2.5 h. After cooling to room temperature, the reaction mixture was concentrated and dried on vacuum to give methyl 2-chlorobenzoxazole-4-carboxylate (0.66 g, quantitative) as a brown solid: ¹H NMR (300 MHz, CDCl₃) δ 8.05 (dd, *J* = 8.1, 1.2 Hz, 1H), 7.72 (dd, *J* = 8.1, 1.2 Hz, 1H), 7.45 (t, *J* = 8.1 Hz, 1H), 4.04 (s, 3H); MS (ESI+) *m/z* 212 (M+H).

[0062] Preparation of methyl 2,6-dichlorobenzoxazole-4-carboxylate




Conditions: (A) potassium O-ethylxanthate, pyridine; (B) PCl_5 , POCl_3

[0063] Step A: To a mixture of methyl 2-amino-5-chloro-3-hydroxybenzoate (4.00 g, 19.84 mmol) in anhydrous pyridine (30 mL) was added potassium-O-ethylxanthate (3.50 g, 21.82 mmol), and the reaction mixture heated to 125 °C for 3 h under nitrogen atmosphere. The warm solution was poured into a mixture of concentrated HCl (12 mL) and ice (120 mL), the resulting precipitate filtered, and dried under vacuum to provide methyl 6-chloro-2-thioxo-2,3-dihydrobenzoxazole-4-carboxylate (4.80 g, 99%) as a yellow solid: ^1H NMR (300 MHz, CDCl_3) δ 8.10 (s, 1H), 7.81 (d, $J = 1.9$ Hz, 1H), 7.48 (d, $J = 1.9$ Hz, 1H), 4.01 (s, 3H); MS (ESI+) m/z 244 (M+H).

[0064] Step B: A mixture of the product from Step A (2.00 g, 8.20 mmol), POCl_3 (1.26 g, 8.21 mmol), and PCl_5 (1.71 g, 8.21 mmol) was heated to 125 °C for 2.5 hours. The reaction mixture was dried under high vacuum for 24 hours to afford methyl 2,6-dichlorobenzoxazole-4-carboxylate (2.00 g, 99%) as a brown solid: ^1H NMR (300 MHz, CDCl_3) δ 8.04 (d, $J = 2.0$ Hz, 1H), 7.72 (d, $J = 2.0$ Hz, 1H), 4.04 (s, 3H); MS (ESI+) m/z 247 (M+H).

[0065] Preparation of methyl 2-chloro-7-fluoro-benzoxazole-4-carboxylate



Conditions: (A) SOCl_2 , methanol; (B) 1,1'-thiocarbonyldiimidazole; (C) PCl_5 , POCl_3

[0066] Step A: To a solution of 2-amino-4-fluoro-3-hydroxybenzoic acid (2.44 g, 9.7 mmol) in methanol (200 mL) was added thionyl chloride (3.8 mL, 50 mmol) at -78°C . The mixture was stirred in the boiling solvent for 17 h. The solvent was removed under reduced pressure; the residue was dissolved in methanol (200 mL). The solution was cooled to -78°C and treated with thionyl chloride (8 mL, 100

mmol). The mixture was stirred in boiling solvent for 48 h. The solvent was removed under reduced pressure and the crude material was purified by column chromatography (silica gel, 0 to 70% ethyl acetate in hexanes) to afford methyl 2-amino-4-fluoro-3-hydroxybenzoate (1.5 g, 44%) as off-white solid. ^1H NMR (300MHz, CDCl_3) δ 7.48–7.43 (m, 1H), 6.40 (t, $J = 9.3$ Hz, 1H), 3.87 (s, 3H); MS (ESI+) m/z 186 (M+H)..

[0067] Step B: A mixture of methyl 2-amino-4-fluoro-3-hydroxybenzoate (1.5 g, 8.11 mmol) and 1,1'-thiocarbonyldiimidazole (1.46 g, 8.2 mmol) in THF (30 mL) was stirred at ambient temperature overnight, and at 50 °C for 6 h. The reaction mixture was cooled to ambient temperature and the solvent was removed under reduced pressure. The residue was washed with ether (3×50 mL) and dried to afford methyl 7-fluoro-2-thioxo-2,3-dihydrobenzoxazole-4-carboxylate (1.3 g, 70%) as a yellow solid. ^1H NMR (500MHz, CDCl_3) δ 7.82–7.78 (m, 1H), 6.40 (t, $J = 9.0$ Hz, 1H), 4.00 (s, 3H); (ESI+) m/z 228 (M+H).

[0068] Step C: A mixture of methyl 7-fluoro-2-thioxo-2,3-dihydrobenzoxazole-4-carboxylate (1.3 g, 5.72 mmol) and phosphorus pentachloride (1.2 g, 5.72 mmol) in phosphorus oxychloride (2.6 mL, 10.25 mmol) was heated to 95 °C for 3.5 h. After cooling to room temperature, the reaction mixture was concentrated and dried under vacuum to afford methyl 2-chloro-7-fluorobenzoxazole-4-carboxylate (1.3 g, quantitative) as a brown solid. ^1H NMR (300MHz, CDCl_3) δ 8.08–8.04 (m, 1H), 7.21 (t, $J = 9.3$ Hz, 1H), 4.02 (s, 3H); MS (ESI+) m/z 229 (M+H).

[0069] In other embodiments where X is not hydrogen or halogen, the method of preparation of the foregoing is similar to those presented in U.S. Patent Application 2006/183769, the entire contents of which are herein incorporated by reference. In situations where an inconsistency in nomenclature between the foregoing application and the present application may exist, the nomenclature and definitions of the present application take precedence.

[0070] Example 1: Preparation of *Endo*-N-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-2-(4-methylpiperazin-1-yl)benzoxazole-4-carboxamide Dihydrochloride

[0071] Step A: Following general procedure GP-A, methyl 2-chlorobenzoxazole-4-carboxylate and 1-methylpiperazine were converted to methyl 2-(4-methylpiperazin-1-yl)benzoxazole-4-carboxylate. ¹H NMR and MS consistent.

[0072] Step B: Following general procedure GP-B1, methyl 2-(4-methylpiperazin-1-yl)benzoxazole-4-carboxylate was converted to 2-(4-methylpiperazin-1-yl)benzoxazole-4-carboxylic acid. ¹H NMR and MS consistent.

[0073] Step C: Following general procedure GP-C1, a mixture of methyl 2-(4-methylpiperazin-1-yl)benzoxazole-4-carboxylate was converted to 2-(4-methylpiperazin-1-yl)benzoxazole-4-carboxylic acid. The acid and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were then coupled to provide *endo*-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-2-(4-methylpiperazin-1-yl)benzoxazole-4-carboxamide, which was converted to the dihydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[0074] Example 2: Preparation of (*S*)-N-(quinuclidin-8-yl)-2-(4-methylpiperazin-1-yl)benzoxazole-4-carboxamide Dihydrochloride

[0075] Following the general procedure GP-C1, 2-(4-methylpiperazin-1-yl)benzoxazole-4-carboxylic acid and (*S*)-(-)-3-aminoquinuclidine dihydrochloride were coupled to provide (*S*)-N-(quinuclidin-8-yl)-2-(4-methylpiperazin-1-yl)benzoxazole-4-carboxamide, which was converted to the dihydrochloride salt following general procedure GP-D1. ¹H-NMR and MS consistent.

[0076] Example 3: Preparation of *Endo*-N-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-2-(piperidin-1-yl)benzoxazole-4-carboxamide Hydrochloride

[0077] Step A: Methyl 2-(piperidin-1-yl)benzoxazole-4-carboxylate was synthesized following general procedure GP-A. ¹H NMR and MS consistent.

[0078] Step B: 2-(piperidin-1-yl)benzoxazole-4-carboxylic acid was synthesized following general procedure GP-B1 except that the reaction was heated to 50 °C for 12 h. ¹H NMR and MS consistent.

[0079] Step C: Following general procedure GP-C1, a mixture of 2-(piperidin-1-yl)benzoxazole-4-carboxylic acid and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to provide *endo*-*N*-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-2-(piperidin-1-yl)benzoxazole-4-carboxamide, which was converted to the dihydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[0080] Example 4: Preparation of (*S*)-*N*-(quinuclidin-8-yl)-2-(piperidin-1-yl)benzoxazole-4-carboxamide hydrochloride

[0081] Step A: Following general procedure GP-C1, a mixture of 2-(piperidin-1-yl)benzoxazole-4-carboxylic acid and (*S*)-(-)-3-aminoquinuclidine dihydrochloride were coupled to provide (*S*)-*N*-(quinuclidin-8-yl)-2-(piperidin-1-yl)benzoxazole-4-carboxamide which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[0082] Example 5: Preparation of *Endo*-*N*-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-2-(phenylamino)benzoxazole-4-carboxamide Hydrochloride

[0083] Step A: Methyl 2-(phenylamino)benzoxazole-4-carboxylate was synthesized following general procedure GP-A. ¹H NMR and MS consistent.

[0084] Step B: 2-(phenylamino)benzoxazole-4-carboxylic acid was synthesized following general procedure GP-B1 except that the reaction was heated to 50 °C for 12 h. ¹H NMR and MS consistent.

[0085] Step C: Following general procedure GP-C1, a mixture of 2-(phenylamino)benzoxazole-4-carboxylic acid and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to provide *endo*-*N*-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-2-(phenylamino)benzoxazole-4-carboxamide, which

was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[0086] Example 6: Preparation of (*S*)-*N*-(quinuclidin-8-yl)-2-(phenylamino)benzoxazole-4-carboxamide Hydrochloride

[0087] Following general procedure GP-C1, A mixture of 2-(phenylamino)benzoxazole-4-carboxylic acid and (*S*)-(-)-3-aminoquinuclidine dihydrochloride were coupled to provide (*S*)-*N*-(quinuclidin-8-yl)-2-(phenylamino)benzoxazole-4-carboxamide, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[0088] Example 7: Preparation of *Endo-N*-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-2-(dimethylamino)benzoxazole-4-carboxamide Hydrochloride

[0089] Step A: Methyl 2-(dimethylamino)benzoxazole-4-carboxylate was synthesized by following general procedure GP-A. ¹H NMR and MS consistent.

[0090] Step B: 2-(dimethylamino)benzoxazole-4-carboxylic acid was synthesized by following general procedure GP-B1. ¹H NMR and MS consistent.

[0091] Step C: Following general procedure GP-C1, A mixture of 2-(dimethylamino)benzoxazole-4-carboxylic acid and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to provide *endo-N*-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-2-(dimethylamino)benzoxazole-4-carboxamide, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H-NMR and MS consistent.

[0092] Example 8: Preparation of (*S*)-*N*-(quinuclidin-8-yl)-2-(dimethylamino)benzoxazole-4-carboxamide Hydrochloride

[0093] Step A: Following general procedure GP-C1, a mixture of 2-(dimethylamino)benzoxazole-4-carboxylic acid and (*S*)-(-)-3-aminoquinuclidine dihydrochloride were coupled to provide (*S*)-*N*-(quinuclidin-8-yl)-2-

(dimethylamino)benzoxazole-4-carboxamide, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[0094] Example 9: Preparation of *Endo-N*-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-2-morpholinobenzoxazole-4-carboxamide Hydrochloride

[0095] Step A: Methyl 2-morpholinobenzoxazole-4-carboxylate was synthesized by following general procedure GP-A. ¹H NMR and MS consistent.

[0096] Step B: 2-morpholinobenzoxazole-4-carboxylic acid was synthesized by following general procedure GP-B1. ¹H NMR and MS consistent.

[0097] Step C: Following general procedure GP-C1, a mixture of 2-morpholinobenzoxazole-4-carboxylic acid and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to provide *endo-N*-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-2-morpholinobenzoxazole-4-carboxamide, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[0098] Example 10: Preparation of (*S*)-*N*-(quinuclidin-8-yl)-2-morpholinobenzoxazole-4-carboxamide Hydrochloride

[0099] Following general procedure GP-C1, a mixture of 2-morpholinobenzoxazole-4-carboxylic acid and (*S*)-(-)-3-aminoquinuclidine dihydrochloride were coupled to provide (*S*)-*N*-(quinuclidin-8-yl)-2-morpholinobenzoxazole-4-carboxamide, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00100] Example 11: Preparation of *Endo-N*-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-2-(4-methyl-1,4-diazepan-1-yl)benzoxazole-4-carboxamide Dihydrochloride

[00101] Step A: Methyl 2-(4-methyl-1,4-diazepan-1-yl)benzoxazole-4-carboxylate was synthesized by following general procedure GP-A. ¹H NMR and MS consistent.

[00102] Step B: 2-(4-methyl-1,4-diazepan-1-yl)benzoxazole-4-carboxylic acid was synthesized by following general procedure GP-B1. ¹H NMR and MS consistent.

[00103] Step C: Following general procedure GP-C1, a mixture of 2-(4-methyl-1,4-diazepan-1-yl)benzoxazole-4-carboxylic acid and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to provide *endo*-*N*-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-2-(4-methyl-1,4-diazepan-1-yl)benzoxazole-4-carboxamide, which was converted to the dihydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00104] Example 12: Preparation of (*S*)-*N*-(quinuclidin-8-yl)-2-(4-methyl-1,4-diazepan-1-yl)benzoxazole-4-carboxamide Dihydrochloride

[00105] Following general procedure GP-C1, a mixture of 2-(4-methyl-1,4-diazepan-1-yl)benzoxazole-4-carboxylic acid and (*S*)-(-)-3-aminoquinuclidine dihydrochloride were coupled to provide (*S*)-*N*-(quinuclidin-8-yl)-2-(4-methyl-1,4-diazepan-1-yl)benzoxazole-4-carboxamide, which was converted to the dihydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00106] Example 13: Preparation of *Endo*-*N*-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-2-methylthiobenzoxazole-4-carboxamide Hydrochloride

[00107] Step A: To a solution of methyl 2-thioxo-2,3-dihydrobenzoxazole-4-carboxylate (1.5 g, 7.2 mmol) in acetone (150 mL) was added potassium carbonate (4.00 g, 28.7 mmol) followed by iodomethane (0.89 mL, 14.0 mmol), then the mixture was stirred at room temperature for 12 h. The reaction mixture was filtered through diatomaceous earth and washed with acetone, then concentrated under reduced pressure. The crude product was purified by column chromatography (silica

gel, 3:1 hexanes/EtOAc) to afford the desired product (1.4 g, 86%) as a light yellow solid: ^1H NMR and MS consistent.

[00108] Step B: 2-(methylthio)benzoxazole-4-carboxylic acid was synthesized by following general procedure GP-B1. ^1H NMR and MS consistent.

[00109] Step C: Following general procedure GP-C1, a mixture of 2-(methylthio)benzoxazole-4-carboxylic acid and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to provide *endo*-*N*-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-2-methylthiobenzoxazole-4-carboxamide, which was converted to the hydrochloride salt following general procedure GP-D1. ^1H NMR and MS consistent.

[00110] Example 14: Preparation of (*S*)-*N*-(quinuclidin-8-yl)-2-(methylthio)benzoxazole-4-carboxamide Hydrochloride

[00111] Following general procedure GP-C1, a mixture of 2-(methylthio)benzoxazole-4-carboxylic acid and (*S*)-(-)-3-aminoquinuclidine dihydrochloride were coupled to provide (*S*)-*N*-(quinuclidin-8-yl)-2-(methylthio)benzoxazole-4-carboxamide, which was converted to the hydrochloride salt following general procedure GP-D1. ^1H NMR and MS consistent.

[00112] Example 15: Preparation of *Endo*-*N*-(1-Methylpiperidin-4-yl)-2-morpholinobenzoxazole-4-carboxamide Hydrochloride

[00113] Following general procedure GP-C1, a mixture of 2-morpholinobenzoxazole-4-carboxylic acid and 4-amino-1-methylpiperidine were coupled to provide *N*-(1-methylpiperidin-4-yl)-2-morpholinobenzoxazole-4-carboxamide, which was converted to the hydrochloride salt following general procedure GP-D1. ^1H NMR and MS consistent.

[00114] Example 16: Preparation of *Endo*-*N*-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-2-(azetidin-3-ylamino)benzoxazole-4-carboxamide Dihydrochloride

[00115] Step A: Methyl 2-(1-(*tert*-butoxycarbonyl)azetidin-3-ylamino)benzoxazole-4-carboxylate was synthesized by following general procedure GP-A. ¹H NMR and MS consistent.

[00116] Step B: 2-(1-(*tert*-butoxycarbonyl)azetidin-3-ylamino)benzoxazole-4-carboxylic acid was synthesized by following general procedure GP-B1. ¹H NMR and MS consistent.

[00117] Step C: Following general procedure GP-C1, a mixture of 2-(1-(*tert*-butoxycarbonyl)azetidin-3-ylamino)benzoxazole-4-carboxylic acid and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to provide *tert*-butyl 3-(4-(9-methyl-9-azabicyclo[3.3.1]nonan-3-ylcarbamoyl)benzoxazol-2-ylamino)azetidine-1-carboxylate. ¹H NMR and MS consistent.

[00118] Step D: To an ice-cold solution of *tert*-butyl 3-(4-(9-methyl-9-azabicyclo[3.3.1]nonan-3-ylcarbamoyl)benzoxazol-2-ylamino)azetidine-1-carboxylate (69 mg, 0.15 mmol) in CH₂Cl₂ (5 mL) was added TFA(0.12 mL, 1.5 mmol). The reaction mixture was stirred at room temperature for 12 h, and then concentrated under reduced pressure. Following general procedure GP-D1, the resulting TFA salt (73 mg, 0.15 mmol) was converted to *endo*-*N*-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-2-(azetidin-3-ylamino)benzoxazole-4-carboxamide dihydrochloride. ¹H NMR and MS consistent.

[00119] Example 17: Preparation of *Endo*-*N*-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-2-[(2*S*,6*R*)-2,6-dimethylmorpholino]benzoxazole-4-carboxamide Hydrochloride

[00120] Step A: Methyl 2-[(2*S*,6*R*)-2,6-dimethylmorpholino]benzoxazole-4-carboxylate was synthesized by following general procedure GP-A. ¹H NMR and MS consistent.

[00121] Step B: 2-[(2*S*,6*R*)-2,6-dimethylmorpholino]benzoxazole-4-carboxylic acid was synthesized by following general procedure GP-B1. ¹H NMR and MS consistent.

[00122] Step C: Following general procedure GP-C1, A mixture of 2-[(2*S*,6*R*)-2,6-dimethylmorpholino]benzoxazole-4-carboxylic acid and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to provide *endo*-*N*-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-2-[(2*S*,6*R*)-2,6-dimethylmorpholino]benzoxazole-4-carboxamide, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00123] Example 18: Preparation of (*S*)-*N*-(quinuclidin-8-yl)-2-((2*S*,6*R*)-2,6-dimethylmorpholino)benzoxazole-4-carboxamide Hydrochloride

[00124] Following general procedure GP-C1, a mixture of 2-[(2*S*,6*R*)-2,6-dimethylmorpholino]benzoxazole-4-carboxylic acid and (*S*)-(-)-3-aminoquinuclidine dihydrochloride were coupled to provide (*S*)-*N*-(quinuclidin-8-yl)-2-((2*S*,6*R*)-2,6-dimethylmorpholino)benzoxazole-4-carboxamide, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00125] Example 19: Preparation of *Endo*-*N*-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-2-(3-phenylmorpholino)benzoxazole-4-carboxamide Hydrochloride

[00126] Step A: Methyl 2-(3-phenylmorpholino)benzoxazole-4-carboxylate was synthesized by following general procedure GP-A using triethylamine (1.5 eq) as the optional base. ¹H NMR and MS consistent.

[00127] Step B: 2-(3-phenylmorpholino)benzoxazole-4-carboxylic acid was synthesized by following general procedure GP-B1. ¹H NMR and MS consistent.

[00128] Step C: Following general procedure GP-C1, A mixture of 2-(3-phenylmorpholino)benzoxazole-4-carboxylic acid and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to provide *endo*-*N*-(9-methyl-

9-azabicyclo[3.3.1]non-3-yl)-2-(3-phenylmorpholino)benzoxazole-4-carboxamide, which was converted to a hydrochloride salt following general procedure GP-D1 and isolated as a mixture of enantiomers. ¹H NMR and MS consistent.

[00129] Example 20: Preparation of (*S*)-*N*-(quinuclidin-8-yl)-2-(3-phenylmorpholino)benzoxazole-4-carboxamide Hydrochloride

[00130] Following general procedure GP-C1, a mixture of 2-(3-phenylmorpholino)benzoxazole-4-carboxylic acid and (*S*)-(-)-3-aminoquinuclidine dihydrochloride were coupled to provide (*S*)-*N*-(quinuclidin-8-yl)-2-(3-phenylmorpholino)benzoxazole-4-carboxamide which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00131] Example 21: Preparation of *Endo-N*-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-2-(piperazin-1-yl)benzoxazole-4-carboxamide Dihydrochloride

[00132] Step A: Methyl 2-(4-(*tert*-butoxycarbonyl)piperazin-1-yl)benzoxazole-4-carboxylate was synthesized by following general procedure GP-A except that the reaction was conducted at room temperature for 1 h prior to concentration. ¹H NMR and MS consistent.

[00133] Step B: 2-[4-(*tert*-butoxycarbonyl)piperazin-1-yl]benzoxazole-4-carboxylic acid was synthesized by following general procedure GP-B1. ¹H NMR and MS consistent.

[00134] Step C: Following general procedure GP-C1, a mixture of 2-(1-(*tert*-butoxycarbonyl)azetidin-3-ylamino)benzoxazole-4-carboxylic acid and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to provide *tert*-butyl 4-(4-(9-methyl-9-azabicyclo[3.3.1]nonan-3-ylcarbamoyl)benzoxazol-2-yl)piperazine-1-carboxylate. ¹H NMR and MS consistent.

[00135] Step D: To an ice-cold solution of *tert*-butyl 4-(4-(9-methyl-9-azabicyclo[3.3.1]nonan-3-ylcarbamoyl)benzoxazol-2-yl)piperazine-1-carboxylate (73 mg, 0.15 mmol) in CH₂Cl₂ (5 mL) was added TFA (0.16 mL, 2.0 mmol). The

reaction mixture was stirred at room temperature for 12 h, and then concentrated under reduced pressure. Following general procedure GP-D1, the resulting TFA salt (92 mg, 0.15 mmol) was converted to *endo-N*-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-2-(piperazin-1-yl)benzoxazole-4-carboxamide dihydrochloride. ¹H NMR and MS consistent.

[00136] Example 22: Preparation of (*S*)-*N*-(quinuclidin-8-yl)-2-(piperazin-1-yl)benzoxazole-4-carboxamide Dihydrochloride

[00137] Following general procedure GP-C1, A mixture of 2-[4-(*tert*-butoxycarbonyl)piperazin-1-yl]benzoxazole-4-carboxylic acid and (*S*)-(-)-3-aminoquinuclidine dihydrochloride were coupled to provide *tert*-butyl 4-[4-(quinuclidin-8-ylcarbamoyl]benzoxazol-2-yl)piperazine-1-carboxylate (85 mg, 0.19 mmol) to which was added TFA (0.17 mL, 2.3 mmol). The reaction mixture was stirred at room temperature for 12 h, and then concentrated under reduced pressure. The TFA salt was converted to the dihydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00138] Example 23: Preparation of *Endo-N*-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-2-(4-methyl-2-phenylpiperazin-1-yl)benzoxazole-4-carboxamide Dihydrochloride

[00139] Step A: Following general procedure GP-A, methyl 2-chlorobenzoxazole-4-carboxylate and 1-methyl-3-phenylpiperazine were converted to methyl 2-(4-methyl-2-phenylpiperazin-1-yl)benzoxazole-4-carboxylate except that the reaction was conducted at room temperature for 1.5 h prior to concentration. ¹H NMR and MS consistent.

[00140] Step B: 2-(4-methyl-2-phenylpiperazin-1-yl)benzoxazole-4-carboxylic acid was synthesized by following general procedure GP-B1. ¹H NMR and MS consistent.

[00141] Step C: Following general procedure GP-C1, a mixture of 2-(4-methyl-2-phenylpiperazin-1-yl)benzoxazole-4-carboxylic acid and *endo*-3-amino-9-

methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to provide *endo-N*-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-2-(4-methyl-2-phenylpiperazin-1-yl)benzoxazole-4-carboxamide which was converted the dihydrochloride salt following general procedure GP-D1 and isolated as a mixture of enantiomers. ¹H NMR and MS consistent.

[00142] Example 24: Preparation of (*S*)-*N*-(quinuclidin-8-yl)-2-(4-methyl-2-phenylpiperazin-1-yl)benzoxazole-4-carboxamide Dihydrochloride

[00143] Following general procedure GP-C1, a mixture of 2-[4-(*tert*-butoxycarbonyl)piperazin-1-yl]benzoxazole-4-carboxylic acid and (*S*)-(-)-3-aminoquinuclidine dihydrochloride were coupled to provide (*S*)-*N*-(quinuclidin-8-yl)-2-(4-methyl-2-phenylpiperazin-1-yl)benzoxazole-4-carboxamide which was converted to the dihydrochloride salt following general procedure GP-D1 and isolated as a mixture of diastereomers. ¹H NMR and MS consistent.

[00144] Example 25: Preparation of *Endo-N*-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-2-(2-methylpiperazin-1-yl)benzoxazole-4-carboxamide Dihydrochloride

[00145] Step A: Methyl 2-[4-(*tert*-butoxycarbonyl)-2-methylpiperazin-1-yl]benzoxazole-4-carboxylate was synthesized by following general procedure GP-A. ¹H NMR and MS consistent.

[00146] Step B: 2-[4-(*tert*-butoxycarbonyl)-2-methylpiperazin-1-yl]benzoxazole-4-carboxylic acid was synthesized by following general procedure GP-B1. ¹H NMR and MS consistent.

[00147] Step C: Following general procedure GP-C1, 2-[4-(*tert*-butoxycarbonyl)-2-methylpiperazin-1-yl]benzoxazole-4-carboxylic acid and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to provide *tert*-butyl 3-methyl-4-(*endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)carbamoyl)benzoxazole-2-yl)piperazine-1-carboxylate. ¹H NMR and MS consistent.

[00148] Step D: To an ice-cold solution of *tert*-butyl 3-methyl-4-(*endo*-*N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-ylcarbamoyl)benzoxazole-2-yl)piperazine-1-carboxylate (120 mg, 0.24 mmol) in CH₂Cl₂ (5 mL) was added TFA (0.29 mL, 3.6 mmol). The reaction mixture was stirred at room temperature for 12 h, and then concentrated under reduced pressure. The resulting TFA salt was converted to *endo*-*N*-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-2-(2-methylpiperazin-1-yl)benzoxazole-4-carboxamide dihydrochloride following general procedure GP-D1. ¹H NMR and MS consistent.

[00149] Example 26: Preparation of (*S*)-*N*-(quinuclidin-8-yl)-2-(2-methylpiperazin-1-yl)benzoxazole-4-carboxamide Dihydrochloride

[00150] Step A: Following general procedure GP-C1, 2-[4-(*tert*-butoxycarbonyl)-2-methylpiperazin-1-yl]benzoxazole-4-carboxylic acid and (*S*)-(-)-3-aminoquinuclidine dihydrochloride were coupled to provide of *tert*-butyl 3-methyl-4-(4-(quinuclidin-8-ylcarbamoyl)benzoxazole-2-yl)piperazine-1-carboxylate. ¹H NMR and MS consistent.

[00151] Step B: To an ice-cold solution of *tert*-butyl 3-methyl-4-(4-(quinuclidin-8-ylcarbamoyl)benzoxazole-2-yl)piperazine-1-carboxylate. (90 mg, 0.19 mmol) in CH₂Cl₂ (5 mL) was added TFA(0.25 mL, 3.2 mmol). The reaction mixture was stirred at room temperature for 12 h, and then concentrated under reduced pressure. The resulting TFA salt was converted to (*S*)-*N*-(quinuclidin-8-yl)-2-(2-methylpiperazin-1-yl)benzoxazole-4-carboxamide dihydrochloride following GP-D1. ¹H NMR and MS consistent.

[00152] Example 27: Preparation of *Endo*-*N*-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-2-(pyridine-4-ylamino)benzoxazole-4-carboxamide Dihydrochloride

[00153] Step A: A mixture of methyl 2-chlorobenzoxazole-4-carboxylate (350 mg, 1.65 mmol), 4-aminopyridine (233 mg, 2.48 mmol), palladium(II) acetate (7.4 mg, 0.033 mmol), 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl (39 mg,

0.083mmol), K₂CO₃ (570 mg, 4.13 mmol) and t-BuOH (4 mL) was heated to 90 °C for 40 min. After cooling to room temperature, the reaction mixture was filtered through diatomaceous earth and concentrated. The crude product was purified by column chromatography (silica gel, 9:1 CH₂Cl₂/CH₃OH) to afford methyl 2-(pyridin-4-ylamino)benzoxazole-4-carboxylate. ¹H NMR and MS consistent.

[00154] Step B: 2-(pyridin-4-ylamino)benzoxazole-4-carboxylic acid was synthesized by following general procedure GP-B1. ¹H NMR and MS consistent.

[00155] Step C: Following general procedure GP-C1, a mixture of 2-(pyridin-4-ylamino)benzoxazole-4-carboxylic acid and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to provide *endo*-*N*-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-2-(pyridine-4-ylamino)benzoxazole-4-carboxamide, which was converted to the dihydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00156] Example 28: Preparation of (*S*)-*N*-(quinuclidin-8-yl)-2-(pyridin-4-ylamino)benzoxazole-4-carboxamide Dihydrochloride

[00157] Following general procedure GP-C1, a mixture of 2-(pyridin-4-ylamino)benzoxazole-4-carboxylic acid and (*S*)-(-)-3-aminoquinuclidine dihydrochloride were coupled to provide (*S*)-*N*-(quinuclidin-8-yl)-2-(pyridin-4-ylamino)benzoxazole-4-carboxamide, which was converted to the dihydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00158] Example 29: Preparation of *Endo*-*N*-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-2-(3,4-dihydroquinoxalin-1(2H)-yl)benzoxazole-4-carboxamide Dihydrochloride

[00159] Step A: Methyl-2-(3,4-dihydroquinoxalin-1(2H)-yl)benzoxazole-4-carboxylate was synthesized by following general procedure GP-A. ¹H NMR and MS consistent.

[00160] Step B: 2-(3,4-dihydroquinoxalin-1(2H)-yl)benzoxazole-4-carboxylic acid was synthesized by following general procedure GP-B3. ¹H NMR and MS consistent.

[00161] Step C: Following general procedure GP-C1 a mixture of 2-(3,4-dihydroquinoxalin-1(2H)-yl)benzoxazole-4-carboxylic acid and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to provide *endo*-*N*-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-2-(3,4-dihydroquinoxalin-1(2H)-yl)benzoxazole-4-carboxamide, which was converted to the dihydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00162] Example 30: Preparation of *Endo*-*N*-(9-methyl-3-oxa-9-azabicyclo[3.3.1]non-7-yl)-2-(dimethylamino)benzoxazole-4-carboxamide Hydrochloride

[00163] Following general procedure GP-C1, a mixture of 2-(dimethylamino)benzoxazole-4-carboxylic acid and *endo*-7-amino-9-methyl-3-oxa-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to provide *endo*-*N*-(9-methyl-3-oxa-9-azabicyclo[3.3.1]non-7-yl)-2-(dimethylamino)benzoxazole-4-carboxamide, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00164] Example 31: Preparation of *Endo*-*N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2-(dimethylamino)ethyl)(methyl)amino)benzoxazole-4-carboxamide hydrochloride

[00165] Step A: Methyl 2-((2-(dimethylamino)ethyl)(methyl)amino)benzoxazole-4-carboxylate was synthesized by following general procedure GP-A. ¹H NMR and MS consistent.

[00166] Step B: A solution of methyl methyl 2-((2-(dimethylamino)ethyl)(methyl)amino)benzoxazole-4-carboxylate (620 mg, 1.4 mmol) and lithium hydroxide monohydrate (130 mg, 3.0 mmol) in H₂O (2.5 mL) and THF (15 mL) was stirred at room temperature for 17 h. The THF was removed under

reduced pressure and the residue was diluted with H₂O to 150 mL and then loaded onto an anion exchange column (Bio Rad AG 1-X8 Cl⁻ form, 2.6 meq/g (dry), 5.5 g resin (wet)). The column was washed with H₂O and then eluted with 0.1 N HCl(aq). The product fractions were combined and concentrated. The residue was concentrated with CH₃OH (3 × 15 mL) and then lyophilized to afford 2-((2-(dimethylamino)ethyl)(methyl)amino)benzoxazole-4-carboxylic acid dihydrochloride (273 mg, 58% (2 steps)) as a tan solid. ¹H NMR and MS consistent.

[00167] Step C: Following general procedure GP-C1, a mixture of 2-[(2-(dimethylamino)ethyl)(methyl)amino]benzoxazole-4-carboxylic acid dihydrochloride and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to provide *endo*-*N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-[(2-(dimethylamino)ethyl)(methyl)amino]benzoxazole-4-carboxamide, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00168] Example 32: Preparation of *Endo*-*N*-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-(2-(dimethylamino)ethylamino)benzoxazole-4-carboxamide Trihydrochloride

[00169] Step A: Methyl 2-(2-(dimethylamino)ethylamino)benzoxazole-4-carboxylate was synthesized by following general procedure GP-A. ¹H NMR and MS consistent.

[00170] Step B: A solution of methyl 2-(2-(dimethylamino)ethylamino)benzoxazole-4-carboxylate (570 mg, 1.4 mmol) and lithium hydroxide monohydrate (130 mg, 3.0 mmol) in H₂O (2.5 mL) and THF (15 mL) was stirred at room temperature for 17 h. The THF was removed under reduced pressure, the residue diluted with H₂O to 150 mL and then loaded onto an anion exchange column (Bio Rad AG 1-X8 Cl⁻ form, 2.6 meq/g (dry), 3.5 g resin (wet)). The column was washed with H₂O and then eluted with 0.1 N HCl(aq). The product fractions were combined and concentrated. The residue was concentrated with CH₃OH (3 × 15 mL) and then lyophilized to afford 2-(2-

(dimethylamino)ethylamino)benzoxazole-4-carboxylic acid dihydrochloride (270 mg, 60% (2 steps)) as a tan solid. ¹H NMR and MS consistent.

[00171] Step C: Following general procedure GP-C1, 2-(2-(dimethylamino)ethylamino)benzoxazole-4-carboxylic acid dihydrochloride and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to provide *endo*-N-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-(2-(dimethylamino)ethylamino)benzoxazole-4-carboxamide, which was converted to the trihydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00172] Example 33: Preparation of *Endo*-N-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-(2-morpholinoethylamino)benzoxazole-4-carboxamide Trihydrochloride

[00173] Step A: Methyl 2-(2-morpholinoethylamino)benzoxazole-4-carboxylate was synthesized by following general procedure GP-A. ¹H NMR and MS consistent.

[00174] Step C: A solution of methyl 2-(2-morpholinoethylamino)benzoxazole-4-carboxylate (220 mg, 0.72 mmol) and lithium hydroxide monohydrate (60 mg, 1.44 mmol) in H₂O (1 mL) and THF (10 mL) was stirred at room temperature for 17 h. The THF was removed under reduced pressure and the residue diluted to 150 mL with H₂O and then loaded onto an anion exchange column (Bio Rad AG 1-X8 Cl⁻ form, 2.6 meq/g (dry), 2.5 g resin (wet)). The column was washed with H₂O and then eluted with 0.1 N HCl(aq). The product fractions were combined and concentrated. The residue was concentrated with CH₃OH (3 × 15 mL) and then lyophilized to afford 2-(2-morpholinoethylamino)benzoxazole-4-carboxylic acid hydrochloride (230 mg, 98%) as an off-white solid. ¹H NMR and MS consistent.

[00175] Step D: Following general procedure GP-C1, a mixture of 2-(2-morpholinoethylamino)benzoxazole-4-carboxylic acid hydrochloride and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to provide *endo*-N-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-(2-

morpholinoethylamino)benzoxazole-4-carboxamide, which was converted to the trihydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00176] Example 34: Preparation of *Endo-N*-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-2-(methylamino)benzoxazole-4-carboxamide Hydrochloride

[00177] Step A: Following general procedure GP-A, a mixture of methyl 2-chlorobenzoxazole-4-carboxylate and methylamine was heated to 80 °C in a sealed tube for 4 h to provide methyl 2-(methylamino-4-yl)benzoxazole-4-carboxylate. ¹H NMR and MS consistent.

[00178] Step B: 2-(methylamino)benzoxazole-4-carboxylic acid was synthesized by following general procedure GP-B1. ¹H NMR and MS consistent.

[00179] Step C: Following general procedure GP-C1, a mixture of 2-(methylamino)benzoxazole-4-carboxylic acid and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to provide *endo-N*-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-2-(methylamino)benzoxazole-4-carboxamide, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent

[00180] Example 35: Preparation of *Endo-N*-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-2-aminobenzoxazole-4-carboxamide Hydrochloride

[00181] Step A: To a solution of imidazole (13.63 g, 200 mmol) in CH₂Cl₂ (750 mL) was added cyanogen bromide at room temperature and the resulting mixture was heated to reflux for 45 min. The reaction mixture was cooled to room temperature and the solid obtained was isolated by filtration. The filtrate was concentrated to afford di(1H-imidazole-1-yl)methanimine as a white solid (10.5 g, 97%). ¹H NMR and MS consistent.

[00182] Step B: Synthesis of methyl 2-aminobenzoxazole-4-carboxylate: To a solution of di(1H-imidazole-1-yl)methanimine (2.05 g, 12.26 mmol) in THF (60 mL)

was added methyl-2-amino-3-hydroxybenzoate (1.98 g, 12.26 mmol) at room temperature and the resulting reaction mixture was heated to reflux for 17 h. The reaction mixture was cooled to room temperature, diluted with EtOAc (100 mL) and washed with H₂O (3 × 100 mL), saturated ammonium chloride (2 × 100 mL), dried (Na₂SO₄), filtered and concentrated under reduced pressure. The crude material was purified by recrystallization from diethyl ether to afford methyl 2-aminobenzoxazole-4-carboxylate (1.10 g, 50%) as a brown solid. ¹H NMR and MS consistent.

[00183] Step C: A mixture of methyl 2-aminobenzoxazole-4-carboxylate (750 mg, 3.9 mmol) and di-*tert*-butyldicarbonate (936 mg, 4.29 mmol) in CH₂Cl₂ (50 mL) was stirred at room temperature for 17 h. The reaction was quenched with a saturated NaHCO₃ (25 mL), and then extracted with CH₂Cl₂ (3 × 100 mL). The combined organic phase was washed with H₂O (2 × 75 mL), brine (1 × 50 mL), and dried (Na₂SO₄), filtered and concentrated under reduced pressure. The crude material was purified by column chromatography (silica gel, 9:1, CH₂Cl₂ /CH₃OH) to afford methyl 2-(*tert*-butoxycarbonylamino-4-yl)benzoxazole-4-carboxylate (930 mg, 82%) as a light yellow solid. ¹H NMR and MS consistent.

[00184] Step D: 2-(*tert*-butoxycarbonylamino-4-yl)benzoxazole-4-carboxylic acid was synthesized by following general procedure GP-B1. ¹H NMR and MS consistent.

[00185] Step E: Following general procedure GP-C1, 2-(*tert*-butoxycarbonylamino-4-yl)benzoxazole-4-carboxylic acid and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to provide *endo*-*N*-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-2-aminobenzoxazole-4-carboxamide. ¹H NMR and MS consistent.

[00186] Step F: A solution of *endo*-*N*-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-2-aminobenzoxazole-4-carboxamide (0.20 g, 0.48 mmol), in CH₂Cl₂ (5 mL) was added TFA(4 mL) and stirred at room temperature for 2 h. The reaction mixture was concentrated and the crude material was purified by preparative TLC (90:9:1 CH₂Cl₂/CH₃OH/concentrated NH₄OH) to afford *endo*-*N*-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-2-aminobenzoxazole-4-carboxamide (45 mg, 30%), which

was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00187] Example 36: Preparation of *Endo-N*-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((*S*)-3-ethylmorpholino)benzoxazole-4-carboxamide Hydrochloride

[00188] Step A: To an ice cold, stirred suspension of sodium hydride (60% in oil, 1.6 g, 39.0 mmol) in toluene (50 mL) was added dropwise a solution of (*S*)-2-aminobutan-1-ol (1.5 g, 17.0 mmol) in toluene (36 mL). After the addition was completed, the reaction mixture was warmed to room temperature and a solution of ethyl chloroacetate (2.3 g, 19.0 mmol) in toluene (9 mL) was added in a dropwise manner. The resulting mixture was then stirred at reflux for 20 h, cooled to room temperature, and solid ammonium chloride (2.0 g, 38.7 mmol) added to the reaction. The mixture was stirred for 20 min and then concentrated under reduced pressure. The crude material was purified by column chromatography (silica gel, 95:5 CH₂Cl₂/CH₃OH) to give (*S*)-5-ethylmorpholin-3-one (1.9 g, 88%) as an off-white semi-solid. ¹H NMR consistent.

[00189] Step B: To ice-cold THF (10 mL) was added lithium aluminum hydride (29.0 mL, 1.0 M solution in THF). Once the addition was complete, a solution of (*S*)-5-ethylmorpholin-3-one (1.9 g, 15 mmol) in THF (10 mL) was added dropwise over 20 min. Once the addition was completed, the ice bath was removed and the reaction mixture stirred at reflux for 20 h. The reaction was cooled in an ice-bath and slowly, added dropwise (in a sequential manner) was H₂O (1.2 mL), a 15% solution of sodium hydroxide (1.2 mL), and H₂O (1.2 mL). The resulting mixture was stirred at room temperature for 1 h and then filtered washing the solid with EtOAc (50 mL). The filtrate was concentrated at room temperature under reduced pressure to provide (*S*)-3-ethylmorpholine (1.6 g, 94%) as a clear, colorless oil. ¹H NMR consistent.

[00190] Step C: (*S*)-methyl-2-(3-ethylmorpholino)benzoxazole-4-carboxylate synthesized by following general procedure GP-A. ¹H NMR and MS consistent.

[00191] Step D: (*S*)-2-(3-ethylmorpholino)benzoxazole-4-carboxylic acid was synthesized by following general procedure GP-B3. ¹H NMR consistent.

[00192] Step E: Following general procedure GP-C2, a mixture of (*S*)-2-(3-ethylmorpholino)benzoxazole-4-carboxylic acid and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to provide *endo*-*N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((*S*)-3-ethylmorpholino)benzoxazole-4-carboxamide, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent

[00193] Example 37: Preparation of *Endo*-*N*-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-(9-Methyl-9-azabicyclo[3.3.1]non-3-ylamino)benzoxazole-4-carboxamide Trihydrochloride

[00194] Step A: Methyl-2-(3-amino-9-methyl-9-azabicyclo[3.3.1]nonan-3-ylamino) benzoxazole-4-carboxylate was synthesized by following general procedure GP-A. ¹H NMR and MS consistent.

[00195] Step B: A mixture of methyl-2(3-amino-9-methyl-9-azabicyclo[3.3.1]nonanylamino)benzoxazole-4-carboxylate (0.43 g, 1.74 mmol), lithium hydroxide monohydrate (252 mg, 5.96 mmol) and THF/H₂O (2:1, 15 mL) was stirred at room temperature for 17 h. The reaction mixture was adjusted to pH 10 with 6 N NaOH. A precipitate formed which was filtered to afford sodium-2-(3-amino-9-methyl-9-azabicyclo[3.3.1]nonanylamino)benzoxazole-4-carboxylate. ¹H NMR and MS consistent.

[00196] Step C: Following general procedure GP-C1, *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride and sodium-2-(3-amino-9-methyl-9-azabicyclo[3.3.1]nonanylamino)benzoxazole-4-carboxylate was coupled with *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride to provide of *endo*-*N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-(9-methyl-9-azabicyclo[3.3.1]nonan-3-ylamino)benzoxazole-4-carboxamide, which was converted to the trihydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00197] Example 38: Preparation of *Endo-N*-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-(2-methoxyethylamino)benzoxazole-4-carboxamide Hydrochloride

[00198] Step A: Methyl-2-(2-methoxyethylamino)benzoxazole-4-carboxylate was synthesized by following general procedure GP-A. ¹H NMR and MS consistent.

[00199] Step B: A mixture of methyl-2-(2-methoxyethylamino)benzoxazole-4-carboxylate (0.30 g, 1.19 mmol), potassium trimethylsilanolate (330 mg, 2.63 mmol) and THF (15 mL) was stirred at room temperature for 48 h, additional potassium trimethylsilanolate (75 mg, 0.59 mmol) was added and the mixture heated to reflux for 6 h. The reaction mixture was cooled to 0 °C and treated with HCl (1.0 M solution in diethyl ether, 3.57 mL, 3.57 mmol). The solvent was removed under vacuum and the crude 2-(2-methoxyethylamino)benzoxazole-4-carboxylic acid directly elaborated without further purification: MS consistent.

[00200] Step C: Following general procedure GP-C1, a mixture of 2-(2-methoxyethylamino)benzoxazole-4-carboxylic acid and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to provide *endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-(2-methoxyethylamino)benzoxazole-4-carboxamide, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00201] Example 39: Preparation of *Endo-N*-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-(3-methoxypropylamino)benzoxazole-4-carboxamide Hydrochloride

[00202] Step A: Methyl 2-chlorobenzoxazole-4-carboxylate and 3-methoxypropylamine were converted to methyl-2-(3-methoxypropylamino)benzoxazole-4-carboxylate. ¹H NMR and MS consistent.

[00203] Step B: A mixture of methyl-2-(3-methoxypropylamino)benzoxazole-4-carboxylate (0.30 g, 1.13 mmol), potassium trimethylsilanolate (323 mg, 2.52

mmol) and THF (15 mL) was stirred at room temperature for 17 h, additional potassium trimethylsilanolate (72 mg, 0.56 mmol) was added and the mixture heated to reflux for 6h. The reaction mixture was cooled to 0 °C and treated with HCl (1.0 M solution in diethyl ether, 3.39 mL, 3.39 mmol). The solvent was removed under vacuum and the crude 2-(3-methoxypropylamino)benzoxazole-4-carboxylic acid directly elaborated without further purification: MS consistent.

[00204] Step C: Following general procedure GP-C1, a mixture of 2-(3-methoxypropylamino)benzoxazole-4-carboxylic acid and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride coupled to provide *endo*-*N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-(3-methoxypropylamino)benzoxazole-4-carboxamide, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00205] Example 40: Preparation of *Endo*-*N*-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-(3-hydroxypropylamino)benzoxazole-4-carboxamide Hydrochloride

[00206] Step A: Methyl-2-(3-hydroxypropylamino)benzoxazole-4-carboxylate was synthesized by following general procedure GP-A. ¹H NMR and MS consistent.

[00207] Step B: 2-(3-hydroxypropylamino)benzoxazole-4-carboxylic acid was synthesized by following general procedure GP-B3. MS consistent.

[00208] Step C: Following general procedure GP-C1, a mixture of methyl-2-(3-hydroxypropylamino)benzoxazole-4-carboxylate and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride coupled to provide *endo*-*N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-(3-hydroxypropylamino)benzoxazole-4-carboxamide, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00209] Example 41a and 41b: Preparation of *Endo*-*N*-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-[(*S*)-2-methylpiperazin-1-yl]benzoxazole-4-carboxamide Hydrochloride and *Endo*-*N*-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-[(*R*)-2-methylpiperazin-1-yl]benzoxazole-4-carboxamide Hydrochloride

[00210] Step A: (*S*) or (*R*)-methyl 2-(4-(*tert*-butoxycarbonyl)-2-methylpiperazin-1-yl)benzoxazole-4-carboxylate were synthesized by following general procedure GP-A. ¹H NMR and MS consistent.

[00211] Step B: (*S*) or (*R*)-2-(4-(*tert*-butoxycarbonyl)-2-methylpiperazin-1-yl)benzoxazole-4-carboxylic acid were synthesized by following general procedure GP-B3. ¹H NMR and MS consistent.

[00212] Step C: Following general procedure GP-C1, a mixture of (*S*) or (*R*)-2-(4-(*tert*-butoxycarbonyl)-2-methylpiperazin-1-yl)benzoxazole-4-carboxylic acid and *endo*-*N*-(9-methyl)-9-azabicyclo[3.3.1]nonan-3-amine dihydrochloride salt was coupled to provide (3*S*) or (3*R*)-*tert*-butyl 3-methyl-4-(4-(9-methyl-9-azabicyclo[3.3.1]nonan-3-ylcarbamoyl)benzoxazole-2-yl)piperazine-1-carboxylate. A solution of this material in CH₂Cl₂ (44 mL) at 0 °C was treated with TFA (3.53 mL, 46 mmol) and stirred at room temperature for 12 hours. The mixture was made basic with 2 N NaOH and the aqueous layer extracted with CH₂Cl₂ (3 × 150 mL). The combined organics were dried (MgSO₄), filtered, and concentrated. The crude material was purified by column chromatography (silica gel, 90:10:1 CH₂Cl₂/CH₃OH/concentrated NH₄OH) to provide *endo*-*N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-[(*S*)-2-methylpiperazin-1-yl]benzoxazole-4-carboxamide and *endo*-*N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-[(*R*)-2-methylpiperazin-1-yl]benzoxazole-4-carboxamide. Both enantiomers were converted to the respective hydrochloride salts following general procedure GP-D1. ¹H NMR and MS consistent.

[00213] Example 42: Preparation of *Endo*-*N*-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-(4-(pyrimidin-2-yl)piperazin-1-yl)benzoxazole-4-carboxamide Hydrochloride

[00214] Step A: Methyl 2-(4-(pyrimidin-2-yl)piperazin-1-yl)benzoxazole-4-carboxylate was synthesized by following general procedure GP-A. ¹H NMR and MS consistent.

[00215] Step B: 2-(4-(pyrimidin-2-yl)piperazin-1-yl)benzoxazole-4-carboxylic acid was synthesized by following general procedure GP-B3. ¹H NMR and MS consistent.

[00216] Step C: Following general procedure GP-C1, a mixture of 2-(4-(pyrimidin-2-yl)piperazin-1-yl)benzoxazole-4-carboxylic acid and *endo-N*-(9-methyl)-9-azabicyclo[3.3.1]nonan-3-amine hydrochloride coupled to provide *endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-(4-(pyrimidin-2-yl)piperazin-1-yl)benzoxazole-4-carboxamide, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00217] Example 43: Preparation of *Endo-N*-(3,9-Dimethyl-3,9-diazabicyclo[3.3.1]nonan-7-yl)-2-morpholinobenzoxazole-4-carboxamide Hydrochloride

[00218] Following general procedure GP-C1, a mixture of 2-morpholinobenzoxazole-4-carboxylic acid and *endo*-3,9-dimethyl-3,9-diazabicyclo[3.3.1]nonan-7-amine hydrochloride salt were coupled to provide *N*-(3,9-dimethyl-3,9-diazabicyclo[3.3.1]nonan-7-yl)-2-morpholinobenzoxazole-4-carboxamide, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00219] Example 44: Preparation of *Endo-N*-(9-Methyl-3-oxa-9-azabicyclo[3.3.1]nonan-7-yl)-2-morpholinobenzoxazole-4-carboxamide Hydrochloride

[00220] Following general procedure GP-C1, a mixture of 2-morpholinobenzoxazole-4-carboxylic acid and *endo*-9-methyl-3-oxa-9-azabicyclo[3.3.1]nonan-7-amine hydrochloride were coupled to provide *N*-(9-methyl-3-oxa-9-azabicyclo[3.3.1]nonan-7-yl)-2-morpholinobenzoxazole-4-carboxamide, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00221] Example 45: Preparation of *Endo-N*-(9-Methyl-3-oxa-9-azabicyclo[3.3.1]nonan-7-yl)-2-(phenylamino)benzoxazole-4-carboxamide Hydrochloride

[00222] Following general procedure GP-C1, a mixture of 2-(phenylamino)benzoxazole-4-carboxylic acid and *endo*-9-methyl-3-oxa-9-azabicyclo[3.3.1]nonan-7-amine hydrochloride salt coupled to provide *endo-N*-(9-methyl-3-oxa-9-azabicyclo[3.3.1]nonan-7-yl)-2-(phenylamino)benzoxazole-4-carboxamide, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00223] Example 46: Preparation of *Endo-N*-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((3a*S*,6a*S*)-hexahydropyrrolo[3,4-*b*]pyrrol-5(1*H*)-yl)benzoxazole-4-carboxamide Hydrochloride

[00224] Step A: Following general procedure GP-A, a mixture of methyl 2-chlorobenzoxazole-4-carboxylate and (3*S*),(4*S*)-5-*tert*-butoxycarbonyl-2,5-diazabicyclo[2.2.1]heptane was converted to methyl 2-((1*S*),(4*S*)-5-(*tert*-butoxycarbonyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)benzoxazole-4-carboxylate. ¹H NMR and MS consistent.

[00225] Step B: 2-((1*S*), (4*S*)-5-(*tert*-butoxycarbonyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)benzoxazole-4-carboxylic acid was synthesized by following general procedure GP-B3. ¹H NMR and MS consistent.

[00226] Step C: Following general procedure GP-C1, a mixture of 2-((1*S*), (4*S*)-5-(*tert*-butoxycarbonyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)benzoxazole-4-carboxylic acid and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride coupled to provide *endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((3a*S*,6a*S*)-hexahydropyrrolo[3,4-*b*]pyrrol-5(1*H*)-yl)benzoxazole-4-carboxamide, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00227] Example 47: Preparation of *Endo-N*-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-(2-(dimethylamino)-2-oxoethylamino)benzoxazole-4-carboxamide Dihydrochloride

[00228] Step A: Following general procedure GP-A, a mixture of methyl 2-chlorobenzoxazole-4-carboxylate and 2-amino-*N,N*-dimethylacetamide provided methyl 2-(2-(dimethylamino)-2-oxoethylamino)benzoxazole-4-carboxylate. ¹H NMR and MS consistent.

[00229] Step B: A solution of methyl 2-(2-(dimethylamino)-2-oxoethylamino)benzoxazole-4-carboxylate (465 mg, 1.68 mmol) and lithium hydroxide monohydrate (106 mg, 2.52 mmol) in H₂O (3 mL) and THF (15 mL) was stirred at room temperature for 17 h. The THF was removed under reduced pressure; the residue diluted H₂O to 150 mL and then loaded onto an anion exchange cartridge (Isolute SAX 10 g). The cartridge was washed with H₂O and then eluted with 0.1 N HCl. The product fractions were combined and concentrated. The residue was concentrated with CH₃OH (3 × 15 mL) and then lyophilized from H₂O to afford 2-(2-(dimethylamino)-2-oxoethylamino)benzoxazole-4-carboxylic acid hydrochloride (280 mg, 56%). ¹H NMR and MS consistent.

[00230] Step C: Following general procedure GP-C1, a mixture of 2-(2-(dimethylamino)-2-oxoethylamino)benzoxazole-4-carboxylic acid hydrochloride and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride coupled to provide *endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-(2-(dimethylamino)-2-oxoethylamino)benzoxazole-4-carboxamide, which was converted to the dihydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00231] Example 48: Preparation of *Endo-N*-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((*S*)-3-isopropylmorpholino)benzoxazole-4-carboxamide Hydrochloride

[00232] Step A: To an ice cold, stirred suspension of sodium hydride (60% in oil, 1.3 g, 34.0 mmol) in toluene (45 mL) was added dropwise a solution of (*S*)-2-

amino-3-methylbutan-1-ol (1.5 g, 15.0 mmol) in toluene (30 mL). After the addition was complete, the reaction mixture was warmed to room temperature and a solution of ethyl chloroacetate (2.0 g, 16.0 mmol) in toluene (8 mL) was added in a dropwise manner. The resulting mixture was then stirred at reflux for 20 h, cooled to room temperature, and solid ammonium chloride (1.8 g, 34.0 mmol) added to the reaction. The mixture was stirred for 20 min and then concentrated under reduced pressure. The crude material was purified by column chromatography (silica gel, 95:5 CH₂Cl₂/CH₃OH) to give (*S*)-5-isopropylmorpholin-3-one (1.4 g, 67%) as a light yellow solid. ¹H NMR and MS consistent.

[00233] Step B: To ice-cold THF (6 mL) was added lithium aluminum hydride (1.0 M solution in THF, 18.0 mL, 18.0 mmol). Once the addition was complete, a solution of (*S*)-5-isopropylmorpholin-3-one (1.3 g, 9.0 mmol) in THF (6 mL) was added dropwise over 20 min. Once the addition was completed, the ice bath was removed and the reaction mixture stirred at reflux for 18 h. The reaction was cooled in an ice-bath and to this was slowly added H₂O (0.75 mL), then a 15% aqueous solution of NaOH (0.75 mL), and then H₂O (0.75 mL). The resulting mixture was stirred at room temperature for 1 h and then filtered washing the solid with EtOAc (50 mL). The filtrate was concentrated at room temperature under reduced pressure to provide (*S*)-3-isopropylmorpholine (0.96 g, 83%) as a clear, colorless oil. ¹H NMR and MS consistent.

[00234] Step C: Following general procedure GP-A, (*S*)-methyl-2-(3-isopropylmorpholino)benzoxazole-4-carboxylate and methyl 2-chlorobenzoxazole-4-carboxylate were converted to (*S*)-methyl-2-(3-isopropylmorpholino)benzoxazole-4-carboxylate. ¹H NMR and MS consistent.

[00235] Step D: (*S*)-2-(3-isopropylmorpholino)benzoxazole-4-carboxylic acid was synthesized by following general procedure GP-B3. ¹H NMR and MS consistent.

[00236] Step E: Following general procedure GP-C2, a mixture of (*S*)-2-(3-isopropylmorpholino)benzoxazole-4-carboxylic acid and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to provide of *endo*-*N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((*S*)-3-isopropylmorpholino)benzoxazole-4-

carboxamide, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00237] Example 49: Preparation of *Endo-N*-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((*S*)-3-methylmorpholino)benzoxazole-4-carboxamide Hydrochloride

[00238] Step A: A solution of (*S*)-(+)-2-amino-1-propanol (5.0 g, 67.0 mmol) in toluene (60 mL) was added dropwise at 0 °C to a stirred suspension of NaH (60% in mineral oil, 6.2 g, 145 mmol) in toluene (150 mL). The cooling bath was removed and the reaction mixture was stirred at room temperature for 30 min. A solution of ethyl chloroacetate (8.0 mL, 73.8 mmol) in toluene (60 mL) was then added dropwise at room temperature and the resulting reaction mixture heated at reflux for 20 h. The reaction was cooled to room temperature and solid NH₄Cl (5 g, 96.7 mmol) added to the reaction. The reaction mixture was stirred for 20 min, filtered and the filtrate concentrated under reduced pressure. Purification by column chromatography (silica gel, 94.5:5:0.5 CH₂Cl₂/CH₃OH/NH₄OH) afforded (*S*)-5-methylmorpholin-3-one (6.5 g, 84%) as an off-white semi-solid. ¹H NMR and MS consistent.

[00239] Step B: A solution of (*S*)-5-methylmorpholin-3-one (6.9 g, 59.9 mmol) in THF (40 mL) was added dropwise at 0 °C to a solution of LiAlH₄ (1.0 M solution in THF, 120.0 mL, 120 mmol) in THF (40 mL). The ice bath was removed and the reaction mixture was heated at reflux for 18 h. The reaction was cooled in an ice-bath and excess hydride reagent was quenched by careful, dropwise addition of H₂O (5 mL), 15% aqueous NaOH (5 mL) and H₂O (15 mL). The resulting mixture was stirred at room temperature for 1 h and the reaction mixture was filtered through a pad of diatomaceous earth and the pad rinsed with EtOAc (100 mL). The filtrate was washed with saturated brine solution, dried over Na₂SO₄, filtered and concentrated under reduced pressure to provide (*S*)-3-methylmorpholine as a red oil. Due to the products suspected high volatility, the (*S*)-3-methylmorpholine was used in the next step without further isolation or purification.

[00240] Step C: (*S*)-methyl-2-(3-methylmorpholino)benzoxazole-4-carboxylate was synthesized by following general procedure GP-A. ¹H NMR and MS consistent.

[00241] Step D: A solution of (*S*)-methyl 2-(3-methylmorpholino)benzoxazole-4-carboxylate (0.58 g, 2.1 mmol) in 1,4-dioxane/CH₃OH/H₂O (2:2:1, 8.5 mL) containing lithium hydroxide monohydrate (150 mg, 6.30 mmol) was stirred at room temperature 24 h. The reaction mixture was concentrated under reduced pressure and residual H₂O was azeotropically removed with benzene (2 x 100 mL) to yield lithium (*S*)-2-(3-methylmorpholino)benzoxazole-4-carboxylate as a white solid which was used in the next step without further isolation or purification.

[00242] Step E: Following general procedure GP-C2, a mixture of lithium (*S*)-2-(3-methylmorpholino)benzoxazole-4-carboxylate and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to provide *endo*-*N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((*S*)-3-methylmorpholino)benzoxazole-4-carboxamide, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00243] Example 50: Preparation of *Endo-N*-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2*S**,6*R**)-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxamide Hydrochloride

[00244] Step A: To an ice-cold solution of cis-2,6-dimethylpiperazine (1.50 g, 13.13 mmol), di-*tert*-butyldicarbonate (3.15 g, 14.45 mmol) and 4-dimethylaminopyridine (1.60 g, 13.13 mmol) in CH₂Cl₂ (20 mL) was added diisopropylethylamine (2.17 mL, 13.13 mmol). The mixture was stirred for 10 min then allowed to warm to room temperature for 4 h. The reaction was quenched with saturated NaHCO₃. The aqueous phase was further extracted with Et₂O (2 x 20 mL). The combined organic phase was washed with brine, dried (Na₂SO₄), filtered and concentrated under reduced pressure. The crude product was purified by column chromatography (silica gel, 0 to 10% CH₃OH in CH₂Cl₂) to afford (3*S**,5*R**)-*tert*-

butyl 3,5-dimethylpiperazine-1-carboxylate (2.18g, 77%) as a clear oil. ¹H NMR and MS consistent.

[00245] Step B: Methyl 2-((2S*,6R*)-4-(*tert*-butoxycarbonyl)-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxylate was synthesized by following general procedure GP-A. ¹H NMR and MS consistent.

[00246] Step C: Lithium 2-((2S*,6R*)-4-(*tert*-butoxycarbonyl)-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxylate was synthesized by following general procedure Gp-B2. MS consistent.

[00247] Step D: Following general procedure GP-C1, lithium 2-((2S*,6R*)-4-(*tert*-butoxycarbonyl)-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxylate (109 mg, 0.28 mmol), and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to provide *endo*-(3S*,5R*)-*tert*-butyl 3,5-dimethyl-4-(4-(9-methyl-9-azabicyclo[3.3.1]nonan-3-ylcarbamoyl)benzoxazol-2-yl)piperazine-1-carboxylate, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00248] Examples 51 and 52: Preparation of Exo-*N*-(3,9-Dimethyl-3,9-diazabicyclo[3.3.1]nonan-7-yl)-2-(phenylamino)benzoxazole-4-carboxamide Hydrochloride and *Endo*-*N*-(3,9-Dimethyl-3,9-diazabicyclo[3.3.1]nonan-7-yl)-2-(phenylamino)benzoxazole-4-carboxamide Hydrochloride

[00249] Following general procedure GP-C1, 2-(phenylamino)benzoxazole-4-carboxylic acid (140 mg, 0.551 mmol) and 3,9-dimethyl-3,9-diazabicyclo[3.3.1]nonan-7-amine hydrochloride salt (214 mg, 0.767mmol) were coupled to provide *exo*-*N*-(3,9-dimethyl-3,9-diazabicyclo[3.3.1]nonan-7-yl)-2-(phenylamino)benzoxazole-4-carboxamide hydrochloride and *endo*-*N*-(3,9-dimethyl-3,9-diazabicyclo[3.3.1]nonan-7-yl)-2-(phenylamino)benzoxazole-4-carboxamide, which were converted to their hydrochloride salts following general procedure GP-D1. ¹H NMR and MS consistent.

[00250] Example 53: Preparation of *Endo-N*-(9-Methyl-9-azabicyclo[3.3.1]non-3-yl)-2-((*S*)-2-carbamoylpyrrolidin-1-yl)benzoxazole-4-carboxamide Hydrochloride

[00251] Step A: Following general procedure GP-A, methyl 2-chlorobenzoxazole-4-carboxylate and (*S*)-prolinamide were converted to (*S*)-methyl 2-(2-carbamoylpyrrolidin-1-yl)benzoxazole-4-carboxylate. ¹H NMR and MS consistent.

[00252] Step B: To an ice cold slurry of *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride (93 mg, 0.41 mmol) in CH₂Cl₂ (3 mL) was added trimethylaluminum (2 N in toluene, 0.17 mL, 0.34 mmol) and stirred for 1 h at room temperature. To the reaction mixture was added (*S*)-methyl 2-(2-carbamoylpyrrolidin-1-yl)benzoxazole-4-carboxylate (50 mg, 0.17 mmol) and the resulting reaction mixture was stirred at room temperature for 4 days. The reaction was quenched with CH₃OH (1 mL), adjusted to pH 7 with 6 N HCl and concentrated under reduced pressure. The crude material was purified by preparative TLC (80:12:1.5 CH₂Cl₂/CH₃OH/concentrated NH₄OH) to afford *endo-N*-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-2-((*S*)-2-carbamoylpyrrolidin-1-yl)benzoxazole-4-carboxamide (35 mg, 50%) as a white solid, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00253] Example 54: Preparation of *Endo-N*-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)benzoxazole-4-carboxamide Hydrochloride

[00254] Step A: Following general procedure GP-A except using sodium hydride as base, 3-(trifluoromethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine and methyl 2-chlorobenzoxazole-4-carboxylate (243 mg, 1.15 mmol) were converted to methyl 2-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)benzoxazole-4-carboxylate. ¹H NMR and MS consistent.

[00255] Step B: Lithium 2-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)benzoxazole-4-carboxylate was synthesized by following general procedure GP-B2. MS consistent.

[00256] Step C: Following general procedure GP-C1, lithium 2-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)benzoxazole-4-carboxylate and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to provide *endo*-*N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)benzoxazole-4-carboxamide, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00257] Example 55: Preparation of *Endo*-*N*-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((*S*)-2,4-dimethylpiperazin-1-yl)benzoxazole-4-carboxamide Hydrochloride

[00258] Step A: (*S*)-methyl 2-(4-(*tert*-butoxycarbonyl)-2-methylpiperazin-1-yl)benzoxazole-4-carboxylate was synthesized by following general procedure GP-A. ¹H NMR and MS consistent.

[00259] Step B: (*R*)-2-(4-(*tert*-butoxycarbonyl)-2-methylpiperazin-1-yl)benzoxazole-4-carboxylic acid was synthesized by following general procedure GP-B3. ¹H NMR and MS consistent.

[00260] Step C: Following general procedure GP-C1, (*R*)-2-(4-(*tert*-butoxycarbonyl)-2-methylpiperazin-1-yl)benzoxazole-4-carboxylic acid and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to provide of *endo*-*N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-(3*S*)-(tert-butylbenzoxazole-2-yl)piperazine-1-carboxylate. A solution of this intermediate in CH₂Cl₂ (44 mL) at 0 °C was treated with TFA (3.53 mL, 46 mmol) and stirred at room temperature for 12 h. The mixture was made basic with 2 N NaOH and the aqueous layer extracted with CH₂Cl₂ (3 × 150 mL). The combined organics were dried (MgSO₄), filtered, and concentrated under reduced pressure. The crude material was purified by column chromatography (silica gel, 90:10:1 CH₂Cl₂/CH₃OH/concentrated NH₄OH), to afford *endo*-*N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((*S*)-2-methylpiperazin-1-yl)benzoxazole-4-carboxamide. ¹H NMR and MS consistent.

[00261] Step D: A mixture of *endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((*S*)-2-methylpiperazin-1-yl)benzoxazole-4-carboxamide (44 mg, 0.11 mmol), formaldehyde (37% aqueous solution, 4 mL, 49 mmol), acetic acid (0.5 mL, 8.73 mmol), and sodium cyanoborohydride (14 mg, 0.22 mmol) in CH₃OH (5 mL) was stirred at room temperature for 12 hours. The mixture was concentrated to dryness, rendered basic to pH 12 with 2 N NaOH and extracted with CH₂Cl₂ (2 × 50 mL). The combined organics were washed with brine (5 mL), dried (MgSO₄), filtered, and concentrated under reduced pressure. The crude material was purified by column chromatography (silica gel, 90:10:1 CH₂Cl₂/CH₃OH/concentrated NH₄OH), to afford *endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((*S*)-2,4-dimethylpiperazin-1-yl)benzoxazole-4-carboxamide as an oil (45 mg, 99%). ¹H NMR and MS consistent.

[00262] Step E: Following general procedure GP-D1, *endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((*S*)-2,4-dimethylpiperazin-1-yl)benzoxazole-4-carboxamide was converted to the hydrochloride salt. ¹H NMR and MS consistent.

[00263] Example 56: Preparation of *Endo-N*-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-oxo-2,3-dihydrobenzoxazole-4-carboxamide Hydrochloride

[00264] Step A: To a solution of methyl 2-chlorobenzoxazole-4-carboxylate (100 mg, 0.47 mmol) in THF (6 mL) was added a solution of lithium hydroxide monohydrate (29.7 mg, 0.71 mmol) in H₂O (3 mL). The reaction mixture was stirred at room temperature for 18 h and then concentrated to dryness to afford lithium 2-oxo-2, 3-dihydrobenzoxazole-4-carboxylate (130 mg, 100%) as a yellow solid that was directly used in the next step without purification. MS consistent

[00265] Step B: Following general procedure GP-C1, lithium 2-oxo-2, 3-dihydrobenzoxazole-4-carboxylate and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to afford *endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-oxo-2,3-dihydrobenzoxazole-4-carboxamide, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00266] Example 57: Preparation of *Endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-6-chloro-2-((*S*)-2-methylpiperazin-1-yl)benzoxazole-4-carboxamide Hydrochloride

[00267] Step A: (*S*)-methyl 2-(4-(*tert*-butoxycarbonyl)-2-methylpiperazin-1-yl)-6-chlorobenzoxazole-4-carboxylate was synthesized by following general procedure GP-A. ¹H NMR and MS consistent.

[00268] Step B: (*S*)-2-(4-(*tert*-butoxycarbonyl)-2-methylpiperazin-1-yl)-6-chlorobenzoxazole-4-carboxylic acid was synthesized by following general procedure GP-B3. ¹H NMR and MS consistent.

[00269] Step C: Following general procedure GP-C1, (*S*)-2-(4-(*tert*-butoxycarbonyl)-2-methylpiperazin-1-yl)-6-chlorobenzoxazole-4-carboxylic acid and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to afford *endo-N*-(3,9-dimethyl-3,9-diazabicyclo[3.3.1]nonan-7-ylcarbamoyl)benzoxazol-2-yl)-(3*S*)-*tert*-butyl 4-(6-chloro-4-(3-methylpiperazine)-1-carboxylate. The intermediate (410 mg, 0.79 mmol) was dissolved in CH₂Cl₂ (10 mL) and treated with TFA (609 mL, 7.9 mmol) at 0 °C. The mixture stirred at room temperature for 12 h. The mixture was made basic with 2 N NaOH and the aqueous layer extracted with CH₂Cl₂ (3 × 150 mL). The combined organics were dried (MgSO₄), filtered, and concentrated. The crude material was purified by column chromatography (silica gel, 90:10:1 CH₂Cl₂/CH₃OH/concentrated NH₄OH) to afford *endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-6-chloro-2-((*S*)-2-methylpiperazin-1-yl)benzoxazole-4-carboxamide, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00270] Example 58: Preparation of *Endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-6-chloro-2-(4-methylpiperazin-1-yl)benzoxazole-4-carboxamide Hydrochloride

[00271] Step A: Methyl 6-chloro-2-(4-methylpiperazin-1-yl)benzoxazole-4-carboxylate was synthesized by following general procedure GP-A except that the reaction was conducted at ambient temperature for 12 h. ¹H NMR and MS consistent.

[00272] Step B: 6-chloro-2-(4-methylpiperazin-1-yl)benzoxazole-4-carboxylic acid was synthesized by following general procedure GP-B3. ¹H NMR and MS consistent.

[00273] Step C: Following general procedure GP-C1, 6-chloro-2-(4-methylpiperazin-1-yl)benzoxazole-4-carboxylic acid and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled provide *endo* *N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-6-chloro-2-(4-methylpiperazin-1-yl)benzoxazole-4-carboxamide, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00274] Example 59: Preparation of *Endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-(4-methoxyphenylamino)benzoxazole-4-carboxamide Hydrochloride

[00275] Step A: Methyl 2-(4-methoxyphenylamino)benzoxazole-4-carboxylate oil was synthesized by following general procedure GP-A. ¹H NMR and MS consistent.

[00276] Step B: 2-(4-methoxyphenylamino)benzoxazole-4-carboxylic acid was synthesized by following general procedure GP-B3. ¹H NMR and MS consistent.

[00277] Step C: Following general procedure GP-C1 2-(4-methoxyphenylamino)benzoxazole-4-carboxylic acid and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to afford *endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-(4-methoxyphenylamino)benzoxazole-4-carboxamide, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS were consistent.

[00278] Example 60: Preparation of *Endo N*-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2*S**,5*R**)-2,5-dimethylpiperazin-1-yl)benzoxazole-4-carboxamide Hydrochloride

[00279] Step A: Following general procedure GP-A, methyl 2-chlorobenzoxazole-4-carboxylate and ($\pm$) trans-1-allyl-2,5-dimethylpiperazine were converted to methyl 2-(4-allyl-(2R*,5S*)-dimethylpiperazin-1-yl)benzoxazole-4-carboxylate. ^1H NMR and MS consistent.

[00280] Step B: 2-(4-allyl-(2R*,5S*)-dimethylpiperazin-1-yl)benzoxazole-4-carboxylic acid was synthesized by following general procedure GP-B3. MS consistent.

[00281] Step C: Following general procedure GP-C1 2-(4-Allyl-(2R*,5S*)-dimethylpiperazin-1-yl)benzoxazole-4-carboxylic acid and 3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to afford *endo* N-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2S*,5R*)-4-allyl-2,5-dimethylpiperazin-1-yl)benzoxazole-4-carboxamide. ^1H NMR and MS were consistent.

[00282] Step D: A solution of *endo* N-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2S*,5R*)-4-allyl-2,5-dimethylpiperazin-1-yl)benzoxazole-4-carboxamide (200 mg, 0.44 mmol), barbituric acid (337 mg, 2.64 mmol) and tetrakis(triphenylphosphine)palladium(0) (25 mg/0.022mmol, 5 mol%) in the mixture of THF/DMF (2:1, 30mL) was stirred for 17 h at 60 °C under an atmosphere of argon. The mixture was poured into saturated NaHCO_3 (100 mL) and extracted with EtOAc (3×50 mL). The combined organic phase was washed sequentially with brine (100 mL), H_2O (100 mL), dried (Na_2SO_4), filtered and concentrated. The crude material was purified twice by column chromatography (silica gel, 100% CH_2Cl_2 to 20:76.5:3.5 $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}/\text{NH}_4\text{OH}$) to afford *endo*-N-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2S*,5R*)-2,5-dimethylpiperazin-1-yl)benzoxazole-4-carboxamide (34 mg, 17%) as a yellow film. ^1H NMR and MS consistent.

[00283] Step E: *Endo* N-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2S*,5R*)-2,5-dimethylpiperazin-1-yl)benzoxazole-4-carboxamide was converted into the dihydrochloride salt following general procedure GP-D1. ^1H NMR and MS consistent.

[00284] Example 61: Preparation of *Endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-(3-hydroxybutylamino)benzoxazole-4-carboxamide Hydrochloride

[00285] Step A: To a solution of 2-hydroxybutylamine (4.00 g, 44.87 mmol) in anhydrous DMF (25 mL) was added *tert*-butyldiphenylsilylchloride (16.9 mL, 66.19 mmol) and imidazole (9.16 g, 13.46 mmol). The reaction mixture was stirred at room temperature for 2 days, then concentrated under reduced pressure, and diluted with CH₂Cl₂ (150 mL). The organics were washed with 5% aqueous NaHCO₃ solution (50 mL), brine (50 mL), dried (MgSO₄), filtered, and concentrated. The crude material was purified by column chromatography (0 to 100% EtOAc in hexane) to give 3-(*tert*-butyldiphenylsilyloxy)butan-1-amine (8.00 g, 54%) as a white solid. ¹H NMR and MS consistent.

[00286] Step B: Methyl 2-(3-(*tert*-butyldiphenylsilyloxy)butylamino)benzoxazole-4-carboxylate was synthesized by following general procedure GP-A. ¹H NMR and MS consistent.

[00287] Step C: 2-(3-(*tert*-butyldiphenylsilyloxy)butylamino)benzoxazole-4-carboxylic acid was synthesized by following general procedure GP-B3. ¹H NMR and MS consistent.

[00288] Step D: Following general procedure GP-C1, 2-(3-(*tert*-Butyldiphenylsilyloxy)butylamino)benzoxazole-4-carboxylic acid and *endo*-9-methyl-9-azabicyclo[3.3.1]nonan-3-amine hydrochloride salt were coupled to afford *endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-(3-(*tert*-butyldiphenylsilyloxy)butylamino)-benzoxazole-4-carboxamide. ¹H NMR and MS consistent.

[00289] Step E: To a solution *endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-(3-(*tert*-butyldiphenylsilyloxy)butylamino)-benzoxazole-4-carboxamide (553 mg, 0.89 mmol) in THF (10 mL) was added a 1M solution TBAF in diethylether (2.65 mL, 2.65 mmol). The reaction mixture stirred at room temperature for 24 h, then concentrated and diluted with CH₂Cl₂ (250 mL). The organics were washed with

saturated NH₄Cl (50 mL) and brine (50 mL), dried (MgSO₄), filtered, and concentrated under reduced pressure. The crude material was purified by column chromatography (silica gel, 90:10:1 CH₂Cl₂/CH₃OH/concentrated NH₄OH) to afford *endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-(3-hydroxybutylamino)benzoxazole-4-carboxamide (342 mg, 99%) as a white solid. ¹H NMR and MS consistent.

[00290] Step F: *endo-N*-2-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-(3-hydroxybutylamino)benzoxazole-4-carboxamide was converted into the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00291] Example 62: Preparation of *Endo-N*-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-6-chloro 2-((*S*)-3-ethylmorpholino)benzoxazole-4-carboxamide Hydrochloride

[00292] Step A: To an ice cold, stirred suspension of NaH(60% in oil, 1.6 g, 39.0 mmol) in toluene (50 mL) was added dropwise a solution of (*S*)-2-aminobutan-1-ol (1.5 g, 17.0 mmol) in toluene (36 mL). After the addition was completed, the reaction mixture was warmed to room temperature and a solution of ethyl chloroacetate (2.3 g, 19.0 mmol) in toluene (9 mL) was added in a dropwise manner. The resulting mixture was then stirred at reflux for 20 h, cooled to room temperature, and solid NH₄Cl (2.0 g, 38.7 mmol) was added to the reaction. The mixture was stirred for 20 min and then concentrated under reduced pressure. The crude material was purified by column chromatography (silica gel, 95:5 methylene chloride/CH₃OH) to give (*S*)-5-ethylmorpholin-3-one (1.9 g, 88%) as an off-white semi-solid: ¹H NMR and MS consistent.

[00293] Step B: To ice-cold THF (10 mL) was added LiAlH₄ (29.0 mL, 1.0 M solution in THF). Once the addition was complete, a solution of (*S*)-5-ethylmorpholin-3-one (1.9 g, 15 mmol) in THF (10 mL) was added dropwise over 20 min. Once the addition was completed, the ice bath was removed and the reaction mixture stirred at reflux for 20 h. The reaction was cooled in an ice-bath and slowly, added dropwise (in a sequential manner) was H₂O (1.2 mL), a 15% solution of sodium hydroxide (1.2 mL), and H₂O (1.2 mL). The resulting mixture was stirred at room temperature for 1 h and then filtered washing the solid with EtOAc (50 mL).

The filtrate was concentrated at room temperature under reduced pressure to provide (*S*)-3-ethylmorpholine (1.6 g, 94%) as a clear, colorless oil: ¹H NMR and MS consistent.

[00294] Step C: Following general procedure GP-A, (*S*)-3-ethylmorpholine and methyl 2,6-dichlorobenzoxazole-4-carboxylate were coupled to provide (*S*)-methyl 6-chloro-2-(3-ethylmorpholino)benzoxazole-4-carboxylate. MS consistent.

[00295] Step D: (*S*)-6-chloro-2-(3-ethylmorpholino)benzoxazole-4-carboxylic acid was synthesized by following general procedure GP-B3. MS consistent.

[00296] Step E: Following general procedure GP-C2, (*S*)-6-chloro-2-(3-ethylmorpholino)benzoxazole-4-carboxylic acid and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to provide *-endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-6-chloro-2-((*S*)-3-ethylmorpholino)benzoxazole-4-carboxamide, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent

[00297] Example 63: Preparation of *Endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-6-chloro-2-((*S*)-2,4-dimethylpiperazin-1-yl)benzoxazole-4-carboxamide Hydrochloride

[00298] Step A: Following general procedure GP-A, methyl 2,6-dichlorobenzoxazole-4-carboxylate and N-Boc-(*S*)-4-methylpiperazine were converted to (*S*)-methyl 2-(4-(*tert*-butoxycarbonyl)-2-methylpiperazin-1-yl)-6-chlorobenzoxazole-4-carboxylate. ¹H NMR and MS were consistent.

[00299] Step B: (*S*)-2-(4-(*tert*-butoxycarbonyl)-2-methylpiperazin-1-yl)-6-chlorobenzoxazole-4-carboxylic acid was synthesized by following general procedure GP B3. ¹H NMR and MS consistent.

[00300] Step C: Following general procedure GP-C2, (*S*)-2-(4-(*tert*-butoxycarbonyl)-2-methylpiperazin-1-yl)-6-chlorobenzoxazole-4-carboxylic acid and *endo*-9-methyl-9-azabicyclo[3.3.1]nonan-3-amine hydrochloride salt were coupled to

provide *endo-N*-(3,9-dimethyl-3,9-diazabicyclo[3.3.1]nonan-7-ylcarbamoyl)benzoxazol-2-yl)-(3*S*)-*tert*-butyl 4-(6-chloro-4-(3-methylpiperazine)-1-carboxylate. This material (410 mg, 0.79 mmol) was dissolved in CH₂Cl₂ (10 mL) at 0 °C, treated with TFA (609 mL, 7.9 mmol) and stirred at room temperature for 12 h. The mixture was made basic with 2 N NaOH and the aqueous layer extracted with CH₂Cl₂ (3 × 150 mL). The combined organics were dried (MgSO₄), filtered, and concentrated. The crude material was purified by column chromatography (silica gel, 90:10:1 CH₂Cl₂/CH₃OH/concentrated NH₄OH) to afford *endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-6-chloro-2-((*S*)-2-methylpiperazin-1-yl)benzoxazole-4-carboxamide. ¹H NMR and MS were consistent.

[00301] Step D: A mixture of *endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-6-chloro-2-((*S*)-2-methylpiperazin-1-yl)benzoxazole-4-carboxamide (60 mg, 0.14 mmol), formaldehyde (37% aqueous solution, 4 mL, 49 mmol), HOAc (0.5 mL, 8.73 mmol), and NaCNBH₃ (17 mg, 0.28 mmol) in CH₃OH (5 mL) was stirred at room temperature for 12 h. The mixture was concentrated to dryness, made basic to pH 12 with 2 N NaOH, and extracted with CH₂Cl₂ (2 × 70 mL). The combined organics were washed with brine (5 mL), dried (MgSO₄), filtered, and concentrated under reduced pressure. The crude material was purified by column chromatography (silica gel, 90:10:1 CH₂Cl₂/CH₃OH/concentrated NH₄OH), to afford *endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-6-chloro-2-((*S*)-2,4-dimethylpiperazin-1-yl)benzoxazole-4-carboxamide which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00302] Example 64: Preparation of *Endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-(2-methoxyphenylamino)benzoxazole-4-carboxamide Hydrochloride

[00303] Step A: Methyl 2-(2-methoxyphenylamino)benzoxazole-4-carboxylate was synthesized by following general procedure GP-A. ¹H NMR and MS consistent.

[00304] Step B: 2-(2-methoxyphenylamino)benzoxazole-4-carboxylic acid was synthesized by following general procedure GP-B3.

[00305] Step C: Following general procedure GP-C1, 2-(2-methoxyphenylamino)benzoxazole-4-carboxylic acid and *endo*-9-methyl-9-azabicyclo[3.3.1]nonan-3-amine dihydrochloride were coupled to provide *endo*-N-9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-(2-methoxyphenylamino)benzoxazole-4-carboxamide, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00306] Example 65: Preparation of *Endo*-N-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((*R*)-3-methylmorpholino)benzoxazole-4-carboxamide

[00307] Step A: Glacial HOAc (1.5 mL) was added dropwise at room temperature to a well stirred solution of (*R*)-(+)-2-amino-1-propanol (10.0 g, 133 mmol) and benzaldehyde (13.5 mL, 133 mmol) in CH₃OH (260 mL). The reaction mixture was stirred at room temperature for 1.5 h followed by addition of NaCNBH₃ (12.6 g, 200 mmol) and the reaction stirred at room temperature overnight. The reaction was concentrated under reduced pressure and the recovered solids dissolved in EtOAc (500 mL) and then washed with saturated bicarbonate (2 × 250 mL), H₂O (250 mL) and saturated brine (250 mL). The organic phase was then dried over Na₂SO₄, filtered and concentrated to yield (*R*)-2-(benzylamino)propan-1-ol (19.8 g, 94%) as a colorless oil: MS consistent.

[00308] Step B: Chloroacetyl chloride (11.6 mL, 120 mmol) was added dropwise at 0 °C to a solution of (*R*)-2-(benzylamino)propan-1-ol (19.9 g, 120 mmol) and triethylamine (30.5 mL) in toluene (600 mL). The cooling bath was removed and the reaction mixture was stirred at room temperature for 18 h. The reaction was concentrated under reduced pressure and the recovered solids dissolved in EtOAc (500 mL) and then washed with saturated bicarbonate (2 × 250 mL), H₂O (250 mL) and saturated brine (250 mL). The organic phase was then dried (Na₂SO₄), filtered and concentrated to afford (*R*)-2-(2-(benzylamino)propoxy)acetyl chloride: MS consistent.

[00309] Step C: (*R*)-2-(2-(benzylamino)propoxy)acetyl chloride was dissolved in *tert*-butanol (500 mL). Sodium *tert*-butoxide (14.0 g, 125 mmol) was then added in one portion and the reaction mixture heated at reflux for 18 h. The reaction was

cooled and concentrated under reduced pressure to remove the solvent. The residue was dissolved in diethyl ether (300 mL) and then washed with 2 N HCl (150 mL), H₂O (150 mL) and saturated brine (100 mL). The organic phase was then dried (Na₂SO₄), filtered, and concentrated under reduced pressure to afford a light yellow oil. Purification by column chromatography (silica gel, 10-50% EtOAc in heptanes) afforded (*R*)-4-benzyl-5-methylmorpholin-3-one (17.2 g, 63%) as a light yellow oil. ¹H NMR and MS consistent.

[00310] Step D: A solution of (*R*)-4-benzyl-5-methylmorpholin-3-one (3.0 g, 14.22 mmol) in THF (10 mL) was added dropwise at 0 °C to a solution of lithium aluminum hydride (1.0 M solution in THF, 28.5 mL, 28.5 mmol) in THF (10 mL). The ice bath was removed and the reaction mixture was heated at reflux for 18 h. The reaction was cooled in an ice-bath and excess hydride reagent was quenched by careful, dropwise addition of H₂O (5 mL), 15% sodium hydroxide (5 mL) and H₂O (15 mL). The resulting mixture was stirred at room temperature for 1 h and the reaction mixture was filtered through a pad of Celite and the pad rinsed with EtOAc (100 mL). The filtrate was washed with saturated brine solution, dried (Na₂SO₄), filtered and concentrated under reduced pressure to provide (*R*)-4-benzyl-3-methylmorpholine (2.66 g, 95%) as a red oil. ¹H NMR and MS consistent.

[00311] Step E: To a solution of (*R*)-4-benzyl-3-methylmorpholine (1.0 g, 5.07 mmol) in EtOAc (40 mL) containing a catalytic amount of HCl (4 M solution in 1,4-dioxane, 2 drops) was added 10% palladium on carbon (400 mg) and the solution agitated in a Parr apparatus under an atmosphere of hydrogen (40 psi) for 18 h. The reaction mixture was filtered through a pad of Celite and the filter cake washed with additional EtOAc. Careful concentration of the filtrate under reduced pressure afforded (*R*)-3-methylmorpholine as a yellow oil, which was used in the next step without further isolation or purification.

[00312] Step F: Synthesis of (*R*)-methyl-2-(3-methylmorpholino)benzoxazole-4-carboxylate: Following general procedure GP-A except using triethylamine as base, (*R*)-3-methylmorpholine and methyl 2-chlorobenzoxazole-4-carboxylate were converted to (*R*)-methyl-2-(3-methylmorpholino)benzoxazole-4-carboxylate. ¹H NMR and MS consistent.

[00313] Step G: Synthesis of lithium (*R*)-2-(3-methylmorpholino)benzoxazole-4-carboxylate: Following general procedure GP-B2, (*R*)-methyl 2-(3-methylmorpholino)benzoxazole-4-carboxylate was converted to lithium (*R*)-2-(3-methylmorpholino)benzoxazole-4-carboxylate, which was used without further isolation or purification. MS consistent.

[00314] Step H: Following general procedure GP-C2, lithium (*R*)-2-(3-methylmorpholino)benzoxazole-4-carboxylate and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride (0.856 g, 3.76 mmol) were coupled to provide *endo*-*N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((*R*)-3-methylmorpholino)benzoxazole-4-carboxamide. MS consistent.

[00315] Step I: To a solution of *endo*-*N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((*R*)-3-methylmorpholino)benzoxazole-4-carboxamide (0.070 g, 0.175 mmol) in 1,4-dioxane (15 mL) was added HCl (4.0 M solution in 1,4-dioxane 5.0 mL, 5.0 mmol) in a dropwise manner. The resulting mixture was stirred at room temperature for 3 h and then filtered. The recovered hygroscopic solid was then dissolved in acetonitrile/H₂O (1:10, 10 mL) and lyophilized 3 times to afford a viscous oil. This material was then dried under high vacuum for 72 h at 60 °C in the presence of phosphorous pentoxide to afford a brown glassy solid which, when scratched from the sides of the flask, afforded *endo*-*N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((*R*)-3-methylmorpholino)benzoxazole-4-carboxamide hydrochloride (0.050 g, 95%) as a hygroscopic brown solid. ¹H NMR and MS consistent.

[00316] Example 66: Preparation of *Endo*-*N*-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((*S*)-3-propylmorpholino)benzoxazole-4-carboxamide Hydrochloride

[00317] Step A: To an ice cold, stirred suspension of NaH (60% in oil, 1.9 g, 46.0 mmol) in toluene (62 mL) was added dropwise a solution of (*S*)-2-aminopentan-1-ol (2.1 g, 20.0 mmol) in toluene (44 mL). After the addition was completed, the reaction mixture was warmed to room temperature and a solution of ethyl chloroacetate (2.7 g, 22.0 mmol) in toluene (12 mL) was added in a dropwise manner.

The resulting mixture was then stirred at reflux for 20 h, cooled to room temperature, and solid ammonium chloride (2.5 g, 46.0 mmol) was added to the reaction. The mixture was stirred for 20 min and then concentrated under reduced pressure. The crude material was purified by column chromatography (silica gel, 98:2 CH₂Cl₂/CH₃OH to 95:5 CH₂Cl₂/CH₃OH) to give (*S*)-5-propylmorpholin-3-one (2.2 g, 76%) as a yellow oil. To ice-cold THF (10 mL) was added lithium aluminum hydride (1.0 M solution in THF, 30 mL, 30 mmol). Once the addition was complete, a solution of (*S*)-5-propylmorpholin-3-one (2.2 g, 15 mmol) in THF (10 mL) was added dropwise over 20 min. Once the addition was completed, the ice bath was removed and the reaction mixture stirred at reflux for 20 h. The reaction was cooled in an ice-bath and to this was slowly added H₂O (1.2 mL), then 15% aqueous solution of sodium hydroxide (1.2 mL), and then H₂O (1.2 mL). The resulting mixture was stirred at room temperature for 1.5 h and then filtered washing the solid with EtOAc (50 mL). The filtrate was concentrated at room temperature under reduced pressure to provide (*S*)-3-propylmorpholine (1.9 g, 98%) as a light yellow oil. ¹H NMR and MS consistent.

[00318] Step B: (*S*)-methyl-2-(3-propylmorpholino)benzoxazole-4-carboxylate was synthesized by following general procedure GP-A. MS consistent.

[00319] Step C: (*S*)-2-(3-propylmorpholino)benzoxazole-4-carboxylic acid was synthesized by following general procedure GP-B3. MS consistent.

[00320] Step D: Following general procedure GP-C3, (*S*)-2-(3-propylmorpholino)benzoxazole-4-carboxylic acid and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to provide *endo*-*N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((*S*)-3-propylmorpholino)benzoxazole-4-carboxamide, which was converted to the hydrochloric acid salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00321] Example 67: Preparation of *Endo*-*N*-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((*S*)-3-isobutylmorpholino)benzoxazole-4-carboxamide Hydrochloride

[00322] Step A: To an ice cold, stirred suspension of NaH (60% in oil, 1.6 g, 39.0 mmol) in toluene (53 mL) was added dropwise a solution of (*S*)-2-amino-4-methylpentan-1-ol (2.0 g, 17.0 mmol) in toluene (37 mL). After the addition was completed, the reaction mixture was warmed to room temperature and a solution of ethyl chloroacetate (2.3 g, 19.0 mmol) in toluene (10 mL) was added in a dropwise manner. The resulting mixture was then stirred at reflux for 20 h, cooled to room temperature, and solid ammonium chloride (2.1 g, 39.0 mmol) was added to the reaction. The mixture was stirred for 20 min and then concentrated under reduced pressure. The crude material was purified by column chromatography (silica gel, 98:2 CH₂Cl₂/CH₃OH to 95:5 CH₂Cl₂/CH₃OH) to give (*S*)-5-iso-butylmorpholin-3-one (1.9 g, 70%) as a light yellow oil. To ice-cold THF (8 mL) was added lithium aluminum hydride (1.0 M solution in THF, 23.0 mL, 23.0 mmol). Once the addition was complete, a solution of (*S*)-5-iso-butylmorpholin-3-one (1.8 g, 12.0 mmol) in THF (7.0 mL) was added dropwise over 20 min. Once the addition was completed, the ice bath was removed and the reaction mixture stirred at reflux for 20 h. The reaction was cooled in an ice-bath and to this was slowly added H₂O (1.2 mL), then 15% aqueous solution of sodium hydroxide (1.2 mL), and then H₂O (1.2 mL). The resulting mixture was stirred at room temperature for 1.5 h and then filtered washing the solids with EtOAc (50 mL). The filtrate was concentrated at room temperature under reduced pressure to provide (*S*)-3-iso-butylmorpholine (1.6 g, 95%) as a light yellow oil. ¹H NMR and MS consistent.

[00323] Step B: Following general method GP-A, (*S*)-3-iso-butylmorpholine (0.38 g, 2.6 mmol) and methyl 2-chlorobenzoxazole-4-carboxylate were converted to (*S*)-methyl-2-(3-iso-butylmorpholino)benzoxazole-4-carboxylate. MS consistent.

[00324] Step C: (*S*)-2-(3-iso-butylmorpholino)benzoxazole-4-carboxylic acid was synthesized by following general method GP-B3. MS consistent.

[00325] Step D: Following general method GP-C1, (*S*)-2-(3-iso-butylmorpholino)benzoxazole-4-carboxylic acid and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to provide *endo*-*N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((*S*)-3-iso-butylmorpholino)benzoxazole-4-carboxamide, which was converted to the hydrochloride salt following general

procedure GP-D1. ¹H NMR and MS consistent.

[00326] Example 68: Preparation of *Endo-N*-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((*S*)-3-*tert*-butylmorpholino)benzoxazole-4-carboxamide Hydrochloride

[00327] Step A: To an ice cold, stirred suspension of NaH (60% in oil, 1.6 g, 39.0 mmol) in toluene (53 mL) was added dropwise a solution of (*S*)-2-amino-4,5-dimethylpentan-1-ol (2.0 g, 17.0 mmol) in toluene (37 mL). After the addition was completed, the reaction mixture was warmed to room temperature and a solution of ethyl chloroacetate (2.3 g, 19.0 mmol) in toluene (10 mL) was added in a dropwise manner. The resulting mixture was then stirred at reflux for 20 h, cooled to room temperature, and solid ammonium chloride (2.1 g, 39.0 mmol) was added to the reaction. The mixture was stirred for 20 min and then concentrated under reduced pressure. The crude material was purified by column chromatography (silica gel, 98:2 CH₂Cl₂/CH₃OH to 95:5 CH₂Cl₂/CH₃OH) to give (*S*)-5-*tert*-butylmorpholin-3-one (2.0 g, 74%) as a light yellow solid. To ice-cold THF (9 mL) was added LiAlH₄ (1.0 M solution in THF, 26.0 mL, 26.0 mmol). Once the addition was complete, a solution of (*S*)-5-*tert*-butylmorpholin-3-one (2.0 g, 13.0 mmol) in THF (8.0 mL) was added dropwise over 20 min. Once the addition was completed, the ice bath was removed and the reaction mixture stirred at reflux for 20 h. The reaction was cooled in an ice-bath and to this was slowly added H₂O (1.2 mL), then 15% aqueous solution of sodium hydroxide (1.2 mL), and then H₂O (1.2 mL). The resulting mixture was stirred at room temperature for 1.5 h and then filtered washing the solids with EtOAc (50 mL). The filtrate was concentrated at room temperature under reduced pressure to provide (*S*)-3-*tert*-butylmorpholine (1.7 g, 97%) as a light yellow oil. ¹H NMR and MS consistent.

[00328] Step B: Following general procedure GP-A, (*S*)-3-*tert*-butylmorpholine (0.38 g, 2.6 mmol) and methyl 2-chlorobenzoxazole-4-carboxylate (0.28 g, 1.3 mmol) were converted to (*S*)-methyl-2-(3-*tert*-butylmorpholino)benzoxazole-4-carboxylate. MS consistent.

[00329] Step C: (*S*)-2-(3-*tert*-butylmorpholino)benzoxazole-4-carboxylic acid was synthesized by following general procedure GP-B3. MS consistent.

[00330] Step D: Following general procedure GP-C1, (*S*)-2-(3-*tert*-butylmorpholino)benzoxazole-4-carboxylic acid and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to provide *endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((*S*)-3-*tert*-butylmorpholino)benzoxazole-4-carboxamide, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00331] Example 69: Preparation of *Endo-N*-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2*R*,6*R*)-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxamide Hydrochloride

[00332] Step A: To a solution of (2*R*,6*R*)-2,6-dimethylpiperazine dihydrochloride (1.60 g, 8.55 mmol), in CH₂Cl₂ (15 mL) at room temperature was added triethylamine (2.50 mL, 17.95 mmol) followed by di-*tert* butyldicarbonate (2.05 g, 9.40 mmol) and the reaction mixture was allowed to stir at room temperature 48 h. The reaction mixture was partitioned between EtOAc (20 mL) and saturated NaHCO₃ (20 mL). The aqueous phase was further extracted with EtOAc (2 x 20 mL). The combined organic phase was washed with brine (20 mL) and dried (Na₂SO₄). The crude product was purified by column chromatography (silica gel, 3 to 10% CH₃OH in CH₂Cl₂) to afford (3*R*,5*R*)-*tert*-butyl 3,5-dimethylpiperazine-1-carboxylate (1.17 g, 64%) as a clear oil. ¹H NMR and MS consistent.

[00333] Step B: Following general procedure GP-A except that the reaction was heated in DMF at 40°C, (3*R*,5*R*)-*tert*-butyl 3,5-dimethylpiperazine-1-carboxylate (500 mg, 2.33 mmol) and methyl 2-chlorobenzoxazole-4-carboxylate were converted to methyl 2-((2*R*,6*R*)-4-(*tert*-butoxycarbonyl)-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxylate. ¹H NMR and MS consistent.

[00334] Step C: Following general procedure GP-B2, methyl 2-((2*R*,6*R*)-4-(*tert*-butoxycarbonyl)-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxylate was

converted to lithium 2-((2R,6R)-4-(*tert*-butoxycarbonyl)-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxylate. MS consistent.

[00335] Step D: Following general procedure GP-C2 at 40°C, lithium 2-((2R,6R)-4-(*tert*-butoxycarbonyl)-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxylate and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to provide *endo*-*N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2R,6R)-4-(*tert*-butoxycarbonyl)-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxylate. ¹H NMR and MS consistent.

[00336] Step E: To solution of *endo*-*N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2R,6R)-4-(*tert*-butoxycarbonyl)-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxylate (387 mg, 0.756 mmol) in CH₂Cl₂/dioxane/CH₃OH (2:1:1, 8 mL) was added HCl (4 M in dioxane, 3.78 mL, 15.12 mmol) and the mixture was stirred at room temperature for 24 h then concentrated under reduced pressure. The amorphous solid was lyophilized from acetonitrile/H₂O (10:1, 22 mL) to afford *endo*-*N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2R,6R)-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxamide dihydrochloride (361 mg, 98%) as a brown solid. ¹H NMR and MS consistent.

[00337] Example 70: Preparation of *Endo*-*N*-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-(cyclohexylamino)benzoxazole-4-carboxamide Hydrochloride

[00338] Step A: Following general procedure GP-A, methyl 2-chlorobenzoxazole-4-carboxylate and cyclohexylamine and were converted to methyl 2-(cyclohexylamino)benzoxazole-4-carboxylate. ¹H NMR and MS consistent.

[00339] Step B: Methyl 2-(cyclohexylamino)benzoxazole-4-carboxylate (220 mg, 0.80 mmol), lithium hydroxide monohydrate (50 mg, 1.20 mmol) and a mixture of THF and H₂O (10:1, 11 mL) was stirred at room temperature for 17 h. The mixture was diluted with H₂O and loaded onto an anion exchange resin (Isolute SAX, 10 g Column). The column was washed with H₂O (50 mL) and eluted with 0.1 N aqueous HCl (50 mL). The solvent was removed under reduced pressure to afford 2-

(cyclohexylamino)benzoxazole-4-carboxylic acid hydrochloride (188 mg, 79%) as a pink solid. ¹H NMR and MS consistent.

[00340] Step C: Following general procedure GP-C1, 2-(cyclohexylamino)benzoxazole-4-carboxylic acid hydrochloride and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to provide *endo* *N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-(cyclohexylamino)benzoxazole-4-carboxamide, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00341] Example 71: Preparation of *Endo-N*-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2*S*)-2-isobutyl-4-benzylpiperazin-1-yl)benzoxazole-4-carboxamide Hydrochloride

[00342] Step A: To a solution of (2*S*)-4-benzyl-2-isobutylpiperazine (100 mg, 0.52 mmol) in 1,2-dimethoxyethane (DME) (10 mL) at room temperature, was added NaH (21 mg, 0.52 mmol, 60% suspension in mineral oil) and the mixture was stirred for 1 h. Methyl 2-chlorobenzoxazole-4-carboxylate (110 mg, 0.52 mmol) was added to the reaction mixture and the reaction was stirred at room temperature for 17 h. The reaction mixture was quenched with CH₃OH (10 mL), silica gel (15 mL) was added, and solvent removed under reduced pressure. The mixture was purified by column chromatography (silica gel, 0 to 100% EtOAc in hexanes) to afford (*S*)-methyl 2-(4-benzyl-2-isobutylpiperazin-1-yl)benzoxazole-4-carboxylate (133 mg, 62%) as a pale yellow oil. ¹H NMR and MS consistent.

[00343] Step B: (*S*)-2-(4-benzyl-2-isobutylpiperazin-1-yl)benzoxazole-4-carboxylic acid was synthesized by following general procedure GP-B3. MS consistent.

[00344] Step C: Following general procedure GP-C1, (*S*)-2-(4-benzyl-2-isobutylpiperazin-1-yl)benzoxazole-4-carboxylic acid and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to provide *endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2*S*)-2-isobutyl-4-

benzylpiperazin-1-yl)benzoxazole-4-carboxamide, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00345] Example 72: Preparation of *Endo N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-thioxo-2,3-dihydrobenzoxazole-4-carboxamide Hydrochloride

[00346] Step A: To a solution of methyl 2-thioxo-2,3-dihydrobenzoxazole-4-carboxylate (150 mg, 0.72 mmol) in THF (6 mL) was added a solution of lithium hydroxide monohydrate (45.1 mg, 1.08 mmol) in H₂O (3 mL). The reaction mixture was heated to 75 °C with stirring for 3 days, cooled down to room temperature and concentrated under reduced pressure to afford the lithium 2-thioxo-2,3-dihydrobenzoxazole-4-carboxylate (135 mg, 96.5%) as a yellow solid. MS consistent

[00347] Step B: Following general procedure GP-C1, lithium 2-thioxo-2,3-dihydrobenzoxazole-4-carboxylate and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to provide *endo N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-thioxo-2,3-dihydrobenzoxazole-4-carboxamide, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00348] Example 73: Preparation of *Endo-N*-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2*S*,6*S*)-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxamide Hydrochloride

[00349] Step A: To a solution of (2*S*,6*S*)-2,6-dimethylpiperazine dihydrochloride (0.30 g, 1.63 mmol), in CH₂Cl₂ (10 mL) at room temperature was added triethylamine (0.48 mL, 3.42 mmol) followed by di-tert butyldicarbonate (0.39 g, 1.79 mmol) and the reaction mixture was allowed to stir at room temperature 48 h. The reaction mixture was partitioned between EtOAc (20 mL) and saturated NaHCO₃ (20 mL). The aqueous phase was further extracted with EtOAc (2 × 20 mL). The combined organic phase was washed with brine (20 mL) and dried (Na₂SO₄). The crude product was purified by column chromatography (silica gel, 3 to 10% CH₃OH

in CH₂Cl₂) to afford (3*S*,5*S*)-*tert*-butyl 3,5-dimethylpiperazine-1-carboxylate (0.34 g, 52%) as a clear oil. ¹H NMR and MS consistent.

[00350] Step B: Following general procedure GP-A except in DMF at 40 °C, (3*S*,5*S*)-*tert*-butyl 3,5-dimethylpiperazine-1-carboxylate (500 mg, 2.33 mmol) and methyl 2-chlorobenzoxazole-4-carboxylate were converted to methyl 2-((2*S*,6*S*)-4-(*tert*-butoxycarbonyl)-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxylate. ¹H NMR and MS consistent.

[00351] Step C: Lithium 2-((2*S*,6*S*)-4-(*tert*-butoxycarbonyl)-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxylate was synthesized by following general procedure GP-B2. MS consistent.

[00352] Step D: Following general procedure GP-C2 at 40 °C, lithium 2-((2*S*,6*S*)-4-(*tert*-butoxycarbonyl)-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxylate and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to provide *endo*-*N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2*S*,6*S*)-4-(*tert*-butoxycarbonyl)-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxylate, which was converted to the hydrochloride salt following general procedure GP-D2. ¹H NMR and MS consistent.

[00353] Example 74: Preparation of *Endo*-*N*-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((3*S*)-3-isobutylpiperazin-1-yl)benzoxazole-4-carboxamide Hydrochloride

[00354] Step A: To a solution of 1-*tert*-butoxycarbonyl-(2*S*)-2-isobutylpiperazine (384 mg, 1.6 mmol) in DME (10 mL) was added NaH (70 mg of 60% suspension in mineral oil, 1.6 mmol) and the mixture was stirred for 1 h at room temperature. Methyl 2-chlorobenzoxazole-4-carboxylate (368 mg, 1.6 mmol) was added to the reaction mixture and suspension formed was stirred at room temperature for 17 h. The reaction mixture was quenched with CH₃OH (10 mL), silica gel (15 mL) was added, and solvent removed under reduced pressure. The mixture was purified by column chromatography ((silica gel, 0 to 80% EtOAc in CH₂Cl₂) to afford methyl 2-(4-(*tert*-butoxycarbonyl)-(3*S*)-3-isobutylpiperazin-1-yl)benzoxazole-4-carboxylate (219 mg, 32%) as a clear oil: ¹H NMR and MS consistent.

[00355] Step B: Following general method GP-B3, methyl 2-(4-(*tert*-butoxycarbonyl)-(3*S*)-3-isobutylpiperazin-1-yl)benzoxazole-4-carboxylate was converted to 2-(4-(*tert*-butoxycarbonyl)-(3*S*)-3-isobutylpiperazin-1-yl)benzoxazole-4-carboxylic acid. MS consistent.

[00356] Step C: Following general procedure GP-C1, 2-(4-(*tert*-butoxycarbonyl)-(3*S*)-3-isobutylpiperazin-1-yl)benzoxazole-4-carboxylic acid and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to provide *endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-(3*S*)-3-isobuty-4-*tert*-butoxycarbonylpiperazin-1-yl)benzoxazole-4-carboxamide, which was converted to the hydrochloride salt following general procedure GP-D2. ¹H NMR and MS consistent.

[00357] Example 75: Preparation of *Endo-N*-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((3*S*,5*S*)-3,5-dimethylmorpholino)benzoxazole-4-carboxamide Hydrochloride

[00358] Step A: To a solution of (3*S*,5*S*)-dimethylmorpholine (209 mg, 1.82 mmol) in 1,2-dimethoxyethane (10 mL) was added NaH(60% suspension in mineral oil, 146 mg, 3.64 mmol). After 10 min the reaction mixture was cooled to 0 °C and methyl 2-chlorobenzoxazole-4-carboxylate (500 mg, 2.36 mmol) was added portion-wise over 5 min. After 10 min, the reaction mixture was warmed to ambient temperature and allowed to stir for 3 days. The reaction mixture was quenched with CH₃OH (10 mL) and then dry loaded onto silica gel (4.5 g). Purification by chromatography (silica gel, 0 to 20% EtOAc in hexanes) gave a 1:1 mixture of methyl 2-((3*S*,5*S*)-3,5-dimethylmorpholino)benzoxazole-4-carboxylate and methyl 2-oxo-2,3-dihydrobenzoxazole-4-carboxylate (312 mg, 59%) as an off-white solid. MS consistent.

[00359] Step B: Lithium 2-((3*S*,5*S*)-3,5-dimethylmorpholino)benzoxazole-4-carboxylate was synthesized by following general procedure GP-B2 which was directly elaborated without purification.

[00360] Step C: Following general procedure GP-C1, lithium 2-((3S,5S)-3,5-dimethylmorpholino)benzoxazole-4-carboxylate and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to provide *endo*-N-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((3S,5S)-3,5-dimethylmorpholino)benzoxazole-4-carboxamide, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00361] Example 76: Preparation of *Endo*-N-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((S)-2-isopropylpiperazin-1-yl)benzoxazole-4-carboxamide Hydrochloride

[00362] Step A: To a solution of (2S)-4-benzyl-2-isopropylpiperazine (363 mg, 1.66 mmol) in 1,2-dimethoxyethane (10 mL) at room temperature, was added NaH (80 mg, 1.66 mmol, 60% suspension in mineral oil) and the mixture was stirred for 1 h. Methyl 2-chlorobenzoxazole-4-carboxylate (351 mg, 1.66 mmol) was added to the reaction mixture and the reaction was stirred at room temperature for 17 h. The reaction mixture was quenched with CH₃OH (10 mL), silica gel (15 mL) was added, and solvent removed under reduced pressure. The mixture was purified by column chromatography (silica gel, 0 to 100% EtOAc in hexanes) to afford (S)-methyl 2-(4-benzyl-2-isopropylpiperazin-1-yl)benzoxazole-4-carboxylate (355 mg, 54%) as a pale yellow oil. MS consistent.

[00363] Step B: (S)-2-(4-benzyl-2-isopropylpiperazin-1-yl)benzoxazole-4-carboxylic acid was synthesized following general procedure GP-B2. MS consistent.

[00364] Step C: Following general procedure GP-C1, a mixture of (S)-2-(4-benzyl-2-isopropylpiperazin-1-yl)benzoxazole-4-carboxylic acid and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to provide *endo*-N-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((4-benzyl-(S)-2-isopropylpiperazin-1-yl)benzoxazole-4-carboxamide except the material was purified by column chromatography (silica gel, 100% CH₂Cl₂ to 20:76.5:3.5 CH₂Cl₂/CH₃OH/NH₄OH). ¹H NMR and MS consistent.

[00365] Step D: To a solution of *endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((4-benzyl-(*S*)-2-isopropylpiperazin-1-yl)benzoxazole-4-carboxamide (0.230 g, 0.44 mmol) in 1,2-dichloroethane (2 mL) was added 1-chloroethylchloroformate (0.12 mL, 1.10 mmol) and the mixture was stirred for 10 h at room temperature and for 10 h at 55 °C. Additional 1-chloroethylchloroformate (0.1 mL, 0.8 mmol) was added and heating was continued for 6 h at 55°C. The solvent was removed under reduced pressure, and the residue consecutively purified by column chromatography (silica gel, 10:1:0.1 CH₂Cl₂/CH₃OH/ concentrated NH₄OH) and preparative HPLC (Luna C18(2), 10% CH₃CN/0.05%TFA in H₂O/0.05%TFA to 100% CH₃CN/0.05%TFA over 20 min, hold for 15 min, λ = 223 nm). The fractions containing desired product were combined and concentrated. The residue was converted to the hydrochloride salt following general procedure GP-D2. ¹H NMR and MS consistent.

[00366] Example 77: Preparation of *Endo-N*-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((*S*)-2-isobutylpiperazin-1-yl)benzoxazole-4-carboxamide Hydrochloride

[00367] Step A: To a solution of (*S*)-1-*tert*-butoxycarbonyl-2-isobutylpiperazine (973 mg, 4.0 mmol) in DME (15 mL) was added sodium hydride (o 60% suspension in mineral oil, 160 mg, 4.0 mmol) and the mixture was stirred for 45 min at room temperature. A solution of allyl bromide (0.35 mL, 4.0 mmol) in DMF (5 mL) was added to the reaction mixture and suspension formed was stirred at room temperature for 3 days. The solvent was removed under reduced pressure to afford a dark oil (1.06 g). The oil obtained was dissolved in CH₂Cl₂ (10 mL) and treated with TFA (5 mL). The resulting solution was stirred at room temperature for 18 h. The solvent was removed under reduced pressure; the residue was dissolved in CH₂Cl₂ and extracted with a saturated aqueous NaHCO₃ solution. The organic phase was washed with brine, H₂O, dried over Na₂SO₄, and concentrated. The residue was dissolved to CH₃OH (5 mL) and passed through ion exchange SCX-2 column to afford (3*S*)-1-allyl-3-isobutylpiperazine (0.44 g, 60%). ¹H NMR and MS consistent.

[00368] Step B: To a solution of (*S*)-1-allyl-3-isobutylpiperazine (442 mg, 2.42 mmol) in DME (10 mL) at room temperature, was added NaH (60% suspension in

mineral oil, 100 mg, 2.42 mmol,) and the mixture was stirred for 45 min. Methyl 2-chlorobenzoxazole-4-carboxylate (510 mg, 2.42 mmol) was added to the reaction mixture and the reaction was stirred at room temperature for 17 h. The reaction mixture was quenched with CH₃OH (10 mL), silica gel (15 mL) was added, and solvent removed under reduced pressure. The mixture was purified by column chromatography (silica gel, 10:1:0.1 CH₂Cl₂/CH₃OH/concentrated NH₄OH) to afford methyl 2-(4-allyl-(*S*)-2-isobutylpiperazin-1-yl)benzoxazole-4-carboxylate (372 mg, 43%) as a yellow oil. ¹H NMR and MS consistent.

[00369] Step C: 2-(4-allyl-(*S*)-2-isobutylpiperazin-1-yl)benzoxazole-4-carboxylic acid was synthesized by following general procedure GP-B3. MS consistent.

[00370] Step D: Following general procedure GP-C1, a mixture of 2-(4-allyl-(*S*)-2-isobutylpiperazin-1-yl)benzoxazole-4-carboxylic acid and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to provide *endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((*S*)-2-isobuty-4-allylpiperazin-1-yl)benzoxazole-4-carboxamide. MS consistent.

[00371] Step E: A solution of *endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((*S*)-2-isobuty-4-allylpiperazin-1-yl)benzoxazole-4-carboxamide (180 mg, 0.37 mmol), barbituric acid (284 mg, 1.2 mmol) and tetrakis(triphenylphosphine)palladium(0) (40 mg, 0.037 mmol, 10 mol%) in DMF (8 mL) was stirred for 17 h at 60 °C in argon atmosphere. The mixture was poured into saturated NaHCO₃ (100 mL) and extracted with CH₂Cl₂ (3 × 50 mL). The combined organic phase was washed sequentially with brine (100 mL), H₂O (100 mL), dried (Na₂SO₄), filtered and concentrated. The crude material was purified by preparative TLC (silica gel, 10:1:0.1 CH₂Cl₂/CH₃OH/concentrated NH₄OH) to afford *endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((*S*)-2-isobutylpiperazin-1-yl)benzoxazole-4-carboxamide (62 mg, 38%), which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00372] Example 78: Preparation of *Endo-N*-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((*S*)-3-propylpiperazin-1-yl)benzoxazole-4-carboxamide Hydrochloride

[00373] Step A: To a solution of 1-*tert*-butoxycarbonyl-(*S*)-2-isopropylpiperazine (384 mg, 1.7 mmol) in DME (10 mL) was added NaH (70 mg of 60% suspension in mineral oil, 1.6 mmol) and the mixture was stirred for 1 h at room temperature. Methyl 2-chlorobenzoxazole-4-carboxylate (368 mg, 1.6 mmol) was added to the reaction mixture and suspension formed was stirred at room temperature for 17 h. The reaction mixture was quenched with CH₃OH (10 mL), silica gel (15 mL) was added, and solvent removed under reduced pressure. The mixture was purified by column chromatography (silica gel, 0 to 80% EtOAc in CH₂Cl₂) to afford methyl 2-(4-(*tert*-butoxycarbonyl)-(*S*)-3-isopropylpiperazin-1-yl)benzoxazole-4-carboxylate (255 mg, 39%) as a white foam. ¹H NMR and MS consistent.

[00374] Step B: 2-(4-(*tert*-butoxycarbonyl)-(*S*)-3-isopropylpiperazin-1-yl)benzoxazole-4-carboxylic acid was synthesized by following general procedure GP-B2, methyl 2-(4-(*tert*-butoxycarbonyl)-(*S*)-3-propylpiperazin-1-yl)benzoxazole-4-carboxylate was converted to. MS consistent.

[00375] Step C: Following general procedure GP-C1, a mixture of 2-(4-(*tert*-butoxycarbonyl)-(*S*)-3-isopropylpiperazin-1-yl)benzoxazole-4-carboxylic acid and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to provide *endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((*S*)-3-isopropyl-4-*tert*-butoxycarbonylpiperazin-1-yl)benzoxazole-4-carboxamide. ¹H NMR and MS consistent.

[00376] Step D: A solution of *endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((*S*)-3-isopropyl-4-*tert*-butoxycarbonylpiperazin-1-yl)benzoxazole-4-carboxamide (230 mg, 0.43 mmol) in CH₂Cl₂ was treated with TFA (0.33 mL, 4.3 mmol). The mixture was stirred at room temperature for 17 h. The solvent was removed under vacuum, and the residue was neutralized by ion-exchange chromatography (SCX-2 column, 5g) to afford *endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((*S*)-3-isopropylpiperazin-1-yl)benzoxazole-4-

carboxamide which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00377] Example 79: Preparation of *Endo-N*-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-(5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)benzoxazole-4-carboxamide Hydrochloride

[00378] Step A: To a solution of NaH (60% dispersion in mineral oil, 0.130 g, 3.25 mmol) in THF (10 mL) was added 5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine (0.33 g, 2.71 mmol) and the reaction mixture stirred for 10 min. Methyl 2-chlorobenzoxazole-4-carboxylate (478 mg, 2.26 mmol), in THF (10 mL) was added and the reaction mixture was allowed to stir at room temperature 17 h. The reaction mixture was quenched with CH₃OH (3 mL), and adsorbed onto silica gel (2 g). The crude product was purified by column chromatography (silica gel, 0.5 to 10% CH₃OH in CH₂Cl₂) to afford methyl 2-(5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)benzoxazole-4-carboxylate (251 mg, 37%) as an orange oil. ¹H NMR and MS consistent.

[00379] Step B: Lithium 2-(5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)benzoxazole-4-carboxylate was synthesized by following general procedure GP-B2. MS consistent.

[00380] Step C: Following general procedure GP-C1, a mixture of lithium 2-(5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)benzoxazole-4-carboxylate (243 mg, 0.84 mmol) and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride (229 mg, 1.01 mmol) were coupled to provide *endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-(5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)benzoxazole-4-carboxamide which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00381] Example 80: Preparation of *Endo N*-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((*S*)-3-*tert*-butylmorpholino)-6-chloro-benzoxazole-4-carboxamide Hydrochloride

[00382] Step A: To an ice cold, stirred suspension of NaH (60% in oil, 1.6 g, 39.0 mmol) in toluene (53 mL) was added drop wise a solution of (*S*)-2-amino-4,5-dimethylpentan-1-ol (2.0 g, 17.0 mmol) in toluene (37 mL). After the addition was completed, the reaction mixture was warmed to room temperature and a solution of ethyl chloroacetate (2.3 g, 19.0 mmol) in toluene (10 mL) was added in a drop wise manner. The resulting mixture was then stirred at reflux for 20 h, cooled to room temperature, and solid ammonium chloride (2.1 g, 39.0 mmol) was added to the reaction. The mixture was stirred for 20 min and then concentrated under reduced pressure. The crude material was purified by column chromatography (silica gel, 98:2 CH₂Cl₂/CH₃OH to 95:5 CH₂Cl₂/CH₃OH) to give (*S*)-5-*tert*-butylmorpholin-3-one (2.0 g, 74%) as a light yellow solid. To ice-cold THF (9 mL) was added lithium aluminum hydride (1.0 M solution in THF, 26.0 mL, 26.0 mmol). Once the addition was complete, a solution of (*S*)-5-*tert*-butylmorpholin-3-one (2.0 g, 13.0 mmol) in THF (8.0 mL) was added drop wise over 20 min. Once the addition was completed, the ice bath was removed and the reaction mixture stirred at reflux for 20 h. The reaction was cooled in an ice-bath and to this was slowly added H₂O (1.2 mL), then 15% aqueous solution of NaOH (1.2 mL), and then H₂O (1.2 mL). The resulting mixture was stirred at room temperature for 1.5 h and then filtered washing the solids with EtOAc (50 mL). The filtrate was concentrated at room temperature under reduced pressure to provide (*S*)-3-*tert*-butylmorpholine (1.7 g, 97%) as a light yellow oil. ¹H NMR consistent.

[00383] Step B: To a solution of methyl 2, 6-dichlorobenzoxazole-4-carboxylate (515 mg, 2.09 mmol) in THF (15 mL) was added (*S*)-3-*tert*-butylmorpholine (600 mg, 4.19 mmol). The mixture was stirred at room temperature for 5 days. The reaction mixture was concentrated to dryness. The crude material was purified by column chromatography (silica gel, 2% EtOAc in hexane) to afford the desired methyl (*S*)-methyl 2-(3-*tert*-butylmorpholino)-6-chlorobenzoxazole-4-carboxylate (149 mg, 20.2%) as yellow solid. MS consistent.

[00384] Step C: Following general procedure GP-B2, (*S*)-methyl 2-(3-*tert*-butylmorpholino)-6-chlorobenzoxazole-4-carboxylate was converted to lithium (*S*)-2-(3-*tert*-butylmorpholino)-6-chlorobenzoxazole-4-carboxylate. MS consistent.

[00385] Step D: Following general procedure GP-C1, a mixture of lithium (S)-2-(3-*tert*-butylmorpholino)-6-chlorobenzoxazole-4-carboxylate and 9-methyl-9-azabicyclo[3.3.1]nonan-3-amine dihydrochloride were coupled to afford *endo* *N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((S)-3-*tert*-butylmorpholino)benzoxazole-4-carboxamide which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00386] Example 81: Preparation of *Endo-N*-(9-Azabicyclo[3.3.1]nonan-3-yl)-2-((3S,5S)-3,5-dimethylmorpholino)benzoxazole-4-carboxamide Hydrochloride

[00387] To *endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((3S,5S)-3,5-dimethylmorpholino)benzoxazole-4-carboxamide (107 mg, 0.24 mmol) in CH₂Cl₂ (3 mL), at 0 °C, was added 1,8-bis(dimethylamino)naphthalene (10 mg, 0.048 mmol) and 1-chloroethyl chloroformate (0.21 mL, 1.90 mmol). After stirring at 0 °C for 0.5 h, the reaction mixture was heated to reflux. After 2 h, additional 1,8-bis(dimethylamino)naphthalene (10 mg, 0.048 mmol) was added. After another 0.5 h, more 1,8-bis(dimethylamino)naphthalene (10 mg, 0.048 mmol) and 1-chloroethyl chloroformate (0.21 mL, 1.90 mmol) were added. After 3 h, the reaction mixture was cooled to ambient temperature and stirred overnight. Next, additional 1,8-bis(dimethylamino)-naphthalene (20 mg, 0.096 mmol) and 1-chloroethyl chloroformate (0.21 mL, 1.90 mmol) were added and the reaction mixture was heated to reflux. After 7.5 h, more 1-chloroethyl chloroformate (0.21 mL, 1.90 mmol) was added and the reaction mixture was refluxed overnight. The reaction mixture was cooled to ambient temperature and concentrated under reduced pressure. CH₃OH (5 mL) was added and the solution was heated to reflux. After 1.5 h, the reaction mixture was concentrated and the resulting residue was dissolved in CH₂Cl₂ (20 mL). The organic layer was washed with saturated NaHCO₃ (10 mL), brine (10 mL), dried (Na₂SO₄) and concentrated under reduced pressure. The crude material was purified by column chromatography (silica gel, 9:1 CH₂Cl₂/CH₃OH to 90:9:1 CH₂Cl₂/CH₃OH /concentrated NH₄OH) to afford *endo-N*-(9-azabicyclo[3.3.1]nonan-3-yl)-2-((3S,5S)-3,5-dimethylmorpholino)benzoxazole-4-carboxamide (62 mg). This material was dissolved in acetonitrile/H₂O (1:4, 10 mL) and HCl (1 N in diethyl ether, 0.31 mL, 0.31 mmol) was added. The solution was lyophilized to afford *endo-N*-(9-azabicyclo[3.3.1]nonan-3-yl)-2-((3S,5S)-3,5-dimethylmorpholino)benzoxazole-4-

carboxamide hydrochloride (71 mg, 68%) as a white powder. ¹H NMR and MS consistent.

[00388] Example 82: Preparation of *Endo-N*-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-(thiomorpholine 1,1-dioxide)benzoxazole-4-carboxamide Hydrochloride

[00389] Step A: A solution of methyl 2-chlorobenzoxazole-4-carboxylate (1.0 g, 4.7 mmol) and thiomorpholine (1.4 mL, 14 mmol) in THF (20 mL) was stirred at ambient temperature for 1 h. Then, the reaction mixture was poured into EtOAc (100 mL) and washed with 1N HCl (20 mL), H₂O (20 mL), brine (20 mL), dried (Na₂SO₄) and concentrated under reduced pressure. Purification by chromatography (silica gel, 5 to 50% EtOAc in hexanes) gave methyl 2-thiomorpholinobenzoxazole-4-carboxylate (1.1 g, 84%) as a yellow solid. ¹H NMR and MS consistent.

[00390] Step B: To methyl 2-thiomorpholinobenzoxazole-4-carboxylate (500 mg, 1.79 mmol) in CH₃OH (10 mL) was added potassium peroxymonosulfate (1.95 g, 5.39 mmol) in H₂O (10 mL). The yellow slurry was stirred at ambient temperature for 2 h and then concentrated under reduced pressure. The residue was taken up in H₂O (30 mL) and extracted with chloroform (3 × 25 mL). The combined organic layers were washed with H₂O (20 mL), brine (20 mL), dried (Na₂SO₄) and concentrated under reduced pressure to give methyl 2-(thiomorpholine 1,1-dioxide)benzoxazole-4-carboxylate (528 mg, 95%) as a yellow solid. ¹H NMR consistent.

[00391] Synthesis of lithium 2-(thiomorpholine 1,1-dioxide)benzoxazole-4-carboxylate: Following general procedure GP-B2, methyl 2-(thiomorpholine 1,1-dioxide)benzoxazole-4-carboxylate was converted to lithium 2-(thiomorpholine 1,1-dioxide)benzoxazole-4-carboxylate which was directly elaborated without purification.

[00392] Step C: Following general procedure GP-C1, a mixture of lithium 2-(thiomorpholine 1,1-dioxide)benzoxazole-4-carboxylate and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled except, after stirring at

ambient temp for 12 h, the reaction mixture was heated in a 50 °C oil bath for 6 h. After the usual work-up, the residue was dissolved in CH₂Cl₂ (5 mL) and HCl (1 M solution in diethyl ether, 1.1 mL, 1.1 mmol) was added. The mixture was concentrated under reduced pressure. The residue was taken up in diethyl ether (10 mL) and a solid precipitated out of solution. The material was further purified by semi-preparative HPLC (Luna C18(2), 10% CH₃CN /0.05%TFA in H₂O/0.05%TFA to 100% CH₃CN /0.05%TFA over 30 min, λ = 223 nm). The desired fractions were combined and concentrated under reduced pressure. The residue was dissolved in CH₂Cl₂ (35 mL) and was washed with saturated NaHCO₃ (20 mL), H₂O (20 mL), brine (20 mL), dried (Na₂SO₄) and concentrated under reduced pressure. To the residue was added an excess of HCl (1 M solution in diethyl ether) and the solution was concentrated under reduced pressure. The material was lyophilized from acetonitrile/H₂O (1:1, 6 mL) to afford *endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-(thiomorpholine 1,1-dioxide)benzoxazole-4-carboxamide hydrochloride. ¹H NMR and MS consistent.

[00393] Example 83: Preparation of (*S*)-*N*-(quinuclidin-8-yl)-2-(ethyl(methyl)amino)benzoxazole-4-carboxamide Hydrochloride

[00394] Step A: Following general procedure GP-A, methyl 2-chlorobenzoxazole-4-carboxylate and *N*-ethylmethanamine were converted to methyl 2-(ethyl(methyl)amino)benzoxazole-4-carboxylate except, the mixture was stirred at room temperature for 16 h and not heated. Also, the crude material was purified by column chromatography (silica gel, 40% EtOAc in hexane). MS consistent.

[00395] Step B: Lithium 2-(ethyl(methyl)amino)benzoxazole-4-carboxylate was synthesized by following general procedure GP-B2. MS consistent.

[00396] Step C: Following general procedure GP-C1, a mixture of lithium 2-(ethyl(methyl)amino)benzoxazole-4-carboxylate and (*S*)-(-)-3-aminoquinuclidine dihydrochloride were coupled and to afford (*S*)-*N*-(quinuclidin-8-yl)-2-(ethyl(methyl)amino)benzoxazole-4-carboxamide, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00397] Example 84: Preparation of *Endo-N*-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((*S*)-2-ethylpiperazin-1-yl)benzoxazole-4-carboxamide Hydrochloride

[00398] Step A: 2-Benzylaminoethanol (3.45 g, 22.8 mmol) was added to solution of *N*-t-Boc- α -aminobutyric acid (4.0 g, 19.7 mmol) and carbonyldiimidazole (3.54 g, 21.8 mmol) in THF (100 mL) and resulting mixture was stirred at room temperature for 17 h. The solvent was removed under vacuum and the residue purified by column chromatography (silica gel, from 0 to 100% EtOAc in hexanes) to afford (*S*)-*tert*-butyl 1-(benzyl(2-hydroxyethyl)amino)-1-oxobutan-2-ylcarbamate (3g, 45 %) as a clear oil. ¹H NMR consistent.

[00399] Step B: TFA(10 mL) was added to (*S*)-*tert*-butyl 1-(benzyl(2-hydroxyethyl)amino)-1-oxobutan-2-ylcarbamate (3g, 8.92 mmol) in CH₂Cl₂ (50 mL) at 0 °C. The mixture was stirred at 0 °C for 1.5 h, followed by solvent removal under reduced pressure. The residue was partitioned between CH₂Cl₂ (300 mL) and 25% aqueous sodium hydroxide (100 mL). The aqueous fraction was further extracted with CH₂Cl₂ (2 × 100 mL), and combined organic fraction was dried (Na₂SO₄), filtered and concentrated to afford (*S*)-2-amino-*N*-benzyl-*N*-(2-hydroxyethyl)butanamide as a yellow oil (1.84 g, 87%). ¹H NMR consistent.

[00400] Step C: Diisopropylazidodicarboxylate (1.82 g, 9.3 mmol) was added to solution of (*S*)-2-amino-*N*-benzyl-*N*-(2-hydroxyethyl)butanamide (1.84 g, 7.8 mmol) and triphenylphosphine (2.62 g, 10.0 mmol) in THF (50 mL). The reaction mixture was stirred at room temperature for 7 d. The solvent was removed under reduced pressure, and the residue was purified by column chromatography (silica gel, 10% CH₃OH in EtOAc) to afford (*S*)-1-benzyl-3-ethylpiperazin-2-one (0.8 g, 47%) as clear oil. ¹H NMR consistent.

[00401] Step D: LiAlH₄ (1 M solution in THF, 11 mL, 11.0 mmol) was added drop wise to solution of (*S*)-1-benzyl-3-ethylpiperazin-2-one (0.8 g, 3.66 mmol) in THF (30 mL) at 0°C. The reaction mixture was stirred at 65 °C for 17 h, then cooled 0 °C and quenched sequentially with H₂O (0.7 mL), 10% NaOH (1 mL) and H₂O (1.5 mL). Diethylether (100 mL) was added to the reaction mixture, and stirring was

continued for 1.5 h. The solid was filtered off, the filtrate was concentrated and dried in vacuum to afford (*S*)-1-benzyl-3-ethylpiperazin (0.67 g, 87%) as an oily solid. ¹H NMR and MS consistent.

[00402] Step E: To a solution of (*S*)-1-benzyl-3-ethylpiperazine (650 mg, 3.22 mmol) in DME (10 mL) at room temperature, was added NaH (60% suspension in mineral oil, 144 mg, 3.50 mmol,) and the mixture was stirred for 45 min. Methyl 2-chlorobenzoxazole-4-carboxylate (510 mg, 2.42 mmol) was added to the reaction mixture and the reaction was stirred at room temperature for 17 h. The reaction mixture was quenched with CH₃OH (10 mL), silica gel (15 mL) was added, and solvent removed under reduced pressure. The mixture was purified by column chromatography (silica gel, 0 to 80% EtOAc in hexanes) to afford (*S*)-methyl 2-(4-benzyl-2-ethylpiperazin-1-yl)benzoxazole-4-carboxylate (0.87 g, 71%) as an oily solid. ¹H NMR and MS consistent.

[00403] Step F: 2-(4-benzyl-(*S*)-2-ethylpiperazin-1-yl)benzoxazole-4-carboxylic acid was synthesized by following general procedure GP-B3. MS consistent.

[00404] Step G: Following general procedure GP-C1, a mixture of 2-(4-benzyl-(*S*)-2-ethylpiperazin-1-yl)benzoxazole-4-carboxylic acid and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to provide *endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((*S*)-2-ethyl-4-benzylpiperazin-1-yl)benzoxazole-4-carboxamide. ¹H NMR and MS consistent.

[00405] Step H: To a solution of *endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((*S*)-2-ethyl-4-benzylpiperazin-1-yl)benzoxazole-4-carboxamide (100 mg, 0.44 mmol) in 1,2-dichloroethane (10 mL) was added 1-chloroethylchloroformate (500 mg, 3.5 mmol) and Cs₂CO₃ (0.5 g, 2 mmol) and the mixture was stirred for 5 h at 55 °C. Solvent was removed under vacuum, and the residue purified by column chromatography (silica gel, 10:1:0.1 CH₂Cl₂:CH₃OH:concentrated NH₄OH) to afford 31 mg (after drying in vacuum) of clear oil with MS (ESI+) *m/z* 312 (M+H). The oil obtained was dissolved in CH₂Cl₂ (2 mL) and HCl (1 M solution in ether, 0.3 mL, 0.3 mmol) was added. The mixture was stirred at room temperature for 5 min then

diluted with ethyl ether (40 mL). The solvent was removed under vacuum, and the residue was dissolved in H₂O/acetonitrile(1:1, 10 mL) and lyophilized to give *endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((*S*)-2-ethylpiperazin-1-yl)benzoxazole-4-carboxamide hydrochloride (20 mg, 21%) as a white powder. ¹H NMR and MS consistent.

[00406] Example 85: Preparation of (*S*)-*N*-(quinuclidin-8-yl)-2-(isopropyl(methyl)amino)benzoxazole-4-carboxamide Hydrochloride

[00407] Step A: Following general procedure GP-A, methyl 2-chlorobenzoxazole-4-carboxylate and *N*-methylpropan-2-amine were converted to methyl 2-(isopropyl(methyl)amino)benzoxazole-4-carboxylate except the mixture was stirred at room temperature for 16 h and not heated. MS consistent.

[00408]

[00409] Step B: Lithium 2-(isopropyl(methyl)amino)benzoxazole-4-carboxylate was synthesized by following general procedure GP-B2. MS consistent.

[00410] Step C: Following general procedure GP-C1, a mixture of lithium 2-(isopropyl(methyl)amino)benzoxazole-4-carboxylate and (*S*)-(-)-3-aminoquinuclidine dihydrochloride were coupled to afford (*S*)-*N*-(quinuclidin-8-yl)-2-(isopropyl(methyl)amino)benzoxazole-4-carboxamide which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00411] Example 86: Preparation of *Endo-N*-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-(3-oxopiperazin-1-yl)benzoxazole-4-carboxamide Hydrochloride

[00412] Step A: A mixture of methyl 2-chlorobenzoxazole-4-carboxylate (750 mg, 3.54 mmol) and piperazin-2-one (780 mg, 7.79 mmol) in THF (60 mL) was stirred at ambient temperature overnight. The reaction mixture was diluted with EtOAc (150 mL) and 1 N HCl (25 mL). The aqueous layer was separated, basified with 1 N NaOH and extracted with EtOAc (6 × 50 mL). The combined organic extracts were dried (Na₂SO₄) and concentrated under reduced pressure to give methyl 2-(3-oxopiperazin-1-yl)benzoxazole-4-carboxylate (690 mg, 72%). ¹H NMR consistent.

[00413] Step B: Lithium 2-(3-oxopiperazin-1-yl)benzoxazole-4-carboxylate was synthesized by following general procedure GP-B2 which was directly elaborated without purification.

[00414] Step C: Following general procedure GP-C1, a mixture of lithium 2-(3-oxopiperazin-1-yl)benzoxazole-4-carboxylate and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to provide *endo*-N-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-(3-oxopiperazin-1-yl)benzoxazole-4-carboxamide except, the reaction mixture was stirred at 40 °C for 3 h. The material was purified by column chromatography (silica gel, 9:1 CH₂Cl₂/CH₃OH to 90:9:1 CH₂Cl₂/CH₃OH /concentrated NH₄OH) followed by semi-prep HPLC (Luna C18(2), 10% CH₃CN /0.05%TFA in H₂O/0.05%TFA to 40% CH₃CN /0.05%TFA in H₂O/0.05%TFA over 30 min, λ = 223 nm). The desired fractions were concentrated under reduced pressure to provide the TFA salt. The residue was dissolved in CH₂Cl₂ (25 mL) and washed with 1N NaOH (10 mL), H₂O (10 mL), brine (10 mL) dried (Na₂SO₄), and concentrated under reduced pressure. The dried residue was converted to the hydrochloride salt following general procedure GP-D1 to afford *endo*-N-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-(3-oxopiperazin-1-yl)benzoxazole-4-carboxamide hydrochloride. ¹H NMR and MS consistent.

[00415] Example 87: Preparation of *Endo*-N-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((3S,5S)-3-ethyl-5-methylmorpholino)benzoxazole-4-carboxamide Hydrochloride

[00416] Step A: A mixture of (S)-2-aminobutan-1-ol (14.5 g, 0.163 mmol), 1-hydroxypropan-2-one (13.3 mL, 0.195 mmol) and platinum(IV) oxide (100 mg, 0.440 mol) were stirred under a hydrogen atmosphere (1 atm). After 30.5 h, the reaction mixture was filtered through diatomaceous earth and the filtrate was concentrated under reduced pressure. The residue was purified by distillation to give (S)-2-(1-hydroxypropan-2-ylamino)butan-1-ol (17.5 g, 74%) as a colorless oil. ¹H NMR consistent.

[00417] Step B: To (S)-2-(1-hydroxypropan-2-ylamino)butan-1-ol (10.5 g, 0.071 mmol), in a 0 °C ice bath, was added concentrated H₂SO₄ (7 mL) in portions

over 10 min. After 5 min the ice bath was removed and the reaction mixture was heated in a 180 °C oil bath. After 5.75 h, the reaction mixture was cooled to ambient temperature and then poured portion-wise into an ice-cold solution of potassium hydroxide (16 g) in H₂O (100 mL). The resulting solids were removed by vacuum filtration. To the filtrate was added di-*tert*-butyl dicarbonate (15.5 g, 0.071 mol) and the mixture was allowed to stir at ambient temperature overnight. The reaction mixture was extracted with diethyl ether (3 × 100 mL) and the combined organic extracts were dried (Na₂SO₄) and concentrated under reduced pressure. The diastereomers were separated by column chromatography (silica gel, hexanes to 10% EtOAc in hexanes) to provide (3S,5S)-*tert*-butyl 3-ethyl-5-methylmorpholine-4-carboxylate (1.82 g, 11%); and (3R,5S)-*tert*-butyl 3-ethyl-5-methylmorpholine-4-carboxylate (1.32 g, 8.1%). ¹H NMR consistent.

[00418] Step C: (3S,5S)-*tert*-Butyl 3-ethyl-5-methylmorpholine-4-carboxylate (1.8 g, 7.8 mmol) was dissolved in ca. 10 M HCl in CH₃OH and allowed to stir at ambient temperature. After 2.5 h, the solution was concentrated under reduced pressure. To the residue was added 1 N NaOH (20 mL) and this was extracted with CH₂Cl₂ (2 × 20 mL). The combined organics were dried (Na₂SO₄) and carefully concentrated under reduced pressure to give (3S,5S)-3-ethyl-5-methylmorpholine (1.0 g, quantitative). ¹H NMR consistent.

[00419] Step C: A mixture of methyl 2-chlorobenzoxazole-4-carboxylate (750 mg, 3.54 mmol) and (3S,5S)-3-ethyl-5-methylmorpholine (1.00 g, 7.75 mmol) in THF (40 mL) was stirred at ambient temperature overnight. Then the reaction mixture was heated in a 50 °C oil bath for 4.5 h. The reaction mixture was cooled to ambient temperature and most of the THF was removed under reduced pressure. The residue was dissolved in EtOAc (150 mL) and washed with 0.5 N HCl (25 mL), H₂O (25 mL), brine (25 mL), dried (Na₂SO₄), and concentrated under reduced pressure. The crude material was purified by column chromatography (silica gel, hexanes to 10% EtOAc in hexanes) to give methyl 2-((3S,5S)-3-ethyl-5-methylmorpholino)benzoxazole-4-carboxylate (540 mg, 50%), as a colorless oil. ¹H NMR consistent.

[00420] Step D: Lithium 2-((3S,5S)-3-ethyl-5-methylmorpholino)benzoxazole-4-carboxylate was synthesized by following general procedure GP-B2 which was directly elaborated without purification.

[00421] Step E: Following general procedure GP-C1, a mixture of 2-((3S,5S)-3-ethyl-5-methylmorpholino)benzoxazole-4-carboxylate and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to provide of *endo*-N-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((3S,5S)-3-ethyl-5-methylmorpholino)benzoxazole-4-carboxamide, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00422] Example 88: Preparation of *Endo*-N-(9-Methyl-3-oxa-9-azabicyclo[3.3.1]nonan-7-yl) 2-((3S,5S)-3,5-dimethylmorpholino)benzoxazole-4-carboxamide Hydrochloride

[00423] Step A: A mixture of methyl 2-chlorobenzoxazole-4-carboxylate (620 mg, 2.96 mmol) and (3S,5S)-3,5-dimethylmorpholine (341 mg, 2.96 mmol) and potassium carbonate (1.0 g, 7.4 mmol), in DMF (15 mL), was stirred in a 35 °C oil bath. After 17 h, the reaction mixture was cooled to ambient temperature, diluted with H₂O (50 mL) and extracted with EtOAc (2 × 30 mL). The combined organic layers were washed with H₂O (3 × 20 mL), brine (20 mL), dried (Na₂SO₄), and concentrated under reduced pressure. Methyl 2-((3S,5S)-3,5-dimethylmorpholino)benzoxazole-4-carboxylate (770 mg, 89%) was obtained as an amber oil. ¹H NMR consistent.

[00424] Step B: Lithium 2-((3S,5S)-3,5-dimethylmorpholino)benzoxazole-4-carboxylate was synthesized by following general procedure GP-B2 which was directly elaborated without purification.

[00425] Step C: Following general procedure GP-C1, a mixture of 2-((3S,5S)-3,5-dimethylmorpholino)benzoxazole-4-carboxylate and *endo*-9-methyl-3-oxa-9-azabicyclo[3.3.1]nonan-7-amine dihydrochloride was converted to *endo*-N-(9-methyl-3-oxa-9-azabicyclo[3.3.1]nonan-7-yl) 2-((3S,5S)-3,5-dimethylmorpholino)benzoxazole-4-carboxamide which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00426] Example 89: Preparation of *Endo-N*-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-(4-methoxypiperidin-1-yl)benzoxazole-4-carboxamide Hydrochloride

[00427] Step A: To a solution of methyl 2-chlorobenzoxazole-4-carboxylate (210 mg, 0.99 mmol) in NMP (5 mL) was added 4-methoxypiperidine (230 mg, 1.98 mmol) in NMP (5 mL) at room temperature. NaH was added to the mixture in two portions in 5 min. The mixture was stirred at room temperature for 18 h. The reaction was quenched by adding 10 mL of CH₃OH followed by concentration to dryness. The crude material was purified by column chromatography (silica gel, 50% EtOAc in hexane) to afford methyl 2-(4-methoxypiperidin-1-yl)benzoxazole-4-carboxylate (146 mg, 50%) as a yellow solid. MS consistent.

[00428] Step B: Lithium 2-(4-methoxypiperidin-1-yl)benzoxazole-4-carboxylate was synthesized by following general procedure GP-B2. MS consistent.

[00429] Step C: Following general procedure GP-C1, a mixture of lithium 2-(4-methoxypiperidin-1-yl)benzoxazole-4-carboxylate and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to provide *endo N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-(4-methoxypiperidin-1-yl)benzoxazole-4-carboxamide, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00430] Example 90: Preparation (*S*)-*N*-(quinuclidin-8-yl)-2-((3*S*,5*S*)-3,5-Dimethylmorpholino)benzoxazole-4-carboxamide Hydrochloride

[00431] Step A: Lithium 2-((3*S*,5*S*)-3,5-dimethylmorpholino)benzoxazole-4-carboxylate was synthesized by following general procedure GP-B2 which was directly elaborated without purification.

[00432] Step B: Following general procedure GP-C1, 2-((3*S*,5*S*)-3,5-dimethylmorpholino)benzoxazole-4-carboxylate and (*S*)-(-)-3-aminoquinuclidine dihydrochloride were coupled to provide 2-((3*S*,5*S*)-3,5-dimethylmorpholino)-*N*-

(quinuclidin-8-yl)benzoxazole-4-carboxamide, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00433] Example 91: Preparation of *Endo-N*-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-(1,4-dioxo-8-azaspiro[4.5]decan-8-yl)benzoxazole-4-carboxamide Hydrochloride

[00434] Step A: Following general procedure GP-A, methyl 2-chlorobenzoxazole-4-carboxylate and 1,4-dioxo-8-azaspiro[4.5]decan-8-yl were converted to methyl 2-(1,4-dioxo-8-azaspiro[4.5]decan-8-yl)benzoxazole-4-carboxylate except the mixture was stirred at room temperature for 3 days and not heated. MS consistent.

[00435] Step B: Lithium 2-(1,4-dioxo-8-azaspiro[4.5]decan-8-yl)benzoxazole-4-carboxylate was synthesized by following general procedure GP-B2. MS consistent.

[00436] Step C: Following general procedure GP-C1, a mixture of lithium 2-(1,4-dioxo-8-azaspiro[4.5]decan-8-yl)benzoxazole-4-carboxylate and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to provide *endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-(1,4-dioxo-8-azaspiro[4.5]decan-8-yl)benzoxazole-4-carboxamide, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00437] Example 92: Preparation of *Endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-(4-oxopiperidin-1-yl)benzoxazole-4-carboxamide Hydrochloride

[00438] Step A: Following general procedure GP-A, methyl 2-chlorobenzoxazole-4-carboxylate and 1,4-dioxo-8-azaspiro[4.5]decan-8-yl were converted to methyl 2-(1,4-dioxo-8-azaspiro[4.5]decan-8-yl)benzoxazole-4-carboxylate except that the mixture was stirred at room temperature for 3 days and not heated. MS consistent.

[00439] Step B: Lithium 2-(1,4-dioxo-8-azaspiro[4.5]decan-8-yl)benzoxazole-4-carboxylate was synthesized by following general procedure GP-B2. MS consistent.

[00440] Step C: Following general procedure GP-C3, a mixture of lithium 2-(1,4-dioxo-8-azaspiro[4.5]decan-8-yl)benzoxazole-4-carboxylate and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to provide *endo*-*N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-(1,4-dioxo-8-azaspiro[4.5]decan-8-yl)benzoxazole-4-carboxamide. ¹H NMR and MS consistent.

[00441] Step D: *Endo*-*N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-(1,4-dioxo-8-azaspiro[4.5]decan-8-yl)benzoxazole-4-carboxamide (100 mg, 0.23 mmol) and PPTS (85 mg, 0.34 mmol) were dissolved in acetone (1 mL) and H₂O (1 mL). The reaction mixture was subjected to microwave irradiation at 170 °C for 90 min. The solvent was removed under reduced pressure. The residual oil was diluted with CH₂Cl₂ (100 mL) and washed with H₂O (3 × 25 mL). The organic layer was dried (MgSO₄), filtered and concentrated to give the crude product. The crude product was purified by semi-prep HPLC (Luna C18(2), 10% CH₃CN /0.05%TFA in H₂O/0.05%TFA to 100% CH₃CN /0.05%TFA over 25 min, λ = 223 nm) to afford *Endo*-*N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-(4-oxopiperidin-1-yl)benzoxazole-4-carboxamide which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00442] Example 93: Preparation of (*S*)-*N*-(Quinulidin-8-yl)-2-aminobenzoxazole-4-carboxamide Hydrochloride

[00443] Step A: To a solution of di (1H-imidazole-1-yl) methanimine (2.05 g, 12.26 mmol) in THF (60 mL) was added methyl-2-amino-3-hydroxybenzoate (1.98 g, 12.26 mmol) at room temperature and the resulting reaction mixture was heated to reflux for 17 h. The reaction mixture was cool to room temperature, diluted with EtOAc (100 mL) and washed with H₂O (3 × 100 mL), saturated ammonium chloride (2 × 100 mL), dried (Na₂SO₄), filtered and concentrated under reduced pressure. The crude material was purified by recrystallization from diethyl ether to afford methyl 2-

aminobenzoxazole-4-carboxylate (1.10 g, 50%) as a brown solid. ¹H NMR and MS consistent.

[00444] Step B: A mixture of the methyl 2-aminobenzoxazole-4-carboxylate (750 mg, 3.9 mmol), di-*tert*-butyldicarbonate (936 mg, 4.29 mmol) in CH₂Cl₂ (50 mL) was stirred at room temperature for 17 h. The reaction was quenched with a saturated NaHCO₃ (25 mL), and then extracted with CH₂Cl₂ (3 × 100 mL). The combined organic phase was washed with H₂O (2 × 75 mL), brine (1 × 50 mL), and dried (Na₂SO₄), filtered and concentrated under reduced pressure. The crude material was purified by column chromatography (silica gel, 9:1, CH₂Cl₂/CH₃OH) to afford methyl 2-(*tert*-butoxycarbonylamino-4-yl)benzoxazole-4-carboxylate (930 mg, 82%) as a light yellow solid. ¹H NMR consistent.

[00445] Step C: 2-(*tert*-butoxycarbonylamino-4-yl)benzoxazole-4-carboxylic acid was synthesized by following general procedure GP-B1. ¹H NMR and MS consistent.

[00446] Step D: Following general procedure GP-C1, 2-(*tert*-butoxycarbonylamino-4-yl)benzoxazole-4-carboxylic acid and, (*S*)-(-)-3-aminoquinuclidine dihydrochloride (199 mg, 1.0 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride were coupled to provide 4-(quinuclidin-8-yl-carbamoyl)benzoxazole-2-yl-carbamate (210 mg, 54%) as an off-white solid. MS consistent.

[00447] Step E: To a solution of *tert*-butyl 4-(quinuclidin-8-yl-carbamoyl)benzoxazole-2-yl-carbamate (0.210 g, 0.54 mmol), in CH₂Cl₂ (5 mL) was added TFA(2 mL) and the reaction mixture was stirred at room temperature for 5 h. The reaction mixture was concentrated and the crude material was treated with aqueous NaHCO₃ to adjust the pH to 7 and then extracted with CH₂Cl₂ (5 × 50 mL). The combined organic phase was concentrated and purified by preparative TLC (90:9:1 CH₂Cl₂/CH₃OH/concentrated NH₄OH) to afford (*S*)-*N*-(quinuclidin-8-yl)-2-aminobenzoxazole-4-carboxamide which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00448] Example 94: Preparation of *Endo-N*-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((*S*)-3-(hydroxymethyl)morpholino)benzoxazole-4-carboxamide Hydrochloride

[00449] Step A: To a solution of (*R*)-methyl-2-amino-3-hydroxypropanoate (33 g, 212 mmol) in 2 N NaOH solution (182 mL) was added benzaldehyde (32 mL, 318 mmol), the mixture stirred at room temperature for 30 min. and cooled to -5°C . Sodium borohydride (4.01 g, 106 mmol) was added in small portions over one hour, additional benzaldehyde (32 mL, 318 mmol) was added and the reaction mixture stirred at room temperature for 30 min, then cooled to -5°C . NaBH_4 (4.01 g, 106 mmol) was added in small portions over one hour and the reaction mixture stirred at room temperature for 12 h. The solution was extracted with diethyl ether (500 mL) and acidified with concentrated HCl to pH 1. The precipitate was filtered off and dried under vacuum to provide (*R*)-2-(benzylamino)-3-hydroxypropanoic acid hydrochloride (9.4 g, 23%) as a white solid. ^1H NMR consistent.

[00450] Step B: To a solution of (*R*)-2-(benzylamino)-3-hydroxypropanoic acid hydrochloride (9.4 g, 48.2 mmol) and sodium hydroxide (2.57 g, 82.9 mmol) in H_2O (30 mL) at 0°C was added drop wise chloroacetyl chloride (4.9 mL, 62.1 mL) while maintaining the temperature below 10°C . The reaction mixture was then warmed to room temperature and stirred for 2 hours. The reaction mixture was extracted with CH_2Cl_2 (2×250 mL) and the organic layer dried (MgSO_4), filtered and concentrated. The residue was purified by flash chromatography (silica gel, 10 to 30% CH_3OH in CH_2Cl_2 with 1% acetic acid) to provide (*R*)-2-(*N*-benzyl-2-chloroacetamido)-3-hydroxypropanoic acid (2.6 g, 20%) as a yellow foam. ^1H NMR consistent.

[00451] Step C: To a solution of (*R*)-2-(*N*-benzyl-2-chloroacetamido)-3-hydroxypropanoic acid (1.53 g, 5.63 mmol) in *tert*-butanol was added potassium *tert*-butoxide and the reaction mixture heated to 110°C for three h, then cooled to room temperature and concentrated to dryness. The residue was acidified with 1 N HCl to pH 1 and the aqueous solution extracted with EtOAc (3×250 mL). The organic layer was dried (MgSO_4), filtered and concentrated under reduced pressure. The residue was purified by flash chromatography (silica gel, 10 to 30% CH_3OH in

CH₂Cl₂ with 1% acetic acid) to provide (*R*)-4-benzyl-5-oxomorpholine-3-carboxylic acid (780 mg, 59%) as a yellow foam. ¹H NMR and MS consistent.

[00452] Step D: To a solution of (*R*)-4-benzyl-5-oxomorpholine-3-carboxylic acid (780 mg, 3.32 mmol) and triethylamine (567 mL, 4.08 mmol) in anhydrous THF (15 mL) at 0 °C was added borane dimethylsulfide complex over 15 min. The reaction mixture was warmed to room temperature and heated to reflux for 6 hours, then cooled in an ice bath. To this mixture was added H₂O (4 mL) drop wise over 30 min., then 2 N NaOH (6 mL) and the mixture concentrated to 30% of the volume. The residue was extracted with EtOAc (3 × 150 mL), the organic layer dried (MgSO₄) and concentrated. The residue was purified by flash chromatography (silica gel, 0 to 5% CH₃OH in CH₂Cl₂) to provide (*S*)-(4-benzylmorpholin-3-yl)CH₃OH (470 mg, 68%) as a colorless oil. ¹H NMR and MS consistent.

[00453] Step E: A solution of (*S*)-(4-benzylmorpholin-3-yl)CH₃OH (450 mg, 2.17 mmol), *tert*-butylchlorodimethylsilane (392 mg, 2.60 mmol) and imidazole (370 mg, 5.42 mmol) in DMF (10 mL) was stirred at room temperature for 18 hours. The reaction mixture was diluted with CH₂Cl₂ (2 × 50 mL), washed with 5% NaHCO₃ solution (50 mL) and brine (3 × 20 mL) and the organic layer dried (MgSO₄) and concentrated. The residue was purified by flash chromatography (silica gel, 10 to 30% CH₃OH in CH₂Cl₂) to provide (*R*)-4-benzyl-3-((*tert*-butyldimethylsilyloxy)methyl)morpholine (576 mg, 82%) as a colorless foam. ¹H NMR and MS consistent.

[00454] Step F: A suspension of (*R*)-4-benzyl-3-((*tert*-butyldimethylsilyloxy)methyl)morpholine (576 mg, 1.79 mmol) and 10% palladium on carbon in EtOAc (20 mL) was placed in a Parr shaker and hydrogenated at 45 psi hydrogen pressure for 48 h. The heterogeneous mixture was filtered through a pad of diatomaceous earth, washed with CH₃OH (200 mL) and concentrated to provide (*R*)-3-((*tert*-butyldimethylsilyloxy)methyl)morpholine (414 mg, quant.) as a colorless oil. MS consistent.

[00455] Step G: Following general procedure GP-A, (*R*)-3-((*tert*-butyldimethylsilyloxy)-methyl)morpholine and-2-chlorobenzoxazole-4-carboxylate

were converted to (*R*)-methyl 2-(3-((*tert*-butyldimethylsilyloxy)methyl)morpholino)benzoxazole-4-carboxylate. ¹H NMR and MS consistent.

[00456] Step H: To a solution of LiI (298 mg, 2.22 mmol) in refluxing anhydrous pyridine (50 mL) was added (*R*)-methyl 2-(3-((*tert*-butyldimethylsilyloxy)methyl)morpholino)benzoxazole-4-carboxylate (226 mg, 0.55 mmol) and the reaction mixture was refluxed for 24 h. The mixture was cooled to room temperature, concentrated to dryness and dried in vacuum to provide lithium (*R*)-2-(3-((*tert*-butyldimethylsilyloxy)methyl)morpholino)benzoxazole-4-carboxylate as a yellow oil which was used without further purification. MS consistent.

[00457] Step I: Following general procedure GP-C1, (*R*)-2-(3-((*tert*-butyldimethylsilyloxy)methyl)morpholino)benzoxazole-4-carboxylate and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to provide *endo*-*N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((*R*)-3-((*tert*-butyldimethylsilyloxy)methyl)-morpholino)benzoxazole-4-carboxamide. ¹H NMR and MS consistent.

[00458] Step J: A solution of *endo*-*N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((*R*)-3-((*tert*-butyldimethylsilyloxy)methyl)morpholino)benzoxazole-4-carboxamide (293 mg, 0.55 mmol) and tetrabutylammonium fluoride (1.7 mL, 1 M solution in THF) in anhydrous THF (80 mL) was stirred at room temperature for 12 hours. The reaction mixture was concentrated to dryness and the residue re-dissolved in CH₂Cl₂ (100 mL), washed with saturated ammonium chloride solution (2 × 25 mL), brine (25 mL), and the organic layer dried (MgSO₄) and concentrated. The crude material was purified by column chromatography (silica gel, 100% CH₂Cl₂ to 90:10:1 CH₂Cl₂/CH₃OH/concentrated NH₄OH) to afford *endo*-*N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((*S*)-3-(hydroxymethyl)morpholino)benzoxazole-4-carboxamide which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00459] Example 95: Preparation of *Endo-N*-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-(3-methylpiperazin-1-yl)benzoxazole-4-carboxamide Hydrochloride

[00460] Step A: To a solution of *tert*-butyl 2-methylpiperazine-1-carboxylate (340 mg, 1.70 mmol) in THF (5 mL) was added sodium hydride (60%, 82 mg, 2.04 mmol). The reaction mixture was stirred at room temperature for 5 min, then methyl 2-chlorobenzoxazole-4-carboxylate (300 mg, 1.41 mmol) in THF (5 mL) was added to the reaction mixture. The reaction mixture was stirred at room temperature for 19 h. The mixture was concentrated under reduced pressure and the resulting residue was purified by column chromatography (silica gel, 20% EtOAc in hexane) to afford methyl 2-(4-(*tert*-butoxycarbonyl)-3-methylpiperazin-1-yl) benzoxazole-4-carboxylate (336 mg, 63%) as yellow solid. MS consistent.

[00461] Step B: Lithium 2-(4-(*tert*-butoxycarbonyl)-3-methylpiperazin-1-yl)benzoxazole-4-carboxylate was synthesized by following general procedure GP-B2. MS consistent.

[00462] Step C: Following general procedure GP-C1, lithium 2-(4-(*tert*-butoxycarbonyl)-3-methylpiperazin-1-yl)benzoxazole-4-carboxylate and 9-methyl-9-azabicyclo[3.3.1]nonan-3-amine dihydrochloride were coupled to provide *tert*-butyl 2-methyl-4-(4-(9-methyl-9-azabicyclo[3.3.1]nonan-3-ylcarbamoyl)benzoxazol-2-yl)piperazine-1-carboxylate. MS consistent.

[00463] Step D: To a solution of provide *tert*-butyl 2-methyl-4-(4-(9-methyl-9-azabicyclo[3.3.1]nonan-3-ylcarbamoyl)benzoxazol-2-yl)piperazine-1-carboxylate (138 mg, 0.27 mmol) in CH₂Cl₂ (2 mL) was added TFA (2 mL) at 0 °C. The reaction mixture was stirred at 0 °C for 1.5 h and concentrated to give the crude product. The crude product was purified by prep-TLC (silica gel, 80:19:1 chloroform/CH₃OH/concentrated NH₄OH) to afford *endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-(3-methylpiperazin-1-yl)benzoxazole-4-carboxamide which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00464] Example 96: Preparation of *Endo-N*-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((*S*)-2-*tert*-butylpiperazin-1-yl)benzoxazole-4-carboxamide Hydrochloride

[00465] Step A: Lithium aluminum hydride (1 M solution in THF, 40 mL, 40.0 mmol) was added drop wise to solution of (*S*)-2-*tert*-butylpiperazin-3,6-dione (1.5 g, 8.82 mmol) in THF (50 mL) at 0 °C. The reaction mixture was stirred at room temperature for 7 days and at 65 °C for 17 h, then cooled to 0 °C and quenched sequentially with H₂O (1.7 mL), 10% NaOH (2.2 mL) and H₂O (3.4 mL). Ether (100 mL) was added to the reaction mixture, and stirring was continued for 1.5 h. The solid was filtered, the filtrate was concentrated and purified by column chromatography (silica gel, 33% EtOAc in hexanes) to afford (*S*)-2-*tert*-butylpiperazine (0.64 g, 52%) as a clear oil. ¹H NMR and MS consistent.

[00466] Step B: To (*S*)-2-*tert*-butylpiperazine (0.5 g, 3.49 mmol), in CH₂Cl₂ (15 mL) at room temperature was added triethylamine (0.5 mL, 3.59 mmol) followed by di-*tert*-butyldicarbonate (0.83 g, 3.79 mmol) and the reaction mixture was allowed to stir at room temperature 17 h. The solvent was removed under vacuum, and the residue purified by column chromatography (silica gel, 10:1:0.1 CH₂Cl₂/CH₃OH/concentrated NH₄OH) to afford (*S*)-4-*tert*-butyloxycarbonyl-2-*tert*-butylpiperazine (0.59 g, 69%) as a clear oil. ¹H NMR consistent.

[00467] Step C: To (*S*)-4-*tert*-butyloxycarbonyl-2-*tert*-butylpiperazine (640 mg, 2.60 mmol) in DME (10 mL) at room temperature, was added NaH (60% suspension in mineral oil, 115 mg, 3.50 mmol,) and the mixture was stirred for 45 min. Methyl 2-chlorobenzoxazole-4-carboxylate (780 mg, 3.69 mmol) was added to the reaction mixture and the reaction was stirred at room temperature for 3d and at 55°C for 24 h. The reaction mixture was quenched with CH₃OH (10 mL), silica gel (15 mL) was added, and solvent removed under reduced pressure. The residue was purified by column chromatography (silica gel, 33% EtOAc in hexanes) to afford (*S*)-methyl 2-(4-*tert*-butyloxycarbonyl-2-*tert*-butyl-piperazin-1-yl)benzoxazole-4-carboxylate (0.42 g, 39%) as a yellow solid. ¹H NMR and MS consistent.

[00468] Step D: Following general procedure GP-B3, (*S*)-methyl 2-(4-*tert*-butyloxycarbonyl-2-*tert*-butyl-piperazin-1-yl)benzoxazole-4-carboxylate was converted to (*S*)-2-(4-*tert*-butyloxycarbonyl-2-*tert*-butylpiperazin-1-yl)benzoxazole-4-carboxylic acid. MS consistent.

[00469] Step E: Following general procedure GP-C1, (*S*)-2-(4-*tert*-butyloxycarbonyl-2-*tert*-butylpiperazin-1-yl)benzoxazole-4-carboxylic acid and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to afford *endo*-*N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((*S*)-2-*tert*-butyl-4-*tert*-butyloxycarbonylpiperazin-1-yl)benzoxazole-4-carboxamide. MS consistent.

[00470] Step F: TFA(1 mL) was added to *endo*-*N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((*S*)-2-*tert*-butyl-4-*tert*-butyloxycarbonylpiperazin-1-yl)benzoxazole-4-carboxamide (100 mg, 0.18 mmol) in CH₂Cl₂ (1 mL) and the mixture was stirred for 1 h at room temperature. The solvent was removed under vacuum, and the residue was neutralized by ion-exchange chromatography (SCX-2 column, 5g) to afford 29 mg of clear oil. The oil obtained was converted to the hydrochloride salt following general procedure GP-D1 to give *endo*-*N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((*S*)-2-*tert*-butylpiperazin-1-yl)benzoxazole-4-carboxamide hydrochloride. ¹H NMR and MS consistent.

[00471] Example 97: Preparation of *Endo*-*N*-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2*S*,6*S*)-4-benzyl-2,6-dimethyl-3-oxopiperazin-1-yl)benzoxazole-4-carboxamide Hydrochloride

[00472] Step A: A mixture of methyl 2-chlorobenzoxazole-4-carboxylate (970 mg, 4.58 mmol) and (3*S*,5*S*)-1-benzyl-3,5-dimethylpiperazin-2-one (1.00 g, 4.58 mmol) in DMF (20 mL), was stirred in a 35 °C oil bath. After 16 h, the reaction mixture was heated to 55 °C. After 3 h, potassium carbonate (630 mg, 4.58 mmol) was added. The reaction mixture was stirred for 2 h at 55 °C and then at ambient temperature for 17 h. The reaction mixture was diluted with H₂O (50 mL) and extracted with EtOAc (2 × 50 mL). The combined organic layers were washed with 0.5 N HCl (25 mL), H₂O (25 mL), brine (25 mL), dried (Na₂SO₄), and concentrated under reduced pressure. Purification by chromatography (silica gel, 10 to 80 %

EtOAc in hexanes) gave methyl 2-((2*S*,6*S*)-4-benzyl-2,6-dimethyl-3-oxopiperazin-1-yl)benzoxazole-4-carboxylate (1.08 g, 60%). ¹H NMR consistent.

[00473] Step B: Lithium 2-((2*S*,6*S*)-4-benzyl-2,6-dimethyl-3-oxopiperazin-1-yl)benzoxazole-4-carboxylate was synthesized by following general procedure GP-B2 which was directly elaborated without purification.

[00474] Step C: Following general procedure GP-C1, lithium 2-((2*S*,6*S*)-4-benzyl-2,6-dimethyl-3-oxopiperazin-1-yl)benzoxazole-4-carboxylate and *endo*-9-methyl-3-oxa-9-azabicyclo[3.3.1]nonan-7-amine dihydrochloride were coupled to provide *endo*-*N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2*S*,6*S*)-4-benzyl-2,6-dimethyl-3-oxopiperazin-1-yl)benzoxazole-4-carboxamide which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00475]

[00476] Example 98: Preparation of *Endo*-*N*-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((*S*)-2-methyl-3-oxopiperazin-1-yl)benzoxazole-4-carboxamide Hydrochloride

[00477]

[00478] Step A: A mixture of methyl 2-chlorobenzoxazole-4-carboxylate (370 mg, 1.75 mmol), (*S*)-3-methylpiperazin-2-one (200 mg, 1.75 mmol) and K₂CO₃ (605 mg, 4.38 mmol), in DMF (15 mL), was stirred at ambient temperature for 17 h. The reaction mixture was diluted with H₂O (30 mL) and extracted with CH₂Cl₂ (2 × 50 mL). The combined organic layers were washed with H₂O (3 × 20 mL), brine (20 mL), dried (Na₂SO₄). The material was concentrated under reduced pressure to give (*S*)-methyl 2-(2-methyl-3-oxopiperazin-1-yl)benzoxazole-4-carboxylate (500 mg, 73%) as a yellow oil. ¹H NMR consistent.

[00479]

[00480] Step B: To (*S*)-methyl 2-(2-methyl-3-oxopiperazin-1-yl)benzoxazole-4-carboxylate (118 mg, 0.407 mmol) in THF (3 mL) was added potassium trimethylsilanolate (58 mg, 0.407 mmol). A yellow precipitate formed and after 1.5 h, additional potassium trimethylsilanolate (58 mg, 0.407 mmol) was added. After 1 h, the reaction mixture was heated at reflux. After 1.5 h, the reaction mixture was cooled to ambient temperature. The solid was collected by vacuum filtration and

rinsed with diethyl ether to afford crude (*S*)-potassium 2-(2-methyl-3-oxopiperazin-1-yl)benzoxazole-4-carboxylate. ¹H NMR consistent.

[00481] Step C: Following general procedure GP-C1, a mixture of (*S*)-potassium 2-(2-methyl-3-oxopiperazin-1-yl)benzoxazole-4-carboxylate and *endo*-9-methyl-3-oxa-9-azabicyclo[3.3.1]nonan-7-amine dihydrochloride were coupled to provide *endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((*S*)-2-methyl-3-oxopiperazin-1-yl)benzoxazole-4-carboxamide hydrochloride following general procedure GP-D1. ¹H NMR and MS consistent.

[00482] Example 99: Preparation of (*S*)-*N*-(Quinulidin-8-yl)-2-((2*S*,6*S*)-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxamide Hydrochloride

[00483] Step A: Lithium 2-((2*S*,6*S*)-4-(*tert*-butoxycarbonyl)-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxylate was synthesized by following general procedure GP-B2. MS consistent.

[00484] Step B: Following general procedure GP-C1, lithium 2-((2*S*,6*S*)-4-(*tert*-butoxycarbonyl)-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxylate and (*S*)-(-)-3-aminoquinuclidine dihydrochloride were coupled to provide (*S*)-*N*-(quinulidin-8-yl)-2-((2*S*,6*S*)-4-(*tert*-butoxycarbonyl)-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxylate. ¹H NMR and MS consistent.

[00485] Step C: To solution of (*S*)-*N*-(quinulidin-8-yl)-2-((2*S*,6*S*)-4-(*tert*-butoxycarbonyl)-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxylate (245 mg, 0.51 mmol) was added HCl (1.25 M solution in CH₃OH, 8.2 mL, 10.13 mmol) and the mixture was stirred at 35°C for 17 h then concentrated under reduced pressure. The crude material was purified by column chromatography (silica gel, 100% 9:1 CH₂Cl₂/CH₃OH to 100% 90:9:1 CH₂Cl₂/CH₃OH/concentrated NH₄OH) to afford (*S*)-*N*-(quinulidin-8-yl)-2-((2*S*,6*S*)-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxamide which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00486] Example 100: Preparation of *Endo-N*-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-(6,9-diazaspiro[4.5]decan-6-yl)benzoxazole-4-carboxamide Hydrochloride

[00487] Step A: To a solution of *tert*-butyl 6,9-diazaspiro[4.5]decane-9-carboxylate (192 mg, 0.80 mmol) in DME (10 mL) was added NaH (60%, 96 mg, 2.4 mmol). The reaction mixture was stirred at room temperature for 10 min, followed by addition of methyl 2-chlorobenzoxazole-4-carboxylate (186 mg, 0.88 mmol). The reaction mixture was stirred at room temperature for 20 h. The reaction was quenched by adding 5 mL of H₂O and extracted with EtOAc (2 × 30 mL). The organic layer was washed by brine, dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The resulting residue was purified by column chromatography (silica gel, 50-100% chloroform in hexane) to afford methyl 2-(9-(*tert*-butoxycarbonyl)-6,9-diazaspiro[4.5]decan-6-yl)benzoxazole-4-carboxylate (61.4 mg, 18.5%) as yellow oil. MS consistent.

[00488] Step B: Following general procedure GP-B2, methyl 2-(9-(*tert*-butoxycarbonyl)-6,9-diazaspiro[4.5]decan-6-yl)benzoxazole-4-carboxylate was converted to lithium 2-(9-(*tert*-butoxycarbonyl)-6,9-diazaspiro[4.5]decan-6-yl)benzoxazole-4-carboxylate. MS consistent.

[00489] Step C: Following general procedure GP-C1, lithium 2-(9-(*tert*-butoxycarbonyl)-6,9-diazaspiro[4.5]decan-6-yl)benzoxazole-4-carboxylate and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to provide *tert*-butyl 6-(4-(9-methyl-9-azabicyclo[3.3.1]nonan-3-ylcarbamoyl)benzoxazol-2-yl)-6,9-diazaspiro[4.5]decane-9-carboxylate (25 mg, 52%) as a yellow solid. MS consistent.

[00490] Step D: To *tert*-butyl 6-(4-(9-methyl-9-azabicyclo[3.3.1]nonan-3-ylcarbamoyl)benzoxazol-2-yl)-6,9-diazaspiro[4.5]decane-9-carboxylate (25 mg, 0.05 mmol) in CH₂Cl₂ (1 mL) was added TFA (1 mL) at 0 °C. The reaction mixture was stirred at 0 °C for 30 min, then at room temperature for 30 min. The reaction mixture was concentrated under reduced pressure and the resulting residue was dissolved in CH₂Cl₂ (50 mL). The organic phase was washed with an aqueous saturated NaHCO₃ solution (25 mL). The organic layer was separated, dried over MgSO₄, filtered, and

concentrated under reduced pressure to afford *endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-(6,9-diazaspiro[4.5]decan-6-yl)benzoxazole-4-carboxamide which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00491] Example 101: Preparation of *N*-(8-Methyl-8-azabicyclo[3.2.1]octan-3-yl)-2-(3*S*,5*S*)-3,5-dimethylmorpholinobenzoxazole-4-carboxamide Hydrochloride

[00492] Step A: Following general procedure GP-A, methyl 2-chlorobenzoxazole-4-carboxylate and (3*S*,5*S*)-3,5-dimethylmorpholine were converted to methyl 2-((3*S*,5*S*)-3,5-dimethylmorpholino)benzoxazole-4-carboxylate. ¹H NMR consistent.

[00493] Step B: 2-((3*S*,5*S*)-3,5-dimethylmorpholino)benzoxazole-4-carboxylic acid was synthesized by following general procedure GP-B3. MS consistent.

[00494] Step C: Following general procedure GP-C1, a mixture of 2-((3*S*,5*S*)-3,5-dimethylmorpholino)benzoxazole-4-carboxylic acid and 8-methyl-8-azabicyclo[3.2.1]octan-3-amine dihydrochloride were coupled to provide *N*-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)-2-(3*S*,5*S*)-3,5-dimethylmorpholino)benzoxazole-4-carboxamide, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00495] Example 102: Preparation of *Endo-N*-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-(2,2-dimethylpiperazin-1-yl)benzoxazole-4-carboxamide Hydrochloride

[00496] Step A: To an iced-cooled solution of 2,2-dimethylpiperazine (1.0 g, 8.76 mmol) in methanol (200 mL) was added di-*tert*-butyl dicarbonate (1.91 g, 8.76 mmol) and triethylamine (2.67 g, 26.27 mmol). The reaction mixture was stirred at room temperature for 20 h. The solvent was removed under reduced pressure and the residual oil was extracted with CHCl₃ (3 × 60 mL). The organic phase was concentrated under reduced pressure to afford *tert*-butyl 3,3-dimethylpiperazine-1-carboxylate (662 mg, 35%) as yellow oil. MS consistent.

[00497] Step B: Following general procedure GP-A, *tert*-butyl 3,3-dimethylpiperazine-1-carboxylate and methyl 2-chlorobenzoxazole-4-carboxylate were converted to methyl 2-(4-(*tert*-butoxycarbonyl)-2,2-dimethylpiperazin-1-yl)benzoxazole-4-carboxylate. ¹H NMR and MS consistent.

[00498] Step C: Lithium 2-(4-(*tert*-butoxycarbonyl)-2,2-dimethylpiperazin-1-yl)benzoxazole-4-carboxylate was synthesized by following general procedure GP-B2. MS consistent.

[00499] Step D: Following general procedure GP-C1, lithium 2-(4-(*tert*-butoxycarbonyl)-2,2-dimethylpiperazin-1-yl)benzoxazole-4-carboxylate and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride coupled to provide *tert*-butyl 3,3-dimethyl-4-(4-(9-methyl-9-azabicyclo[3.3.1]nonan-3-ylcarbamoyl)benzoxazol-2-yl)piperazine-1-carboxylate. MS consistent.

[00500] Step E: To a solution of *tert*-butyl 3,3-dimethyl-4-(4-(9-methyl-9-azabicyclo[3.3.1]nonan-3-ylcarbamoyl)benzoxazol-2-yl)piperazine-1-carboxylate (63 mg, 0.12 mmol) in CH₂Cl₂ (1 mL) was added TFA (1 mL) at 0 °C. The reaction mixture was stirred at 0 °C for 30 min, then at room temperature for 30 min. The reaction mixture was concentrated under reduced pressure and the resulting residue was dissolved in CH₂Cl₂ (50 mL) and washed with an aqueous saturated NaHCO₃ solution (25 mL). The organic layer was separated, dried over MgSO₄, filtered, and concentrated under reduced pressure to afford *endo*-*N*-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-(2,2-dimethylpiperazin-1-yl)benzoxazole-4-carboxamide (28.5 mg, 56%) as a white solid, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00501] Example 103: Preparation of (*S*)-*N*-(Quinulidin-8-yl)-2-amino-6-chlorobenzoxazole-4-carboxamide Hydrochloride

[00502] Step A: To a solution of di(1H-imidazole-1-yl)methanimine (1.74 g, 10.83 mmol) in tetrahydrofuran (50 mL) was added methyl-2-amino-3-chloro-3-hydroxybenzoate (1.75 g, 8.66 mmol) at room temperature and the resulting reaction

mixture was heated to reflux for 17 h. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The residue was dissolved in CH₂Cl₂ (100 mL) and washed with H₂O (1 × 100 mL), saturated aqueous NH₄Cl (3 × 100 mL), brine (1 × 100 mL), dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The crude material was purified by trituration from EtOAc to afford methyl 2-amino-6-chlorobenzoxazole-4-carboxylate (1.05 g, 54%) as a light brown solid. ¹H NMR and MS consistent.

[00503] Step B: A mixture of methyl 2-amino-6-chlorobenzoxazole-4-carboxylate (1.05 g, 4.65 mmol) and di-*tert*-butyldicarbonate (3.15 g, 3.25 mmol) in CH₂Cl₂ (50 mL) was stirred at room temperature for 17 h. The reaction was concentrated under reduced pressure. The crude material was purified by column chromatography (99:1, CH₂Cl₂/CH₃OH) to afford methyl 2-(*tert*-butoxycarbonylamino)-6-chlorobenzoxazole-4-carboxylate (720 mg, 36%) as a light yellow solid. ¹H NMR and MS consistent.

[00504] Step C: Following general procedure GP-B3, methyl 2-(*tert*-butoxycarbonylamino)-6-chlorobenzoxazole-4-carboxylate was converted to 2-(*tert*-butoxycarbonylamino-4-yl)benzoxazole-4-carboxylic acid. MS consistent

[00505] Step D: Following general procedure GP-C1, 2-(*tert*-butoxycarbonylamino-4-yl)benzoxazole-4-carboxylic acid and (*S*)-(-)-3-aminoquinuclidine dihydrochloride coupled to provide *tert*-butyl 6-chloro-4-(quinuclidin-8-yl-carbamoyl)benzoxazole-2-yl-carbamate. MS consistent.

[00506] Step E: To a solution of *tert*-butyl 6-chloro-4-(quinuclidin-8-yl-carbamoyl)benzoxazole-2-yl-carbamate (71 mg, 0.17 mmol) in CH₂Cl₂ (1 mL) was added TFA (1 mL). The reaction mixture stirred at room temperature for 3 h. The reaction mixture was concentrated under reduced pressure and the crude material was treated with concentrated ammonium hydroxide to adjust the pH to 7. The mixture was concentrated under reduced pressure and the crude material was purified by preparative TLC (90:9:1 CH₂Cl₂/CH₃OH/concentrated NH₄OH) to afford (*S*)-*N*-(quinuclidin-8-yl)-2-amino-6-chlorobenzoxazole-4-carboxamide (21 mg, 38%) as a

white solid, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00507] Example 104: Preparation of (*S*)-*N*-(Quinulidin-8-yl)-2-ethylaminobenzoxazole-4-carboxamide Hydrochloride

[00508] Step A: Following general procedure GP-A, methyl 2-chlorobenzoxazole-4-carboxylate and ethylamine converted to methyl 2-(ethylamino)benzoxazole-4-carboxylate. ¹H NMR and MS consistent.

[00509] Step B: Lithium 2-(4-(*tert*-butoxycarbonyl)-2,2-dimethylpiperazin-1-yl)benzoxazole-4-carboxylate was synthesized by following general procedure GP-B3. MS consistent.

[00510] Step C: Following general procedure GP-C1, 2-(ethylamino)benzoxazole-4-carboxylic acid and (*S*)-(-)-3-aminoquinuclidine dihydrochloride were coupled to provide (*S*)-*N*-(quinulidin-8-yl)-2-ethylaminobenzoxazole-4-carboxamide, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00511] Example 105: Preparation of *Endo-N*-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-ethylbenzoxazole-4-carboxamide Hydrochloride

[00512] Following general procedure GP-C1, 2-(ethylamino)benzoxazole-4-carboxylic acid and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to provide *endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-ethylbenzoxazole-4-carboxamide, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00513] Example 106: Preparation of *Endo*-6-Chloro-*N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((*S*)-3-methylmorpholino)benzoxazole-4-carboxamide Hydrochloride

[00514] Step A: A solution of (*S*)-(+)-2-amino-1-propanol (5.0 g, 67.0 mmol) in toluene (60 mL) was added drop wise at 0 °C to a stirred suspension of NaH (60% in mineral oil, 6.2 g, 145 mmol) in toluene (150 mL). The cooling bath was removed and the reaction mixture was stirred at room temperature for 0.5 h. A solution of ethyl chloroacetate (8.0 mL, 73.8 mmol) in toluene (60 mL) was then added drop wise at room temperature and the resulting reaction mixture heated at reflux for 20 h. The reaction was cooled to room temperature and solid ammonium chloride (5 g, 96.7 mmol) added to the reaction. The reaction mixture was stirred for 20 min, filtered and the filtrate concentrated under reduced pressure to yield a yellow syrup. Purification by column chromatography (silica gel, 94.5:5:0.5 CH₂Cl₂/CH₃OH/NH₄OH) afforded (*S*)-5-methylmorpholin-3-one (6.5 g, 84%) as an off-white semi-solid. ¹H NMR and MS consistent.

[00515] Step B: A solution of (*S*)-5-methylmorpholin-3-one (6.9 g, 59.9 mmol) in tetrahydrofuran (40 mL) was added drop wise at 0 °C to a solution of LiAlH₄ hydride (1.0 M solution in THF, 120.0 mL, 120 mmol) in tetrahydrofuran (40 mL). The ice bath was removed and the reaction mixture was heated at reflux for 18 h. The reaction was cooled in an ice-bath and excess hydride reagent was quenched by careful, drop wise addition of water (5 mL), 15% sodium hydroxide (5 mL) and water (15 mL). The resulting mixture was stirred at room temperature for 1 h and the reaction mixture was filtered through a pad of Celite and the pad rinsed with ethyl acetate (100 mL). The filtrate was washed with saturated brine solution, dried over Na₂SO₄, filtered and concentrated under reduced pressure to provide (*S*)-3-methylmorpholine as a red oil. Due to the products suspected high volatility, the (*S*)-3-methylmorpholine was used in the next step without further isolation or purification.

[00516] Step C: Following general procedure GP-A, 2,6-dichlorobenzoxazole-4-carboxylate and (*S*)-3-methylmorpholine hydrochloride converted to (*S*)-methyl 6-chloro-2-(3-methylmorpholino)-benz-oxazole-4-carboxylate. ¹H NMR consistent.

[00517] Step D: To (*S*)-methyl 6-chloro-2-(3-methylmorpholino)benzoxazole-4-carboxylate (390 mg, 1.25 mmol) in tetrahydrofuran (20 mL) was added potassium trimethyl-silanolate (178 mg, 1.25 mmol). The reaction mixture was heated to reflux

for 45 min. Then, additional potassium trimethylsilanolate (178 mg, 1.25 mmol) was added. After 30 min, the reaction mixture was cooled to ambient temperature. The solid was collected by vacuum filtration, rinsed with diethyl ether and dried to afford crude (*S*)-potassium 6-chloro-2-(3-methylmorpholino)benzoxazole-4-carboxylate (454 mg, quantitative) which was directly elaborated without purification. ¹H NMR consistent.

[00518] Step E: Following general procedure GP-C2, (*S*)-potassium 6-chloro-2-(3-methylmorpholino)benzoxazole-4-carboxylate and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to provide 6-chloro-*N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((*S*)-3-methylmorpholino)benzoxazole-4-carboxamide, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00519] Example 107: Preparation of *Endo-N*-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2*S*,6*S*)-2,6-dimethylpiperazine-1-yl)-7-fluorobenzoxazole-4-carboxamide hydrochloride

[00520] Step A: Methyl 2-((2*S*,6*S*)-4-(*tert*-butoxycarbonyl)-2,6-dimethylpiperazin-1-yl)-7-fluorobenzoxazole-4-carboxylate was synthesized by following general procedure GP-A. ¹H NMR and MS consistent.

[00521] Step B: Following general procedure GP-B3, methyl 2-((2*S*,6*S*)-4-(*tert*-butoxycarbonyl)-2,6-dimethylpiperazin-1-yl)-7-fluorobenzoxazole-4-carboxylate converted to 2-((2*S*,6*S*)-4-(*tert*-butoxycarbonyl)-2,6-dimethylpiperazin-1-yl)-7-fluorobenzoxazole-4-carboxylic acid. MS consistent

[00522] Step C: Following general procedure GP-C1, 2-((2*S*,6*S*)-4-(*tert*-butoxycarbonyl)-2,6-dimethylpiperazin-1-yl)-7-fluorobenzoxazole-4-carboxylic acid and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to provide *endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2*S*,6*S*)-2,6-dimethyl-4-*tert*-butoxycarbonyl-piperazine-1-yl)-7-fluorobenzoxazole-4-carboxamide. MS consistent.

[00523] Step D: *Endo-N*-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2*S*,6*S*)-2,6-dimethyl-4-*tert*-butoxycarbonyl-piperazine-1-yl)-7-fluorobenzoxazole-4-carboxamide was dissolved in 3 ml of 50% TFA in CH₂Cl₂ and stirred for 3.5 h at ambient temperature. The solvent was removed under vacuum, and the residue was neutralized by ion-exchange chromatography (SCX-2 column, 5g) to afford *endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2*S*,6*S*)-2,6-dimethylpiperazine-1-yl)-7-fluorobenzoxazole-4-carboxamide hydrochloride (62 mg) as a clear oil, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00524] Example 108: Preparation of (*S*)-*N*-(quinuclidin-8-yl)-6-chloro-2-(dimethylamino)benzoxazole-4-carboxamide Hydrochloride

[00525] Step A: Methyl 2-(dimethylamino)-6-chlorobenzoxazole-4-carboxylate was synthesized by following general procedure GP-A. MS consistent.

[00526] Step C: Lithium 2-(dimethylamino)-6-chlorobenzoxazole-4-carboxylate was synthesized by following general procedure GP-B2. MS consistent

[00527] Step D: Following general procedure GP-C1, lithium 2-(dimethylamino)-6-chlorobenzoxazole-4-carboxylate and (*S*)-(-)-3-aminoquinuclidine dihydrochloride were coupled to provide (*S*)-*N*-(quinuclidin-8-yl)-6-chloro-2-(dimethylamino)benzoxazole-4-carboxamide, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00528] Example 109: Preparation of (*S*)-*N*-(quinulidin-8-yl)-2-(2,2,2-trifluoroethylethylamino)benzoxazole-4-carboxamide Hydrochloride

[00529] Step A: Methyl 2-(2,2,2-trifluoroethylamino)benzoxazole-4-carboxylate was synthesized by following general procedure GP-A. ¹H NMR and MS consistent.

[00530] Step B: 2-(2,2,2-trifluoroethylamino)benzoxazole-4-carboxylic acid synthesized by following general procedure GP-B3. ¹H NMR and MS consistent.

[00531] Step C: Following general procedure GP-C1, 2-(2,2,2-trifluoroethylamino)benzoxazole-4-carboxylic acid and (*S*)-(-)-3-aminoquinuclidine dihydrochloride coupled to provide (*S*)-*N*-(quinulidin-8-yl)-2-(2,2,2-trifluoroethylethylamino)benzoxazole-4-carboxamide, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00532] Example 110: Preparation of *Endo-N*-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2*S*,6*S*)-4-acetyl-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxamide Hydrochloride

[00533] Step A: To an ice-cold solution of (2*S*,6*S*)-2,6-dimethylpiperazine (712 mg, 6.24 mmol) in CH₂Cl₂ (28 mL) was added di-*tert*-butyl dicarbonate (1.50 g, 6.86 mmol), triethylamine (1.33 g, 13.09 mmol) and *N,N*-dimethylpyridin-4-amine (38.1 mg, 0.31 mmol). The reaction mixture was stirred at 0 °C for 15 min, then warmed to room temperature and stirred for 20 h. The solvent was removed under reduced pressure. The residue was dried to afford (3*S*,5*S*)-*tert*-butyl 3,5-dimethylpiperazine-1-carboxylate (1.79 g, 100%) as white solid. MS consistent.

[00534] Step B: Methyl 2-(4-(*tert*-butoxycarbonyl)-2*S*, 6*S*-dimethylpiperazin-1-yl)benzoxazole-4-carboxylate was synthesized by following general procedure GP-A. MS consistent.

[00535] Step C: To an ice-cold solution of methyl 2-(4-(*tert*-butoxycarbonyl)-2*S*, 6*S*-dimethylpiperazin-1-yl)benzoxazole-4-carboxylate (360.1 mg, 0.924 mmol) in CH₂Cl₂ (5 mL) was added TFA (0.343 mL, 4.62 mmol). The reaction stirred for 18 h under an atmosphere of nitrogen while gradually warming to room temperature. The reaction was quenched with saturated aqueous sodium bicarbonate solution (15 mL). The organic layer was separated, washed with brine (10 mL), dried (Na₂SO₄), filtered, and concentrated under reduced pressure to provide methyl 2-((2*S*,6*S*)-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxylate as an oil (285 mg, >99%). This material was carried on to the next step without characterization.

[00536] Step D: To an ice-cold solution of methyl 2-((2*S*,6*S*)-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxylate (273 mg, 0.943 mmol) in CH₂Cl₂ (5 mL) was added pyridine (0.114 mL, 1.41 mmol) followed by acetyl chloride (0.100 mL, 1.41 mmol) under an atmosphere of nitrogen. The mixture stirred for 18 h while gradually warming to room temperature. The reaction was diluted with CH₂Cl₂ (10 mL) and washed with saturated aqueous NaHCO₃ solution (10 mL), 1 N HCl solution (10 mL), and brine (10 mL). The organic layer was dried (Na₂SO₄), filtered, and concentrated under reduced pressure. The resulting residue was purified by column chromatography over silica gel (0% to 50%, 95:15:1.5, CH₂Cl₂/CH₃OH/concentrated NH₄OH in CH₂Cl₂) to give methyl 2-((2*S*,6*S*)-4-acetyl-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxylate as an oil (62.1 mg, 20%). ¹H NMR and MS consistent.

[00537] Step E: Following general procedure GP-B2, methyl 2-((2*S*,6*S*)-4-acetyl-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxylate was reacted with lithium hydroxide monohydrate to provide lithium 2-((2*S*,6*S*)-4-acetyl-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxylate. ¹H NMR and MS consistent.

[00538] Step F: Following general procedure GP-C2, lithium 2-((2*S*,6*S*)-4-acetyl-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxylate and 9-methyl-9-azabicyclo[3.3.1]nonan-3-amine dihydrochloride were coupled to provide *endo*-*N*-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2*S*,6*S*)-4-acetyl-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxamide, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00539] Example 111: Preparation of *Endo*-2-amino-6-chloro-*N*-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)benzoxazole-4-carboxamide Hydrochloride

[00540] Step A: 2-amino-6-chlorobenzoxazole-4-carboxylic acid was synthesized by following general procedure GP-B2. ¹H NMR and MS consistent.

[00541] Step B: Following general procedure GP-C1, 2-amino-6-chlorobenzoxazole-4-carboxylic acid and 9-methyl-9-azabicyclo[3.3.1]nonan-3-amine dihydrochloride coupled to provide *endo*-2-amino-6-chloro-*N*-(9-methyl-9-

azabicyclo[3.3.1]nonan-3-yl)benzoxazole-4-carboxamide, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00542] Example 112: Preparation of (*S*)-*N*-(quinulidin-8-yl)-2-amino-7-fluorobenzoxazole-4-carboxamide Hydrochloride

[00543] Step A: A mixture of methyl 2-chloro-7-fluoro- 2,3-dihydrobenzoxazole-4-carboxylate (720 mg, 3.14 mmol), o-nitrophenol (660 mg, 4.71 mmol) and K₂CO₃ (0.96 g, 7.0 mmol), in THF (10 mL), was stirred at ambient for 2.5 h. The reaction mixture was filtered and gaseous ammonia was bubbled through the mother liquor for 10 min. The precipitate formed was filtered and washed with THF (20 mL). The combined THF fractions were concentrated, and the resulting residue crystallized from methanol to afford methyl 2-amino-7-fluorobenzoxazole-4-carboxylate (173 mg, 26%) as a pale yellow solid. ¹H NMR and MS consistent.

[00544] Step B: 2-amino-7-fluorobenzoxazole-4-carboxylic acid synthesized by following general procedure GP-B3. ¹H NMR and MS consistent.

[00545] Step C: Following general procedure GP-C1, 2-amino-7-fluorobenzoxazole-4-carboxylic acid and (*S*)-(-)-3-aminoquinuclidine dihydrochloride were coupled to provide (*S*)-*N*-(quinulidin-8-yl)-2-amino-7-fluorobenzoxazole-4-carboxamide, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00546] Example 113: Preparation of (*S*)-*N*-(quinulidin-8-yl)-2-methylaminobenzoxazole-4-carboxamide Hydrochloride

[00547] Step A: Methyl 2-methylaminobenzoxazole-4-carboxylate was synthesized by following general procedure GP-A. ¹H NMR and MS consistent.

[00548] Step B: 2-methylaminobenzoxazole-4-carboxylic acid was synthesized by following general procedure GP-B3. ¹H NMR and MS consistent.

[00549] Step C: Following general procedure GP-C1, 2-methylaminobenzoxazole-4-carboxylic acid and (*S*)-(-)-3-aminoquinuclidine dihydrochloride were coupled to provide (*S*)-*N*-(quinulidin-8-yl)-2-methylaminobenzoxazole-4-carboxamide, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00550] Example 114: Preparation of *Endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-6-chloro-2-((2*S*,6*S*)-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxamide Hydrochloride

[00551] Step A: Methyl 2-((2*S*,6*S*)-4-(*tert*-butoxycarbonyl)-2,6-dimethylpiperazin-1-yl)-6-chlorobenzoxazole-4-carboxylate was synthesized by following general procedure GP-A. ¹H NMR and MS consistent.

[00552] Step B: Lithium 2-((2*S*,6*S*)-4-(*tert*-butoxycarbonyl)-2,6-dimethylpiperazin-1-yl)-6-chlorobenzoxazole-4-carboxylate was synthesized by following general procedure GP-B2. ¹H NMR and MS consistent.

[00553] Step C: Following general procedure GP-C1, lithium 2-((2*S*,6*S*)-4-(*tert*-butoxycarbonyl)-2,6-dimethylpiperazin-1-yl)-6-chlorobenzoxazole-4-carboxylate and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to provide *endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-6-chloro-2-((2*S*,6*S*)-2,6-dimethylpiperazin-1-yl) benzoxazole-4-carboxamide. ¹H NMR and MS consistent.

[00554] Step D: To solution of *endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-6-chloro-2-((2*S*,6*S*)-2,6-dimethylpiperazin-1-yl) benzoxazole-4-carboxamide (294 mg, 0.53 mmol) in CH₂Cl₂ (10 mL) was added TFA (3.0 mL, 38.90 mmol) and the mixture was stirred at room temperature for 2 h then concentrated under reduced pressure. The crude material was purified by preparative TLC (silica gel, 100% 9:1 CH₂Cl₂/CH₃OH) to 100% 90:9:1 CH₂Cl₂/CH₃OH/concentrated NH₄OH) followed by semi-preparative HPLC (Luna C18(2), 10% CH₃CN /0.05%TFA in H₂O/0.05%TFA to 100% CH₃CN/0.05%TFA over 30 min, λ = 223 nm). The desired fractions were first treated with 10% aqueous K₂CO₃ until pH=9 and then the aqueous phase was

concentrated to 1/3 of its original volume under reduced pressure and the aqueous phase was extracted with ethyl acetate (2 x 25 mL). The combined organic phase was washed with brine (10 mL) dried (Na₂SO₄), and concentrated under reduced pressure to afford *endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-6-chloro-2-((2*S*,6*S*)-2,6-dimethylpiperazin-1-yl) benzoxazole-4-carboxamide which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00555] Example 115: Preparation of (*S*)-*N*-(Quinuclidin-8-yl)-2-diethylaminobenzoxazole-4-carboxamide Hydrochloride

[00556] Step A: Lithium 2-(diethylamino)benzoxazole-4-carboxylate was synthesized by following general procedure GP-B2. ¹H NMR and MS consistent

[00557] Step B: Following general procedure GP-C2, lithium 2-(diethylamino)benzoxazole-4-carboxylate and (*S*)-(-)-3-aminoquinuclidine dihydrochloride were coupled to provide (*S*)-*N*-(quinuclidin-8-yl)-2-diethylaminobenzoxazole-4-carboxamide, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00558] Example 116: Preparation of (*S*)-*N*-(Quinuclidin-8-yl)-2-amino-6-fluorobenzoxazole-4-carboxamide Hydrochloride

[00559] Step A: To a solution of fuming nitric acid (18 mL) and glacial acetic acid (36 mL) preheated to 55 °C was added 3-fluoro-5-methoxybenzoic acid (3.00 g, 17.63 mmol) portion wise over 5 min. The mixture was maintained at 55 °C for an additional 90 min. The reaction was cooled to ambient temperature and poured onto ice-water (200 mL). The pH of the solution was adjusted to 2 using aqueous NaHCO₃ solution. The precipitate formed was filtered and washed with hexanes (100 mL) to afford 5-fluoro-3-methoxy-2-nitrobenzoic acid (2.52 g, 66%) as a white solid. ¹H NMR and MS consistent.

[00560] Step B: 5-Fluoro-3-methoxy-2-nitrobenzoic acid (2.78 g, 12.92 mmol) was suspended in a mixture of 48% aqueous hydrobromic acid/glacial acetic acid (7:2, 90 mL) and the mixture heated at 135 °C for 41 h. The solvent was removed

under reduced pressure, the crude 5-fluoro-3-hydroxy-2-nitrobenzoic acid (2.60 g) was directly elaborated without further characterization/purification. MS consistent.

[00561] Step C: Crude 5-fluoro-3-hydroxy-2-nitrobenzoic acid (2.60 g, 12.92 mmol), was suspended in CH₃OH (50 mL) and cooled to 0 °C. Thionyl chloride (9.4 ml, 129.26 mmol) was added drop wise at 0 °C. The mixture was allowed to warm to ambient temperature then heated to reflux for 17 h. The reaction mixture was allowed to cool to ambient temperature, and the solvent removed under reduced pressure. The crude material was purified by column chromatography (silica gel, 0 to 20% CH₃OH in CH₂Cl₂) to afford methyl 5-fluoro-3-hydroxy-2-nitrobenzoate (1.15 g, 41%) as a white solid. ¹H NMR and MS consistent.

[00562] Step D: To a solution of methyl 5-fluoro-3-hydroxy-2-nitrobenzoate (1.15g, 5.34 mmol) in a mixture of CH₃OH and glacial acetic acid (3:1, 40 mL) was added 10 wt % palladium on activated charcoal (0.20g, 17 wt%). The suspension was placed in a Parr hydrogenation apparatus under a H₂ atmosphere at 50 psi for 1.5 h. The suspension was filtered through diatomaceous earth eluting with CH₂Cl₂/CH₃OH (9:1, 100 mL). Purification by column chromatography (silica gel, 5 to 100% EtOAc in hexanes) afforded methyl 2-amino-5-fluoro-3-hydroxybenzoate (0.80 g, 83%) as a white solid. ¹H NMR and MS consistent.

[00563] Step E: To a solution of di-(1H-imidazole-1-yl) methanimine (1.05 g, 6.52 mmol) in THF (30 mL) was added methyl-2-amino-5-fluoro-3-hydroxybenzoate (0.96 g, 5.22 mmol) at room temperature and the resulting reaction mixture was heated to reflux for 6 h. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The residue was dissolved in EtOAc (200 mL) and washed with H₂O (4 × 100 mL), saturated aqueous ammonium chloride (2 × 100 mL), brine (2 × 100 mL), dried over Na₂SO₄, filtered, and concentrated under reduced pressure to afford methyl 2-amino-6-fluorobenzoxazole-4-carboxylate (0.95 g, 87%) as a yellow solid. ¹H NMR and MS consistent.

[00564] Step F: 2-amino-6-fluorobenzoxazole-4-carboxylic acid was synthesized by following general procedure GP-B3. ¹H NMR consistent

[00565] Step G: Following general procedure GP-C1, 2-amino-6-fluorobenzoxazole-4-carboxylic acid and (*S*)-(-)-3-aminoquinuclidine dihydrochloride were coupled to provide (*S*)-*N*-(quinulidin-8-yl)-2-amino-6-fluorobenzoxazole-4-carboxamide, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00566] Example 117: Preparation of *Endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2*S*,6*S*)-4-benzoyl-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxamide Hydrochloride

[00567] Step A: A mixture of *endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2*S*,6*S*)-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxamide (81.4 mg, 0.19 mmol), benzoyl chloride (34 mL, 0.30 mmol) and triethylamine (55 mL, 0.40 mmol), in CH₂Cl₂ (5 mL) was stirred at ambient temperature for 6 h. The reaction mixture was quenched with saturated NaHCO₃ (10 mL) and extracted with CH₂Cl₂ (2 × 30 mL). The combined organic layers were washed successively with 1N HCl (30 mL) brine (25 mL), dried (Na₂SO₄) and concentrated under reduced pressure. Purification by column chromatography (silica gel, 9:1 CH₂Cl₂/CH₃OH to 90:9:1 CH₂Cl₂/CH₃OH/NH₄OH) afforded *endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-(4-benzoyl-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxamide (36 mg, 35 %) as a white solid. ¹H NMR and MS consistent.

[00568] Step B: Following general procedure GP-D1, *endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2*S*,6*S*)-4-benzoyl-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxamide was converted to the hydrochloride salt. ¹H NMR and MS consistent.

[00569] Example 118: Preparation of (*S*)-*N*-(Quinulidin-8-yl)-2-((2*S*,6*S*)-2,6-dimethylpiperazine-1-yl)-7-fluorobenzoxazole-4-carboxamide hydrochloride

[00570] Step A: Following general procedure GP-C1, a mixture of 2-((2*S*,6*S*)-4-(*tert*-butoxycarbonyl)-2,6-dimethylpiperazin-1-yl)-7-fluorobenzoxazole-4-carboxylic acid and (*S*)-(-)-3-aminoquinuclidine dihydrochloride were coupled to provide (*S*)-*N*-(quinulidin-8-yl)-2-((2*S*,6*S*)-2,6-dimethyl-4-*tert*-butoxycarbonyl-

piperazine-1-yl)-7-fluorobenzoxazole-4-carboxamide. The carboxamide was dissolved in 3 ml of 50% TFA in CH₂Cl₂ and stirred for 2 h at ambient temperature. The solvent was removed under vacuum, and the residue was neutralized by ion-exchange chromatography (SCX-2 column, 2 g) to afford a clear oil (15.4 mg). The hydrochloride salt was obtained following general procedure GP-D1. ¹H NMR and MS consistent.

[00571] Example 119: Preparation of *Endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2*S*,6*S*)-4-(cyclopropylmethyl)-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxamide Hydrochloride

[00572] Step A: A mixture of *endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2*S*,6*S*)-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxamide (51 mg, 0.12 mmol), cyclopropane carboxaldehyde (28 mL, 0.37 mmol) and NaBH(OAc)₃ (79 mg, 0.37 mmol), in CH₂Cl₂/HOAc (100:1, 10.1 mL), was stirred at ambient temperature for 17 h. The reaction mixture was diluted with saturated NaHCO₃ (10 mL) and extracted with EtOAc/ CH₂Cl₂ (1:1, 2 × 20 mL). The combined organic layers were washed with brine (25 mL), dried (Na₂SO₄) and concentrated under reduced pressure. Purification by preparative TLC (silica gel, :9:1 CH₂Cl₂/CH₃OH/NH₄OH) afforded *endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2*S*,6*S*)-4-(cyclopropylmethyl)-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxamide (35.8 mg, 62 %) as a white foam: ¹H NMR and MS consistent.

[00573] Step B: Following general procedure GP-D1, *endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2*S*,6*S*)-4-(cyclopropylmethyl)-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxamide was converted to the hydrochloride salt. ¹H NMR and MS consistent.

[00574] Example 120: Preparation of *Endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2*S*,6*S*)-2,4,6-trimethyl-3-oxopiperazin-1-yl)benzoxazole-4-carboxamide Hydrochloride

[00575] Step A: To a -30 °C solution of N-t-Boc-L-alanine (20.0 g, 0.106 mol) and triethylamine (16.8 mL, 0.119 mol) in THF (300 mL) was added isobutyl

chloroformate (15.0 mL, 0.114 mol) drop wise. The reaction mixture was warmed to ambient temperature over 1.25 h and then stirred for 3.5 h. The reaction mixture was cooled to 0 °C and a solution of *N*-methylbenzylamine (14.3 mL, 0.111 mol) and triethylamine (18.8 mL, 0.134 mol) in THF (60 mL) was added drop wise. The reaction mixture was allowed to warm to ambient temperature. After 16 h, saturated NaHCO₃ (200 mL) was added and most of the THF was removed under reduced pressure. The remaining aqueous layer was extracted with EtOAc (2 × 250 mL). The combined organic layers were washed with brine (100 mL), dried (Na₂SO₄) and concentrated under reduced pressure. Purification by column chromatography (silica gel, 10% EtOAc in hexanes to 40% EtOAc in hexanes) gave (*S*)-*tert*-butyl 1-(benzyl(methyl)amino)-1-oxopropan-2-ylcarbamate (26.3 g, 85%) as a colorless oil. ¹H NMR consistent.

[00576] Step B: To an ice-cold solution of (*S*)-*tert*-butyl 1-(benzyl(methyl)amino)-1-oxopropan-2-ylcarbamate (26.3 g, 0.090 mol) in CH₂Cl₂ (100 mL) was added TFA(100 mL) drop wise. The reaction mixture was warmed to ambient temperature. After 18.5 h, the reaction mixture was concentrated under reduced pressure. The residue was partitioned between CH₂Cl₂ (250 mL) and saturated NaHCO₃ (250 mL). The aqueous layer was separated and basified to pH = 9-10 with 1 N NaOH and extracted again with CH₂Cl₂ (100 mL). The combined organic layers were washed with saturated NaHCO₃ (100 mL), H₂O (100 mL), brine (100 mL), dried (Na₂SO₄) and concentrated under reduced pressure to give (*S*)-2-amino-*N*-benzyl-*N*-methylpropanamide (14.7 g, 85%) as an amber oil. ¹H NMR consistent.

[00577] Step C: To an ice-cold solution of (*S*)-2-amino-*N*-benzyl-*N*-methylpropanamide (1.70 g, 8.80 mmol) in THF (25 mL) was added lithium aluminum hydride (18 mL of a 1.0 M solution in THF, 17.6 mmol) drop wise. The reaction mixture was heated at reflux for 2 h. After cooling to 0 °C, the reaction mixture was quenched by the drop wise addition of H₂O (0.7 mL), 15% sodium hydroxide (0.7 mL), and H₂O (2.1 mL). Diethyl ether (25 mL) was added during the quench. The mixture was filtered through Celite and the Celite pad was rinsed with diethyl ether. The filtrate was concentrated under reduced pressure to give (*S*)-*N*-1-

benzyl-*N*-1-methylpropane-1,2-diamine (1.3 g, 82%) as a colorless oil: ^1H NMR consistent.

[00578] Step D: To an ice-cold solution of (*R*)-(+)-lactate (0.91 g, 8.7 mmol) in CH_2Cl_2 (40 mL) was added TiF_4 (1.5 mL, 8.7 mmol). After 10 min a solution of 2,6-lutidine (1.2 mL, 10 mmol) in CH_2Cl_2 (3 mL) was added. After another 10 min, a solution of (*S*)-*N*-1-benzyl-*N*-1-methylpropane-1,2-diamine (1.3 g, 7.3 mmol) and triethylamine (1.6 mL, 12 mmol) in CH_2Cl_2 (10 mL) was added. The reaction mixture was allowed to warm to ambient temperature. After 15.25 h, the reaction mixture was partitioned between saturated NaHCO_3 (100 mL) and CH_2Cl_2 (100 mL). The aqueous layer was separated and extracted again with CH_2Cl_2 (20 mL). The combined organic layers were washed with H_2O (50 mL), brine (50 mL), dried (Na_2SO_4) and concentrated under reduced pressure. Purification by column chromatography (silica gel, EtOAc) gave (*S*)-methyl 2-((*S*)-1-(benzyl(methyl)-amino)propan-2-ylamino)propanoate (0.98 g, 50% which contains 2,6-lutidine, ca 2:1 product:2,6-lutidine). ^1H NMR consistent.

[00579] Step E: (*S*)-Methyl 2-((*S*)-1-(benzyl(methyl)- amino)propan-2-ylamino)-propanoate (0.98 g, 3.7 mmol), concentrated HCl (mL) and 10% Pd on carbon (200 mg) were combined in ethanol (25 mL). The reaction mixture was shaken on a Parr apparatus under a hydrogen atmosphere (15 psi). After 16.75 h, the reaction mixture was filtered through Celite and the Celite pad was rinsed with CH_3OH and CH_2Cl_2 . The filtrate was concentrated under reduced pressure to give (*S*)-methyl 2-((*S*)-1-(methylamino)propan-2-ylamino)propanoate which was used directly in the next reaction. MS consistent.

[00580] Step F: The crude (*S*)-methyl 2-((*S*)-1-(methylamino)propan-2-ylaminopropanoate was dissolved in ethanol (30 mL) and *p*-toluenesulfonic acid (175 mg) was added. The reaction mixture was heated to reflux for 18 h and then concentrated under reduced pressure. The residue was partitioned between CH_2Cl_2 (40 mL) and saturated NaHCO_3 (20 mL). The aqueous layer was separated and extracted again with CH_2Cl_2 (20 mL). The combined organic layers were dried (Na_2SO_4) and concentrated under reduced pressure to give (3*S*,5*S*)-1,3,5-

trimethylpiperazin-2-one (230 mg, 43% which contains 2,6-lutidine, ca 2:1 product:2,6-lutidine) as an amber oil. ¹H NMR consistent.

[00581] Synthesis of methyl 2-((2*S*,6*S*)-2,4,6-trimethyl-3-oxopiperazin-1-yl)benzoxazole-4-carboxylate: A mixture of methyl 2-chlorobenzoxazole-4-carboxylate (342 mg, 1.62 mmol), (3*S*,5*S*)-1,3,5-trimethylpiperazin-2-one (230 mg, 1.62 mmol) and potassium carbonate (670 mg, 4.85 mmol), in DMF (10 mL), was stirred at ambient temperature for 16 h. The reaction mixture was diluted with H₂O (20 mL) and extracted with EtOAc (2 × 40 mL). The combined organic layers were washed with 0.5 N HCl (10 mL), H₂O (10 mL), brine (10 mL), dried (Na₂SO₄), filtered, and concentrated under reduced pressure. The residue was triturated with diethyl ether and the solids were removed by filtration. The filtrate was concentrated and purified by column chromatography (silica gel, 10% CH₂Cl₂ in EtOAc to 100% EtOAc) to give methyl 2-((2*S*,6*S*)-2,4,6-trimethyl-3-oxopiperazin-1-yl)benzoxazole-4-carboxylate (98 mg, 19%): ¹H NMR consistent.

[00582] Step G: Following general procedure GP-B3, A mixture of methyl 2-((2*S*,6*S*)-2,4,6-trimethyl-3-oxopiperazin-1-yl)benzoxazole-4-carboxylate was converted to 2-((2*S*,6*S*)-2,4,6-trimethyl-3-oxopiperazin-1-yl)benzoxazole-4-carboxylic acid which was directly elaborated directly without purification.

[00583] Step H: Following general procedure GP-C2, 2-((2*S*,6*S*)-2,4,6-trimethyl-3-oxopiperazin-1-yl)benzoxazole-4-carboxylic acid and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to provide *endo*-*N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2*S*,6*S*)-2,4,6-trimethyl-3-oxopiperazin-1-yl)benzoxazole-4-carboxamide hydrochloride, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00584] Example 121: Preparation of *Endo*-2-amino-6-fluoro-*N*-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)benzoxazole-4-carboxamide Hydrochloride

[00585] Step A: To a solution of di(1*H*-imidazole-1-yl)methanimine (1.05 g, 6.52 mmol) in THF (30 mL) was added methyl-2-amino-5-fluoro-3-hydroxybenzoate (0.96 g, 5.22 mmol) at room temperature and the resulting reaction mixture was

heated to reflux for 6 h. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The residue was dissolved in EtOAc (200 mL) and washed with H₂O (4 × 100 mL), saturated aqueous ammonium chloride (2 × 100 mL), brine (2 × 100 mL), dried over Na₂SO₄, filtered, and concentrated under reduced pressure to afford methyl 2-amino-6-fluorobenzoxazole-4-carboxylate (0.95 g, 87%). ¹H NMR and MS consistent.

[00586] Step B: 2-amino-6-fluorobenzoxazole-4-carboxylic acid was synthesized by following general procedure GP-B3. ¹H NMR and MS consistent.

[00587] Step C: Following general procedure GP-C1, 2-amino-6-fluorobenzoxazole-4-carboxylic acid and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to provide *endo*-2-amino-6-fluoro-*N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)benzoxazole-4-carboxamide, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00588] Example 122: Preparation of *Endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2*S*,6*S*)-2,4,6-trimethylpiperazin-1-yl)benzoxazole-4-carboxamide Hydrochloride

[00589] A mixture of *endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2*S*,6*S*)-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxamide (80 mg, 0.19 mmol), formaldehyde 37% aqueous solution, 6.0 mL, 76.9 mmol) and NaCNBH₃ (25 mg, 0.39 mmol), in CH₃OH/HOAc 10:1, 5.5 mL), was stirred at ambient temperature for 24 h. The reaction mixture was concentrated, diluted with saturated ammonium chloride (5 mL), and extracted with CH₂Cl₂ (2 × 25 mL). The aqueous phase was adjusted to pH 8 and extracted with CH₂Cl₂ (2 × 25 mL) and the combined organic phase was washed with brine (10 mL), dried (Na₂SO₄) and concentrated under reduced pressure to provide *endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2*S*,6*S*)-2,4,6-trimethylpiperazin-1-yl)benzoxazole-4-carboxamide, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00590] Example 123: Preparation of *Endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((3*S*,5*S*)/(3*R*,5*R*)-3,5-dimethylthiomorpholine 1,1-dioxide)benzoxazole-4-carboxamide Hydrochloride

[00591] Step A: To solution of freshly distilled chloroacetone (31.0 g, 0.33 mol) in ethanol (335 mL) was added drop wise at 75 °C under N₂ a solution of Na₂S·9H₂O (40.2g, 0.17 mol) in H₂O (110 mL). After addition was complete the reaction mixture was heated for a further 45 min before it was allowed to cool to ambient temperature. The reaction mixture was concentrated to approximately half volume under reduced pressure and then partitioned with EtOAc (400 mL) and brine (200 mL). The layers were separated and the organic layer washed with brine (200 mL) and dried over Na₂SO₄ before concentrating under reduced pressure. The residual orange oil was distilled under high vacuum (140 °C, <1 mm Hg) to afford 1,1'-thiodipropen-2-one (10.3 g, 42%). ¹H NMR and MS consistent.

[00592] Step B: To a stirred solution of diphenylmethanamine (2.36 mL, 13.7 mmol), HOAc (0.86 mL, 15.1 mmol), and potassium hydroxide (0.19 g, 3.4 mmol) in CH₃OH (25 mL) cooled to 0 °C was added a solution of 1,1'-thiodipropen-2-one (2.0 g, 13.7 mmol) in CH₃OH (10 mL). NaCNBH₃ (0.86 g, 13.7 mmol) was then added and the reaction mixture stirred at ambient temperature for 16 h. A further portion of NaCNBH₃ (0.43 g, 6.9 mmol) was added and the reaction mixture stirred for another 4 h. The reaction mixture was partitioned with EtOAc (150 mL) and H₂O (150 mL) and the layers separated. The organic layer was washed with H₂O (150 mL), brine (150 mL) then dried over Na₂SO₄. After concentration under reduced pressure, the resulting residue was purified by flash column chromatography (silica gel, 10-50% EtOAc in hexanes) to afford (3*S*,5*S*)/(3*R*,5*R*)-4-benzhydryl-3,5-dimethylthiomorpholine (0.52 g, 13%). ¹H NMR consistent.

[00593] Step C: A mixture of (3*S*,5*S*)/(3*R*,5*R*)-4-benzhydryl-3,5-dimethylthiomorpholine (0.52 g, 1.75 mmol), triethylsilane (1.12 mL, 7.00 mmol) and TFA (20 mL) was heated at reflux for 20 h. After cooling to ambient temperature the reaction mixture was concentrated under reduced pressure and the residue partitioned with 1 N HCl (10 mL) and Et₂O (20 mL). The aqueous layer was separated and

lyophilized to afford (3S,5S)/(3R,5R)-3,5-dimethylthiomorpholine hydrochloride (285 mg, 97%). ¹H NMR and MS consistent.

[00594] Step D: A mixture of methyl 2-chlorobenzoxazole-4-carboxylate (360 mg, 1.70 mmol), (3S,5S)/(3R,5R)-3,5-dimethylthiomorpholine hydrochloride (270 mg, 1.62 mmol) and potassium carbonate (672 mg, 4.86 mmol), in DMF (5 mL), was stirred at ambient temperature for 6 h. The reaction was then heated at 55 °C for 2 h before it was diluted with H₂O (20 mL) and extracted with EtOAc (2 × 40 mL). The combined organic layers were washed with brine, dried (Na₂SO₄) and concentrated under reduced pressure. The crude methyl ester was retained for future purification. The remaining aqueous phase was then acidified to pH 5 by addition of 1 N HCl and extracted with CH₂Cl₂ (2 × 40 mL). The combined organic extracts were dried (Na₂SO₄) and concentrated under reduced pressure to afford crude (3S,5S)/(3R,5R)-3,5-dimethylthiomorpholino)benzoxazole-4-carboxylic acid (70 mg, 15%) which was directly elaborated without purification.

[00595] Step E: To a solution of (3S,5S)/(3R,5R)-3,5-dimethylthiomorpholino)benzoxazole-4-carboxylic acid (68 mg, 0.23 mmol) in CH₃OH (3 mL) and dioxane (0.5 mL) was added a solution of Oxone (215 mg 0.35 mmol) in H₂O (1.5 mL). The resulting slurry was stirred at ambient temperature for 2 h then partitioned with CH₂Cl₂ (50 mL) and H₂O (50 mL). The layers were separated and the aqueous phase extracted further with CH₂Cl₂ (50 mL). The combined organic extracts were washed with brine, dried over Na₂SO₄ and concentrated under reduced pressure to afford crude 2-((3S,5S)/(3R,5R)-3,5-dimethylthiomorpholine 1,1-dioxide)benzoxazole-4-carboxylic acid which was directly elaborated without purification. ¹H NMR consistent.

[00596] Step F: Following general procedure GP-C1, 2-((3S,5S)/(3R,5R)-3,5-dimethylthiomorpholine 1,1-dioxide)benzoxazole-4-carboxylic acid and *endo*-9-methyl-3-oxa-9-azabicyclo[3.3.1]nonan-7-amine dihydrochloride were coupled to provide *endo*-N-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((3S,5S)/(3R,5R)-3,5-dimethylthiomorpholine 1,1-dioxide)benzoxazole-4-carboxamide, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00597] Example 124: Preparation of *N*-(Quinuclidin-8-yl)-2-((2*S*,6*S*)-2,4,6-trimethyl-3-oxopiperazin-1-yl)benzoxazole-4-carboxamide Hydrochloride

[00598] Step A: Following general procedure GP-A, mixture of methyl 2-chlorobenzoxazole-4-carboxylate and (3*S*,5*S*)-1,3,5-trimethylpiperazin-2-one converted to methyl 2-((2*S*,6*S*)-2,4,6-trimethyl-3-oxopiperazin-1-yl)benzoxazole-4-carboxylate. ¹H NMR consistent.

[00599] Step B: 2-((2*S*,6*S*)-2,4,6-trimethyl-3-oxopiperazin-1-yl)benzoxazole-4-carboxylic acid Following general procedure GP-B3 which was directly elaborated without characterization.

[00600] Step C: Following general procedure GP-C2, 2-((2*S*,6*S*)-2,4,6-trimethyl-3-oxopiperazin-1-yl)benzoxazole-4-carboxylic acid (237 mg, 0.78 mmol) and (*S*)-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to provide *N*-(quinuclidin-8-yl)-2-((2*S*,6*S*)-2,4,6-trimethyl-3-oxopiperazin-1-yl)benzoxazole-4-carboxamide, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00601] Example 125: Preparation of *Endo*-(3*S*, 5*S*)-Methyl 3, 5-dimethyl-4-(4-(9-methyl-9-azabicyclo[3.3.1]nonan-3-ylcarbamoyl)benzoxazol-2-yl)piperazine-1-carboxylate Hydrochloride

[00602] Step A: To an ice-cold mixture of *endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2*S*,6*S*)-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxamide (222.1 mg, 0.54 mmol), and triethylamine (82.1 mL, 0.59 mmol), in CH₂Cl₂ (5 mL) was added methyl chloroformate (45.1 mL, 0.59 mmol), the mixture was stirred and allowed to warm to ambient temperature and stirred for an additional 20 h. The reaction mixture was quenched with CH₃OH/brine (1:2, 15 mL) and extracted with CH₂Cl₂ (2 × 30 mL). The combined organic layers were washed successively with 1N aqueous HCl (30 mL), brine (25 mL), dried (Na₂SO₄) and concentrated under reduced pressure. Purification by column chromatography (silica gel, 9:1 CH₂Cl₂ /CH₃OH to 90:9:1 CH₂Cl₂/CH₃OH/NH₄OH) afforded (3*S*,5*S*)-methyl 3,5-dimethyl-4-(4-(9-methyl-9-azabicyclo[3.3.1]nonan-3-ylcarbamoyl)benzoxazol-2-

yl)piperazine-1-carboxylate (51.2 mg, 20 %) as an off-white solid. ¹H NMR and MS consistent

[00603] Step B: 3,5-Dimethyl-4-(4-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)carbamoyl)benzoxazol-2-yl)piperazine-1-carboxylate was converted to the hydrochloride salt following of general procedure GP-D1. ¹H NMR and MS consistent

[00604] Example 126: Preparation of *Endo-N*-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((4a*S*,8a*S*)-octahydroquinoxalin-1(2*H*)-yl)benzoxazole-4-carboxamide Dihydrochloride

[00605] Step A: To an ice-cold solution of (1*S*, 2*S*)-(+)-1,2-diaminocyclohexane in H₂O (120 mL) was added chloroacetic acid (3.31 g, 35.02 mmol) and KHCO₃ (3.51 g, 35.02 mmol). The mixture stirred at room temperature for 16 h then heated at 90 °C for 4 h. The mixture cooled to room temperature and was concentrated under reduced pressure to provide (4a*S*,8a*S*)-octahydroquinoxalin-2(1*H*)-one (8.82 g, >99%).

[00606] Step B: A mixture of (4a*S*,8a*S*)-octahydroquinoxalin-2(1*H*)-one (8.82 g, 57.19 mmol), 2,4-dimethoxybenzaldehyde (9.50 g, 57.19 mmol), and sodium triacetoxyborohydride (36.31 g, 171.57 mmol) in 1% HOAc in CH₂Cl₂ (250 mL) was stirred at room temperature for 16 h. The mixture was neutralized with saturated aqueous NaHCO₃ solution (200 mL). The organic layer was separated and washed with H₂O (100 mL), brine (100 mL), dried (Na₂SO₄), filtered, and concentrated under reduced pressure. Purification of the residue by column chromatography (silica gel, 0% to 100% 90:9:1 CH₂Cl₂/CH₃OH/NH₄OH in CH₂Cl₂) afforded (4a*S*,8a*S*)-4-(2,4-dimethoxybenzyl)octahydroquinoxalin-2(1*H*)-one (1.10 g, 11.1% over two steps). ¹H NMR and MS consistent.

[00607] Step C: To an ice-cold 1.0M solution of LiAlH₄ in THF (4.10 mL, 4.10 mmol) was added a solution of (4a*S*,8a*S*)-4-(2,4-dimethoxybenzyl)octahydroquinoxalin-2(1*H*)-one (500 mg, 1.64 mmol) in THF (10 mL). The mixture was heated at reflux for 8 h. The reaction was cooled to 0 °C and

carefully quenched with EtOAc (50 mL) and 1 N NaOH solution (20 mL). The mixture stirred for 30 min and the layers were separated. The organic layer was washed with brine (20 mL), dried (Na₂SO₄), filtered, and concentrated under reduced pressure. Purification of the residue by column chromatography (silica gel, 0% to 60% 90:9:1 CH₂Cl₂/CH₃OH/NH₄OH in CH₂Cl₂) afforded (4aS,8aS)-1-(2,4-dimethoxybenzyl)decahydroquinoxaline (120.1 mg, 25.4%). ¹H NMR and MS consistent.

[00608] Step D: Following of general procedure GP-A, (4aS,8aS)-1-(2,4-dimethoxybenzyl)decahydroquinoxaline (120.1 mg, 0.41 mmol) and methyl 2-chlorobenzoxazole-4-carboxylate were converted to methyl 2-((4aS,8aS)-4-(2,4-dimethoxybenzyl)octahydroquinoxalin-1(2H)-yl)benzoxazole-4-carboxylate. ¹H NMR and MS consistent

[00609] Step E: 2-((4aS,8aS)-4-(2,4-dimethoxybenzyl)octahydroquinoxalin-1(2H)-yl)benzoxazole-4-carboxylic acid was synthesized by following general procedure GP-B3. MS consistent.

[00610] Step F: Following general procedure GP-C2, 2-((4aS,8aS)-4-(2,4-dimethoxybenzyl)octahydroquinoxalin-1(2H)-yl)benzoxazole-4-carboxylic acid and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to provide *endo*-2-((4aS,8aS)-4-(2,4-dimethoxybenzyl)octahydroquinoxalin-1(2H)-yl)-*N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)benzoxazole-4-carboxamide. MS consistent.

[00611] Step G: A mixture of *endo*-2-((4aS,8aS)-4-(2,4-dimethoxybenzyl)octahydroquinoxalin-1(2H)-yl)-*N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)benzoxazole-4-carboxamide (200 mg, 0.34 mmol) 10% palladium on carbon (25 mg, 0.04 mmol) in CH₃OH (10 mL) was subjected to an atmosphere of hydrogen gas under a pressure of 30 psi at room temperature for 7 h. The mixture was filtered and the filter cake was rinsed with CH₃OH. The filtrate was concentrated under reduced pressure. Purification of the residue by column chromatography (silica gel, 0% to 100% 90:9:1 CH₂Cl₂ /CH₃OH/NH₄OH in CH₂Cl₂) afforded *endo*-*N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((4aS,8aS)-

octahydroquinoxalin-1(2H)-yl)benzoxazole-4-carboxamide (25.1 mg, 16.9%). ¹H NMR and MS consistent.

[00612] Step H: Following general procedure GP-D1 *endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((4a*S*,8a*S*)-octahydroquinoxalin-1(2H)-yl)benzoxazole-4-carboxamide was converted in the dihydrochloride salt. ¹H NMR and MS consistent.

[00613] Example 127: Preparation of (*S*)-*N*-(quinulidin-8-yl)-2-amino-6-methylbenzoxazole-4-carboxamide Hydrochloride

[00614] Step A: To a solution of methyl 2-amino-3-methoxybenzoate (13.0 g, 71.8 mmol) in DMF (30 mL) was added NBS (14.38 g, 80.8 mmol) at room temperature and the resulting reaction mixture was stirred for 17 h. The reaction mixture was filtered through Celite, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography (silica gel, 2% to 5% EtOAc in hexanes) to afford methyl 2-amino-5-bromo-3-methoxybenzoate (13.7 g, 73%). ¹H NMR consistent.

[00615] Step B: A mixture of methyl 2-amino-5-bromo-3-methoxybenzoate (6.50 g, 25 mmol), methylboronic acid (3.0 g, 50 mmol), potassium fluoride (5.8 g, 100 mmol) and tri-*t*-butylphosphonium tetrafluoroborate (0.87 g, 3.0 mmol) in THF (200 mL) was deoxygenated and then backfilled with argon. Tris(dibenzylideneacetone)dipalladium(0) (1.43 g, 1.5 mmol), was added and the mixture was heated at 70 °C for 17 h under an argon atmosphere. The reaction mixture was concentrated and the residue purified by column chromatography (silica gel, 0% to 5% EtOAc in hexanes) to afford methyl 2-amino-5-methoxy-3-methylbenzoate (3.55 g, 73%) ¹H NMR consistent.

[00616] Step C: A mixture of methyl 2-amino-5-methoxy-3-methylbenzoate (2.96 g, 15.21 mmol), 48 % HBr (25 mL) and HOAc (2.5 mL) was heated at reflux for 8 h. The reaction mixture was cooled to room temperature to afford a slurry. The solid was isolated and dried under high vacuum to afford desired 2-amino-3-hydroxy-5-methylbenzoic acid hydrobromide (2.32 g, 61%). ¹H NMR consistent.

[00617] Step D: To a solution of 2-amino-3-hydroxy-5-methylbenzoic acid hydrobromide (2.65 g, 10.7 mmol) in anhydrous CH₃OH (50 mL) was added thionyl chloride (3.9 mL, 53.4 mmol) at -78 °C. The resulting reaction mixture was allowed to warm to room temperature and then heated to reflux for 17 h. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The residue was treated with a saturated aqueous NaHCO₃ solution to adjust pH to 7 and then extracted with EtOAc (4 × 100 mL). The combined organic phase was washed with H₂O, brine, dried (Na₂SO₄), filtered and concentrated under reduced pressure to afford methyl 2-amino-3-hydroxy-5-methylbenzoate (1.40 g, 72%): ¹H NMR consistent.

[00618] Step E: To a solution of di (1H-imidazole-1-yl) methanimine (1.56g, 9.67 mmol) in THF (30 mL) was added methyl 2-amino-3-hydroxy-5-methylbenzoate (1.40 g, 7.73 mmol) at room temperature and the resulting reaction mixture was heated at reflux for 6 h. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The residue was dissolved in CH₂Cl₂ (100 mL), treated with saturated aqueous ammonium chloride (25 mL), and then extracted with CH₂Cl₂ (2 × 100 mL). The combined organic phase was washed with brine (2 × 100 mL), dried (Na₂SO₄), filtered, and concentrated under reduced pressure to afford a yellow solid. The solid was triturated from CH₃OH to afford methyl 2-amino-6-methylbenzoxazole-4-carboxylate (0.717 g, 45%). ¹H NMR and MS consistent.

[00619] Step F: Following of general procedure GP-B3, methyl 2-amino-6-methylbenzoxazole-4-carboxylate was converted to 2-amino-6-methylbenzoxazole-4-carboxylic acid. ¹H NMR and MS consistent.

[00620] Step G: Following of general procedure GP-C1, 2-amino-6-methylbenzoxazole-4-carboxylic acid (0.35 g, 1.79 mmol) and (S)-(-)-3-aminoquinuclidine dihydrochloride were coupled to (S)-N-(quinulidin-8-yl)-2-amino-6-methylbenzoxazole-4-carboxamide, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00621] Example 128: Preparation of *Endo-N*-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-amino-5-fluorobenzoxazole-4-carboxamide Hydrochloride

[00622] Step A: A solution of sodium persulfate (15.4 g, 64.5 mmol) in H₂O (160 mL) was added dropwise to a solution of 2-amino-6-fluorobenzoic acid (10 g, 64.5 mmol) in 2 N NaOH (60 mL) over 3 h. The resulting black mixture was stirred for 2 days at ambient temperature, and extracted sequentially with ether (3 L) and EtOAc (1 L). The aqueous layer was concentrated under reduced pressure and the resulting residue was suspended in CH₃OH (1 L) and stirred overnight at ambient temperature. The precipitate was filtered off; the mother liquor was concentrated to 1/3 of initial volume, cooled to -78 °C and treated with SOCl₂ (15 mL, 128 mmol). The mixture was allowed to warm to room temperature then was heated at reflux for 16 h. The mixture was concentrated under reduced pressure and the resulting residue was suspended in EtOAc (1 L) and extracted with saturated aqueous NaHCO₃ (300 mL). The organic fraction was washed with brine, dried (Na₂SO₄), filtered, and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 1:3 EtOAc/hexanes) to afford methyl 2-amino-6-fluoro-3-hydroxybenzoate (0.4 g, 3.3 %). ¹H and MS consistent.

[00623] Step B: To a solution of methyl 2-amino-6-fluoro-3-hydroxybenzoate (0.4 g, 2.2 mmol) in THF (10 mL) was added di-(1H-imidazole-1-yl) methanimine (0.44 g, 2.75 mmol) at room temperature and the resulting reaction mixture was heated at reflux for 16 h. The reaction mixture cooled to room temperature and was concentrated under reduced pressure. The residue was dissolved in CH₂Cl₂ (100 mL), and the solution was treated with saturated aqueous ammonium chloride (25 mL). The organic layer was separated and the aqueous layer was extracted with additional CH₂Cl₂ (2 × 100 mL). The combined organic phase was washed with brine (2 × 100 mL), dried (Na₂SO₄), filtered, and concentrated under reduced pressure to afford a yellow solid. The solid was triturated from ether to afford methyl 2-amino-5-fluorobenzoxazole-4-carboxylate. MS consistent.

[00624] Step C: 2-amino-5-fluorobenzoxazole-4-carboxylic acid was synthesized by following of general procedure GP-B3. MS consistent

[00625] Step D: Following general procedure GP-C1, mixture of 2-amino-5-fluorobenzoxazole-4-carboxylic acid and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to provide *endo*-*N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-amino-5-fluorobenzoxazole-4-carboxamide, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00626] Example 129: Preparation of *Endo*-2-amino-6-methyl-*N*-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)benzoxazole-4-carboxamide Hydrochloride

[00627] Following of general procedure GP-C-1, 2-amino-6-methylbenzoxazole-4-carboxylic acid and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to provide *endo*-2-amino-6-methyl-*N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)benzoxazole-4-carboxamide, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00628] Example 130: Preparation of *Endo*-*N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2*S*,6*S*)-2,6-dimethyl-4-pivaloylpiperazin-1-yl)benzoxazole-4-carboxamide Hydrochloride

[00629] Following general procedure GP-E, *endo*-*N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2*S*,6*S*)-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxamide and pivaloyl chloride were coupled to provide *endo*-*N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2*S*,6*S*)-2,6-dimethyl-4-pivaloylpiperazin-1-yl)benzoxazole-4-carboxamide, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00630] Example 131: Preparation of *Endo*-*N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2*S*,6*S*)-2,6-dimethyl-4-(methylsulfonyl)piperazin-1-yl)benzoxazole-4-carboxamide Hydrochloride

[00631] Following general procedure GP-E, *endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2*S*,6*S*)-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxamide and methane sulfonyl chloride were coupled to provide *endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2*S*,6*S*)-2,6-dimethyl-4-(methanesulfonyl)piperazin-1-yl)benzoxazole-4-carboxamide, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00632] Example 132: Preparation of *Endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2*S*,6*S*)-4-(cyclohexanecarbonyl)-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxamide Hydrochloride

[00633] Following general procedure GP-E, *endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2*S*,6*S*)-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxamide and cyclohexanoyl chloride were coupled to provide *endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2*S*,6*S*)-4-(cyclohexanecarbonyl)-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxamide, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent

[00634] Example 133: Preparation of *Endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2*S*,6*S*)-4-(cyclopentanecarbonyl)-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxamide Hydrochloride

[00635] Following general procedure GP-E, *endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2*S*,6*S*)-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxamide and cyclopentanoyl chloride were coupled to provide *endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2*S*,6*S*)-4-(cyclopentanecarbonyl)-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxamide, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00636] Example 134: Preparation of *Endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2*S*,6*S*)-2,6-dimethyl-4-propionylpiperazin-1-yl)benzoxazole-4-carboxamide Hydrochloride

[00637] Following general procedure GP-E, *endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2*S*,6*S*)-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxamide and propionyl chloride were coupled to provide *endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2*S*,6*S*)-2,6-dimethyl-4-propionylpiperazin-1-yl)benzoxazole-4-carboxamide, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00638] Example 135: Preparation of *Endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2*S*,6*S*)-4-isobutyryl-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxamide Hydrochloride

[00639] Following general procedure GP-E, *endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2*S*,6*S*)-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxamide and isobutyryl chloride were coupled to provide *endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2*S*,6*S*)-2,6-dimethyl-4-isobutyrylpiperazin-1-yl)benzoxazole-4-carboxamide, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00640] Example 136: Preparation of *Endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2*S*,6*S*)-2,6-dimethyl-4-(dimethylcarbamoyl)piperazin-1-yl)benzoxazole-4-carboxamide Hydrochloride

[00641] Step A: To a solution of methyl 2-((2*S*,6*S*)-2,6-dimethyl-4-piperazin-1-yl)benzoxazole-4-carboxylate (235 mg, 0.81 mmol) and diisopropylethylamine (339 mL, 1.95 mmol) in CH₂Cl₂ (5 mL) was added 1-dimethylcarbamoylcarbonyl chloride (163 mL, 1.79 mmol). The reaction mixture was stirred at ambient temperature for 90 min then partitioned with CH₂Cl₂ (50 mL) and 0.5 M citric acid (20 mL). The organic layer was washed with brine, dried (Na₂SO₄), filtered, and concentrated under reduced pressure. The crude material was purified by column chromatography (silica gel, dichloromethane then 90:9:1 CH₂Cl₂/CH₃OH/concentrated NH₄OH) to afford methyl 2-((2*S*,6*S*)-2,6-dimethyl-4-(dimethylcarbamoyl)piperazin-1-yl)benzoxazole-4-carboxylate as a colorless oil (270 mg, 92%). ¹H NMR and MS consistent.

[00642] Step B: To a solution of methyl 2-((2*S*,6*S*)-2,6-dimethyl-4-(dimethylcarbamoyl)piperazin-1-yl)benzoxazole-4-carboxylate (265 mg, 0.74 mmol) in pyridine (5 mL) was added LiI (984 mg, 7.35 mmol). The mixture was heated at 110 °C for 14 h and allowed to cool to ambient temperature. The reaction was partially concentrated under reduced pressure before partitioning with 9:1 CH₂Cl₂/2-propanol (50 mL) and 1 N HCl (20 mL). The organic layer was washed with brine, dried (Na₂SO₄) and concentrated under reduced pressure to afford crude 2-((2*S*,6*S*)-2,6-dimethyl-4-(dimethylcarbamoyl)piperazin-1-yl)benzoxazole-4-carboxylic acid as an orange oil which was directly elaborated without purification.

[00643] Step C: Following general procedure GP-C1, 2-((2*S*,6*S*)-2,6-dimethyl-4-(dimethylcarbamoyl)piperazin-1-yl)benzoxazole-4-carboxylic acid and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to provide *endo*-*N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2*S*,6*S*)-2,6-dimethyl-4-(dimethylcarbamoyl)piperazin-1-yl)benzoxazole-4-carboxamide, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00644] Example 137: Preparation of *Endo*-*N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2*S*,6*S*)-2,6-dimethyl-4-(2,2,2-trifluoroethyl)piperazin-1-yl)benzoxazole-4-carboxamide Hydrochloride

[00645] To a mixture of *endo*-*N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2*S*,6*S*)-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxamide (150 mg, 0.36 mmol), and pyridine (65 mL, 0.80 mmol) in *N,N*-dimethylformamide (10 mL) was added 2,2,2-trifluoroethyl trifluoromethanesulfonate (115 mL, 0.80 mmol) and the mixture was heated to 110 °C for 20 h. The reaction was quenched with saturated ammonium chloride (10 mL) and extracted with CH₂Cl₂ (2 × 30 mL). The combined organic layers were washed successively with NaHCO₃ (10 mL) and brine (25 mL), and then dried (Na₂SO₄), filtered, and the solution concentrated under reduced pressure. Purification by column chromatography (silica gel, 9:1 CH₂Cl₂/CH₃OH to 90:9:1 CH₂Cl₂/CH₃OH/NH₄OH) afforded *endo*-*N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2*S*,6*S*)-2,6-dimethyl-4-(2,2,2-trifluoroethyl)piperazin-1-yl)benzoxazole-4-carboxamide (52 mg, 29%) which was

converted to the hydrochloride salt following general procedure GP-D1. ^1H NMR and MS consistent.

[00646] Example 138: Preparation of *Endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2*S*,6*S*)-4-(isobutoxycarbonyl)-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxamide Hydrochloride

[00647] Step A: To a solution of lithium iodide (185 mg, 1.38 mmol) in refluxing anhydrous pyridine (10 mL) was added methyl 2-((2*S*,6*S*)-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxylate (100 mg, 0.346 mmol) and the reaction mixture was refluxed for 24 hours. The mixture was cooled to room temperature, concentrated to dryness and dried in vacuo to provide lithium 2-((2*S*,6*S*)-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxylate as a solid which was used without further purification: MS consistent

[00648] Step B: To a vigorously stirred suspension of lithium 2-((2*S*,6*S*)-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxylate (97 mg, 0.346 mmol) and NaHCO_3 (87 mg, 1.037 mmol) in chloroform (6 mL) and H_2O (6 mL) was added dropwise isobutyl chloroformate (54 mL, 0.415 mmol). The reaction mixture was stirred at room temperature for 2 h, then neutralized with 1N aqueous HCl, and concentrated under reduced pressure to provide 2-((2*S*,6*S*)-4-(isobutoxycarbonyl)-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxylic acid. MS consistent.

[00649] Step C: Following general procedure GP-C1, a mixture of 2-((2*S*,6*S*)-4-(isobutoxycarbonyl)-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxylic acid and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to provide *endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2*S*,6*S*)-4-(isobutoxycarbonyl)-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxamide which was converted to the hydrochloride salt following general procedure GP-D1. ^1H NMR and MS consistent.

[00650] Example 139: Preparation of (*S*)-*N*-(quinulidin-8-yl)-2-amino-5-fluorobenzoxazole-4-carboxamide Hydrochloride

[00651] Following the general procedure GP-C2, 2-amino-5-fluorobenzoxazole-4-carboxylic acid and (*S*)-(-)-3-aminoquinuclidine dihydrochloride were coupled to (*S*)-*N*-(quinulidin-8-yl)-2-amino-5-fluorobenzoxazole-4-carboxamide which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00652] Example 140: Preparation of *Endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2*S*,6*S*)-2,6-dimethyl-4-(pyrrolidine-1-carbonyl)piperazin-1-yl)benzoxazole-4-carboxamide hydrochloride

[00653] Step A: Following of general procedure GP-E, methyl 2-((2*S*,6*S*)-2,6-dimethyl-4-piperazin-1-yl)benzoxazole-4-carboxylate and 1-pyrrolidinecarbonyl chloride were coupled to provide methyl 2-((2*S*,6*S*)-2,6-dimethyl-4-(pyrrolidine-1-carbonyl)piperazin-1-yl)benzoxazole-4-carboxylate. ¹H NMR and MS consistent.

[00654] Step B: To a solution of methyl 2-((2*S*,6*S*)-2,6-dimethyl-4-(pyrrolidine-1-carbonyl)piperazin-1-yl)benzoxazole-4-carboxylate (200 mg, 0.52 mmol) in pyridine (2 mL) was added lithium iodide (550 mg, 4.11 mmol). The mixture was heated at 110 °C for 18 h and allowed to cool to ambient temperature before partitioning with 9:1 mixture of dichloromethane and isopropanol (100 mL) and 1 N HCl (50 mL). The non-homogenous organic layer was washed with brine and concentrated under reduced pressure. The residue was treated with 9:1 toluene/methanol (100 mL) and concentrated in vacuo to afford crude 2-((2*S*,6*S*)-2,6-dimethyl-4-(pyrrolidine-1-carbonyl)piperazin-1-yl)benzoxazole-4-carboxylic acid as a brown solid which was directly elaborated without purification.

[00655] Step C: Following general procedure GP-C1, mixture of 2-((2*S*,6*S*)-2,6-dimethyl-4-(pyrrolidine-1-carbonyl)piperazin-1-yl)benzoxazole-4-carboxylic acid and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to provide *endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2*S*,6*S*)-2,6-dimethyl-4-(pyrrolidine-1-carbonyl)piperazin-1-yl)benzoxazole-4-carboxamide except that reaction mixture was extracted with CH₂Cl₂/2-propanol (9/1). The carboximide was converted to the dihydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00656] Example 141: Preparation of *Endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2*S*,6*S*)-2,6-dimethyl-4-(piperidine-1-carbonyl)piperazin-1-yl)benzoxazole-4-carboxamide hydrochloride

[00657] Step A: Following general procedure GP-E, methyl 2-((2*S*,6*S*)-2,6-dimethyl-4-piperazin-1-yl)benzoxazole-4-carboxylate and 1-piperidinecarbonyl chloride were coupled to provide methyl 2-((2*S*,6*S*)-2,6-dimethyl-4-(piperidine-1-carbonyl)piperazin-1-yl)benzoxazole-4-carboxylate. ¹H NMR and MS consistent.

[00658] Step B: To a solution of methyl 2-((2*S*,6*S*)-2,6-dimethyl-4-(piperidine-1-carbonyl)piperazin-1-yl)benzoxazole-4-carboxylate (200 mg, 0.52 mmol) in pyridine (2 mL) was added lithium iodide (495 mg, 3.70 mmol). The mixture was heated at 110 °C for 18 h and allowed to cool to ambient temperature before partitioning with 9:1 dichloromethane/2-propanol (100 mL) and 1 N HCl (50 mL). The non-homogenous organic layer was washed with brine and concentrated in vacuo. The residue was treated with 9:1 mixture of toluene and methanol (100 mL) and concentrated under reduced pressure to afford crude 2-((2*S*,6*S*)-2,6-dimethyl-4-(piperidine-1-carbonyl)piperazin-1-yl)benzoxazole-4-carboxylic acid as a brown solid which was directly elaborated without purification.

[00659] Step C: Following the general procedure GP-C1, a mixture of 2-((2*S*,6*S*)-2,6-dimethyl-4-(piperidine-1-carbonyl)piperazin-1-yl)benzoxazole-4-carboxylic acid and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to provide *endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2*S*,6*S*)-2,6-dimethyl-4-(piperidine-1-carbonyl)piperazin-1-yl)benzoxazole-4-carboxamide except that the reaction mixture was extracted with 9:1 CH₂Cl₂/2-propanol (9/1). The carboxamide was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00660] Example 142: Preparation of (*S*)-*N*-(quinuclidin-8-yl) 2-((2*S*,6*S*)-4-benzyl-2,6-dimethyl-3-oxopiperazin-1-yl)benzoxazole-4-carboxamide Hydrochloride

[00661] Step A: 2-((2*S*,6*S*)-4-benzyl-2,6-dimethyl-3-oxopiperazin-1-yl)benzoxazole-4-carboxylic acid was synthesized by following general procedure GP-B3. ¹H NMR consistent.

[00662] Step B: Following the general procedure GP-C2, a mixture of 2-((2*S*,6*S*)-4-benzyl-2,6-dimethyl-3-oxopiperazin-1-yl)benzoxazole-4-carboxylic acid and (*S*)-(-)-3-aminoquinuclidine dihydrochloride were coupled to provide (*S*)-*N*-(quinuclidin-8-yl) 2-((2*S*,6*S*)-4-benzyl-2,6-dimethyl-3-oxopiperazin-1-yl)benzoxazole-4-carboxamide which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00663] Example 143: Preparation of *Endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2*S*,6*S*)-4-(isopropoxycarbonyl)-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxamide Hydrochloride

[00664] Step A: To a vigorously stirred suspension of lithium 2-((2*S*,6*S*)-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxylate (208 mg, 0.743 mmol) and NaHCO₃ (187 mg, 2.23 mmol) in chloroform (12 mL) and H₂O (2 mL) was added dropwise isopropylchloroformate (1M solution in toluene, 892 mL, 0.891 mmol). The reaction mixture was stirred at room temperature for 2 h, then neutralized with 1N aqueous HCl. The mixture was concentrated under reduced pressure to provide lithium 2-((2*S*,6*S*)-4-(isopropoxycarbonyl)-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxylate. MS consistent.

[00665] Step B: Following general procedure GP-C1, lithium 2-((2*S*,6*S*)-4-(isopropoxycarbonyl)-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxylate and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to provide *endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2*S*,6*S*)-4-(isopropoxycarbonyl)-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxamide which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00666] Example 144: Preparation of *Endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2*S*,6*S*)-4-(ethoxycarbonyl)-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxamide Hydrochloride

[00667] Step A: To a vigorously stirred suspension of methyl 2-((2*S*,6*S*)-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxylate (208 mg, 0.743 mmol) and NaHCO₃ (187 mg, 2.23 mmol) in chloroform (12 mL) and H₂O (2 mL) was added dropwise ethylchloroformate (85 mL, 0.891 mmol). The reaction mixture was stirred at room temperature for 2 h, then neutralized with 1N aqueous HCl, and concentrated under reduced pressure to provide lithium 2-((2*S*,6*S*)-4-(ethoxycarbonyl)-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxylate. MS consistent.

[00668] Step B: Following general procedure GP-C1, lithium 2-((2*S*,6*S*)-4-(ethoxycarbonyl)-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxylate and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to provide *endo-N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2*S*,6*S*)-4-(ethoxycarbonyl)-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxamide which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00669] Example 145: Preparation of *N*-((4-methyl-1H-imidazol-5-yl)methyl)2-amino-6-chlorobenzoxazole-4-carboxamide

[00670] Step A: A solution of 5-(chloromethyl)-4-methyl-1-trityl-1H-imidazole (1.00 g, 2.68 mmol) in ammonia (7 N in CH₃OH, 4 mL, 28 mmol) was heated to 50 °C in a sealed tube for 16 h. The reaction mixture was concentrated under reduced pressure and the crude material purified by column chromatography (silica gel, 100% CH₂Cl₂ to 50% CH₃OH) to provide (4-methyl-1-trityl-1H-imidazol-5-yl)methanamine (250 mg, 26%). ¹H NMR consistent.

[00671] Step B: A solution of (4-methyl-1-trityl-1H-imidazol-5-yl)methanamine (250 mg, 0.07 mmol) in glacial acetic acid (50 mL) was heated to reflux for 2 h. The reaction mixture was cooled to room temperature and concentrated to dryness to provide (4-methyl-1H-imidazol-5-yl)methanamine (79 mg, quant.). ¹H NMR and MS consistent.

[00672] Step C: Following general procedure GP-C1, 2-amino-6-chlorobenzoxazole-4-carboxylic acid and (4-methyl-1H-imidazol-5-yl)methanamine were coupled to provide *N*-((4-methyl-1H-imidazol-5-yl)methyl)2-amino-6-chlorobenzoxazole-4-carboxamide which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00673] Example 146: Preparation of *Endo-N*-(9-azabicyclo[3.3.1]nonan-3-yl)-2-((2*S*,6*S*)-2,6-dimethyl-4-(pyrrolidine-1-carbonyl)piperazin-1-yl)benzoxazole-4-carboxamide hydrochloride

[00674] *Endo-N*-(9-azabicyclo[3.3.1]nonan-3-yl)-2-((2*S*,6*S*)-2,6-dimethyl-4-(pyrrolidine-1-carbonyl)piperazin-1-yl)benzoxazole-4-carboxamide was unexpectedly isolated as a side product from the coupling of 2-((2*S*,6*S*)-2,6-dimethyl-4-(pyrrolidine-1-carbonyl)piperazin-1-yl)benzoxazole-4-carboxylic acid and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride (see Example 141) following general procedure GP-C1 except that reaction mixture was extracted with CH₂Cl₂/2-propanol (9/1). The carboxamide was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00675] Example 147: Preparation of *Endo-N*-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2*S**,5*R**)-4-allyl-2,5-dimethylpiperazin-1-yl)benzoxazole-4-carboxamide Dihydrochloride

[00676] Step A: Following general procedure GP-A, methyl 2-chlorobenzoxazole-4-carboxylate and (±) trans-1-allyl-2,5-dimethylpiperazine were converted methyl 2-((2*S**,5*R**)-4-allyl-2,5-dimethylpiperazin-1-yl)benzoxazole-4-carboxylate. ¹H NMR and MS consistent.

[00677] Step B: 2-((2*S**,5*R**)-4-allyl-2,5-dimethylpiperazin-1-yl)benzoxazole-4-carboxylic acid was synthesized by following general procedure GP-B3 which was subsequently used without further purification. MS consistent.

[00678] Step C: 2-((2S*,5R*)-4-allyl-2,5-dimethylpiperazin-1-yl)benzoxazole-4-carboxylic acid and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled following general procedure GP-C1 to afford *endo*-N-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2S*,5R*)-4-allyl-2,5-dimethylpiperazin-1-yl)benzoxazole-4-carboxamide. ¹H NMR and MS consistent.

[00679] Step D: Following general procedure GP-D1, *endo*-N-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2S*,5R*)-4-allyl-2,5-dimethylpiperazin-1-yl)benzoxazole-4-carboxamide was converted to *endo*-N-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2S*,5R*)-4-allyl-2,5-dimethylpiperazin-1-yl)benzoxazole-4-carboxamide dihydrochloride except that the product was isolated from an aqueous solution by lyophilization. ¹H NMR and MS consistent.

[00680] Example 148: Preparation of *Endo*-N-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2S,6S)-4-benzyl-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxamide Hydrochloride

[00681] Step A: Following general procedure GP-A, methyl 2-chlorobenzoxazole-4-carboxylate was treated with potassium carbonate and (3S,5S)-1-benzyl-3,5-dimethylpiperazine in N,N-dimethylformamide at 40 °C for 60 h to provide methyl 2-((2S,6S)-4-benzyl-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxylate. ¹H NMR and MS consistent.

[00682] Step B: Lithium 2-((2S,6S)-4-benzyl-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxylate was synthesized by following general procedure GP-B2. ¹H NMR consistent

[00683] Step C: Following general procedure GP-C1, lithium 2-((2S,6S)-4-benzyl-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxylate and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride coupled to provide *endo*-N-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((2S,6S)-4-benzyl-2,6-dimethylpiperazin-1-yl)benzoxazole-4-carboxamide, which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00684] Example 151: Preparation of *Endo-N*-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((*R*)-3-ethylmorpholino)-benzoxazole-4-carboxamide Hydrochloride

[00685] Step A: To an ice cold, stirred suspension of sodium hydride (60% in oil, 2.1 g, 52.0 mmol) in toluene (65 mL) was added dropwise a solution of (*R*)-2-aminobutan-1-ol (2.0 g, 22.0 mmol) in toluene (48 mL). After the addition was completed, the reaction mixture was warmed to room temperature and a solution of ethyl chloroacetate (3.0 g, 25.0 mmol) in toluene (12 mL) was added in a dropwise manner. The resulting mixture was then stirred at reflux for 20 h, cooled to room temperature, and solid ammonium chloride (2.7 g, 52.0 mmol) added to the reaction. The mixture was stirred for 20 min and then concentrated under reduced pressure. The crude material was purified by column chromatography (silica gel, 95:5 dichloromethane/methanol) to give (*R*)-5-ethylmorpholin-3-one (2.0 g, 70%) as a light yellow solid. To ice-cold tetrahydrofuran (10 mL) was added lithium aluminum hydride (1.0 M solution in tetrahydrofuran, 31.0 mL, 31.0 mmol). Once the addition was complete, a solution of (*R*)-5-ethylmorpholin-3-one (2.0 g, 16 mmol) in tetrahydrofuran (10 mL) was added dropwise over 20 min. Once the addition was completed, the ice bath was removed and the reaction mixture stirred at reflux for 20 h. The reaction was cooled in an ice-bath and to this was slowly added water (1.3 mL), then a 15% solution of sodium hydroxide (1.3 mL), and then water (1.3 mL). The resulting mixture was stirred at room temperature for 1.5 h and then filtered washing the solid with ethyl acetate (50 mL). The filtrate was concentrated at room temperature under reduced pressure to provide (*R*)-3-ethylmorpholine (1.6 g, 90%) as a light yellow oil. ¹H NMR and MS consistent.

[00686] Step B: (*R*)-Methyl-2-(3-ethylmorpholino)benzoxazole-4-carboxylate was synthesized by following general procedure GP-A. MS consistent.

[00687] Step C: (*R*)-2-(3-Ethylmorpholino)benzoxazole-4-carboxylic acid was synthesized following general procedure GP-B3. MS consistent.

[00688] Step D: Following general procedure GP-C2, (*R*)-2-(3-ethylmorpholino)benzoxazole-4-carboxylic acid and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride

[00689] Were coupled to provide *endo*-*N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((*R*)-3-ethylmorpholino)-benzoxazole-4-carboxamide which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00690] Example 152: Preparation of *Endo*-*N*-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((*R*)-3-isopropylmorpholino)benzoxazole-4-carboxamide Hydrochloride

[00691] Step A: To an ice cold, stirred suspension of sodium hydride (60% in oil, 1.6 g, 40.0 mmol) in toluene (52 mL) was added dropwise a solution of (*R*)-2-amino-3-methylbutan-1-ol (1.8 g, 17.0 mmol) in toluene (38 mL). After the addition was completed, the reaction mixture was warmed to room temperature and a solution of ethyl chloroacetate (2.3 g, 19.0 mmol) in toluene (8 mL) was added in a dropwise manner. The resulting mixture was then stirred at reflux for 20 h, cooled to room temperature, and solid ammonium chloride (2.1 g, 40.0 mmol) added to the reaction. The mixture was stirred for 20 min and then concentrated under reduced pressure. The crude material was purified by column chromatography (silica gel, 95:5 dichloromethane/methanol) to give (*R*)-5-isopropylmorpholin-3-one (1.7 g, 68%) as a light yellow solid.

[00692] To ice-cold tetrahydrofuran (8.0 mL) was added lithium aluminum hydride (1.0 M solution in tetrahydrofuran, 23.0 mL, 23.0 mmol). Once the addition was complete, a solution of (*R*)-5-isopropylmorpholin-3-one (1.7 g, 12.0 mmol) in tetrahydrofuran (8 mL) was added dropwise over 20 min. Once the addition was completed, the ice bath was removed and the reaction mixture stirred at reflux for 20 h. The reaction was cooled in an ice-bath and to this was slowly added water (1.0 mL), then a 15% solution of sodium hydroxide (1.0 mL), and then water (1.0 mL). The resulting mixture was stirred at room temperature for 1.5 h and then filtered washing the solid with ethyl acetate (50 mL). The filtrate was concentrated at room

temperature under reduced pressure to provide (*R*)-3-isopropylmorpholine (1.4 g, 93%) as a light yellow oil. ¹H NMR consistent.

[00693] Step B: (*R*)-Methyl-2-(3-isopropylmorpholino)benzoxazole-4-carboxylate was synthesized following general procedure GP-A. MS consistent.

[00694] Step C: (*R*)-2-(3-Isopropylmorpholino)benzoxazole-4-carboxylic acid was synthesized following general procedure GP-B3. MS consistent.

[00695] Step D: Following general procedure GP-C2, (*R*)-2-(3-isopropylmorpholino)benzoxazole-4-carboxylic acid and *endo*-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane dihydrochloride were coupled to provide *endo*-*N*-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2-((*R*)-3-isopropylmorpholino)-benzoxazole-4-carboxamide which was converted to the hydrochloride salt following general procedure GP-D1. ¹H NMR and MS consistent.

[00696] In other embodiments where R² is not hydrogen or halogen, the method of preparation of the foregoing is similar to those presented in U.S. Patent Application 2006/183769, the entire contents of which are herein incorporated by reference. In situations where an inconsistency in nomenclature between the foregoing application and the present application may exist, the nomenclature and definitions of the present application take precedence.

[00697] Compound Affinity for the human 5-HT₃ Receptor (Assay A)

[00698] Compounds were tested by MDS Pharma Services – Taiwan Ltd., 158 Li-The Road, Peitou, Taipei, Taiwan 112 R.O.C. In order to evaluate the relative affinity of the various compounds for the human 5-HT₃ receptor, N1E-155 cell lines were developed to express the target protein. For binding, these cells were homogenized, centrifuged and washed with buffer (20 mM HEPES, 150 mM NaCl, pH 7.4) then suspended in 0.5mL of buffer and [³H]-GR65630 added at a concentration of 3.5x10⁻¹⁰ M. An initial single concentration of 10⁻⁷ M of the test compound was then added. Incubation was carried out at room temperature for 60 minutes at 25 °C then was terminated by rapid removal of the incubation medium.

Radioactivity was assessed using liquid scintillation spectrophotometry after exposure to scintillation cocktail for at least three hours. Compounds displaying greater than 75% inhibition of radioligand binding at 10^{-7} M were then resubmitted to the above protocol using the following range of test compound concentrations: 10^{-9} M, 10^{-8} M, 3×10^{-8} M, 10^{-7} M, 3×10^{-7} M and 10^{-6} M. Competition curves were then plotted and IC₅₀ determinations made using non-linear regression analysis. K_i values were then calculated from the Cheng-Prusoff equation. In all of the above binding studies the non-specific determinant was MDL-72222 (1.0 μ M).


[00699] Compound Affinity for the human 5-HT₃ Receptor (Assay B)







[00700] The relative affinity of the various compounds for the human 5-HT₃ receptor was measured in a radioligand binding assay, using a scintillation proximity assay (SPA) format. Test compounds were dissolved to 10 mM in 100% DMSO, then serially diluted at 10x assay concentrations in 100% DMSO in 96-well polypropylene plates and further diluted to 4x assay concentrations with the assay buffer. Samples were incubated in 50 mM Tris-HCl, pH 7.5, 3 mM MgCl₂, 1 mM EDTA and 10% DMSO with 10 nM [9-methyl-³H]BRL-43694 (Perkin Elmer), 3 μ g of human 5-HT₃ receptor membranes (Perkin Elmer) and 0.5 mg/mL SPA beads (WGA PVT, Amersham Biosciences) in a final volume of 0.2 mL. Binding reactions were set up in wells of PicoPlates-96 (Perkin Elmer) by adding consecutively 50 μ L of each competing compound or buffer, SPA beads, the radioligand and 5-HT₃ receptor membranes. After 60-min incubation at room temperature on a Nutator mixer, plates were centrifuged for 15 min at 1,500 rpm, followed by incubation in the dark for 30 min. Radioactivity was counted in the TopCount microplate counter (Perkin Elmer) for 5 min. Total binding control contained buffer only; nonspecific binding was determined in the presence of 30 μ M MDL-72222. Specific binding was determined by subtracting nonspecific binding from total binding. All experiments were performed in duplicate using ten concentrations of a competing ligand, with ondansetron included as a control in every run. IC₅₀ values were determined from specific binding data using XLfit4.1 curve fitting software from IDBS Ltd. K_i values were then calculated from the Cheng-Prusoff equation.







[00701] Compound Affinity for the mouse 5-HT₃ Receptor (Assay C)







[00702] Compounds were tested by Novoscreen Biosciences Corporation, 7170 Standard Drive, Hanover, Maryland in a radioligand binding assay using the mouse 5-HT₃ receptor derived from mouse neuroblastoma cells and [3H]-GR65630 (ligand). The non-specific binding determinant was MDL 72222. Compounds were tested at a single concentration of 100 nM in duplicate. Percent inhibition is reported. In order to evaluate the relative affinity of the various compounds for the 5-HT₃ receptor, N1E-155 cell lines were developed to express the target protein. For binding, these cells were homogenized, centrifuged and washed with buffer (20 mM HEPES, 150 mM NaCl, pH 7.4) then suspended in 0.5mL of buffer and [3H]-GR65630 added at a concentration of 3.5x10⁻¹⁰ M. An initial single concentration of 10⁻⁷ M of the test compound was then added. Incubation was carried out at room temperature for 60 minutes at 25 °C then was terminated by rapid removal of the incubation medium. Radioactivity was assessed using liquid scintillation spectrophotometry after exposure to scintillation cocktail for at least three hours. Compounds displaying greater than 75% inhibition of radioligand binding at 10⁻⁷ M were then resubmitted to the above protocol using the following range of test compound concentrations: 10⁻⁹ M, 10⁻⁸ M, 3x10⁻⁸ M, 10⁻⁷ M, 3x10⁻⁷ M and 10⁻⁶ M. Competition curves were then plotted and IC₅₀ determinations made using non-linear regression analysis. K_i values were then calculated from the Cheng-Prusoff equation. In all of the above binding studies the non-specific determinant was MDL-72222 (1.0 μM).







[00703] In the table below, the assay in which the data were obtained is shown (as A, B or C) along with the data. The data presented was obtained by method B unless otherwise annotated.






Structure	Ex.	NMR and MS data	5-HT ₃ K _i (nM)
	1	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.49 (br s, 1H), 10.48 (br s, 0.4H), 9.71 (br s, 0.6H), 9.11 (d, <i>J</i> = 5.5 Hz, 0.4H), 8.86 (d, <i>J</i> = 5.5 Hz, 0.6H), 7.81–7.77 (m, 1H), 7.69–7.65 (m, 1H), 7.23–7.18 (m, 1H), 4.60–4.50 (m, 0.6H), 4.38–4.25 (m, 2.4H), 3.72 (t, <i>J</i> = 12.5 Hz, 2H), 3.63 (d, <i>J</i> = 9.5 Hz, 1H), 3.58–3.50 (m, 3H), 3.30–3.18 (m, 2H), 2.86–2.75 (m, 6H), 2.72–2.58 (m, 2H), 2.25 (d, <i>J</i> = 6.0 Hz, 1H), 2.18–2.05	85






		(m, 2H), 1.85–1.70 (m, 3H), 1.60–1.42 (m, 2H); MS (ESI+) <i>m/z</i> 398 (M+H).	
	2	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.56 (br s, 1H), 10.39 (br s, 1H), 9.23 (d, <i>J</i> = 6.5 Hz, 1H), 7.77 (dd, <i>J</i> = 8.0, 1.0 Hz, 1H), 7.69 (dd, <i>J</i> = 8.0, 1.0 Hz, 1H), 7.21 (t, <i>J</i> = 8.0 Hz, 1H), 4.45–4.36 (m, 1H), 4.30 (d, <i>J</i> = 14.0 Hz, 2H), 3.78–3.63 (m, 3H), 3.54 (d, <i>J</i> = 11.5 Hz, 2H), 3.40–3.31 (m, 1H), 3.30–3.18 (m, 6H), 2.80 (s, 3H), 2.23 (dd, <i>J</i> = 6.0, 3.0 Hz, 1H), 2.10–2.02 (m, 1H), 1.98–1.85 (m, 3H); MS (ESI+) <i>m/z</i> 370 (M+H).	382
	3	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.37 (br s, 0.4H), 9.70 (br s, 0.6H), 9.28 (d, <i>J</i> = 6.0 Hz, 0.4H), 9.03 (d, <i>J</i> = 6.0 Hz, 0.6H), 7.76–7.72 (m, 1H), 7.59–7.57 (m, 1H), 7.13–7.09 (m, 1H), 4.64–4.45 (m, 0.6H), 4.38–4.30 (m, 0.4H), 3.68 (br s, 4H), 3.63–3.50 (m, 2H), 2.85–2.82 (m, 3H), 2.72–2.60 (m, 2H), 2.32–2.08 (m, 3H), 1.85–1.72 (m, 3H), 1.65 (br s, 6H), 1.51 (t, <i>J</i> = 11.0 Hz, 2H); MS (ESI+) <i>m/z</i> 383 (M+H).	10.4
	4	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.34 (br s, 1H), 9.42 (d, <i>J</i> = 6.5 Hz, 1H), 7.71 (dd, <i>J</i> = 9.0, 1.0 Hz, 1H), 7.60 (dd, <i>J</i> = 9.0, 1.0 Hz, 1H), 7.12 (t, <i>J</i> = 8.0 Hz, 1H), 4.40–4.32 (m, 1H), 3.74 (t, <i>J</i> = 12.5 Hz, 1H), 3.68 (br s, 4H), 3.29 (t, <i>J</i> = 8.0 Hz, 2H), 3.23 (t, <i>J</i> = 8.0 Hz, 2H), 3.12 (dd, <i>J</i> = 13.5, 4.0 Hz, 1H), 2.27–2.22 (m, 1H), 2.14–2.08 (m, 1H), 1.98–1.88 (m, 3H), 1.66 (br s, 6H); MS (ESI+) <i>m/z</i> 355 (M+H).	34.2
	5	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.15 (s, 0.8H), 11.10 (s, 0.2H), 10.29 (br s, 0.2H), 9.47 (br s, 0.8H), 9.04 (d, <i>J</i> = 6.0 Hz, 0.2H), 9.00 (d, <i>J</i> = 6.0 Hz, 0.8H), 7.85–7.65 (m, 4H), 7.45–7.38 (m, 2H), 7.24 (t, <i>J</i> = 8.0 Hz, 1H), 7.13 (t, <i>J</i> = 8.0 Hz, 1H), 4.69–4.62 (m, 0.8H), 4.41–4.35 (m, 0.2H), 3.70 (d, <i>J</i> = 9.5 Hz, 1.6H), 3.61 (d, <i>J</i> = 9.5 Hz, 0.4H), 2.88–2.82 (m, 3H), 2.78–2.60 (m, 2H), 2.16–1.97 (m, 3H), 1.80–1.70 (m, 2H), 1.68–1.40 (m, 3H); MS (ESI+) <i>m/z</i> 391 (M+H).	6.25
	6	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.14 (s, 1H), 10.24 (br s, 1H), 9.23 (d, <i>J</i> = 6.0 Hz, 1H), 7.79 (dd, <i>J</i> = 8.0, 1.0 Hz, 1H), 7.72 (dd, <i>J</i> = 8.0, 1.0 Hz, 3H), 7.43 (dd, <i>J</i> = 8.5, 7.5 Hz, 2H), 7.26 (t, <i>J</i> = 8.0 Hz, 1H), 7.13 (t, <i>J</i> = 7.5 Hz, 1H), 4.45–4.35 (m, 1H), 3.79 (t, <i>J</i> = 11.5 Hz, 1H), 3.30–3.12 (m, 5H), 2.31–2.28 (m, 1H), 2.20–2.10 (m, 1H), 2.02–1.85 (m, 3H); MS (ESI+) <i>m/z</i> 363 (M+H).	8.1
	7	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.27 (br s, 0.4H), 9.61 (br s, 0.6H), 9.32 (d, <i>J</i> = 6.0 Hz, 0.4H), 9.09 (d, <i>J</i> = 6.0 Hz, 0.6H), 7.76–7.72 (m, 1H), 7.60–7.58 (m, 1H), 7.12–7.08 (m, 1H), 4.55–4.47 (m, 0.6H), 4.38–4.30 (m, 0.4H), 3.67–3.52 (m, 2H), 3.25–3.18 (m, 6H), 2.86–2.83 (m, 3H), 2.75–2.60 (m, 2H), 2.30–	6.1






		2.08 (m, 3H), 1.83–1.72 (m, 3H), 1.60–1.44 (m, 2H); MS (ESI+) m/z 343 (M+H).	
	8	^1H NMR (500 MHz, DMSO- d_6) δ 10.06 (br s, 1H), 9.51 (d, J = 6.5 Hz, 1H), 7.72 (dd, J = 8.0, 1.0 Hz, 1H), 7.61 (dd, J = 8.0, 1.0 Hz, 1H), 7.11 (t, J = 8.0 Hz, 1H), 4.42–4.37 (m, 1H), 3.75 (t, J = 11.5 Hz, 1H), 3.35–3.20 (m, 10H), 3.13 (d, J = 13.0 Hz, 1H), 2.28–2.21 (m, 1H), 2.18–2.08 (m, 1H), 1.98–1.88 (m, 3H); MS (ESI+) m/z 315 (M+H).	18.1
	9	^1H NMR (500 MHz, DMSO- d_6) δ 10.53 (br s, 0.4 H), 9.80 (br s, 0.6H), 9.20 (d, J = 5.8 Hz, 0.4H), 8.94 (d, J = 6.6 Hz, 0.6H), 7.78–7.74 (m, 1H), 7.65–7.60 (m, 1H), 7.18–7.12 (m, 1H), 4.56–4.50 (m, 0.6H), 4.30–4.25 (m, 0.4H), 3.80–3.75 (m, 4H), 3.72–3.66 (m, 4H), 3.65–3.60 (m, 1.2H), 3.55–3.50 (m, 0.8H), 2.85–2.80 (m, 3H), 2.70–2.65 (m, 2H), 2.30–2.20 (m, 1H), 2.15–2.05 (m, 2H), 1.85–1.72 (m, 3H), 1.55–1.45 (m, 2H); MS (ESI+) m/z 385 (M+H).	42
	10	^1H NMR (500 MHz, DMSO- d_6) δ 12.64 (br s, 1H), 9.36 (d, J = 7.2 Hz, 1H), 7.74 (dd, J = 8.0, 1.0 Hz, 1H), 7.64 (dd, J = 8.0, 1.0 Hz, 1H), 7.16 (t, J = 7.9 Hz, 1H), 4.42–4.35 (m, 1H), 3.78–3.70 (m, 4H), 3.78–3.65 (m, 4H), 3.35–3.32 (m, 5H), 3.12 (dd, J = 14.1, 4.2 Hz, 1H), 2.30–2.20 (m, 1H), 2.18–2.10 (m, 1H), 2.00–1.90 (m, 3H); MS (ESI+) m/z 357 (M+H).	164
	11	^1H NMR (500 MHz, DMSO- d_6) δ 11.10 (br s, 0.6H), 10.98 (br s, 0.4H), 10.34 (br s, 0.4H), 9.61 (br s, 0.6H), 9.19 (br s, 0.4H), 8.98 (d, J = 3.5 Hz, 0.6H), 7.79–7.63 (m, 2H), 7.17–7.13 (m, 1H), 4.58–4.47 (m, 0.6H), 4.38–4.30 (m, 0.4H), 4.22–4.10 (m, 1H), 4.00–3.75 (m, 3H), 3.65–3.55 (m, 2H), 3.40–3.25 (m, 3H), 3.05–2.95 (m, 1H), 2.85–2.75 (m, 6H), 2.72–2.60 (m, 3H), 2.30–2.15 (m, 2H), 2.14–2.05 (m, 2H), 1.82–1.70 (m, 3H), 1.60–1.42 (m, 2H); MS (ESI+) m/z 412 (M+H).	89.6
	12	^1H NMR (500 MHz, DMSO- d_6) δ 11.26 (br s, 1H), 10.35 (br s, 1H), 9.39 (br s, 1H), 7.75 (d, J = 8.0 Hz, 1H), 7.66 (d, J = 8.0 Hz, 1H), 7.16 (t, J = 8.0 Hz, 1H), 4.45–4.32 (m, 1H), 4.28–4.10 (m, 1H), 4.00–3.70 (m, 4H), 3.55–2.98 (m, 9H), 2.80–2.70 (m, 4H), 2.30–1.85 (m, 6H); MS (ESI+) m/z 384 (M+H).	317
	13	^1H NMR (500 MHz, DMSO- d_6) δ 10.20 (br s, 0.3H), 9.45 (br s, 0.7H), 8.95 (d, J = 6.5 Hz, 0.3H), 8.74 (d, J = 6.5 Hz, 0.7H), 7.92–7.86 (m, 2H), 7.47–7.42 (m, 1H), 4.63–4.55 (m, 0.7H), 4.40–4.32 (m, 0.3H), 3.70–3.52 (m, 2H), 2.88–2.82 (m, 6H), 2.72–2.54 (m, 2H), 2.20–2.04 (m, 3H), 1.85–1.75 (m, 3H), 1.60–1.42 (m, 2H); MS (ESI+) m/z 346 (M+H).	4.6 (A)







	14	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.11 (br s, 1H), 9.12 (d, <i>J</i> = 6.5 Hz, 1H), 7.90–7.86 (m, 2H), 7.46 (t, <i>J</i> = 8.0 Hz, 1H), 4.45–4.36 (m, 1H), 3.74 (t, <i>J</i> = 11.0 Hz, 1H), 3.30–3.16 (m, 5H), 2.85 (s, 3H), 2.30–2.27 (m, 1H), 2.20–2.10 (m, 1H), 1.98–1.85 (m, 3H); MS (ESI+) <i>m/z</i> 318 (M+H).	2.6 (A)
	15	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.27 (br s, 0.2H), 10.12 (br s, 0.8H), 9.10 (br s, 0.2H), 8.95 (d, <i>J</i> = 7.0 Hz, 0.8H), 7.74 (d, <i>J</i> = 7.5 Hz, 1H), 7.61 (d, <i>J</i> = 7.5 Hz, 1H), 7.14 (t, <i>J</i> = 7.5 Hz, 1H), 4.21–4.18 (m, 0.2H), 4.09–4.00 (m, 0.8H), 3.79–3.75 (m, 4H), 3.70–3.65 (m, 4H), 3.45 (d, <i>J</i> = 11.5 Hz, 2H), 3.12 (t, <i>J</i> = 11.5 Hz, 2H), 2.75 (s, 3H), 2.18 (d, <i>J</i> = 12.5 Hz, 2H), 1.85–1.75 (m, 2H); MS (ESI+) <i>m/z</i> 345 (M+H).	87 (C)
	16	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 9.52 (br s, 1.2H), 9.50–9.40 (m, 1H), 9.16 (br s, 0.8H), 9.07 (d, <i>J</i> = 6.0 Hz, 0.4H), 8.89 (d, <i>J</i> = 6.0 Hz, 0.6H), 7.76–7.73 (m, 1H), 7.65–7.60 (m, 1H), 7.19–7.15 (m, 1H), 5.05–4.51 (m, 2H), 4.38–4.02 (m, 4H), 3.70–3.62 (m, 2H), 3.10–2.93 (m, 1H), 2.85–2.80 (m, 3H), 2.75–2.60 (m, 3H), 2.18–2.02 (m, 2H), 1.90–1.72 (m, 3H), 1.65–1.50 (m, 2H); MS (ESI+) <i>m/z</i> 370 (M+H).	179
	17	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.32 (br s, 0.4H), 9.69 (br s, 0.6H), 9.23 (d, <i>J</i> = 6.0 Hz, 0.4H), 9.02 (d, <i>J</i> = 6.0 Hz, 0.6H), 7.79–7.74 (m, 1H), 7.61–7.60 (m, 1H), 7.16–7.12 (m, 1H), 4.53–4.45 (m, 0.6H), 4.38–4.30 (m, 0.4H), 4.10–4.00 (m, 2H), 3.70–3.69 (m, 2H), 3.65–3.50 (m, 2H), 2.95–2.80 (m, 5H), 2.72–2.60 (m, 2H), 2.35–2.05 (m, 3H), 1.86–1.70 (m, 3H), 1.60–1.45 (m, 2H), 1.20–1.13 (m, 6H); MS (ESI+) <i>m/z</i> 413 (M+H).	54.2
	18	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.11 (br s, 1H), 9.39 (d, <i>J</i> = 7.0 Hz, 1H), 7.73 (dd, <i>J</i> = 8.0, 1.0 Hz, 1H), 7.62 (dd, <i>J</i> = 8.0, 1.0 Hz, 1H), 7.16 (t, <i>J</i> = 8.0 Hz, 1H), 4.42–4.37 (m, 1H), 4.08–4.01 (m, 2H), 3.78–3.70 (m, 3H), 3.35–3.22 (m, 4H), 3.15 (dd, <i>J</i> = 13.5, 4.5 Hz, 1H), 2.97–2.88 (m, 2H), 2.28–2.21 (m, 1H), 2.18–2.08 (m, 1H), 1.98–1.89 (m, 3H), 1.17 (d, <i>J</i> = 6.0 Hz, 6H); MS (ESI+) <i>m/z</i> 385 (M+H).	443
	19	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.12 (br s, 0.4H), 9.47 (br s, 0.6H), 9.10 (d, <i>J</i> = 6.0 Hz, 0.4H), 8.88 (d, <i>J</i> = 6.0 Hz, 0.6H), 7.79–7.74 (m, 1H), 7.68–7.60 (m, 1H), 7.50–7.30 (m, 5H), 7.19–7.12 (m, 1H), 5.40–5.35 (m, 1H), 4.53–4.45 (m, 1H), 4.38–4.25 (m, 1H), 4.10–3.95 (m, 3H), 3.80–3.69 (m, 1H), 3.65–3.45 (m, 3H), 2.85–2.78 (m, 3H), 2.70–2.55 (m, 2H), 2.12–1.93 (m, 3H), 1.80–1.52 (m, 3H), 1.47–1.37 (m, 2H); MS (ESI+) <i>m/z</i> 461 (M+H).	17






	20	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.10 (br s, 1H), 9.27–9.23 (m, 1H), 7.74 (d, <i>J</i> = 8.0 Hz, 1H), 7.65 (d, <i>J</i> = 8.0 Hz, 1H), 7.50–7.28 (m, 5H), 7.20–7.14 (m, 1H), 5.40–5.33 (m, 1H), 4.45–4.27 (m, 2H), 4.10–3.96 (m, 3H), 3.80–3.52 (m, 3H), 3.25–3.00 (m, 5H), 2.25–2.03 (m, 1H), 1.93–1.62 (m, 4H); MS (ESI+) <i>m/z</i> 433 (M+H).	34.4
	21	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.48 (br s, 0.4H), 9.72 (br s, 0.6H), 9.56 (br s, 2H), 9.11 (d, <i>J</i> = 5.5 Hz, 0.4H), 8.86 (d, <i>J</i> = 5.5 Hz, 0.6H), 7.80–7.74 (m, 1H), 7.68–7.62 (m, 1H), 7.22–7.15 (m, 1H), 4.60–4.51 (m, 0.6H), 4.38–4.30 (m, 0.4H), 3.98–3.88 (m, 4H), 3.63 (d, <i>J</i> = 9.0 Hz, 2H), 3.35–3.27 (m, 4H), 2.85–2.80 (m, 3H), 2.75–2.60 (m, 2H), 2.40–2.05 (m, 3H), 1.85–1.72 (m, 3H), 1.60–1.45 (m, 2H); MS (ESI+) <i>m/z</i> 384 (M+H).	74.6
	22	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.35 (br s, 1H), 9.59 (br s, 2H), 9.25 (d, <i>J</i> = 6.5 Hz, 1H), 7.76 (d, <i>J</i> = 8.0 Hz, 1H), 7.66 (dd, <i>J</i> = 8.0, 1.0 Hz, 1H), 7.19 (t, <i>J</i> = 8.0 Hz, 1H), 4.42–4.37 (m, 1H), 3.94 (t, <i>J</i> = 5.0 Hz, 4H), 3.74 (t, <i>J</i> = 11.6 Hz, 1H), 3.36–3.20 (m, 8H), 3.15 (dd, <i>J</i> = 13.4, 4.2 Hz, 1H), 2.27–2.20 (m, 1H), 2.10–2.02 (m, 1H), 1.98–1.83 (m, 3H); MS (ESI+) <i>m/z</i> 356 (M+H).	321
	23	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.67 (br s, 0.2H), 10.52 (br s, 0.4H), 10.10–9.56 (m, 1.4H), 9.03–8.52 (m, 1H), 7.88–7.61 (m, 2H), 7.48–7.29 (m, 5H), 7.20–7.15 (m, 1H), 5.94 (br s, 0.8H), 5.55–5.37 (m, 0.2H), 4.60–4.26 (m, 3H), 3.82–3.25 (m, 6H), 2.98–2.80 (m, 6H), 2.76–2.52 (m, 2H), 2.07–1.90 (m, 3H), 1.81–1.20 (m, 5H); MS (ESI+) <i>m/z</i> 474 (M+H).	25.2
	24	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.81 (br s, 0.2H), 10.70–10.45 (m, 1H), 10.17 (br s, 0.8H), 9.20–8.97 (m, 1H), 7.80–7.73 (m, 2H), 7.42–7.23 (m, 5H), 7.18–7.08 (m, 1H), 6.02–5.50 (m, 1H), 4.71–4.15 (m, 3H), 3.84–3.20 (m, 5H), 3.18–2.81 (m, 8H), 2.18–1.45 (m, 5H); MS (ESI+) <i>m/z</i> 446 (M+H).	103
	25	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.58 (br s, 0.4H), 9.85 (br s, 1.6H), 9.49 (br s, 1H), 9.11 (d, <i>J</i> = 7.0 Hz, 0.4H), 8.89 (d, <i>J</i> = 7.0 Hz, 0.6H), 7.80–7.74 (m, 1H), 7.68–7.62 (m, 1H), 7.22–7.15 (m, 1H), 4.65–4.58 (m, 1H), 4.55–4.47 (m, 0.6H), 4.38–4.28 (m, 0.4H), 4.20–4.12 (m, 1H), 3.68–3.60 (m, 2H), 3.52–3.25 (m, 4H), 3.18–3.08 (m, 1H), 2.85–2.80 (m, 3H), 2.75–2.60 (m, 2H), 2.32–2.05 (m, 3H), 1.80–1.72 (m, 3H), 1.60–1.45 (m, 5H); MS (ESI+) <i>m/z</i> 398 (M+H).	27.5







	26	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.49 (br s, 1H), 9.91 (d, <i>J</i> = 10.0 Hz, 1H), 9.53 (d, <i>J</i> = 9.0 Hz, 1H), 9.29 (d, <i>J</i> = 6.5 Hz, 1H), 7.76 (d, <i>J</i> = 8.0 Hz, 1H), 7.66 (d, <i>J</i> = 8.0 Hz, 1H), 7.17 (t, <i>J</i> = 8.0 Hz, 1H), 4.68–4.59 (m, 1H), 4.41–4.32 (m, 1H), 4.18 (d, <i>J</i> = 14.0 Hz, 1H), 3.72 (t, <i>J</i> = 12.0 Hz, 1H), 3.61 (t, <i>J</i> = 12.0 Hz, 1H), 3.40–3.05 (m, 9H), 2.27–2.20 (m, 1H), 2.10–2.02 (m, 1H), 1.98–1.83 (m, 3H), 1.50–1.45 (m, 3H); MS (ESI+) <i>m/z</i> 370 (M+H).	241
	27	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.38 (br s, 0.2H), 9.54 (br s, 0.8H), 8.72 (d, <i>J</i> = 6.5 Hz, 2.2H), 8.61 (d, <i>J</i> = 6.5 Hz, 0.8H), 8.18–8.05 (m, 2H), 7.88–7.80 (m, 2H), 7.43–7.36 (m, 1H), 4.73–4.63 (m, 0.8H), 4.42–4.38 (m, 0.2H), 3.72–3.55 (m, 2H), 2.87–2.82 (m, 3H), 2.78–2.53 (m, 3H), 2.20–2.05 (m, 3H), 1.86–1.45 (m, 5H); MS (ESI+) <i>m/z</i> 392 (M+H).	4.5
	28	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.48 (br s, 1H), 8.89 (d, <i>J</i> = 6.0 Hz, 1H), 8.80 (d, <i>J</i> = 7.0 Hz, 2H), 8.17 (d, <i>J</i> = 7.0 Hz, 2H), 7.89 (dd, <i>J</i> = 8.0, 1.0 Hz, 1H), 7.84 (dd, <i>J</i> = 8.0, 1.0 Hz, 1H), 7.43 (t, <i>J</i> = 8.0 Hz, 1H), 4.42 (d, <i>J</i> = 5.5 Hz, 1H), 3.78 (t, <i>J</i> = 11.0 Hz, 1H), 3.38–3.15 (m, 6H), 2.38–2.34 (m, 1H), 2.20–2.10 (m, 1H), 2.01–1.87 (m, 3H); MS (ESI+) <i>m/z</i> 364 (M+H).	5.3
	29	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.70 (br s, 0.3H), 9.77 (br s, 0.7H), 9.17 (d, <i>J</i> = 5.5 Hz, 0.3H), 9.01 (d, <i>J</i> = 7.0 Hz, 0.7H), 7.84 (d, <i>J</i> = 8.0 Hz, 1H), 7.79 (d, <i>J</i> = 7.5 Hz, 1H), 7.69 (d, <i>J</i> = 7.5 Hz, 1H), 7.21 (t, <i>J</i> = 8.0 Hz, 1H), 6.96 (t, <i>J</i> = 7.5 Hz, 1H), 6.73 (d, <i>J</i> = 8.0 Hz, 1H), 6.63 (d, <i>J</i> = 7.5 Hz, 1H), 4.65–4.55 (m, 0.7H), 4.40–4.30 (m, 0.3H), 4.08–4.40 (m, 2H), 3.64 (d, <i>J</i> = 9.0 Hz, 1.3H), 3.60–3.50 (m, 0.7H), 3.48–3.42 (m, 2H), 2.86–2.80 (m, 3H), 2.70–2.58 (m, 2H), 2.20–1.96 (m, 3H), 1.80–1.60 (m, 2H), 1.56–1.50 (m, 1H), 1.48–1.36 (m, 2H); MS (ESI+) <i>m/z</i> 432 (M+H).	3.6
	30	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.26 (br s, 0.7H), 10.80 (br s, 0.3H), 9.80 (d, <i>J</i> = 9.6 Hz, 1H), 7.75 (d, <i>J</i> = 7.9 Hz, 1H), 7.54 (dd, <i>J</i> = 7.9, 0.9 Hz, 1H), 7.08–7.04 (m, 1H), 4.75–4.65 (m, 1H), 4.28–4.20 (m, 2H), 4.04 (d, <i>J</i> = 12.9 Hz, 1.4 H), 3.86 (d, <i>J</i> = 12.9 Hz, 0.6H), 3.48–3.40 (m, 2H), 3.20 (s, 6H), 3.01 (d, <i>J</i> = 5.0 Hz, 1H), 2.88 (d, <i>J</i> = 5.0 Hz, 2H), 2.85–2.80 (m, 0.6H), 2.72–2.62 (m, 1.4H), 1.97 (m, 0.6H), 1.75 (m, 1.4H); MS (ESI+) <i>m/z</i> 345 (M+H).	79






	31	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.02–10.96 (m, 1H), 10.79 (br s, 0.3H), 9.85 (br s, 0.7H), 9.08 (br s, 0.3H), 8.81 (br s, 0.7H), 7.78–7.75 (m, 1H), 7.62 (dd, <i>J</i> = 7.9, 0.8 Hz, 1H), 7.15–7.12 (m, 1H), 5.95 (br s, 3H), 4.69–4.62 (m, 0.7H), 4.38–4.35 (m, 0.3H), 4.07–4.00 (m, 2H), 3.65–3.62 (m, 1.5H), 3.56–3.52 (m, 0.5H), 3.47–3.42 (m, 2H), 3.25 (s, 3H), 2.85–2.82 (m, 9H), 2.69–2.57 (m, 2H), 2.31–2.05 (m, 3H), 1.82–1.73 (m, 3H), 1.53–1.48 (m, 3H); MS (ESI+) <i>m/z</i> 400 (M+H).	107
	32	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.95 (br s, 0.7H), 10.86 (br s, 0.3H), 10.50 (br s, 0.3H), 9.72 (br s, 0.7H), 9.15 (br s, 0.3H), 8.93–8.90 (m, 1.7H), 7.76–7.73 (m, 1H), 7.60–7.58 (m, 1H), 7.16–7.12 (1H), 4.64–4.55 (m, 0.8H), 4.36–4.32 (m, 0.2H), 4.21 (br s, 6H), 3.87–3.77 (m, 2H), 3.65–3.62 (m, 1.4H), 3.55–3.52 (m, 0.6H), 3.40–3.35 (m, 2H), 2.84–2.82 (m, 9H), 2.69–2.57 (m, 2H), 2.29–2.05 (m, 3H), 1.84–1.71 (m, 2.6H), 1.57–1.49 (m, 2.4H); MS (ESI+) <i>m/z</i> 386 (M+H).	234
	33	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.45 (br s, 0.7), 11.18 (br s, 0.3H), 10.32 (br s, 0.3H), 9.57 (br s, 0.7H), 9.16 (br s, 0.3H), 8.93–8.90 (m, 1.7H), 7.76–7.73 (m, 1H), 7.59 (d, <i>J</i> = 7.9 Hz, 1H), 7.16–7.12 (m, 1H), 4.61–4.52 (m, 0.6H), 4.35–4.31 (m, 0.4H), 3.99–3.84 (m, 3.5H), 3.66–3.43 (m, 3.5H), 3.17–3.13 (m, 1H), 2.85–2.81 (m, 3H), 2.67–2.59 (m, 3H), 2.22–2.05 (m, 3H), 1.87–1.71 (m, 4H), 1.56–1.50 (m, 2H), 0.89–0.62 (m, 2H); MS (ESI+) <i>m/z</i> 428 (M+H).	168
	34	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.46 (br s, 0.4H), 9.81 (br s, 0.6H), 9.42 (d, <i>J</i> = 5.9 Hz, 0.4H), 9.17 (d, <i>J</i> = 6.5 Hz, 0.6H), 8.55–8.45 (m, 1H), 7.75–7.66 (m, 1H), 7.57–7.50 (m, 1H), 7.10–7.04 (m, 1H), 4.55–4.45 (m, 1.2H), 4.35–4.25 (m, 0.8H), 3.65–3.57 (m, 1.2 H), 3.55–3.50 (m, 0.8H), 3.02–2.94(m, 3H), 2.88–2.80 (m,3H), 2.74–2.70 (m, 2H), 2.30–2.20 (m, 1H), 2.15–2.05 (m, 2H), 1.84–1.72 (m, 3H), 1.60–1.45 (m, 2H); MS (ESI+) <i>m/z</i> 329 (M+H).	5.3
	35	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.54 (br s, 0.3H), 9.81 (br s, 0.7H), 9.37 (d, <i>J</i> = 5.5 Hz, 0.3H), 9.03 (d, <i>J</i> = 7.1 Hz, 0.7H), 8.30 (br s, 1.4H), 8.18 (br s, 0.6H), 7.78–7.70 (m, 1H), 7.60–7.50 (m, 1H), 7.15–7.05 (m, 1H), 4.65–4.55 (m, 0.7H), 4.35–4.25 (m, 0.3H), 3.70–3.50 (m, 2H), 2.90–2.80 (m, 3H), 2.72–2.55 (m, 2H), 2.15–2.05 (m, 3H), 1.90–1.70 (m, 3H), , 1.54–1.45 (m, 2H); MS (ESI+) <i>m/z</i> 315 (M+H).	9.1






	36	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.69 (br s, 0.4H), 9.89 (br s, 0.6H), 9.15–9.14 (m, 0.4H), 8.96–8.95 (m, 0.6H), 7.77–7.74 (m, 1H), 7.61–7.59 (m, 1H), 7.15–7.11 (m, 1H), 4.57–4.53 (m, 0.6H), 4.34–4.33 (m, 0.4H), 4.04–4.03 (m, 1H), 3.94–3.84 (m, 3H), 3.68–3.46 (m, 5H), 2.83–2.81 (m, 3H), 2.68–2.62 (m, 2H), 2.27–2.25 (m, 1H), 2.12–2.10 (m, 2H), 1.91–1.74 (m, 5H), 1.53–1.47 (m, 2H), 0.93–0.86 (m, 3H); MS (ESI+) <i>m/z</i> 413 (M+H).	4.7
	37	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.35–11.15 (m, 0.8H), 10.96–10.85 (m, 0.2H), 10.62 (s, 0.2H), 10.00–9.60 (m, 0.8H), 9.18–9.06 (m, 0.5H), 8.98 (d, <i>J</i> = 7.0 Hz, 0.5H), 8.74–8.66 (m, 1H), 7.80–7.70 (m, 1H), 7.60–7.54 (m, 1H), 7.18–7.12 (m, 1H), 4.96–4.82 (m, 1H), 4.68–4.60 (m, 0.6H), 4.40–4.24 (m, 0.4H), 3.66–3.50 (m, 4H), 2.90–2.74 (m, 6H), 2.70–2.60 (m, 3H), 2.36–2.20 (m, 2H), 2.16–2.00 (m, 5H), 1.94–1.88 (m, 1H), 1.86–1.70 (m, 2H), 1.68–1.46 (m, 5H); MS (ESI+) <i>m/z</i> 452 (M+H).	243
	38	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.77 (s, 0.4H), 10.05 (s, 0.6H), 9.30 (d, <i>J</i> = 5.5 Hz, 0.4H), 9.12 (d, <i>J</i> = 6.5 Hz, 0.6H), 8.77 (s, 1H), 8.30–7.80 (br s, 1H), 7.74–7.71 (m, 1H), 7.55 (dd, <i>J</i> = 8.0, 1.0 Hz, 1H), 7.10 (app t, <i>J</i> = 8.0 Hz, 1H), 4.56–4.48 (m, 0.6H), 4.38–4.30 (m, 0.4H), 3.64–3.50 (m, 6H), 3.30 (d, <i>J</i> = 3.5 Hz, 3H), 2.84–2.80 (m, 3H), 2.74–2.62 (m, 2H), 2.38–2.24 (m, 1.2H), 2.11 (d, <i>J</i> = 6.5 Hz, 1.8H), 1.82–1.70 (m, 3H), 1.50–1.46 (m, 2H); MS (ESI+) <i>m/z</i> 373 (M+H).	7.5
	39	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.70 (s, 0.4H), 9.99 (s, 0.6H), 9.34 (d, <i>J</i> = 5.5 Hz, 0.4H), 9.16 (d, <i>J</i> = 6.5 Hz, 0.6H), 8.73–8.66 (m, 1H), 7.90–7.50 (br s, 1H), 7.80–7.66 (m, 1H), 7.56–7.53 (m, 1H), 7.09 (app t, <i>J</i> = 8.0 Hz, 1H), 4.56–4.50 (m, 0.6H), 4.36–4.30 (m, 0.4H), 3.61 (d, <i>J</i> = 9.0 Hz, 1H), 3.53 (br s, 1H), 3.46–3.38 (m, 4H), 3.23 (d, <i>J</i> = 1.0 Hz, 3H), 2.82 (dd, <i>J</i> = 8.5, 5.0 Hz, 3H), 2.75–2.62 (m, 2H), 2.16–2.08 (m, 1.2H), 2.12 (d, <i>J</i> = 7.0 Hz, 1.8H), 1.92–1.82 (m, 2H), 1.80–1.70 (m, 3H), 1.60–1.44 (m, 2H); MS (ESI+) <i>m/z</i> 387 (M+H).	13.2
	40	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.76 (s, 0.4H), 10.03 (s, 0.6H), 9.36 (d, <i>J</i> = 6.0 Hz, 0.4H), 9.20 (d, <i>J</i> = 6.0 Hz, 0.6H), 8.70–8.62 (m, 1H), 7.90–7.50 (br s, 1H), 7.80–7.70 (m, 1H), 7.60–7.52 (m, 1H), 7.10 (app t, <i>J</i> = 8.0 Hz, 1H), 4.60–4.50 (m, 0.6H), 4.40–4.30 (m, 0.4H), 3.61 (d, <i>J</i> = 9.0 Hz, 1H), 3.54–3.50 (m, 2H), 3.49–3.40 (m, 2H), 2.85–2.80 (m, 2H), 2.74–2.60 (m, 2H), 2.38–2.28 (m, 1H), 2.16–2.08 (m, 2H), 1.82–1.70 (m, 4H), 1.60–1.46 (m, 2H); MS (ESI+) <i>m/z</i> 373 (M+H).	7.8






	41a	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.47 (br s, 0.4H), 9.50–9.57 (m, 1.6H), 9.41 (br s, 1H), 9.10 (s, 0.4H), 8.89 (s, 0.6H), 7.88–7.72 (m, 1H), 7.65 (s, 1H), 7.32–7.06 (m, 1H), 4.64 (br s, 1H), 4.54–4.49 (m, 1H), 4.27–4.09 (m, 1H), 3.75–3.56 (m, 2H), 3.53 (s, 1H), 3.34–3.22 (m, 3H), 3.22–3.01 (m, 1H), 2.84 (s, 3H), 2.72–2.60 (m, 2H), 2.26 (s, 1H), 2.11 (s, 2H), 1.93–1.64 (m, 3H), 1.63–1.33 (m, 5H); MS (ESI+) <i>m/z</i> 398 (M+H).	14.2
	41b	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.47 (br s, 0.4H), 9.50–9.57 (m, 1.6H), 9.41 (br s, 1H), 9.10 (s, 0.4H), 8.89 (s, 0.6H), 7.88–7.72 (m, 1H), 7.65 (s, 1H), 7.32–7.06 (m, 1H), 4.64 (br s, 1H), 4.54–4.49 (m, 1H), 4.27–4.09 (m, 1H), 3.75–3.56 (m, 2H), 3.53 (s, 1H), 3.34–3.22 (m, 3H), 3.22–3.01 (m, 1H), 2.84 (s, 3H), 2.72–2.60 (m, 2H), 2.26 (s, 1H), 2.11 (s, 2H), 1.93–1.64 (m, 3H), 1.63–1.33 (m, 5H); MS (ESI+) <i>m/z</i> 398 (M+H).	125
	42	¹ H NMR (500 MHz, CD ₃ OD) δ 8.41 (s, 2H), 7.84 (s, 1H), 7.62–7.47 (m, 1H), 7.28–7.05 (m, 1H), 6.81–6.61 (m, 1H), 4.66–4.29 (m, 1H), 4.17–3.97 (m, 4H), 3.96–3.78 (m, 4H), 3.78–3.58 (m, 2H), 3.08–2.91 (m, 3H), 2.91–2.62 (m, 2H), 2.37–2.11 (m, 3H), 2.11–1.91 (m, 2.5H), 1.80–1.59 (m, 2.5H); MS (ESI+) <i>m/z</i> 462 (M+H).	11
	43	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 9.14–8.93 (m, 0.5H), 7.85–7.65 (m, 0.8H), 7.65–7.53 (m, 0.8H), 7.25–6.99 (m, 0.9H), 5.39–5.00 (m, 1H), 4.74–3.98 (m, 6H), 3.86–3.39 (m, 9H), 3.29–2.58 (m, 6H), 2.48–1.93 (m, 5H); MS (ESI+) <i>m/z</i> 400 (M+H).	480
	44	¹ H NMR (500 MHz, CD ₃ OD) δ 10.21 (br s, 1H), 7.94–7.68 (m, 1H), 7.56–7.38 (m, 1H), 7.26–6.96 (m, 1H), 4.81–4.63 (m, 1H), 4.11–3.89 (m, 2H), 3.88–3.70 (m, 10H), 2.85–2.67 (m, 2H), 2.68–2.48 (m, 5H), 1.71–1.51 (m, 2H); MS (ESI+) <i>m/z</i> 387 (M+H).	323
	45	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.91–10.88 (m, 0.6H), 10.86–10.53 (m, 0.4H), 10.53–10.10 (m, 0.2H), 9.42–9.13 (m, 0.8H), 7.98–7.79 (m, 1H), 7.79–7.60 (m, 3.9H), 7.58–7.34 (m, 2H), 7.34–7.17 (m, 1H), 7.15–6.98 (m, 1H), 4.79–4.51 (m, 1H), 4.35–4.12 (m, 0.9H), 4.12–3.90 (m, 2.4H), 3.90–3.65 (m, 1H), 3.65–3.40 (m, 2.3H), 3.10–2.96 (m, 1.3H), 2.96–2.84 (m, 1.8H), 2.84–2.62 (m, 2.4H), 2.17–1.97 (m, 0.8H), 1.95–1.73 (m, 1.2H); MS (ESI+) <i>m/z</i> 393 (M+H).	22.6






	46	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.56 (br s, 0.5H), 10.07 (s, 0.5H), 10.01 (s, 0.5H), 9.52 (s, 1H), 9.22 (d, <i>J</i> = 5.5 Hz, 0.4H), 8.99 (d, <i>J</i> = 5.5 Hz, 0.6H), 7.78 (t, <i>J</i> = 7.5 Hz, 1H), 7.67 (d, <i>J</i> = 8.0 Hz, 1H), 7.19–7.16 (m, 1H), 4.91 (s, 0.5H), 4.87 (s, 0.5H), 4.34–4.31 (d, <i>J</i> = 10.5 Hz, 1H), 3.79–3.76 (m, 1H), 3.62–3.59 (m, 1H), 3.52 (s, 1H), 3.42 (s, 1H), 3.34–3.32 (m, 1H), 2.89–2.83 (m, 3H), 2.78–2.62 (m, 2H), 2.30–2.23 (m, 2H), 2.17–2.08 (m, 1H), 2.05 (d, <i>J</i> = 10.0 Hz, 1H), 1.83–1.78 (m, 3H), 1.63–1.58 (m, 1H), 1.51–1.49 (m, 1H); MS (ESI+) <i>m/z</i> 396 (M+H).	284
	47	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.40 (br s, 1H), 9.62 (br s, 1H), 9.21–9.20 (m, 0.3H), 9.08–9.06 (m, 0.7H), 8.75 (br s, 0.7H), 8.67–8.65 (m, 0.3H), 7.74–7.71 (m, 1H), 7.58 (d, <i>J</i> = 7.8 Hz, 1H), 7.13–7.09 (m, 1H), 4.80 (br s, 4H), 4.31 (m, 2.5H), 3.65–3.63 (m, 1.5H), 3.54 (br s, 0.5H), 3.03 (s, 3H), 3.00 (s, 1H), 2.87–2.80 (m, 6H), 2.70–2.59 (m, 2H), 2.20 (br s, 0.8H), 2.11–2.09 (m, 2.2H), 1.78–1.74 (m, 3H), 1.53–1.45 (2.5H); MS (ESI+) <i>m/z</i> 400 (M+H).	137
	48	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.77 (br s, 0.4H), 9.98 (br s, 0.6H), 9.14–9.13 (m, 0.4H), 8.98–8.97 (m, 0.6H), 7.77–7.74 (m, 1H), 7.60–7.58 (m, 1H), 7.14–7.10 (m, 1H), 4.58–4.51 (m, 0.6H), 4.34–4.33 (m, 0.4H), 4.04–3.91 (m, 3H), 3.76–3.71 (m, 1H), 3.68–3.44 (m, 5H), 2.83–2.77 (m, 3H), 2.73–2.64 (m, 2H), 2.46–2.35 (m, 1H), 2.32–2.18 (m, 1H), 2.12–2.08 (m, 2H), 1.80–1.73 (m, 3H), 1.54–1.45 (m, 2H), 1.07–0.99 (m, 3H), 0.91–0.81 (m, 3H); MS (ESI+) <i>m/z</i> 427 (M+H).	6.0
	49	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.59 (br s, 0.4H), 9.89 (br s, 0.6H), 9.18–9.17 (m, 0.4H), 8.98–8.98 (m, 0.6H), 7.77–7.74 (m, 1H), 7.62–7.61 (m, 1H), 7.16–7.12 (m, 1H), 5.50–5.00 (br s, 4H), 4.57–4.53 (m, 0.6H), 4.34–4.33 (m, 0.4H), 4.04–4.03 (m, 1H), 3.95 (m, 1H), 3.86 (m, 1H), 3.74–3.72 (m, 2H), 3.60–3.51 (m, 4H), 2.83–2.81 (m, 3H), 2.68–2.62 (m, 2H), 2.27–2.25 (m, 1H), 2.12–2.10 (m, 2H), 1.80–1.78 (m, 3H), 1.53–1.47 (m, 2H), 1.36–1.34 (m, 3H); MS (ESI+) <i>m/z</i> 399 (M+H).	10.9
	50	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.70 (s, 0.4H), 10.49 (s, 1H), 9.99 (s, 0.6H), 9.80–9.60 (m, 1H), 9.07 (d, <i>J</i> = 5.5 Hz, 0.5H), 8.98 (d, <i>J</i> = 6.0 Hz, 0.5H), 7.78 (dd, <i>J</i> = 11.0, 8.0 Hz, 1H), 7.67 (d, <i>J</i> = 8.0 Hz, 1H), 7.17 (app. t, <i>J</i> = 8.0 Hz, 1H), 4.60–4.55 (m, 3H), 4.54–4.49 (m, 1.5H), 4.38–4.28 (m, 0.5H), 3.66–3.58 (m, 1.2H), 3.56–3.48 (m, 0.8H), 3.38–3.22 (m, 4H), 2.88–2.78 (m, 3H), 2.74–2.64 (m, 2H), 2.38–2.18 (m, 1.2H), 2.16–2.06 (m, 1.8H), 1.82–1.72 (m, 3H), 1.60–1.46 (m, 6H); MS (ESI+) <i>m/z</i> 412 (M+H).	13.6






	51	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.0–10.71 (m, 1H), 10.39 (br s, 0.8H), 10.01–9.73 (m, 0.8H), 7.89–7.56 (m, 4H), 7.56–7.36 (m, 2H), 7.26–7.17 (m, 1H), 7.17–6.98 (m, 1H), 4.62–4.33 (m, 1H), 3.60–3.35 (m, 2.5H), 3.32–3.10 (m, 1H), 2.98–2.73 (m, 5.5H), 2.73–2.62 (m, 1.6H), 2.62–2.53 (m, 2H), 2.09–1.59 (m, 4.8H); MS (ESI+) <i>m/z</i> 406 (M+H). <i>endo</i>	212
	52	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.30–11.00 (m, 1H), 10.68 (br s, 0.5H), 8.81 (br s, 0.5H), 8.97–8.66 (m, 1H), 7.93–7.63 (m, 4H), 7.62–7.37 (m, 2H), 7.34–7.19 (m, 1H), 7.19–7.02 (m, 1H), 5.47–5.10 (m, 1H), 3.85–3.62 (m, 3H), 3.27–3.03 (m, 2H), 3.03–2.86 (m, 4H), 2.86–2.61 (m, 2H), 2.43–1.93 (m, 6H); MS (ESI+) <i>m/z</i> 406 (M+H). <i>exo</i>	27.6
	53	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.15 (br s, 0.3H), 9.40 (br s, 0.7H), 9.14 (br s, 1H), 7.76–7.73 (m, 1H), 7.69 (s, 1H), 7.63 (d, <i>J</i> = 6.3 Hz, 1H), 7.22 (br s, 1H), 7.14–7.09 (m, 1H), 4.54–4.32 (m, 4H), 3.83–3.54 (m, 4H), 2.84–2.82 (m, 3H), 2.73–2.52 (m, 2H), 2.38–2.30 (m, 1H), 2.12–1.95 (m, 5H), 1.80–1.68 (m, 2H), 1.55–1.45 (m, 2H); MS (ESI+) <i>m/z</i> 412 (M+H).	212
	54	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.32 (s, 0.4H), 9.63 (s, 0.6H), 9.07 (d, <i>J</i> = 6.0 Hz, 0.4H), 8.88 (d, <i>J</i> = 6.0 Hz, 0.6H), 7.78 (dd, <i>J</i> = 8.0, 1.0 Hz, 1H), 7.70 (d, <i>J</i> = 8.0 Hz, 1H), 7.24–7.18 (m, 1H), 5.20 (d, <i>J</i> = 12.0 Hz, 2H), 4.58–4.50 (m, 0.6H), 4.40–4.34 (m, 2.4H), 4.25–4.20 (m, 2H), 3.64 (d, <i>J</i> = 9.0 Hz, 2H), 2.85–2.84 (m, 3H), 2.73–2.60 (m, 2H), 2.32–2.22 (m, 1H), 2.20–2.08 (m, 2H), 1.90–1.78 (m, 2H), 1.60–1.46 (m, 2H); MS (ESI+) <i>m/z</i> 490 (M+H).	118
	55	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.02–10.84 (m, 0.7H), 10.29–10.17 (m, 0.3H), 9.61–9.46 (m, 0.5H), 9.10–9.00 (m, 0.4H), 8.90–8.80 (m, 0.6H), 7.84–7.71 (m, 1H), 7.71–7.58 (m, 1H), 7.26–7.07 (m, 1H), 4.79–4.65 (m, 1H), 4.59–4.44 (m, 0.7H), 4.39–4.20 (m, 1.5H), 3.79–3.59 (m, 2.5H), 3.59–3.45 (m, 3H), 3.26–3.09 (m, 1.2H), 2.88–2.78 (m, 6.3H), 2.75–2.57 (m, 2.5H), 2.29–2.15 (m, 1.5H), 2.14–2.01 (m, 2H), 1.86–1.68 (m, 3H), 1.59–1.40 (m, 4H); MS (ESI+) <i>m/z</i> 412 (M+H).	28.8
	56	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.7–8.47 (br m, 2.5H), 7.70 (d, <i>J</i> = 8.1 Hz, 1H), 7.44 (d, <i>J</i> = 7.8 Hz, 1H), 7.16 (t, <i>J</i> = 8.0 Hz, 1H), 4.73–4.12 (br m, 1H), 3.60 (d, <i>J</i> = 9.0 Hz, 2H), 3.17 (s, 1H), 2.81 (s, 3H), 2.42 (br s, 2H), 2.25–2.07 (m, 3H), 1.87 (t, <i>J</i> = 11.9 Hz, 2H), 1.70–1.35 (m, 3H); MS (ESI+) <i>m/z</i> 316 (M+H).	72







	57	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.43–10.14 (m, 0.3H), 9.86–9.63 (m, 0.7H), 9.60–9.48 (m, 0.5H), 9.48–9.16 (m, 0.8H), 9.07–8.94 (m, 0.4H), 8.85–8.62 (m, 0.7H), 7.94–7.81 (s, 1H), 7.80–7.53 (s, 1H), 4.71–4.56 (m, 1H), 4.56–4.43 (m, 0.7H), 4.40–4.37 (m, 0.5H), 4.27–4.02 (m, 1H), 3.76–3.58 (m, 2.5H), 3.58–3.45 (m, 1H), 3.21–3.03 (m, 1.4H), 2.95–2.76 (m, 3.4H), 2.76–2.56 (m, 2.7H), 2.32–1.98 (m, 3.4H), 1.98–1.64 (m, 3H), 1.63–1.34 (m, 6H); MS (ESI+) <i>m/z</i> 432 (M+H).	11.4
	58	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.54–10.34 (m, 0.3H), 9.79–9.53 (m, 0.6H), 9.11–8.94 (m, 0.4H), 8.87–8.62 (m, 0.6H), 7.95–7.81 (s, 1H), 7.80–7.67 (s, 1H), 4.66–4.44 (m, 0.6H), 4.44–4.10 (m, 2.4H), 3.83–3.49 (m, 6H), 3.28–3.09 (m, 2.5H), 2.91–2.75 (m, 6H), 2.74–2.54 (m, 2.5H), 2.35–2.17 (m, 1H), 2.17–1.97 (m, 2H), 1.87–1.71 (m, 3H), 1.60–1.41 (m, 2H); MS (ESI+) <i>m/z</i> 432 (M+H).	11.9
	59	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.01–10.91 (m, 0.7H), 10.91–10.84 (m, 0.2H), 10.34–10.08 (m, 0.2H), 9.60–9.40 (m, 0.7H), 9.16–9.00 (m, 1H), 7.86–7.50 (m, 4H), 7.31–7.16 (m, 1H), 7.06–6.85 (m, 2H), 4.72–4.49 (m, 0.7H), 4.48–4.26 (m, 0.2H), 3.87–3.72 (m, 3H), 3.72–3.52 (m, 2H), 2.94–2.78 (m, 3H), 2.78–2.59 (m, 1.5H), 2.23–1.89 (m, 3H), 1.89–1.32 (m, 5H); MS (ESI+) <i>m/z</i> 421 (M+H).	7.6
	60	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.63 (s, 0.4H), 9.87 (br s, 1.6H), 9.67 (d, <i>J</i> = 10.0 Hz, 1H), 9.07 (d, <i>J</i> = 6.5.0 Hz, 0.4H), 8.90 (d, <i>J</i> = 6.5.0 Hz, 0.6H), 7.79–7.75 (m, 1H), 7.65 (d, <i>J</i> = 8.5 Hz, 1H), 7.19–7.16 (m, 1H), 4.57–4.50 (m, 1.6H), 4.34–4.32 (m, 0.4H), 3.91–3.79 (m, 2H), 3.70–3.62 (m, 2H), 3.53–3.45 (m, 2H), 3.16–3.13 (m, 1H), 2.83 (t, <i>J</i> = 5.2 Hz, 3H), 2.73–2.61 (m, 2H), 2.30–2.23 (m, 1H), 2.18–2.06 (m, 2H), 1.79–1.68 (m, 3H), 1.56–1.42 (m, 5H), 1.37–1.34 (m, 3H). MS (ESI+) <i>m/z</i> 412 (M+H).	10.5
	61	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.25–10.03 (m, 0.5H), 9.52–9.09 (m, 1H), 9.30–9.09 (m, 0.5H), 8.66–8.47 (m, 1H), 7.79–7.65 (m, 1H), 7.65–7.46 (m, 1H), 7.15–7.03 (m, 1H), 4.61–4.41 (m, 1H), 4.41–4.25 (m, 0.5H), 3.84–3.61 (m, 2H), 3.61–3.52 (m, 1H), 3.25–3.03 (m, 0.75H), 2.94–2.78 (m, 2.75H), 2.78–2.55 (m, 2H), 2.35–1.94 (m, 3H), 1.90–1.62 (m, 5H), 1.62–1.37 (m, 3H), 1.37–1.21 (m, 0.5H), 1.19–0.99 (m, 3H), 0.99–0.82 (m, 0.5H); MS (ESI+) <i>m/z</i> 387 (M+H).	19.9







	62	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.43 (br s, 0.35H), 9.65 (br s, 0.65H), 9.05–9.04 (m, 0.35H), 8.85–8.83 (m, 0.65H), 7.81 (apt s, 1H), 7.71–7.64 (m, 1H), 4.58–4.50 (m, 0.7H), 4.35–4.32 (m, 0.3H), 4.03–4.00 (m, 1H), 3.95–3.80 (m, 3H), 3.72–3.44 (m, 5H), 2.83–2.82 (m, 3H), 2.71–2.54 (m, 2H), 2.24–2.17 (m, 1H), 2.13–2.01 (m, 2H), 1.93–1.74 (m, 5H), 1.58–1.44 (m, 2H), 0.94–0.86 (m, 3H); MS (ESI+) <i>m/z</i> 447 (M+H).	6.3
	63	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 9.58–8.62 (m, 1H), 7.94–7.77 (m, 1H), 7.77–7.58 (m, 1H), 4.81–4.58 (m, 0.3H), 4.56–4.06 (m, 2H), 4.06–3.83 (m, 0.8H), 3.83–3.59 (m, 1.5H), 3.55–3.39 (m, 2H), 2.92–2.79 (m, 4.5H), 2.79–2.56 (m, 3.5H), 2.40–1.93 (m, 7.3H), 1.86–1.65 (m, 2.8H), 1.61–1.17 (m, 5.5H); MS (ESI+) <i>m/z</i> 446 (M+H).	16.1
	64	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.32–10.24 (m, 1H), 10.09–9.89 (m, 0.25H), 9.38–9.20 (m, 0.75H), 9.20–9.10 (m, 0.25H), 9.10–8.91 (m, 0.75H), 8.09–7.95 (m, 0.75H), 7.87–7.59 (m, 1.25H), 7.72–7.60 (m, 1H), 7.31–7.08 (m, 3H), 7.08–6.86 (m, 1H), 4.71–4.45 (m, 0.75H), 4.41–4.22 (m, 0.25H), 3.97–3.79 (m, 3H), 3.76–3.59 (m, 1.5H), 2.92–2.79 (m, 3H), 2.74–2.53 (m, 2H), 2.20–1.78 (m, 3H), 1.78–1.19 (m, 5H); MS (ESI+) <i>m/z</i> 421 (M+H).	16.2
	65	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.59 (br s, 0.4H), 9.89 (br s, 0.6H), 9.18–9.17 (m, 0.4H), 8.98–8.98 (m, 0.6H), 7.77–7.74 (m, 1H), 7.62–7.61 (m, 1H), 7.16–7.12 (m, 1H), 4.60–4.20 (m, 2H), 3.95 (m, 1H), 3.74–3.72 (m, 1H), 3.56–3.46 (m, 4H), 2.83–2.81 (m, 3H), 2.68–2.62 (m, 2H), 2.27–2.25 (m, 2H), 2.12–2.10 (m, 2H), 1.80–1.78 (m, 3H), 1.53–1.47 (m, 3H), 1.36–1.34 (m, 3H); MS (ESI+) <i>m/z</i> 399 (M+H).	89
	66	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.66 (br s, 0.35H), 9.81 (br s, 0.65H), 9.14–9.12 (m, 0.35H), 8.92–8.90 (m, 0.65H), 7.77–7.74 (m, 1H), 7.61–7.59 (m, 1H), 7.14–7.11 (m, 1H), 4.61–4.53 (m, 0.65H), 4.36–4.32 (m, 0.35H), 4.17–4.14 (m, 1H), 3.94–3.89 (m, 2H), 3.85–3.81 (m, 1H), 3.69–3.47 (m, 5H), 2.83–2.78 (m, 3H), 2.73–2.61 (m, 2H), 2.32–2.17 (m, 1H), 2.14–2.02 (m, 2H), 1.92–1.70 (m, 5H), 1.55–1.22 (m, 4H), 0.96–0.89 (m, 3H); MS (ESI+) <i>m/z</i> 427 (M+H).	4.1







	67	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.67 (br s, 0.3H), 9.73 (br s, 0.7H), 9.10–9.09 (m, 0.3H), 8.82–8.81 (m, 0.7H), 7.77–7.72 (m, 1H), 7.61–7.59 (m, 1H), 7.15–7.11 (m, 1H), 4.63–4.60 (m, 0.7H), 4.37–4.35 (m, 0.3H), 4.27–4.20 (m, 1H), 3.94–3.90 (m, 2H), 3.83–3.78 (m, 1H), 3.71–3.64 (m, 2H), 3.60–3.49 (m, 3H), 2.87–2.77 (m, 3H), 2.74–2.54 (m, 2H), 2.36–2.17 (m, 1H), 2.13–2.00 (m, 2H), 1.86–1.37 (m, 8H), 1.02–0.89 (m, 6H); (ESI+) <i>m/z</i> 441 (M+H).	3.9
	68	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.76 (br s, 0.35H), 9.87 (br s, 0.65H), 9.13–9.12 (m, 0.35H), 8.98–8.97 (m, 0.65H), 7.79–7.70 (m, 1H), 7.63–7.59 (m, 1H), 7.16–7.09 (m, 1H), 4.61–4.59 (m, 0.65H), 4.38–4.33 (m, 0.35H), 4.25–4.14 (m, 1H), 4.13–4.02 (m, 1H), 3.95–3.77 (m, 2H), 3.72–3.36 (m, 5H), 2.87–2.78 (m, 3H), 2.77–2.58 (m, 2H), 2.41–1.95 (m, 3H), 1.77–1.70 (m, 3H), 1.56–1.36 (m, 2H), 1.09–1.08 (m, 9H); MS (ESI+) <i>m/z</i> 441 (M+H).	2.0
	69	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.79 (br s, 0.2H), 10.20–9.95 (m, 2H), 9.05–8.90 (m, 0.8H), 7.84–7.77 (m, 1H), 7.72–7.65 (m, 1H), 7.15–7.05 (m, 1H), 6.80 (br s, 1H), 4.60–4.45 (m, 0.5H), 4.41–4.32 (m, 2H), 3.60–3.40 (m, 4.5H), 3.39–3.17 (m, 2H), 2.82 (s, 3H), 2.73–2.62 (m, 2H), 2.28–2.22 (m, 0.6H), 2.20–2.00 (m, 2H), 1.80–1.62 (m, 2.4H), 1.60–1.20 (m, 8H); MS (ESI+) <i>m/z</i> 412 (M+H).	32.7
	70	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.56 (s, 0.4H), 9.79 (s, 0.6H), 9.25 (d, <i>J</i> = 5.5 Hz, 0.4H), 9.21 (d, <i>J</i> = 5.5 Hz, 0.6H), 8.60–8.53 (m, 1H), 7.73–7.68 (m, 1H), 7.55–7.50 (m, 1H), 7.07 (app t, <i>J</i> = 8.0 Hz, 1H), 4.54–4.50 (m, 1H), 3.60–3.52 (m, 3H), 2.90–2.80 (m, 3H), 2.75–2.65 (m, 2H), 2.27 (s, 1H), 2.22–1.97 (m, 4H), 1.75–1.60 (m, 5H), 1.57–1.46 (m, 4H), 1.37–1.26 (m, 4H); MS (ESI+) <i>m/z</i> 397 (M+H).	19.2
	71	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.40 (s, 0.3H), 9.52 (s, 0.7H), 8.96 (s, 0.4H), 8.61 (s, 0.6H), 7.78 (d, <i>J</i> = 7.5 Hz, 1H), 7.69 (br s, 2H), 7.63 (d, <i>J</i> = 7.5 Hz, 1H), 7.44 (br s, 3H), 7.36 (s, 1H), 7.18–7.15 (m, 1H), 4.71–4.52 (m, 1H), 4.50–4.38 (m, 1H), 4.34–4.27 (m, 2H), 3.84–3.70 (m, 1H), 3.65 (d, <i>J</i> = 9.0 Hz, 2H), 3.54 (br s, 1H), 3.32–3.30 (m, 1H), 3.25–3.11 (m, 1H), 2.84–2.82 (m, 3H), 2.75–2.62 (m, 1H), 2.60–2.52 (m, 2H), 2.30–2.14 (m, 1H), 2.11–2.06 (m, 3H), 1.91–1.80 (m, 1H), 1.72–1.62 (m, 3H), 1.53–1.35 (m, 3H), 1.30–1.23 (m, 1H), 0.95–0.89 (m, 6H); (ESI+) <i>m/z</i> 530 (M+H).	48.6







	72	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 9.59–7.91 (br m, 2H), 7.58–7.49 (m, 1H), 7.26 (d, <i>J</i> = 7.6 Hz, 1H), 6.95 (t, <i>J</i> = 7.8 Hz, 1H), 5.76–4.52 (br m, 1H), 3.62 (br s, 2H), 3.32 (br s, 1H), 2.82 (br s, 3H), 2.57 (br s, 2H), 2.09 (br s, 3H), 1.72 (br s, 2H), 1.55 (br s, 3H); MS (ESI+) <i>m/z</i> 332 (M+H).	30.8
	73	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.69 (br s, 0.2H), 10.00–9.70 (m, 2H), 9.10–8.90 (m, 0.8H), 7.84–7.76 (m, 1H), 7.70–7.68 (m, 1H), 7.20–7.14 (m, 1H), 5.20 (br s, 1H), 4.60–4.45 (m, 0.6H), 4.41–4.32 (m, 2.4H), 3.66–3.42 (m, 4H), 3.32–3.20 (m, 2H), 2.85 (s, 3H), 2.80–2.60 (m, 2H), 2.30–2.00 (m, 3H), 1.80–1.62 (m, 2H), 1.60–1.20 (m, 9H); MS (ESI+) <i>m/z</i> 412 (M+H).	2.2
	74	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.35 (s, 0.4H), 9.85–9.78 (m, 1H), 9.61–9.56 (m, 1.6H), 9.05 (d, <i>J</i> = 5.8 Hz, 0.4H), 8.85 (d, <i>J</i> = 7.1 Hz, 0.6H), 7.80–7.77 (m, 1H), 7.67–7.64 (m, 1H), 7.21–7.15 (m, 1H), 4.63–4.56 (m, 0.7H), 4.40–4.56 (m, 1H), 4.23 (t, <i>J</i> = 9.2 Hz, 1.3H), 3.73–3.64 (m, 3H), 3.56 (br. s, 1H), 3.52–3.35 (m, 9H), 3.27–3.23 (m, 1H), 2.84–2.80 (m, 3H), 2.73–2.63 (m, 1H), 2.62–2.58 (m, 2H), 2.28–2.22 (m, 1H), 1.87–1.72 (m, 4H), 1.61–1.51 (m, 3H), 1.45 (t, <i>J</i> = 12.0 Hz, 2H), 0.95–0.93 (m, 6H); (ESI+) <i>m/z</i> 440 (M+H).	72.9
	75	¹ H NMR (500 MHz, CD ₃ OD) δ 7.89–7.84 (m, 1H), 7.57–7.55 (m, 1H), 7.23–7.20 (m, 1H), 4.60–4.45 (m, 1H), 4.19–4.15 (m, 2H), 3.97–3.93 (m, 2H), 3.76–3.65 (m, 2H), 3.64–3.60 (m, 2H), 3.02 (s, 0.75H), 2.98 (s, 2.25H), 2.90–2.70 (m, 2H), 2.30–2.10 (m, 3H), 1.97–1.86 (m, 2.5H), 1.73–1.60 (m, 2.5H), 1.49–1.46 (m, 6H); MS (ESI+) <i>m/z</i> 413 (M+H).	0.59
	76	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.50 (s, 0.3H), 9.75 (s, 0.7H), 9.76 (d, <i>J</i> = 5.0 Hz, 1H), 9.53–9.43 (m, 1H), 9.04 (d, <i>J</i> = 5.5 Hz, 0.4H), 8.91 (d, <i>J</i> = 5.5 Hz, 0.6H), 7.80–7.75 (m, 1H), 7.64–7.62 (m, 1H), 7.18–7.14 (m, 1H), 4.57–4.52 (m, 0.6H), 4.40–4.22 (m, 1.4H), 4.08 (dd, <i>J</i> = 10.0, 3.0 Hz, 0.7 H), 4.04 (dd, <i>J</i> = 10.0, 3.0 Hz, 0.3 H), 3.81–3.61 (m, 5H), 3.66–3.48 (m, 3H), 3.34–3.22 (m, 2H), 3.20–3.08 (m, 1H), 2.87–2.82 (m, 3H), 2.75–2.62 (m, 3H), 2.25–2.21 (m, 1H), 2.18–2.14 (m, 1H), 1.81–1.72 (m, 2H), 1.55–1.45 (m, 2H), 1.07–1.03 (m, 3H), 0.89–0.86 (m, 3H); MS (ESI+) <i>m/z</i> 426 (M+H).	9.8







	77	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.56 (s, 0.4H) 9.82 (d, <i>J</i> = 7.5 Hz, 1H), 9.68 (m, 0.7H), 9.42 (d, <i>J</i> = 7.5 Hz, 1H), 9.00 (d, <i>J</i> = 6.0 Hz, 0.3H), 8.75 (d, <i>J</i> = 7.0 Hz, 0.6H), 7.79–7.77 (m, 1H), 7.65–7.63 (m, 1H), 7.17 (t, <i>J</i> = 8.0 Hz, 1H), 4.64–4.61 (m, 1H), 4.55 (s, 0.5H), 4.35 (s, 0.5H), 4.24–4.19 (m, 1H), 3.70–3.53 (m, 3H), 3.40–3.28 (m, 2H), 3.18–3.05 (m, 1H), 2.80 (s, 3H), 2.75–2.65 (m, 1H), 2.62–2.55 (m, 2H), 2.35–2.20 (m, 1H), 2.15–1.98 (m, 2H), 1.97–1.78 (m, 2H), 1.75–1.63 (m, 2H), 1.60–1.50 (m, 2H), 1.56 (t, <i>J</i> = 13.5 Hz, 2H), 1.00–0.86 (m, 6H); MS (ESI+) <i>m/z</i> 440 (M+H).	6.4
	78	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.30 (s, 0.3H) 9.70–9.52 (m, 1H), 9.44 (br s, 0.7H), 9.35 (s, 1H), 9.03 (d, <i>J</i> = 6.0 Hz, 0.3H), 8.87 (d, <i>J</i> = 6.0 Hz, 0.7H), 7.80–7.77 (m, 1H), 7.70–7.64 (m, 1H), 7.21–7.17 (m, 1H), 4.64–4.56 (m, 0.7H), 4.42–4.37 (m, 1H), 4.26 (d, <i>J</i> = 12.5 Hz, 1.3H), 3.72–3.62 (m, 2H), 3.51 (br s, 1H), 3.48–3.41 (m, 2H), 3.40–3.25 (m, 2H), 2.88 (s, 3H), 2.72–2.64 (m, 1H), 2.62–2.54 (m, 1H), 2.28–2.18 (m, 1H), 2.10–1.97 (m, 3H), 1.82–1.65 (m, 2H), 1.58–1.49 (m, 1H), 1.42 (t, <i>J</i> = 15.0 Hz, 2H), 1.21–0.95 (m, 6H); MS (ESI+) <i>m/z</i> 426 (M+H).	25.8
	79	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.40 (s, 0.4H), 9.60 (s, 0.6H), 9.08 (d, <i>J</i> = 5.5 Hz, 0.4H), 8.86 (d, <i>J</i> = 5.5 Hz, 0.6H), 7.85–7.78 (m, 1H), 7.75–7.66 (m, 3H), 7.26–7.20 (m, 1H), 5.25–5.15 (m, 2H), 4.62–4.50 (m, 0.7H), 4.40–4.30 (m, 2.3H), 4.25–4.15 (m, 2H), 3.72–3.64 (m, 1.5H), 3.60–3.48 (m, 1H), 2.85 (s, 3H), 2.80–2.62 (m, 2.5H), 2.32–2.24 (m, 1H), 2.15–2.05 (m, 2H), 1.88–1.80 (m, 2.7H), 1.64–1.54 (m, 2.3H); MS (ESI+) <i>m/z</i> 421 (M+H).	29.3
	80	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.68–9.74 (br m, 1H), 9.02–8.86 (br m, 1H), 7.82–7.80 (m, 1H), 7.69–7.67 (m, 1H), 4.59 (br s, 1H), 4.18 (d, <i>J</i> = 12.4 Hz, 2H), 4.07 (br s, 1H), 3.95 (d, <i>J</i> = 9.3 Hz, 1H), 3.72–3.55 (m, 5H), 2.82 (d, <i>J</i> = 4.3 Hz, 3H), 2.73–2.59 (m, 2H), 2.29–2.23 (m, 1H), 2.15–2.05 (m, 2H), 1.80–1.65 (m, 3H), 1.55–1.53 (m, 1H), 1.47–1.40 (m, 1H), 1.31–1.18 (m, 1H), 1.10–1.07 (m, 8H); MS (ESI+) <i>m/z</i> 475 (M+H).	29.4
	81	¹ H NMR (500 MHz, CD ₃ OD) δ 7.86–7.84 (m, 1H), 7.57–7.56 (m, 1H), 7.21 (app t, <i>J</i> = 8.0 Hz, 1H), 4.44–4.35 (m, 1H), 4.19–4.16 (m, 2H), 3.96–3.90 (m, 4H), 3.64–3.60 (m, 2H), 2.69–2.61 (m, 2H), 2.17–2.06 (m, 1H), 1.96–1.90 (m, 2H), 1.79–1.67 (m, 5H), 1.49 (d, <i>J</i> = 6.5 Hz, 6H); MS (ESI+) <i>m/z</i> 399 (M+H).	16.8








	82	¹ H NMR (500 MHz, CD ₃ OD) δ 7.88–7.84 (m, 1H), 7.58–7.56 (m, 1H), 7.23–7.19 (m, 1H), 4.57–4.51 (m, 0.7H), 4.47–4.43 (m, 0.3H), 4.31–4.29 (m, 4H), 3.74–3.67 (m, 2H), 3.36–3.32 (m, 4H), 3.00–2.98 (m, 3H), 2.88–2.80 (m, 0.6H), 2.77–2.70 (m, 1.4H), 2.43–2.14 (m, 3H), 2.03–1.93 (m, 2.5H), 1.70–1.62 (m, 2.5H); MS (ESI+) <i>m/z</i> 433 (M+H).	132
	83	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.39 (br s, 1H), 9.52 (d, <i>J</i> = 6.6 Hz, 1H), 7.73–7.71 (m, 1H), 7.61–7.60 (m, 1H), 7.11 (t, <i>J</i> = 7.9 Hz, 1H), 4.37 (br s, 1H), 3.78–3.70 (m, 1H), 3.65–3.60 (m, 2H), 3.29 (t, <i>J</i> = 8.1 Hz, 2H), 3.23 (t, <i>J</i> = 8.1 Hz, 2H), 3.20 (s, 3H), 3.12–3.07 (m, 1H), 2.25–2.23 (m, 1H), 2.18–2.06 (m, 1H), 1.97–1.90 (m, 3H), 1.23 (t, <i>J</i> = 7.1 Hz, 3H); MS (ESI+) <i>m/z</i> 329 (M+H).	6.8
	84	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.74 (s, 0.4H) 9.93–9.87 (m, 1.6H), 9.59–9.53 (m, 1H), 9.06 d, <i>J</i> = 5.5 Hz, 0.4 H), 8.88 (d, <i>J</i> = 5.5 Hz, 0.6H), 7.76 (t, <i>J</i> = 8.0 Hz, 1H), 7.64 (d, <i>J</i> = 7.5 Hz, 1H), 4.62–4.42 (m, 4H), 4.41–4.25 (m, 2H), 4.23 (t, <i>J</i> = 13.0 Hz, 1H), 3.70–3.48 (m, 3H), 3.42–3.22 (m, 3H), 3.20–3.05 (m, 1H), 2.83–2.81 (m, 3H), 2.72–2.61 (m, 2H), 2.32–2.27 (m, 1H), 2.20–2.01 (m, 3H), 2.00–1.86 (m, 1H), 1.85–1.65 (m, 3H), 1.60–1.40 (m, 2H), 0.93–0.88 (m, 3H); MS (ESI+) <i>m/z</i> 412 (M+H).	11.3
	85	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.44 (br s, 1H), 9.52 (d, <i>J</i> = 6.6 Hz, 1H), 7.72–7.71 (m, 1H), 7.61–7.59 (m, 1H), 7.11 (t, <i>J</i> = 7.9 Hz, 1H), 4.52–4.43 (m, 1H), 4.40–4.32 (m, 1H), 3.77–3.72 (m, 1H), 3.29 (t, <i>J</i> = 8.0 Hz, 2H), 3.23 (t, <i>J</i> = 7.9 Hz, 2H), 3.08 (s, 3H), 2.25–2.23 (m, 1H), 2.16–2.08 (m, 1H), 1.97–1.94 (m, 3H), 1.28–1.26 (m, 6H), 0.99 (s, 1H); MS (ESI+) <i>m/z</i> 343 (M+H).	28.9
	86	¹ H NMR (500 MHz, CD ₃ OD) δ 7.88–7.84 (m, 1H), 7.58–7.56 (m, 1H), 7.21–7.18 (m, 1H), 4.73–4.46 (m, 1H), 4.38 (s, 2H), 4.35 (s, 1H), 4.01–3.97 (m, 2H), 3.74–3.71 (m, 1.4H), 3.69–3.65 (m, 0.6H), 3.55–3.53 (m, 2H), 3.01 (s, 1H), 2.99 (s, 2H), 2.89–2.81 (m, 0.6H), 2.78–2.72 (m, 1.4H), 2.49–2.56 (m, 0.3H), 2.30–2.14 (m, 2.7H), 2.05–1.96 (m, 2.5H), 1.75–1.64 (m, 2.5H); MS (ESI+) <i>m/z</i> 398 (M+H).	66.2
	87	¹ H NMR (500 MHz, CD ₃ OD) δ 7.89–7.83 (m, 1H), 7.57–7.53 (m, 1H), 7.23–7.16 (m, 1H), 4.64–4.49 (m, 1H), 4.09–4.03 (m, 2H), 4.01–3.93 (m, 1H), 3.91–3.89 (m, 2H), 3.77–3.73 (m, 2H), 3.55–3.48 (m, 1H), 3.02 (s, 0.6H), 2.97 (s, 2.4H), 2.90–2.68 (m, 2H), 2.30–1.68 (m, 9H), 1.57–1.52 (m, 4H), 1.01–0.94 (m, 3H); MS (ESI+) <i>m/z</i> 427 (M+H).	1.0







	88	¹ H NMR (500 MHz, CD ₃ OD) δ 9.96 (br s, 1H), 7.89 (dd, <i>J</i> = 8.0, 0.9 Hz, 1H), 7.52 (dd, <i>J</i> = 8.0, 0.9 Hz, 1H), 7.17 (appt t, <i>J</i> = 8.0 Hz, 1H), 4.44–4.30 (m, 1H), 4.24–4.19 (m, 3H), 4.12–4.05 (m, 1H), 4.02–3.93 (m, 3H), 3.60 (dd, <i>J</i> = 11.6, 5.4 Hz, 2H), 3.56–3.48 (m, 2H), 3.20–3.02 (m, 3H), 2.90–2.70 (m, 2H), 2.24–2.22 (m, 1H), 2.02–2.00 (m, 1H), 1.44 (dd, <i>J</i> = 6.5 Hz, 6H); MS (ESI+) <i>m/z</i> 415 (M+H).	19.9
	89	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.61–9.92 (br m, 1H), 9.26–9.00 (br m, 1H), 7.76–7.73 (m, 1H), 7.60–7.58 (m, 1H), 7.14–7.10 (m, 1H), 4.52–4.33 (m, 1H), 3.92–3.86 (m, 2H), 3.61 (d, <i>J</i> = 8.5 Hz, 1H), 3.57–3.49 (m, 4H), 3.30 (s, 3H), 2.84–2.81 (m, 3H), 2.72–2.64 (m, 2H), 2.29 (d, <i>J</i> = 6.3 Hz, 1H), 2.18–2.08 (m, 2H), 1.99–1.95 (m, 2H), 1.84–1.75 (m, 3H), 1.64–1.57 (m, 2H), 1.53–1.48 (m, 2H); MS (ESI+) <i>m/z</i> 413 (M+H).	36.9
	90	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.0 (br s, 1H), 9.30 (d, <i>J</i> = 6.4 Hz, 1H), 7.77 (dd, <i>J</i> = 8.0, 0.8 Hz, 1H), 7.68 (dd, <i>J</i> = 8.0, 0.7 Hz, 1H), 7.21 (appt t, <i>J</i> = 8.0 Hz, 1H), 4.41–4.35 (m, 1H), 4.11–4.08 (m, 2H), 3.90 (dd, <i>J</i> = 11.6, 3.6 Hz, 2H), 3.80–3.74 (m, 1H), 3.56 (dd, <i>J</i> = 11.6, 5.4 Hz, 2H), 3.30–3.23 (m, 4H), 3.18–3.12 (m, 1H), 2.21–2.19 (m, 1H), 2.12–2.05 (m, 1H), 1.97–1.88 (m, 3H), 1.38 (dd, <i>J</i> = 6.5 Hz, 6H); MS (ESI+) <i>m/z</i> 385 (M+H).	6.8
	91	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.52–9.84 (br m, 1H), 9.24–8.99 (m, 1H), 7.76–7.73 (m, 1H), 7.60–7.58 (m, 1H), 7.14–7.11 (m, 1H), 4.52–4.33 (m, 1H), 3.95 (s, 3H), 3.79–3.76 (m, 4H), 3.61 (d, <i>J</i> = 8.5 Hz, 1H), 3.53–3.46 (m, 5H), 2.83 (t, <i>J</i> = 5.5 Hz, 2H), 2.73–2.63 (m, 2H), 2.28–2.26 (m, 1H), 2.15–2.08 (m, 1H), 1.83–1.77 (m, 6H), 1.54–1.47 (m, 2H); MS (ESI+) <i>m/z</i> 441 (M+H).	14.5
	92	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.37–9.69 (br m, 1H), 9.24–8.99 (m, 1H), 7.79–7.76 (m, 1H), 7.66–7.64 (m, 1H), 7.18–7.14 (m, 1H), 4.53–4.34 (m, 1H), 4.05–4.01 (m, 4H), 3.62 (d, <i>J</i> = 8.5 Hz, 1H), 3.49 (br s, 1H), 3.32 (s, 1H), 2.83 (t, <i>J</i> = 4.4 Hz, 3H), 2.72–2.58 (m, 6H), 2.36–2.22 (m, 1H), 2.17–2.08 (m, 2H), 1.85–1.75 (m, 2H), 1.53–1.49 (m, 2H); MS (ESI+) <i>m/z</i> 397 (M+H).	21.2
	93	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.33 (s, 1H), 9.50 (d, <i>J</i> = 6.6 Hz, 1H), 8.09 (br s, 2H), 7.69 (d, <i>J</i> = 7.9 Hz, 1H), 7.54 (d, <i>J</i> = 7.9 Hz, 1H), 7.09 (t, <i>J</i> = 7.9 Hz, 1H), 4.40–4.35 (m, 1H), 3.74 (t, <i>J</i> = 11.4 Hz, 1H), 3.31–3.20 (m, 4H), 3.10–3.03 (m, 1H), 2.25–2.16 (m, 2H), 1.97–1.85 (m, 3H); MS (ESI+) <i>m/z</i> 287 (M+H).	12.1








	94	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 9.20 (br s, 0.5H), 8.85 (br s, 1H), 7.73 (d, <i>J</i> = 7.9 Hz, 1H), 7.56 (d, <i>J</i> = 7.9 Hz, 1H), 7.11 (d, <i>J</i> = 7.9 Hz, 1H), 5.09–4.96 (m, 1H), 4.53–4.22 (m, 1H), 4.21–4.02 (m, 2H), 4.02–3.81 (m, 3H), 3.81–3.39 (m, 5H), 3.26–3.14 (m, 1.5H), 3.13–2.87 (m, 1.5 H), 2.48–2.22 (m, 3H), 2.22–0.75 (m, 8H); MS (ESI+) <i>m/z</i> 415 (M+H).	27.5
	95	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 8.96 (br s, 1H), 7.74 (dd, <i>J</i> = 8.0, 0.8 Hz, 1H), 7.58 (dd, <i>J</i> = 7.9, 0.8 Hz, 1H), 7.12 (t, <i>J</i> = 8.0 Hz, 1H), 4.38–4.32 (m, 1H), 4.07 (d, <i>J</i> = 9.9 Hz, 2H), 3.38–3.20 (m, 7H), 3.13 (d, <i>J</i> = 12.4 Hz, 1H), 2.99 (d, <i>J</i> = 7.7 Hz, 2H), 2.98–2.85 (m, 1H), 2.60 (br s, 3H), 2.15–2.02 (m, 3H), 1.58–1.45 (m, 3H), 1.35–1.20 (m, 2H), 1.13 (d, <i>J</i> = 5.3 Hz, 3H); MS (ESI+) <i>m/z</i> 398 (M+H).	52.4
	96	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.49 (s, 0.4H) 9.64 (br s, 1.6H), 9.15 (s, 1H), 9.00 (s, 0.3 H), 8.93 (d, <i>J</i> = 5.0 Hz, 0.7H), 7.83–7.75 (m, 1H), 7.67–7.63 (m, 1H), 7.23–7.14 (m, 1H), 4.67–4.57 (m, 1H), 4.41–4.25 (m, 2H), 3.68–3.63 (m, 2H), 3.56 (s, 1H), 3.48–3.32 (m, 2H), 3.26 (br s, 2H), 2.83 (s, 3H), 2.75–2.61 (m, 2H), 2.27–2.18 (m, 1H), 2.15–2.01 (m, 2H), 1.82–1.62 (m, 3H), 1.58–1.53 (m, 1H), 1.50–1.38 (m, 1H), 1.04–0.99 (m, 9H); MS (ESI+) <i>m/z</i> 440 (M+H).	7.5
	97	¹ H NMR (500 MHz, CD ₃ OD) δ 7.85–7.83 (m, 1H), 7.56–7.54 (m, 1H), 7.38–7.31 (m, 5H), 7.18 (app t <i>J</i> = 8.0 Hz, 1H), 4.76–4.63 (m, 3H), 4.52–4.47 (m, 2H), 3.91 (dd, <i>J</i> = 13.7, 3.5 Hz, 1H), 3.64–3.61 (m, 2H), 3.41–3.37 (m, 1H), 2.92 (s, 3H), 2.82–2.71 (m, 2H), 2.23–2.19 (m, 3H), 1.90–1.88 (m, 2H), 1.73–1.60 (m, 6H), 1.13 (d, <i>J</i> = 6.5 Hz, 3H); MS (ESI+) <i>m/z</i> 516 (M+H).	0.40
	98	¹ H NMR (500 MHz, CD ₃ OD) δ 7.87–7.83 (m, 1H), 7.56–7.54 (m, 1H), 7.20–7.16 (m, 1H), 4.79–4.76 (m, 1H), 4.54–4.41 (m, 1H), 4.30–4.25 (m, 1H), 3.78–3.65 (m, 3H), 3.62–3.55 (m, 1H), 3.48–3.42 (m, 1H), 3.01–2.99 (m, 3H), 2.90–2.80 (m, 0.7H), 2.80–2.72 (m, 1.3H), 2.50–2.37 (m, 0.3H), 2.30–2.14 (m, 2.7H), 2.04–1.94 (m, 2.5H), 1.75–1.61 (m, 5.5H); MS (ESI+) <i>m/z</i> 412 (M+H).	14.6
	99	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 9.70 (br s, 2H), 9.33 (d, <i>J</i> = 6.5 Hz, 1H), 7.76 (d, <i>J</i> = 8.0 Hz, 1H), 7.67 (d, <i>J</i> = 8.0 Hz, 1H), 7.18 (app t, <i>J</i> = 8.0 Hz, 1H), 4.40–4.30 (m, 3H), 3.76–3.73 (m, 1H), 3.42–3.00 (m, 10H), 2.20 (br s, 1H), 2.18–2.05 (m, 3H), 1.48 (d, <i>J</i> = 6.5 Hz, 3H), 1.44 (d, <i>J</i> = 6.5 Hz, 3H); MS (ESI+) <i>m/z</i> 384 (M+H).	13.2








	100	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.39–9.56 (br m, 1H), 8.87–8.65 (m, 1H), 7.81–7.78 (m, 1H), 7.71–7.66 (m, 1H), 7.24–7.19 (m, 1H), 4.72–4.37 (m, 1H), 4.00–3.98 (m, 2H), 3.68–3.58 (m, 2H), 3.28–3.25 (m, 4H), 3.17 (s, 1H), 2.85–2.83 (m, 3H), 2.75–2.54 (m, 2H), 2.46–2.27 (m, 2H), 2.23–2.10 (m, 3H), 2.07 (s, 1H), 2.03–1.94 (m, 1H), 1.91–1.84 (m, 2H), 1.72–1.62 (m, 4H), 1.59–1.53 (m, 1H), 1.45 (d, <i>J</i> = 13.8 Hz, 2H); MS (ESI+) <i>m/z</i> 438 (M+H).	11.4
	101	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.89 (s, 1H), 8.95 (d, <i>J</i> = 7.0 Hz, 1H), 7.76 (d, <i>J</i> = 8.0 Hz, 1H), 7.63 (d, <i>J</i> = 8.0 Hz, 1H), 7.18 (t, <i>J</i> = 8.0 Hz, 1H), 4.37–4.33 (m, 1H), 4.15–4.08 (m, 2H), 3.90 (br s, 2H), 3.86 (dd, <i>J</i> = 11.5, 0.5 Hz, 2H), 3.57–3.52 (m, 2H), 3.33 (br s, 3H), 2.66 (d, <i>J</i> = 5.0 Hz, 1H), 2.28–2.21 (m, 2H), 2.20–2.10 (m, 4H), 2.04–1.99 (m, 2H), 1.41–1.39 (m, 6H); MS (ESI+) <i>m/z</i> 399 (M+H).	2.6
	102	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 8.94–8.89 (br m, 1H), 7.78 (dd, <i>J</i> = 7.9, 0.6 Hz, 1H), 7.66 (dd, <i>J</i> = 7.9, 0.7 Hz, 1H), 7.20 (t, <i>J</i> = 8.0 Hz, 1H), 4.52 (br s, 1H), 3.87 (t, <i>J</i> = 5.4 Hz, 2H), 3.58–3.52 (m, 2H), 3.31 (br s, 3H), 3.22 (t, <i>J</i> = 5.4 Hz, 2H), 3.11 (br s, 2H), 2.78 (br s, 3H), 2.67–2.61 (m, 2H), 2.12–2.01 (m, 3H), 1.65 (s, 6H), 1.61–1.52 (m, 2H), 1.50–1.40 (m, 2H); MS (ESI+) <i>m/z</i> 412 (M+H).	15.8
	103	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.22 (s, 1H), 9.38 (d, <i>J</i> = 6.7 Hz, 1H), 8.27 (br, s, 2H), 7.76 (d, <i>J</i> = 2.0 Hz, 1H), 7.62 (d, <i>J</i> = 2.0 Hz, 1H), 4.37–4.33 (m, 1H), 3.73 (t, <i>J</i> = 11.4 Hz, 1H), 3.30–3.20 (m, 4H), 3.10–3.06 (m, 1H), 2.22–2.12 (m, 2H), 1.97–1.85 (m, 3H); MS (ESI+) <i>m/z</i> 321 (M+H).	5.1
	104	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.51 (s, 1H), 9.57 (d, <i>J</i> = 7.0 Hz, 1H), 8.71–8.69 (m, 1H), 7.69 (dd, <i>J</i> = 7.0, 1.0 Hz, 1H), 7.56 (dd, <i>J</i> = 7.0, 0.7 Hz, 1H), 7.10 (t, <i>J</i> = 8.0 Hz, 1H), 4.75 (br s, 2H), 4.37 (s, 1H), 3.74 (t, <i>J</i> = 6.0 Hz, 1H), 3.42–3.38 (m, 2H), 3.33–3.23 (m, 2H), 3.21–3.17 (m, 2H), 3.09 (d, <i>J</i> = 12.0 Hz, 1H), 2.24–2.22 (m, 1H), 3.18–3.08 (m, 1H), 1.97–1.94 (m, 3H), 1.24 (t, <i>J</i> = 7.5 Hz, 3H); (ESI+) <i>m/z</i> 315 (M+H).	13.5
	105	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.30 (s, 04H), 9.65 (s, 0.6H), 9.35 (d, <i>J</i> = 6.0 Hz, 0.4H), 9.17 (d, <i>J</i> = 6.0 Hz, 0.6H), 8.60–8.58 (m, 1H), 7.73–7.68 (m, 1H), 7.55 (d, <i>J</i> = 7.5 Hz, 1H), 7.10–7.05 (m, 1H), 4.60–4.48 (m, 1.5H), 4.40–4.30 (m, 0.5H), 3.70–3.60 (m, 1H), 3.59–3.52 (m, 1H), 3.45–3.33 (m, 2H), 2.83 (s, 3H), 2.80–2.60 (m, 2H), 2.30–2.20 (m, 1H), 2.18–2.05 (m, 2H), 1.60–1.40 (m, 3H), 1.28–1.15 (m, 3H) (ESI+) <i>m/z</i> 343 (M+H).	3.3

	106	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 9.67 (br s, 0.35H), 9.18 (br s, 0.65H), 9.07 (d, <i>J</i> = 5.3 Hz, 0.35H), 8.84 (d, <i>J</i> = 6.7 Hz, 0.65H), 7.83 (d, <i>J</i> = 2.0 Hz, 1H), 7.70–7.67 (m, 1H), 4.49–4.25 (m, 2H), 3.98–3.95 (m, 1H), 3.85–3.52 (m, 7H), 2.86–2.83 (m, 3H), 2.72–2.52 (m, 2H), 2.14–2.05 (m, 3H), 1.82–1.78 (m, 3H), 1.53–1.47 (m, 2H), 1.36–1.33 (m, 3H); MS (ESI+) <i>m/z</i> 433 (M+H).	12.6
	107	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.38 (s, 0.3H), 9.86 (s, 2H), 9.58 (s, 0.7H), 8.83 (d, <i>J</i> = 5.5 Hz, 0.4H), 8.75 (d, <i>J</i> = 5.5 Hz, 0.6H), 7.82–7.77 (m, 1H), 7.16–7.12 (m, 1H), 4.60–4.52 (m, 0.7H), 4.45–4.40 (m, 2H), 4.36 (br s, 0.3H), 3.66–3.62 (m, 1H), 3.55 (br s, 1H), 3.52–3.43 (m, 2H), 3.28–3.22 (m, 3H), 2.86 (s, 3H), 2.76–2.71 (m, 1H), 2.70–2.58 (m, 1H), 2.28–2.00 (m, 3H), 1.82–1.65 (m, 3H), 1.60–1.39 (m, 8H); (ESI+) <i>m/z</i> 430 (M+H).	14.2
	108	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.68–9.74 (br m, 1H), 9.02–8.86 (br m, 1H), 7.82–7.80 (m, 1H), 7.69–7.67 (m, 1H), 4.59 (br s, 1H), 4.18 (d, <i>J</i> = 12.4 Hz, 2H), 4.07 (br s, 1H), 3.95 (d, <i>J</i> = 9.3 Hz, 1H), 3.72–3.55 (m, 5H), 2.82 (d, <i>J</i> = 4.3 Hz, 3H), 2.73–2.59 (m, 2H), 2.29–2.23 (m, 1H), 2.15–2.05 (m, 2H), 1.80–1.65 (m, 3H), 1.55–1.53 (m, 1H), 1.47–1.40 (m, 1H), 1.31–1.18 (m, 1H), 1.10–1.07 (m, 8H); MS (ESI+) <i>m/z</i> 349 (M+H).	14.4
	109	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.33 (br s, 1H), 9.50–9.39 (m, 1H), 9.33 (d, <i>J</i> = 6.7, 1H), 7.75 (dd, <i>J</i> = 8.2, 0.8 Hz, 1H), 7.65 (dd, <i>J</i> = 8.0, 0.8 Hz, 1H), 7.19 (t, <i>J</i> = 8.0 Hz, 1H), 4.47–4.07 (m, 3H), 3.72 (t, <i>J</i> = 11.0 Hz, 1H), 3.28 (t, <i>J</i> = 8.4 Hz, 2H), 3.24 (t, <i>J</i> = 8.4 Hz, 2H), 3.19–3.10 (m, 1H), 2.24–2.22 (m, 1H), 2.17–2.06 (m, 1H), 1.97–1.93 (m, 2H), 1.92–1.82 (m, 1H); MS (ESI+) <i>m/z</i> 369 (M+H).	47.9
	110	¹ H NMR (300 MHz, DMSO- <i>d</i> ₆) δ 9.90 (br m, 0.4H), 9.16 (br m, 0.6H), 7.78 (dd, <i>J</i> = 7.9, 0.6 Hz, 1H), 7.66 (d, <i>J</i> = 7.9, 1H), 7.16 (t, <i>J</i> = 8.0 Hz, 1H), 4.39 (br m, 3H), 3.89 (m, 2H), 3.68–3.34 (m, 4H), 2.86 (m, 3H), 2.85–2.51 (m, 3H), 2.12–2.08 (m, 3H), 1.48–1.23 (m, 8H); MS (ESI+) <i>m/z</i> 454 (M+H).	2.2
	111	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.30 (br s, 0.25H), 9.58 (br s, 0.75H), 9.26 (d, <i>J</i> = 5.8 Hz, 0.25H), 8.91 (d, <i>J</i> = 5.8 Hz, 0.75H), 8.28 (br s, 2H), 7.75 (d, <i>J</i> = 2.0 Hz, 1H), 7.63 (d, <i>J</i> = 2.0 Hz, 1H), 4.64–4.59 (m, 0.75H), 4.35–4.25 (m, 0.25H), 3.64 (d, <i>J</i> = 9.2 Hz, 1.2H), 3.60–3.55 (m, 0.25H), 2.85–2.80 (m, 3H), 2.72–2.54 (m, 2H), 2.27–2.10 (m, 3H), 2.85–2.65 (m, 3H), 1.60–1.42 (m, 2H); MS (ESI+) <i>m/z</i> 349 (M+H).	2.0





	112	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.00 (s, 1H), 9.30 (d, <i>J</i> = 6.6 Hz, 1H), 8.32 (s, 2H), 7.71–7.68 (m, 1H), 7.04 (t, <i>J</i> = 8.0 Hz, 1H), 4.40–4.28 (m, 1H), 3.80–3.70 (m, 1H), 3.35–3.26 (m, 2H), 3.25–3.20 (m, 2H), 3.10–3.02 (m, 1H), 2.28–2.22 (m, 1H), 2.18–2.10 (m, 1H), 1.98–1.92 (m, 3H); MS (ESI+) <i>m/z</i> 305 (M+H).	33.3
	113	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.33 (br s, 1H), 9.61 (d, <i>J</i> = 6.8 Hz, 1H), 8.55–8.52 (m, 1H), 7.70 (dd, <i>J</i> = 8.1, 0.9 Hz, 1H), 7.65 (dd, <i>J</i> = 8.1, 1.0 Hz, 1H), 7.10 (t, <i>J</i> = 8.0 Hz, 1H), 4.39–4.37 (m, 1H), 3.75 (t, <i>J</i> = 11.4 Hz, 1H), 3.31 (t, <i>J</i> = 7.3 Hz, 2H), 3.24 (t, <i>J</i> = 8.8 Hz, 2H), 3.15–3.11 (m, 1H), 2.97 (s, 3H), 2.24–2.23 (m, 1H), 2.21–2.16 (m, 1H), 1.97–1.90 (m, 3H); MS (ESI+) <i>m/z</i> 301 (M+H).	14.5
	114	¹ H NMR (500 MHz, CD ₃ OD) δ 9.15 (d, <i>J</i> =6.0Hz, 0.3H), 9.08 (d, <i>J</i> =6.0Hz, 0.3H), 7.84–7.82 (m, 1H), 7.66 (d, <i>J</i> =1.5Hz, 1H), 4.62–4.46 (m, 3H), 3.82–3.60 (m, 4H), 3.44–3.38 (m, 2H), 3.01–2.97 (m, 3H), 2.92–2.70 (m, 2H), 2.32–2.16 (m, 3H), 2.00–1.82 (m, 3H), 1.72–1.64 (m, 1H), 1.63 (d, <i>J</i> =7.0Hz, 6H); MS (ESI+) <i>m/z</i> 446 (M+H).	6.6
	115	¹ H NMR (300 MHz, DMSO- <i>d</i> ₆) δ 9.55 (br m, 1H), 7.73 (d, <i>J</i> = 7.9 Hz, 1H), 7.62 (d, <i>J</i> = 7.9 Hz, 1H), 7.12 (t, <i>J</i> = 7.9 Hz, 1H), 4.29 (br m, 1H), 3.65 (m, 5H), 3.12 (m, 4H), 2.99 (m, 1H), 2.15 (m, 2H), 1.87 (m, 3H), 1.23 (t, <i>J</i> = 3.6 Hz, 6H); MS (ESI+) <i>m/z</i> 343 (M+H).	4.8
	116	¹ H NMR (300 MHz, DMSO- <i>d</i> ₆) δ 9.39 (d, <i>J</i> = 7.2 Hz, 1H), 8.10, (br, s, 2H), 7.60 (dd, <i>J</i> = 8.1, 2.7 Hz, 1H), 7.40 (dd, <i>J</i> = 8.1, 2.7 Hz, 1H), 4.23–4.06 (m, 1H), 3.55–3.45 (m, 1H), 3.09–2.95 (m, 4H), 2.79 (dd, <i>J</i> = 13.5, 4.5 Hz, 1H), 2.10–1.90 (m, 2H), 1.82–1.64 (m, 3H); MS (ESI+) <i>m/z</i> 305 (M+H).	9.4
	117	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 9.90–9.80 (m, 0.25H), 9.40–9.00 (m, 1.5H), 7.74 (d, <i>J</i> = 8.0 Hz, 1H), 7.65 (d, <i>J</i> = 8.0 Hz, 1H), 7.55–7.48 (m, 5H), 7.13 (d, <i>J</i> = 8.0 Hz, 1H), 4.53–4.20 (m, 2H), 4.05–3.85 (m, 3H), 3.70–3.42 (m, 2H), 2.85–2.75 (m, 2.5H), 2.70–2.40 (m, 4.25H), 2.16–1.90 (m, 3H), 1.88–1.62 (m, 2.5H), 1.60–1.40 (m, 5H), 1.28–1.20 (m, 4H); MS (ESI+) <i>m/z</i> 516 (M+H).	2.3
	118	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.08–9.90 (br s, 1H), 9.78–9.60 (br s, 2H), 9.10 (d, <i>J</i> = 6.8 Hz, 1H), 7.80–7.77 (m, 1H), 7.17–7.13 (m, 1H), 4.44–4.40 (m, 3H), 3.80–3.75 (m, 1H), 3.51–3.47 (m, 2H), 3.38–3.20 (m, 6H), 3.17–3.08 (m, 1H), 2.62–2.60 (m, 0.5H), 2.38–2.36 (m, 0.5H), 2.19–2.18 (m, 1H), 2.10–2.00 (m, 1H), 1.98–1.85 (m, 3H), 1.52–1.49 (m, 6H). (ESI+) <i>m/z</i> 402 (M+H).	26.8

	119	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.20–11.00 (m, 1H), 10.32 (br s, 0.3H), 9.50 (s, 0.7H), 9.00–8.90 (m, 1H), 7.86–7.80 (m, 1H), 7.72–7.68 (m, 1H), 7.26–7.18 (m, 1H), 4.86–4.74 (m, 1H), 4.68–4.58 (m, 0.7H), 4.40–4.32 (m, 0.3H), 4.28–4.20 (m, 1H), 3.70–3.56 (m, 4H), 3.20–3.00 (m, 3H), 2.86 (s, 3H), 2.40–1.92 (m, 3H), 1.80–1.72 (m, 6H), 1.70–1.54 (m, 4H), 1.50–1.40 (m, 2H), 1.30–1.18 (m, 1H), 0.70–0.60 (m, 2H), 0.50–0.30 (m, 2H); MS (ESI+) <i>m/z</i> 466 (M+H).	6.6
	120	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆ , mixture of rotomers) δ 9.95 (br s, 0.35H), 9.34 (br s, 0.65H), 9.08 (d, <i>J</i> = 5.4 Hz, 0.35H), 9.01 (d, <i>J</i> = 6.9 Hz, 0.65H), 7.80–7.66 (m, 2H), 7.19–7.14 (m, 1H), 4.55–4.34 (m, 3H), 3.97–3.93 (m, 1H), 3.67–3.58 (m, 2H), 3.39–3.36 (m, 1H), 3.00 (s, 3H), 2.285 (d, <i>J</i> = 4.6 Hz, 3H), 2.73–2.61 (m, 2H), 2.15–2.06 (m, 3H), 1.80–1.69 (m, 3H), 1.59–1.46 (m, 5H), 1.30–1.23 (m, 3H). MS (ESI+) <i>m/z</i> 440 (M+H).	1.9
	121	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.30 (br s, 0.25H), 9.58 (br s, 0.75H), 9.26 (d, <i>J</i> = 5.8 Hz, 0.25H), 8.91 (d, <i>J</i> = 5.8 Hz, 0.75H), 8.28 (br s, 2H), 7.75 (d, <i>J</i> = 2.0 Hz, 1H), 7.63 (d, <i>J</i> = 2.0 Hz, 1H), 4.64–4.59 (m, 0.75H), 4.35–4.25 (m, 0.25H), 3.64 (d, <i>J</i> = 9.2 Hz, 1.2H), 3.60–3.55 (m, 0.25H), 2.85–2.80 (m, 3H), 2.72–2.54 (m, 2H), 2.27–2.10 (m, 3H), 2.85–2.65 (m, 3H), 1.60–1.42 (m, 2H). MS (ESI+); <i>m/z</i> 333 (M+H).	9.0
	122	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.20–11.00 (m, 1H), 10.36 (br s, 0.25H), 9.51 (br s, 0.75H), 7.82–7.76 (m, 1H), 7.70–7.68 (m, 1H), 7.25–7.20 (m, 1H), 4.76–4.70 (m, 1H), 4.62–4.58 (m, 0.7H), 4.40–4.30 (m, 0.3H), 4.20–4.10 (m, 1H), 3.70–3.45 (m, 2H), 3.10–3.02 (m, 1H), 2.95–2.85 (m, 5H), 2.75–2.50 (m, 7H), 2.30–1.85 (m, 3H), 1.80–1.38 (m, 10H); MS (ESI+) <i>m/z</i> 426 (M+H).	2.3
	123	¹ H NMR (500 MHz, CD ₃ OD) δ 7.85–7.92 (m, 1H), 7.59 (d, <i>J</i> = 7.8 Hz, 1H), 7.24 (t, <i>J</i> = 8.0 Hz, 1H), 4.47–4.60 (m, 1H), 3.68–3.77 (m, 2H), 3.40–3.58 (m, 6H), 3.12 (s, 0.75H), 2.97 (s, 2.25), 2.72–2.86 (m, 2H), 2.08–2.37 (m, 3H), 1.60–2.00 (m, 12H); MS (ESI+) <i>m/z</i> 461 (M+H).	57
	124	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.22 (br s, 1H), 9.39 (d, <i>J</i> = 6.9 Hz, 1H), 7.76 (dd, <i>J</i> = 7.9, 0.9 Hz, 1H), 7.69 (dd, <i>J</i> = 7.9, 0.9 Hz, 1H), 7.17 (app t, <i>J</i> = 7.9 Hz, 1H), 4.49–4.40 (m, 3H), 3.93 (dd, <i>J</i> = 13.7, 3.3 Hz, 1H), 3.76–3.72 (m, 1H), 3.39–3.36 (m, 1H), 3.34–3.30 (m, 2H), 3.26–3.23 (m, 2H), 3.19–3.15 (m, 1H), 3.01 (s, 3H), 2.22–2.20 (m, 1H), 2.19–2.15 (m, 1H), 1.98–1.91 (m, 3H), 1.53 (d, <i>J</i> = 6.9 Hz, 3H), 1.28 (d, <i>J</i> = 6.5 Hz, 3H); MS (ESI+) <i>m/z</i> 412 (M+H).	17.7

	125	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 9.89 (m, 0.3H), 9.23 (m, 0.7H), 7.78 (m, 1H), 7.63 (m, 1H), 7.15 (m, 1H), 4.52 (m, 0.3H), 4.44 (m, 2.7H), 3.87–3.52 (m, 9H), 2.90 (s, 3H), 2.77–2.65 (m, 2H), 2.36–2.10 (m, 3H), 1.87–1.31 (m, 11H); MS (ESI+) <i>m/z</i> 470 (M+H).	2.1
	126	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 9.85–9.30 (m, 2H), 9.00–8.85 (m, 1H), 7.80 (m, 1H), 7.68 (m, 1H), 7.16 (m, 1H), 4.61 (m, 0.8H), 4.33 (m, 0.2H), 4.16 (m, 1H), 3.96–3.40 (m, 6H), 2.84 (s, 3H), 2.72–2.56 (m, 3H), 2.39–1.41 (m, 19H); MS (ESI+) <i>m/z</i> 438 (M+H).	16.5
	127	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.31 (br s, 1H), 9.44 (d, <i>J</i> = 6.7 Hz, 1H), 7.97, (br s, 2H), 7.51 (s, 1H), 7.39 (s, 1H), 4.40–4.30 (m, 1H), 3.74 (t, <i>J</i> = 11.6 Hz, 1H), 3.55–3.20 (m, 4H), 3.05–3.01 (m, 1H), 2.37 (s, 3H), 2.22–2.12 (m, 2H), 1.95–1.85 (m, 3H); MS (ESI+) <i>m/z</i> 301 (M+H).	20.0
	128	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.20 (s, 0.2H), 9.42 (s, 0.8H), 8.93 (d <i>J</i> = 7.5 Hz, 0.2H), 8.65 (d, <i>J</i> = 7.5 Hz, 0.8H), 7.85 (s, 2H), 7.43–7.39 (m, 1H), 6.84–6.79 (m, 1H), 4.61–4.44 (m, 0.8H), 4.31–4.18 (m, 0.2H), 3.63–3.55 (m, 2H), 2.82–2.81 (m, 3H), 2.66–2.54 (m, 1H), 2.47–2.42 (m, 1H), 2.19–1.92 (m, 3H), 1.74–1.68 (m, 3H), 1.58–1.49 (m, 1H); 1.47–1.36 (m, 2H); (ESI+) <i>m/z</i> 333 (M+H).	124
	129	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.30 (br s, 0.3H), 9.42 (br s, 0.7H), 9.32 (d, <i>J</i> = 5.7 Hz, 0.3H), 8.95 (d, <i>J</i> = 5.7 Hz, 0.7H), 7.88 (br s, 1.4H), 7.86 (s, 0.6H), 7.52 (s, 0.7H), 7.51 (s, 0.3H), 7.37 (s, 1H), 4.60–4.55 (m, 0.7H), 4.35–4.25 (m, 0.3H), 3.65 (d, <i>J</i> = 8.9 Hz, 1.4H), 3.60–3.55 (m, 0.3H), 2.85–2.80 (m, 3H), 2.75–2.55 (m, 2H), 2.37 (s, 3H), 2.20–2.00 (m, 3H), 1.85–1.65 (m, 3H), 1.60–1.40 (m, 2H); MS (APCI) <i>m/z</i> 329 (M+H).	10.7
	130	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.20–10.10 (m, 0.4H), 9.50–9.40 (m, 0.6H), 9.18–9.06 (m, 1H), 7.84–7.74 (m, 1H), 7.66 (d, <i>J</i> = 8.0 Hz, 1H), 7.13 (dt, <i>J</i> = 8.0, 2.0 Hz, 1H), 4.54–4.50 (m, 0.7H), 4.42–4.30 (m, 2.3H), 3.96–3.86 (m, 2H), 3.82–3.68 (m, 2H), 3.64–3.50 (m, 2H), 2.85 (m, 3H), 2.76–2.52 (m, 2H), 2.12–1.90 (m, 2H), 1.82–1.42 (m, 5H), 1.40–1.30 (m, 6H), 1.25 (s, 9H); MS (ESI+) <i>m/z</i> 496 (M+H).	2.8
	131	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.40 (s, 0.4H), 9.64 (s, 0.6H), 9.12–9.00 (m, 1H), 7.82–7.74 (m, 1H), 7.65 (dd, <i>J</i> = 8.0, 2.0 Hz, 1H), 7.17 (app t, <i>J</i> = 8.0 Hz, 1H), 4.60–4.54 (m, 0.6H), 4.42–4.32 (m, 2.4H), 3.70–3.36 (m, 8H), 3.02 (s, 3H), 2.84 (s, 1H), 2.80–2.58 (m, 2H), 2.30–1.98 (m, 2H), 1.80–1.68 (m, 2H), 1.60–1.52 (m, 1H), 1.50–1.38 (m, 7H); MS (ESI+) <i>m/z</i> 490 (M+H).	1.0

	132	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.30–10.10 (m, 0.4H), 9.80–9.30 (m, 0.6H), 7.75 (d, <i>J</i> = 8.0 Hz, 1H), 7.64 (d, <i>J</i> = 8.0 Hz, 1H), 7.13 (app t, <i>J</i> = 8.0 Hz, 1H), 4.60–4.30 (m, 3H), 3.96–3.90 (m, 2H), 3.86–3.78 (m, 1H), 3.60–3.46 (m, 3H), 2.80 (s, 3H), 2.64–2.55 (m, 3H), 2.30–2.00 (m, 3H), 1.80–1.60 (m, 7H), 1.60–1.10 (m, 14H); MS (ESI+) <i>m/z</i> 522 (M+H).	1.9
	133	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 9.60–9.30 (m, 0.2H), 9.20–9.02 (m, 0.8H), 7.75 (d, <i>J</i> = 7.5 Hz, 1H), 7.64 (d, <i>J</i> = 8.0 Hz, 1H), 7.13 (app t, <i>J</i> = 8.0 Hz, 1H), 4.54–4.30 (m, 3H), 4.00–3.82 (m, 3H), 3.70–3.40 (m, 2H), 3.38–3.26 (m, 6H), 3.02–2.96 (m, 1H), 2.90–2.50 (m, 4H), 2.40–1.90 (m, 3H), 1.88–1.40 (m, 10H), 1.40–1.30 (m, 6H); MS (ESI+) <i>m/z</i> 508 (M+H).	1.8
	134	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.05 (s, 1H), 7.76 (d, <i>J</i> = 8.0 Hz, 1H), 7.62 (d, <i>J</i> = 8.0, 2.0 Hz, 1H), 7.12 (app t, <i>J</i> = 8.0 Hz, 1H), 4.50–4.34 (m, 3H), 3.96 (dd, <i>J</i> = 13, 1.5 Hz, 1H), 3.88 (dd, <i>J</i> = 13.5, 4.0 Hz, 1H), 3.73 (dd, <i>J</i> = 13, 1.5 Hz, 1H), 3.51 (dd, <i>J</i> = 13.5, 4.0 Hz, 1H), 3.32–3.27 (m, 5H), 2.60–2.30 (m, 3H), 2.15–1.85 (m, 3H), 1.60–1.30 (m, 9H), 1.15–1.05 (m, 3H); MS (ESI+) <i>m/z</i> 468 (M+H).	1.7
	135	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 9.16–8.96 (m, 1H), 7.75 (d, <i>J</i> = 8.0 Hz, 1H), 7.63 (d, <i>J</i> = 8.0 Hz, 1H), 7.12 (app t, <i>J</i> = 8.0 Hz, 1H), 4.50–4.30 (m, 2H), 3.96–3.90 (m, 2H), 3.86–3.80 (m, 1H), 3.60–3.46 (m, 2H), 3.30–3.26 (s, 6H), 2.96–2.80 (m, 2H), 2.20–1.90 (m, 3H), 1.70–1.20 (m, 9H), 1.16–1.08 (m, 6H). MS (ESI+) <i>m/z</i> 482 (M+H).	2.0
	136	¹ H NMR (500 MHz, CD ₃ OD) δ 7.80–7.87 (m, 1H), 7.55–7.61 (m, 1H), 7.17–7.25 (m, 1H), 4.44–4.69 (m, 3H), 3.90–3.97 (m, 2H), 3.67–3.77 (m, 2H), 3.42–3.47 (m, 2H), 2.97–3.03 (m, 3H), 2.89 (s, 6H), 2.69–2.82 (m, 2H), 2.15–2.42 (m, 3H), 1.87–2.02 (m, 2.5 H), 1.59–1.75 (m, 2.5 H), 1.47–1.53 (m, 6H); MS (ESI+) <i>m/z</i> 483 (M+H).	2.6
	137	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 8.96–8.80 (s, 1H), 7.76 (d, <i>J</i> = 8.0 Hz, 1H), 7.62 (d, <i>J</i> = 8.0 Hz, 1H), 7.18 (app t, <i>J</i> = 8.0 Hz, 1H), 4.40–4.24 (m, 1H), 4.20–4.14 (m, 2H), 3.36–3.22 (m, 6H), 3.16–2.88 (m, 3H), 2.72–2.62 (m, 2H), 2.60–2.34 (m, 3H), 2.12–1.88 (m, 3H), 1.60–1.40 (m, 8H), 1.38–0.88 (m, 3H); ¹⁹ F { ¹ H}NMR (282 MHz, DMSO- <i>d</i> ₆), δ –64.02; MS (ESI+) <i>m/z</i> 494 (M+H).	1.8
	138	¹ H NMR (500 MHz, CD ₃ OD) δ 7.90–7.72 (m, 1H), 7.59–7.45 (m, 1H), 7.25–7.03 (m, 1H), 4.59–4.34 (m, 3H), 4.07–3.88 (m, 2H), 3.88–3.67 (m, 4H), 3.50–3.36 (m, 2H), 2.83–2.54 (m, 5H), 2.22–2.06 (m, 3H), 2.06–1.87 (m, 1H), 1.80–1.58 (m, 3H), 1.58–1.36 (m, 8H), 1.08–0.91 (m, 6H); MS (ESI+) <i>m/z</i> 513 (M+H).	2.4







	139	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.24 (s, 1H), 9.04 (d, <i>J</i> = 6.5 Hz, 1H), 7.93 (s, 2H), 7.45–7.42 (m, 1H), 6.85–6.81 (m, 1H), 4.33–4.31 (m, 1H), 3.69–3.65 (m, 1H), 3.25–3.19 (m, 4H), 3.06–2.98 (m, 2H), 2.24–2.08 (m, 2H), 1.92–1.89 (m, 2H), 1.81–1.71 (m, 1H); MS (ESI+) <i>m/z</i> 305 (M+H).	67.4
	140	¹ H NMR (500 MHz, CD ₃ OD) δ 7.82–7.87 (m, 1H), 7.55–7.61 (m, 1H), 7.16–7.24 (m, 1H), 4.45–4.63 (m, 3H), 3.92 (dd, <i>J</i> = 13.0, 3.3 Hz, 1H), 3.67–3.78 (m, 2H), 3.49–3.56 (m, 4H), 3.30–3.38 (m, 2H), 3.02 (s, 1H), 2.97 (s, 2H), 2.72–2.91 (m, 2H), 2.15–2.43 (m, 3H), 1.60–2.02 (m, 9H), 1.47–1.53 (m, 6H); MS (ESI+) <i>m/z</i> 509 (M+H).	2.2
	141	¹ H NMR (500 MHz, CD ₃ OD) δ 7.82–7.87 (m, 1H), 7.53–7.57 (m, 1H), 7.15–7.20 (m, 1H), 4.43–4.58 (m, 3H), 3.90–3.96 (m, 2H), 3.67–3.78 (m, 2H), 3.44 (dd, <i>J</i> = 13.1, 2.3 Hz, 2H), 3.17–3.25 (m, 2H), 3.02 (s, 0.75 H), 2.97 (s, 2.25 H), 2.72–2.92 (m, 2H), 2.13–2.42 (m, 3H), 1.86–2.02 (m, 2H), 1.46–1.75 (14 H); MS (ESI+) <i>m/z</i> 523 (M+H).	1.8
	142	¹ H NMR (500 MHz, CD ₃ OD) δ 7.84 (dd, <i>J</i> = 8.0, 1.0 Hz, 1H), 7.57 (dd, <i>J</i> = 8.0, 0.9 Hz, 1H), 7.39–7.32 (m, 5H), 7.19 (app t, <i>J</i> = 8.0 Hz, 1H), 4.77–4.65 (m, 3H), 4.55–4.45 (m, 2H), 3.93–3.89 (m, 2H), 3.48–3.38 (m, 5H), 3.30–3.25 (m, 1H), 2.38–2.36 (m, 2H), 2.17–2.12 (m, 3H), 1.67 (d, <i>J</i> = 7.0 Hz, 3H), 1.12 (d, <i>J</i> = 6.5 Hz, 3H); MS (ESI+) <i>m/z</i> 488 (M+H).	11.5
	143	¹ H NMR (500 MHz, CD ₃ OD) δ 7.90–7.78 (m, 1H), 7.57–7.49 (m, 1H), 7.21–7.12 (m, 1H), 5.04–4.89 (m, 1H), 4.58–4.41 (m, 3H), 3.87–3.66 (m, 6H), 3.00 (s, 3H), 2.92–2.65 (m, 2H), 2.47–1.58 (m, 8H), 1.53–1.43 (m, 6H), 1.36–1.22 (m, 6H); MS (ESI+) <i>m/z</i> 498 (M+H).	1.4
	144	¹ H NMR (500 MHz, CD ₃ OD) δ 7.89–7.80 (m, 1H), 7.60–7.49 (m, 1H), 7.20–7.12 (m, 1H), 4.61–4.41 (m, 3H), 4.30–4.16 (m, 2H), 3.91–3.63 (m, 6H), 3.06–2.95 (m, 3H), 2.90–2.69 (m, 2H), 2.38–1.53 (m, 8H), 1.53–1.36 (m, 6H), 1.36–1.23 (m, 3H); MS (ESI+) <i>m/z</i> 484 (M+H).	1.0
	145	¹ H NMR (500 MHz, CD ₃ OD) δ 8.20 (s, 1H), 7.76 (s, 1H), 7.48 (s, 1H), 4.61 (s, 2H), 2.35 (s, 3H); MS (ESI+) <i>m/z</i> 306 (M+H).	127
	146	¹ H NMR (500 MHz, CD ₃ OD) δ 7.82 (d, <i>J</i> = 8.0 Hz, 1H), 7.54 (d, <i>J</i> = 7.9 Hz, 1H), 7.15 (t, <i>J</i> = 8.0 Hz, 1H), 4.43–4.52 (m, 2H), 4.33–4.42 (m, 1H), 3.88–3.93 (m, 4H), 3.48–3.55 (m, 4H), 3.30–3.35 (m, 2H), 2.62–2.72 (m, 2H), 2.10–2.22 (m, 1H), 1.65–2.02 (m, 11H), 1.52 (d, <i>J</i> = 6.7 Hz, 6H); MS (ESI+) <i>m/z</i> 495 (M+H).	32.2


	147	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.40–10.30 (m, 0.4H), 9.60–9.53 (m, 0.6H), 9.10–9.00 (m, 0.4H), 8.89–8.83 (d, <i>J</i> = 6.0 Hz, 0.6H), 7.80–7.76 (m, 1H), 7.65 (d, <i>J</i> = 10 Hz, 1H), 7.20–7.17 (m, 1H), 6.26–6.16 (m, 0.8 H), 6.07–6.02 (m, 0.2H), 5.61–5.50 (m, 2H), 4.68 (d, <i>J</i> = 6.0 Hz, 1H), 4.60–4.48 (m, 1H), 4.32–4.30 (m, 0.5H), 4.16–4.05 (m, 1H), 4.02–3.98 (m, 1H), 3.60–3.54 (m, 2H), 3.52–3.48 (m, 1H), 3.46–3.16 (m, 5H), 2.85 (s, 3H), 2.75–2.55 (m, 2H), 2.27–2.18 (m, 1H), 2.12–2.05 (m, 2H), 1.78–1.68 (m, 3H), 1.60–1.40 (m, 2H), 1.30–1.22 (m, 3H); (ESI+) <i>m/z</i> 452 (M+H).	10.8
	148	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.62–11.44 (m, 1H), 10.40–10.32 (m, 0.3H), 9.58–9.50 (m, 0.7H), 8.96–8.78 (m, 1H), 7.84–7.64 (m, 4H), 7.54–7.30 (m, 3H), 7.22–7.18 (m, 1H), 4.80–4.72 (m, 1H), 4.68–4.58 (m, 1H), 4.56–4.46 (m, 1H), 4.40–4.22 (m, 2H), 3.90–3.50 (3H), 3.42–3.30 (m, 1H), 3.22–3.12 (m, 2H), 2.86 (s, 3H), 2.78–2.62 (m, 2H), 2.20–1.90 (m, 3H), 1.76–1.60 m, 5H), 1.56–1.44 (m, 6H); MS (ESI+) <i>m/z</i> 502 (M+H).	1.6
	151	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) □ 10.66 (br s, 0.4H), 9.86 (br s, 0.6H), 9.16–9.15 (m, 0.4H), 8.96–8.95 (m, 0.6H), 7.77–7.72 (m, 1H), 7.61–7.57 (m, 1H), 7.15–7.11 (m, 1H), 4.59–4.51 (m, 0.6H), 4.36–4.31 (m, 0.4H), 4.06–4.03 (m, 1H), 3.95–3.84 (m, 3H), 3.68–3.46 (m, 5H), 2.83–2.81 (m, 3H), 2.75–2.62 (m, 2H), 2.31–2.19 (m, 1H), 2.11–2.09 (m, 2H), 1.94–1.74 (m, 5H), 1.58–1.45 (m, 2H), 0.93–0.87 (m, 3H); MS (ESI+) <i>m/z</i> 413 (M+H)	34
	152	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) □ 10.66 (br s, 0.4H), 9.84 (br s, 0.6H), 9.14–9.13 (m, 0.4H), 8.98–8.97 (m, 0.6H), 7.77–7.73 (m, 1H), 7.60–7.58 (m, 1H), 7.14–7.10 (m, 1H), 4.58–4.50 (m, 0.6H), 4.36–4.31 (m, 0.4H), 4.04–3.91 (m, 3H), 3.76–3.71 (m, 1H), 3.63–3.44 (m, 5H), 2.83–2.81 (m, 3H), 2.73–2.62 (m, 2H), 2.46–2.36 (m, 1H), 2.26–2.18 (m, 1H), 2.12–2.01 (m, 2H), 1.81–1.73 (m, 3H), 1.54–1.45 (m, 2H), 1.09–0.99 (m, 3H), 0.95–0.85 (m, 3H); MS (ESI+) <i>m/z</i> 427 (M+H)	75

[00704] Bezold-Jarisch Assay *in vivo*. In order to demonstrate functional antagonism of 5-HT₃ receptors, compounds (see below) were evaluated for their ability to inhibit serotonin induced bradycardia *in vivo* in the mouse [Saxena, P.R. and Lawang, A. A comparison of cardiovascular and smooth muscle effects of 5-hydroxytryptamine and 5-carboxamidotryptamine, a selective agonist of 5-HT₁ receptors. Arch. Int. Pharmacodyn. 277: 235-252, 1985]. Test substances and vehicle

[2 %Tween 80] were each administered orally (0.3 to 3 mg/kg) to a group of 5 male or female CD-1(Crl.) mice each weighing 24 ± 2 g. A dosing volume of 10 mL/kg was used. Sixty minutes later, 5-HT (0.1 mg/kg IV)-induced bradycardia was recorded in urethane (2225-2500 mg/kg IP, given 10 minutes before 5-HT)-anesthetized animals.

[00705] *In vivo* 5-HT₃ Antagonism in the mouse (Bradycardia Reflex)

Compound	Example	% Inhibition @ dose of test substance (p.o.)
	8	83% @ 0.3 mg/kg
	49	86% @ 1 mg/kg
	75	98% @ 1 mg/kg
	50	80% @ 3 mg/kg
	93	85% @ 3 mg/kg
	103	97% @ 3 mg/kg

	112	97% @ 3 mg/kg
---	-----	---------------

[00706] The compounds of the invention may be administered orally or via injection at a dose from 0.001 to 2500 mg/kg per day. The dose range for adult humans is generally from 0.005 mg to 10 g/day. Tablets or other forms of presentation provided in discrete units may conveniently contain an amount of compound of the invention which is effective at such dosage or as a multiple of the same, for instance, units containing 5 mg to 500 mg, usually around 10mg to 200mg. The precise amount of compound administered to a patient will be the responsibility of the attendant physician. However, the dose employed will depend on a number of factors, including the age and sex of the patient, the precise disorder being treated, and its severity. Also, the route of administration may vary depending on the condition and its severity.

[00707] While it may be possible for the compounds of formulas I and II to be administered as the raw chemical, it is preferable to present them as a pharmaceutical composition. According to a further aspect, the present invention provides a pharmaceutical composition comprising a compound of formula I or II or a pharmaceutically acceptable salt or solvate thereof, together with one or more pharmaceutically carriers thereof and optionally one or more other therapeutic ingredients. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

[00708] The formulations include those suitable for oral, parenteral (including subcutaneous, intradermal, intramuscular, intravenous and intraarticular), rectal and topical (including dermal, buccal, sublingual and intraocular) administration. The most suitable route may depend upon the condition and disorder of the recipient. The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing into association a compound of formula I or II or a pharmaceutically acceptable salt or solvate thereof ("active ingredient") with the carrier which

constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired formulation. Preferred unit dosage formulations are those containing an effective dose or an appropriate fraction thereof, of the active ingredient.

[00709] Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion. The active ingredient may also be presented as a bolus, electuary or paste.

[00710] A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, lubricating, surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The tablets may optionally be coated or scored and may be formulated so as to provide sustained, delayed or controlled release of the active ingredient therein.

[00711] Formulations for parenteral administration include aqueous and non-aqueous sterile injection solutions, which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient. Formulations for parenteral administration also include aqueous and non-aqueous sterile suspensions, which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of a sterile liquid carrier, for example saline, phosphate-buffered saline (PBS) or the like, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.

[00712] Formulations for rectal administration may be presented as a suppository with the usual carriers such as cocoa butter or polyethylene glycol.

[00713] Formulations for topical administration in the mouth, for example buccally or sublingually, include lozenges comprising the active ingredient in a flavored basis such as sucrose and acacia or tragacanth, and pastilles comprising the active ingredient in a basis such as gelatin and glycerin or sucrose and acacia.


[00714] It should be understood that in addition to the ingredients particularly mentioned above, the formulations of this invention may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavoring agents.

[00715] Although the foregoing invention has been described in some detail for purposes of illustration, it will be readily apparent to one skilled in the art that changes and modifications may be made without departing from the scope of the invention described herein.

CLAIMS

What is claimed is:

1. A compound of formula I, II or III:



wherein

R₁, R₂ and R₃ are independently selected from hydrogen, halogen, cyano, alkyl or aryl sulfoxide, alkyl or aryl sulfone, amino, alkylamino, dialkylamino, acylamino, morpholinyl, -O-loweralkyl, hydroxy, loweralkyl, fluoroloweralkyl, O lowerfluoroalkyl, methylenedioxy, ethylenedioxy, alkoxy-loweralkyl and hydroxyloweralkyl;

R₄ is a residue chosen from:

- (i) a saturated nitrogen heterocycle or methyl-substituted saturated nitrogen heterocycle, in which said nitrogen is tertiary, said heterocycle containing at least one 5 or 6-membered ring; and
- (ii) an imidazolylalkyl residue wherein the imidazole of said imidazolylalkyl is optionally substituted with up to three groups chosen from halogen, (C₁-C₄)alkyl, substituted (C₁-C₄)alkyl and NH₂; and

R₁₀ is chosen from the group consisting of

- (i) hydrogen;
- (ii) (C₁-C₁₀)alkyl;
- (iii) substituted (C₁-C₁₀)alkyl;
- (iv) heterocyclyl;

(v) substituted heterocyclyl;

(vi) aryl; and


(vii) substituted aryl;

R₁₁ is chosen from the group consisting of hydrogen and (C₁-C₁₀)alkyl;


or

taken together R₁₀, R₁₁ and the nitrogen to which they are attached form a nitrogenous heterocycle or substituted nitrogenous heterocycle, with the proviso that, when R₁₀, R₁₁ and nitrogen form a morpholine ring, the compound does not have the structure of example 57.


2. A compound according to claim 1 of formula Ia or Ib:




3. A compound according to claim 1 of formula IIa or IIb:



4. A compound according to claim 1 of formula IIIa or IIIb:



5. A compound according to claim 1 wherein R₄ is chosen from:



and

wherein

m is 1, 2, 3 or 4;

n is 0, 1, 2, 3 or 4;

Q is N(CH₃) or -O-; and

R₅ is hydrogen or methyl.

6. A compound according to claim 1 wherein R₄ is chosen from quinuclidine, tropane, azabicyclo[3.3.1]nonane, methyl azabicyclo[3.3.1]nonane, dimethyl diazabicyclo[3.3.1]nonane, methylpiperidine and methyl-3-oxa-9-azabicyclo[3.3.1]nonane.
7. A compound according to claim 1 wherein R₁, R₂ and R₃ are hydrogen.
8. A compound according to claim 1 wherein one of R₁, R₂ and R₃ is halogen.
9. A compound according to any of claims 1-8 wherein R₁₀ is chosen from the group consisting of hydrogen and (C₁ to C₃)alkyl.
10. A compound according to claim 3 wherein R₁₁ is H or CH₃.
11. A compound according to any of claims 1-8 wherein R₁₀ is chosen from the group consisting of phenyl, substituted phenyl, (C₁-C₆)alkyl, 4 to 7-membered monocyclic nitrogenous heterocycle, 4 to 10 carbon bicyclic nitrogenous heterocycle, 4 to 7-membered monocyclic nitrogenous heterocycle substituted with one or more

(C₁-C₆)alkyl, 4 to 10 carbon bicyclic nitrogenous heterocycle substituted with one or more (C₁-C₆)alkyl, dimethylamino(C₁-C₆)alkyl, 4 to 7-membered monocyclic nitrogenous heterocycle(C₁-C₆)alkyl, (C₁-C₆)alkoxy(C₁-C₆)alkyl, hydroxy(C₁-C₆)alkyl, and dialkylaminocarbonyl(C₁-C₆)alkyl.

12. A compound according to claim 3 wherein R₁₀ and R₁₁, taken together, form a nitrogenous heterocycle or substituted nitrogenous heterocycle.

13. A compound according to claim 10 wherein R₁₀ and R₁₁, taken together, form a morpholine, piperazine, piperidine, diazepane, tetrahydroquinoxaline, triazolopyrazine, azabicyclo[3.3.1]nonane, diazabicyclo[2.2.1]heptane, or any of the foregoing substituted with one, two or three substituents chosen independently from (C₁-C₆)alkyl, (C₁-C₆)haloalkyl, (C₁-C₆)alkoxy phenyl and heteroaryl.

14. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to any of claims 1-13.

15. A pharmaceutical composition according to claim 14 additionally comprising a second antiemetic agent.

16. A pharmaceutical composition according to claim 15 wherein said second antiemetic agent is a neurokinin antagonist.

17. A pharmaceutical composition according to claim 14 or 15 additionally comprising a corticosteroid.

18. A method of treating a disorder which is dependent upon modulation of the serotonin type 3 receptor, which comprises administering to a patient in need of such treatment a therapeutically effective amount of a compound according to any of claims 1-13.

19. A method according to claim 18 wherein said disorder is irritable bowel syndrome.

20. A method according to claim 18 for treating emesis.
21. A method according to claim 18 for treating post-operative nausea or vomiting.
22. A method according to claim 18 for treating a psychological disorder.
23. A method according to claim 22 wherein said psychological disorder is chosen from depression, psychosis, schizophrenia, anxiety and appetite disorder.
24. A method according to claim 18 for treating obesity.
25. A method according to claim 18 for treating substance abuse disorders.
26. A method according to claim 25 wherein said substance abuse disorder is chosen from chemical dependency, cocaine addiction, alcohol dependence and amphetamine addiction.
27. A method according to claim 18 for treating dementia associated with a neurodegenerative disease.
28. A method according to claim 18 for treating cognition deficits.
29. A method according to claim 18 for treating pain or for pain management.
30. A method according to claim 18 for treating fibromyalgia syndrome.
31. A method according to claim 18 for treating chronic fatigue syndrome.
32. A method according to claim 18 for treating or preventing bronchial asthma.
33. A method according to claim 18 for treating bulimia nervosa.

- 34. A method according to claim 18 for treating sleep apnea.
- 35. A method according to claim 18 for treating pruritis.
- 36. A method according to claim 18 for treating radiation-induced nausea and vomiting.
- 37. A method according to claim 18 for treating epilepsy.